{"docstore/data": {"c89b6943-ceba-41a7-bd7c-e961a261e049": {"__data__": {"id_": "c89b6943-ceba-41a7-bd7c-e961a261e049", "embedding": null, "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.  ", "original_text": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0ada1e1-f202-4a39-9cd8-4d0f835fb0cc", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.  ", "original_text": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc. "}, "hash": "a1a6dab736002219f12a02eada26cd9581666f8797158c97c10723c98c04bd76", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0ada1e1-f202-4a39-9cd8-4d0f835fb0cc": {"__data__": {"id_": "a0ada1e1-f202-4a39-9cd8-4d0f835fb0cc", "embedding": null, "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.  ", "original_text": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c89b6943-ceba-41a7-bd7c-e961a261e049", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.  ", "original_text": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1211dca2b6440c2ebf20bd43661d0a60f5efa046b24bc2df621998c2890607a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdd6a008-1f96-4e64-bc2e-c23a86f28355", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n", "original_text": "second quarter fiscal year 2020 earnings call.  "}, "hash": "ddeabfb4a3b558684eefbee1ccdefa8fa52e117c04f6f7e41e068eb86d8683dd", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc. ", "start_char_idx": 48, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdd6a008-1f96-4e64-bc2e-c23a86f28355": {"__data__": {"id_": "bdd6a008-1f96-4e64-bc2e-c23a86f28355", "embedding": null, "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n", "original_text": "second quarter fiscal year 2020 earnings call.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0ada1e1-f202-4a39-9cd8-4d0f835fb0cc", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.  ", "original_text": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3466f3bffe3e3b669b660fd6ae543e9d5aa1f7ace6425f0bc0dc1e7e20414b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a34a219-7e3f-4499-8f0d-490b07bb4378", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  ", "original_text": "Today's \nconference is being recorded.  "}, "hash": "7058dfe20d2dd41f4d93373a37f4fbac7f31a6e6529a9974a0c8ca96077e65f3", "class_name": "RelatedNodeInfo"}}, "text": "second quarter fiscal year 2020 earnings call.  ", "start_char_idx": 179, "end_char_idx": 227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a34a219-7e3f-4499-8f0d-490b07bb4378": {"__data__": {"id_": "3a34a219-7e3f-4499-8f0d-490b07bb4378", "embedding": null, "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  ", "original_text": "Today's \nconference is being recorded.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdd6a008-1f96-4e64-bc2e-c23a86f28355", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n", "original_text": "second quarter fiscal year 2020 earnings call.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ea2fce5ac40cbe184cb391b78e202ffea9e0bb69eac398fe9cce87d455d8e60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f7f91b7-68a8-421b-a2be-1d8f55c81392", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.  ", "original_text": "At this time I would like to turn the conference over to Kevin Moran.  "}, "hash": "546376dfcf70e2a1516ed87fd22c3e5345e70938604de42ab1f919aab9de5bbb", "class_name": "RelatedNodeInfo"}}, "text": "Today's \nconference is being recorded.  ", "start_char_idx": 227, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f7f91b7-68a8-421b-a2be-1d8f55c81392": {"__data__": {"id_": "0f7f91b7-68a8-421b-a2be-1d8f55c81392", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.  ", "original_text": "At this time I would like to turn the conference over to Kevin Moran.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a34a219-7e3f-4499-8f0d-490b07bb4378", "node_type": "1", "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  ", "original_text": "Today's \nconference is being recorded.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "240cbdf25be11f475ec840cc88a1bf66d01ecbc85067bbfcb3e73018403a0e47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60e38a5-62b3-44a4-978e-949494c6beca", "node_type": "1", "metadata": {"window": "second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  ", "original_text": "Please go \nahead.  \n \n"}, "hash": "f89f5f9fa0a4f0f9dc0520a85a060f8fd22de37b29f1fd2226e1c6b68f64f1b4", "class_name": "RelatedNodeInfo"}}, "text": "At this time I would like to turn the conference over to Kevin Moran.  ", "start_char_idx": 267, "end_char_idx": 338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a60e38a5-62b3-44a4-978e-949494c6beca": {"__data__": {"id_": "a60e38a5-62b3-44a4-978e-949494c6beca", "embedding": null, "metadata": {"window": "second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  ", "original_text": "Please go \nahead.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f7f91b7-68a8-421b-a2be-1d8f55c81392", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.  ", "original_text": "At this time I would like to turn the conference over to Kevin Moran.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78d85c48eb740e83f1feac613345cfcd4a6845c787f08450ae01e74844715760", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ae358db-f428-43cc-b1cd-e0c3213c9183", "node_type": "1", "metadata": {"window": "Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n ", "original_text": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  "}, "hash": "a4cb3bd86c57f1e531277799291ded536bb997ca07742f568387f29f4b79692e", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 338, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ae358db-f428-43cc-b1cd-e0c3213c9183": {"__data__": {"id_": "3ae358db-f428-43cc-b1cd-e0c3213c9183", "embedding": null, "metadata": {"window": "Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n ", "original_text": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a60e38a5-62b3-44a4-978e-949494c6beca", "node_type": "1", "metadata": {"window": "second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  ", "original_text": "Please go \nahead.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdd55efe1280ed4dc13604a623d02b15ae925e4fe4ff30f2ce87fb52411ec54c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d76d0c58-49a5-4776-a2ea-71708dc2f0da", "node_type": "1", "metadata": {"window": "At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.  ", "original_text": "I'm Kevin Moran, Vice President o f Investor Relations.  "}, "hash": "d2ebf1ca58e58fefa383c1db0264b740c843b9b2c8a4e18b1cf28862356bc8a7", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  ", "start_char_idx": 360, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d76d0c58-49a5-4776-a2ea-71708dc2f0da": {"__data__": {"id_": "d76d0c58-49a5-4776-a2ea-71708dc2f0da", "embedding": null, "metadata": {"window": "At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.  ", "original_text": "I'm Kevin Moran, Vice President o f Investor Relations.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ae358db-f428-43cc-b1cd-e0c3213c9183", "node_type": "1", "metadata": {"window": "Today's \nconference is being recorded.   At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n ", "original_text": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adc28832cfd7a36907081c982f1330b226e3cb9461665b890975baaa11c414f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18399038-8cca-4dc1-ba4c-b7109c0bd8d8", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  ", "original_text": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  "}, "hash": "9a7d18d600fdd674f1df6935018e5c53fefd40cece2253da1aa2b8d95e792e5b", "class_name": "RelatedNodeInfo"}}, "text": "I'm Kevin Moran, Vice President o f Investor Relations.  ", "start_char_idx": 485, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18399038-8cca-4dc1-ba4c-b7109c0bd8d8": {"__data__": {"id_": "18399038-8cca-4dc1-ba4c-b7109c0bd8d8", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  ", "original_text": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d76d0c58-49a5-4776-a2ea-71708dc2f0da", "node_type": "1", "metadata": {"window": "At this time I would like to turn the conference over to Kevin Moran.   Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.  ", "original_text": "I'm Kevin Moran, Vice President o f Investor Relations.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c8cfb6087b87824c9dc1a7425baa639b225197bcb9dd6441bf46be982a6dfb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a761b164-f8b7-4389-ac10-d7f534de31fe", "node_type": "1", "metadata": {"window": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "original_text": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n "}, "hash": "4f10c695c506c1e0450d6c1ef0d32359af83d6211785ceaa2d26a0cf6237ca8d", "class_name": "RelatedNodeInfo"}}, "text": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  ", "start_char_idx": 542, "end_char_idx": 666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a761b164-f8b7-4389-ac10-d7f534de31fe": {"__data__": {"id_": "a761b164-f8b7-4389-ac10-d7f534de31fe", "embedding": null, "metadata": {"window": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "original_text": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18399038-8cca-4dc1-ba4c-b7109c0bd8d8", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  ", "original_text": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a49438ae9ee5ca562ff9142bb5fe35f4a9aaaae1e1e984af4f0896b74760576b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dafcb8d-757f-440b-951f-5676dc82751a", "node_type": "1", "metadata": {"window": "I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  ", "original_text": "During the call we will be making forward -looking statements.  "}, "hash": "da26d178f23c461c909b7883231e2df8b67bc7cbd70f6d3ce1f06fe7a0e7f0d0", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n ", "start_char_idx": 666, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dafcb8d-757f-440b-951f-5676dc82751a": {"__data__": {"id_": "7dafcb8d-757f-440b-951f-5676dc82751a", "embedding": null, "metadata": {"window": "I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  ", "original_text": "During the call we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a761b164-f8b7-4389-ac10-d7f534de31fe", "node_type": "1", "metadata": {"window": "Kevin Moran :  Good morning and thank you for joining us as we discuss Cardinal Health second quarter fiscal 2020 \nresults.   I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "original_text": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad98563470488c27d88b4e86fcc2607cd571a4266f62ab1df0264299afaec662", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91ac359f-5026-4789-82b5-b1a408320fed", "node_type": "1", "metadata": {"window": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n ", "original_text": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  "}, "hash": "d844887ee91ac8ae9b02916386b7ae9ae983ac1e5bb773309fb69e7ab0611e7e", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will be making forward -looking statements.  ", "start_char_idx": 784, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91ac359f-5026-4789-82b5-b1a408320fed": {"__data__": {"id_": "91ac359f-5026-4789-82b5-b1a408320fed", "embedding": null, "metadata": {"window": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n ", "original_text": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dafcb8d-757f-440b-951f-5676dc82751a", "node_type": "1", "metadata": {"window": "I'm Kevin Moran, Vice President o f Investor Relations.   And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  ", "original_text": "During the call we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55f47e63b1b0c1d9b614e0d3cac6b9456948a92420893745bfe11c3b76287078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c63a7d-5780-4dfe-8929-d8009ef1234c", "node_type": "1", "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n "}, "hash": "a1a39cd0bbd255521d63593006acd3b179609984b03969c3e61fdc83ae144901", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  ", "start_char_idx": 848, "end_char_idx": 1020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c63a7d-5780-4dfe-8929-d8009ef1234c": {"__data__": {"id_": "42c63a7d-5780-4dfe-8929-d8009ef1234c", "embedding": null, "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91ac359f-5026-4789-82b5-b1a408320fed", "node_type": "1", "metadata": {"window": "And joining me today are Mike Kaufmann, our \nChief Executive Officer, and Dave Evans, our Interim Chief Financial Officer.   You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n ", "original_text": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19f83d6e66aae20365a2e7bfabf4746ff81701ae4145f4e53b24bc062aeb76ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19262729-0c15-4bce-b65a-6d4cac96e8e2", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  "}, "hash": "38fc2a369b2c19691f06475cda464b8e8483fdc49c75a83b76872cf7f4a81a70", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "start_char_idx": 1020, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19262729-0c15-4bce-b65a-6d4cac96e8e2": {"__data__": {"id_": "19262729-0c15-4bce-b65a-6d4cac96e8e2", "embedding": null, "metadata": {"window": "During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c63a7d-5780-4dfe-8929-d8009ef1234c", "node_type": "1", "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our Web site at ir.cardinalhealth.com . \n \n  During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06b731579f5682031a00b27faabae420e4d30ce90af86b6a0b419efd5583b4e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "902b1233-9101-45f4-8f78-4a78a0fdb558", "node_type": "1", "metadata": {"window": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n "}, "hash": "b689299516ce3c52e88fba3f5d49e77f580ee1ae931829747e42ac92567f9808", "class_name": "RelatedNodeInfo"}}, "text": "During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  ", "start_char_idx": 1190, "end_char_idx": 1355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "902b1233-9101-45f4-8f78-4a78a0fdb558": {"__data__": {"id_": "902b1233-9101-45f4-8f78-4a78a0fdb558", "embedding": null, "metadata": {"window": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19262729-0c15-4bce-b65a-6d4cac96e8e2", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.   The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fced7f3bf60d52d7c136835d2e6fb0c9808da7503eaa660c50d0644900f5dd8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74cc82c9-998c-464e-8b6b-287cf2b79b5c", "node_type": "1", "metadata": {"window": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n "}, "hash": "cd799a27abf810800bb836fc78bfda6661541c0cf37a616b87e47f8c12d9aa2d", "class_name": "RelatedNodeInfo"}}, "text": "GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n ", "start_char_idx": 1355, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74cc82c9-998c-464e-8b6b-287cf2b79b5c": {"__data__": {"id_": "74cc82c9-998c-464e-8b6b-287cf2b79b5c", "embedding": null, "metadata": {"window": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af269006-76bc-4068-96c6-227a07e11bb7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2961932c17be9fe0df451e0a160d0352d36bce1f02a824eea4e9188802861cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "902b1233-9101-45f4-8f78-4a78a0fdb558", "node_type": "1", "metadata": {"window": "The matters addressed in the statements are \nsubject to the risks and uncertainties that could cause actual results to differ materially from those projected or \nimplied.   Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d531c8a5ff004751fd20725829f2404402b0901dda84c96917dcf69aa5b34e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8fba7c2-c137-4daa-8fa3-dc320f9e5009", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "original_text": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n"}, "hash": "8a967def45ad986fc086f0c1267b99e0ec8894e92693f2617fc857bb373f15e1", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "start_char_idx": 1481, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8fba7c2-c137-4daa-8fa3-dc320f9e5009": {"__data__": {"id_": "d8fba7c2-c137-4daa-8fa3-dc320f9e5009", "embedding": null, "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "original_text": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74cc82c9-998c-464e-8b6b-287cf2b79b5c", "node_type": "1", "metadata": {"window": "Please refer to our  SEC filings and the forward -looking statements slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  During the discussion today, our comments, including an update to our FY20 outlook, will be on a non -GAAP \nbasis  unless they are specifically called out as GAAP.   GAAP -to-non-GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "original_text": "During the Q&A portion of today's call, we kindly ask that you limit yourself to one  question with one follow -up so \nthat we can try and get everyone an opportunity to ask a question.  \n ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6409e87d93037e63d8d03ed44396113474077eed83a0cadb3583f817f00153f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d37f99ee-f3e3-4385-a36e-b558c0128f4f", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.  ", "original_text": "Mike Kaufmann :  Good morning, and thanks for joining us.  "}, "hash": "37da6b16492ab0dc26be4af1fc6219b04a24f5eaa391663626b1d1a150f6878a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n", "start_char_idx": 0, "end_char_idx": 70, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d37f99ee-f3e3-4385-a36e-b558c0128f4f": {"__data__": {"id_": "d37f99ee-f3e3-4385-a36e-b558c0128f4f", "embedding": null, "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.  ", "original_text": "Mike Kaufmann :  Good morning, and thanks for joining us.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8fba7c2-c137-4daa-8fa3-dc320f9e5009", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "original_text": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fcb2e74e3d356201c22deaa7b6c601c4da1e56580f0064320cc3d09da6f5dee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3fea566-03c1-4c7f-8bb9-a8e1135f49fd", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  ", "original_text": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.  "}, "hash": "c5254224939bf4bb46168afde0451ae4767307618e65349e467a0b409e6b8bad", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Good morning, and thanks for joining us.  ", "start_char_idx": 70, "end_char_idx": 129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3fea566-03c1-4c7f-8bb9-a8e1135f49fd": {"__data__": {"id_": "f3fea566-03c1-4c7f-8bb9-a8e1135f49fd", "embedding": null, "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  ", "original_text": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d37f99ee-f3e3-4385-a36e-b558c0128f4f", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.  ", "original_text": "Mike Kaufmann :  Good morning, and thanks for joining us.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68d908086fdfbff572598c54e132b8429d385d6b1e50c7d491b4f03d37e5101b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e33f761-cf28-4a57-b335-75cbad2954e8", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n ", "original_text": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n "}, "hash": "86a52d80097c64273188521d6c63be3b773198f4c5f840977986097a02809a75", "class_name": "RelatedNodeInfo"}}, "text": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.  ", "start_char_idx": 129, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e33f761-cf28-4a57-b335-75cbad2954e8": {"__data__": {"id_": "2e33f761-cf28-4a57-b335-75cbad2954e8", "embedding": null, "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n ", "original_text": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3fea566-03c1-4c7f-8bb9-a8e1135f49fd", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  ", "original_text": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0c6e9392a18d083c7cc396cdcac996d947c183c4feb0844cc4467f22aeb638c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eb55bc8-ed9d-40f9-8893-ace50c047c8b", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n ", "original_text": "First and foremost we apologize to our customers and their patients.  "}, "hash": "cb14df69dff9e0f0923406efa43bc8ff72e8c8dda7abfc2e29d60e0ff78759f1", "class_name": "RelatedNodeInfo"}}, "text": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "start_char_idx": 382, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eb55bc8-ed9d-40f9-8893-ace50c047c8b": {"__data__": {"id_": "8eb55bc8-ed9d-40f9-8893-ace50c047c8b", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n ", "original_text": "First and foremost we apologize to our customers and their patients.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e33f761-cf28-4a57-b335-75cbad2954e8", "node_type": "1", "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n ", "original_text": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0be2e7b2b775a5554e5f1d29a526f018cf7f1c235e75754248468856b1da788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4800b25-2eb2-4cda-9481-4e4c85d163ac", "node_type": "1", "metadata": {"window": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  ", "original_text": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  "}, "hash": "4db6c4fa5fdf9a0595c24eb323b43165d02b4ff643e8fa38d0efb2cf075396c8", "class_name": "RelatedNodeInfo"}}, "text": "First and foremost we apologize to our customers and their patients.  ", "start_char_idx": 489, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4800b25-2eb2-4cda-9481-4e4c85d163ac": {"__data__": {"id_": "f4800b25-2eb2-4cda-9481-4e4c85d163ac", "embedding": null, "metadata": {"window": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  ", "original_text": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eb55bc8-ed9d-40f9-8893-ace50c047c8b", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n ", "original_text": "First and foremost we apologize to our customers and their patients.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25f18d4b1db498260ff6c4effb9b305dccd200043ff7155637084963932dbac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c15c8f24-c1c7-41f1-9c79-8c1890cddf22", "node_type": "1", "metadata": {"window": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n ", "original_text": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n "}, "hash": "e083fb9566f3ff34fd7f5caeb8c640e6f8efe6fcd9bb3ff55df20ce003956e83", "class_name": "RelatedNodeInfo"}}, "text": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  ", "start_char_idx": 559, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c15c8f24-c1c7-41f1-9c79-8c1890cddf22": {"__data__": {"id_": "c15c8f24-c1c7-41f1-9c79-8c1890cddf22", "embedding": null, "metadata": {"window": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n ", "original_text": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4800b25-2eb2-4cda-9481-4e4c85d163ac", "node_type": "1", "metadata": {"window": "Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  ", "original_text": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0fa7017faef332b3ebbfa9caec8f8de10d95205aa9b76e205c4cefd40562f92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95dc3cd4-efa1-4551-bdcf-b929ccc6cf5b", "node_type": "1", "metadata": {"window": "First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  ", "original_text": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n "}, "hash": "07ff1fdc239e76c55e9aed5b98fa43a7fcb829905fa7e2742a102198792d6592", "class_name": "RelatedNodeInfo"}}, "text": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n ", "start_char_idx": 671, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95dc3cd4-efa1-4551-bdcf-b929ccc6cf5b": {"__data__": {"id_": "95dc3cd4-efa1-4551-bdcf-b929ccc6cf5b", "embedding": null, "metadata": {"window": "First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  ", "original_text": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c15c8f24-c1c7-41f1-9c79-8c1890cddf22", "node_type": "1", "metadata": {"window": "The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n  First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n ", "original_text": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eba5a735ee0a5045cbb28ac759d7ff35c68b238406150fcd419f7b0f64c36805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "900d24f4-583f-45fe-a4a0-a773f4ba6b25", "node_type": "1", "metadata": {"window": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n ", "original_text": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  "}, "hash": "f32e1b29a4fee74e071cd28bd96c43de33a21f56fdea45002f8effff184598b1", "class_name": "RelatedNodeInfo"}}, "text": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n ", "start_char_idx": 761, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "900d24f4-583f-45fe-a4a0-a773f4ba6b25": {"__data__": {"id_": "900d24f4-583f-45fe-a4a0-a773f4ba6b25", "embedding": null, "metadata": {"window": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n ", "original_text": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95dc3cd4-efa1-4551-bdcf-b929ccc6cf5b", "node_type": "1", "metadata": {"window": "First and foremost we apologize to our customers and their patients.   We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  ", "original_text": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "756fe796defeffc84ea1be80cd30fc38aa0a9b60c2a958377184351b286033c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1f73120-8229-4a94-b3fe-7c161e2bfb79", "node_type": "1", "metadata": {"window": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  ", "original_text": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n "}, "hash": "94f12b4cfa84ab6db27ff6719f250a160a36499e6e96018d800268aac43e7cf6", "class_name": "RelatedNodeInfo"}}, "text": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  ", "start_char_idx": 968, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1f73120-8229-4a94-b3fe-7c161e2bfb79": {"__data__": {"id_": "d1f73120-8229-4a94-b3fe-7c161e2bfb79", "embedding": null, "metadata": {"window": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  ", "original_text": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "900d24f4-583f-45fe-a4a0-a773f4ba6b25", "node_type": "1", "metadata": {"window": "We understand the gravity of this situation \nand are dedicated to resolving this issue as quickly as possible.   Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n ", "original_text": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "705bd5b9fe11cb16d71241374d51e279f9b19287a565ebce26e9fed60c98c72b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abfc2837-c4da-4fe6-b677-ddefed700d69", "node_type": "1", "metadata": {"window": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  "}, "hash": "f6e75b8e113e5f385c502291ea9b8c3c2d4df88f4f7edeb37f38754883195029", "class_name": "RelatedNodeInfo"}}, "text": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n ", "start_char_idx": 1074, "end_char_idx": 1281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abfc2837-c4da-4fe6-b677-ddefed700d69": {"__data__": {"id_": "abfc2837-c4da-4fe6-b677-ddefed700d69", "embedding": null, "metadata": {"window": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1f73120-8229-4a94-b3fe-7c161e2bfb79", "node_type": "1", "metadata": {"window": "Simultaneously we are doing everything we can \nto prevent this from happening again.  \n \n  We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  ", "original_text": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48700930ad3154a6c55069829e583a1acd333934adc5fc8a58a2e4c3f89c7d5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dd1f6a2-0620-476f-b960-fcbc3cbf9fc9", "node_type": "1", "metadata": {"window": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n "}, "hash": "b8123a22a869b96ec9324e89c02ebd8035ea2fa8de3ddd19cea86e293cfeeaff", "class_name": "RelatedNodeInfo"}}, "text": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  ", "start_char_idx": 1281, "end_char_idx": 1391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dd1f6a2-0620-476f-b960-fcbc3cbf9fc9": {"__data__": {"id_": "9dd1f6a2-0620-476f-b960-fcbc3cbf9fc9", "embedding": null, "metadata": {"window": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abfc2837-c4da-4fe6-b677-ddefed700d69", "node_type": "1", "metadata": {"window": "We are engaging third -party experts to conduct a comprehensive review of our quality assurance processes and \nbusiness practices and we are committed to executing correcti ve and preventative actions.  \n \n  As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fbb106ed2a1a135ded0c89bea82f077d98332390f3e89d442513720f649bdd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e6fe5f8-6aca-4140-b280-601e330bc3d2", "node_type": "1", "metadata": {"window": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  "}, "hash": "7c5f1a0af340099cc295db9715be75fec75550078d8f142834bb337bd0442092", "class_name": "RelatedNodeInfo"}}, "text": "This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n ", "start_char_idx": 1391, "end_char_idx": 1503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e6fe5f8-6aca-4140-b280-601e330bc3d2": {"__data__": {"id_": "8e6fe5f8-6aca-4140-b280-601e330bc3d2", "embedding": null, "metadata": {"window": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dd1f6a2-0620-476f-b960-fcbc3cbf9fc9", "node_type": "1", "metadata": {"window": "As we shared last week related to these recalls we recorded a $96 million charge in our Q2 GAAP results.   This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71c31324e875a9b65ca93135fed369021a717d8fdf311506e20435fa1a1dc4a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc1913d-dc30-40de-9adc-6df0a0fdd418", "node_type": "1", "metadata": {"window": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  "}, "hash": "5ba8dfb278f71f5a68fdc48245552b356b304b7a00195b54806d8239f0532e1e", "class_name": "RelatedNodeInfo"}}, "text": "On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  ", "start_char_idx": 1503, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc1913d-dc30-40de-9adc-6df0a0fdd418": {"__data__": {"id_": "2bc1913d-dc30-40de-9adc-6df0a0fdd418", "embedding": null, "metadata": {"window": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01561c28043b132ea41050d9c2dd4a943817c7b5fe23974c2959afb50b6e0a11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e6fe5f8-6aca-4140-b280-601e330bc3d2", "node_type": "1", "metadata": {"window": "This \ncharge represents our best estimate of cost for the recalls, including inventory write -offs as well as certain \nremediation and supply disruption costs such as cost to replace recalled products.  \n \n  To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8b922d500bb66fb23c5a1abfdb39437145ea8009a6462fc760d00cc18b957f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2efd8089-b1a5-42fd-9522-5e3bb253d199", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "original_text": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n"}, "hash": "07cc5c3a8db2edc1cf954be18b482476e7da06ba5df5ce798a100398aff5e457", "class_name": "RelatedNodeInfo"}}, "text": "All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "start_char_idx": 1640, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2efd8089-b1a5-42fd-9522-5e3bb253d199": {"__data__": {"id_": "2efd8089-b1a5-42fd-9522-5e3bb253d199", "embedding": null, "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "original_text": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc1913d-dc30-40de-9adc-6df0a0fdd418", "node_type": "1", "metadata": {"window": "To provide some clarity, $56 million of this is within cost of products sold and $40 million is within SG&A.   This \ncharge and any future adjustments made to it will be exclud ed from our non -GAAP financial results.  \n \n  On behalf of the entire Cardinal Health leadership team, I would like to thank our employees for their dedication \nand tireless effort.   All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "original_text": "All of us, myself included, are focused on resolving this issue as quickly as possible for our \ncustomers and their patients.  ", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa9320251337d34ccb623ade0b98609c23508d6163d286c93670dcfb08ed1450", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17034fbe-c1c9-4666-84a7-0a67f7b75ae9", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  ", "original_text": "David Evans :  Thanks, Mike.  "}, "hash": "1eef4701531808eb79a2fcac622dedc8355da48aae8765abf1dd5ac00ec0a1b3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n", "start_char_idx": 0, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17034fbe-c1c9-4666-84a7-0a67f7b75ae9": {"__data__": {"id_": "17034fbe-c1c9-4666-84a7-0a67f7b75ae9", "embedding": null, "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  ", "original_text": "David Evans :  Thanks, Mike.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2efd8089-b1a5-42fd-9522-5e3bb253d199", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "original_text": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d89d0429043034a72f1f650d9ff341725959ae077444faeb887c920b97a215", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8d46667-a64f-4b02-b362-dcea7e4ffa45", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n ", "original_text": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.  "}, "hash": "71a9d7493f0c611f254c3bcadc1fbb429e6084977a65a7844cef64d4bff221b4", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Thanks, Mike.  ", "start_char_idx": 179, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8d46667-a64f-4b02-b362-dcea7e4ffa45": {"__data__": {"id_": "e8d46667-a64f-4b02-b362-dcea7e4ffa45", "embedding": null, "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n ", "original_text": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17034fbe-c1c9-4666-84a7-0a67f7b75ae9", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  ", "original_text": "David Evans :  Thanks, Mike.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00e208c48b9084074eeeea864ba402806d229a7c0cebb8a12b8eba5d554b0c5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85b50308-1d45-411b-875a-b57527220867", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.  ", "original_text": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n "}, "hash": "eb8559db08ec9cffbd9f173f32bd5d4e2587ac5fe410b22af9ed1fa2b85c1afd", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.  ", "start_char_idx": 209, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85b50308-1d45-411b-875a-b57527220867": {"__data__": {"id_": "85b50308-1d45-411b-875a-b57527220867", "embedding": null, "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.  ", "original_text": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8d46667-a64f-4b02-b362-dcea7e4ffa45", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n ", "original_text": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "677ae63e64ae1601ffe05e81e11623c801c69ccce2950f857a072758fb83ab11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5505e726-4674-4007-adbe-4b28af49a1c0", "node_type": "1", "metadata": {"window": "David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  ", "original_text": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  "}, "hash": "b97388f4bc480d23e5f89bea40b555fdfb25b0d6b27bf22c7d58972093d9b3f2", "class_name": "RelatedNodeInfo"}}, "text": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "start_char_idx": 344, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5505e726-4674-4007-adbe-4b28af49a1c0": {"__data__": {"id_": "5505e726-4674-4007-adbe-4b28af49a1c0", "embedding": null, "metadata": {"window": "David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  ", "original_text": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85b50308-1d45-411b-875a-b57527220867", "node_type": "1", "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.  ", "original_text": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "813f54da8819d28f3280d8b5b04a9697831c7ab7d9a847d6268272ac89ccf856", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06148208-620c-4638-8a66-736166bf947b", "node_type": "1", "metadata": {"window": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  ", "original_text": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n "}, "hash": "d320b88d9cdf089a1b8e08af05c3a6db7e4663c7b3cd910155163834cc657e03", "class_name": "RelatedNodeInfo"}}, "text": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  ", "start_char_idx": 439, "end_char_idx": 603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06148208-620c-4638-8a66-736166bf947b": {"__data__": {"id_": "06148208-620c-4638-8a66-736166bf947b", "embedding": null, "metadata": {"window": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  ", "original_text": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5505e726-4674-4007-adbe-4b28af49a1c0", "node_type": "1", "metadata": {"window": "David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  ", "original_text": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46219f5459c53594dd2f7d48dfaa174478b8b2624817d22072776a86a9a2839e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a7608f4-2a6f-4a17-b2be-635769ec8ae4", "node_type": "1", "metadata": {"window": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n ", "original_text": "SG&A  increased 3% to $1.1 billion.  "}, "hash": "e66c9119124bd1461a5cdc0ef30ee599e311407dd611e3434480034ae5b7d733", "class_name": "RelatedNodeInfo"}}, "text": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n ", "start_char_idx": 603, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a7608f4-2a6f-4a17-b2be-635769ec8ae4": {"__data__": {"id_": "9a7608f4-2a6f-4a17-b2be-635769ec8ae4", "embedding": null, "metadata": {"window": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n ", "original_text": "SG&A  increased 3% to $1.1 billion.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06148208-620c-4638-8a66-736166bf947b", "node_type": "1", "metadata": {"window": "I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  ", "original_text": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f24e0ff1982ea52d9cfc8a61ae6027ef98b75a382d502f017f3046dcc211eeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac88de4f-5d0e-4f7d-9b12-301c6a4f06d5", "node_type": "1", "metadata": {"window": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  ", "original_text": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  "}, "hash": "32d4082e6cd9515383e1d56971e9449c164c7c71ec52c37731db6024b8374797", "class_name": "RelatedNodeInfo"}}, "text": "SG&A  increased 3% to $1.1 billion.  ", "start_char_idx": 753, "end_char_idx": 790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac88de4f-5d0e-4f7d-9b12-301c6a4f06d5": {"__data__": {"id_": "ac88de4f-5d0e-4f7d-9b12-301c6a4f06d5", "embedding": null, "metadata": {"window": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  ", "original_text": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a7608f4-2a6f-4a17-b2be-635769ec8ae4", "node_type": "1", "metadata": {"window": "In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n  This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n ", "original_text": "SG&A  increased 3% to $1.1 billion.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "884aedbb62c36e830dc633972dfcf7f2decbbf74213caf6b070060f7614fdfb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcd8d0e0-4462-462c-a080-1814eb4e847b", "node_type": "1", "metadata": {"window": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n ", "original_text": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  "}, "hash": "cdb7b313fdcc6629fc67d818c34e8c46586c8e76b457bd6ecdd2251202cd186e", "class_name": "RelatedNodeInfo"}}, "text": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  ", "start_char_idx": 790, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcd8d0e0-4462-462c-a080-1814eb4e847b": {"__data__": {"id_": "dcd8d0e0-4462-462c-a080-1814eb4e847b", "embedding": null, "metadata": {"window": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n ", "original_text": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac88de4f-5d0e-4f7d-9b12-301c6a4f06d5", "node_type": "1", "metadata": {"window": "This result exceeded our expectations and was driven by a combination of operating and non -operating activities, \nwhich I'll elaborate on the comments to follow.   Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  ", "original_text": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c40fb14a11806e2cccdd080f71acfa3f6a7130089e21470cfa585f6fadd5a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fadea879-ae05-44f9-a8b1-2816e96a9161", "node_type": "1", "metadata": {"window": "SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n "}, "hash": "749c163f9029680a3b0f2aff49a04872ed63681c3bfce8f73374231259df474f", "class_name": "RelatedNodeInfo"}}, "text": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  ", "start_char_idx": 914, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fadea879-ae05-44f9-a8b1-2816e96a9161": {"__data__": {"id_": "fadea879-ae05-44f9-a8b1-2816e96a9161", "embedding": null, "metadata": {"window": "SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcd8d0e0-4462-462c-a080-1814eb4e847b", "node_type": "1", "metadata": {"window": "Total company revenue increased 5% versus last year to $39.7 \nbillion and consolidated gross margin increased 2% from last year to $1.8 billion.  \n \n  SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n ", "original_text": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "170657f82f08701b1a86114c199f961f62c864cdcd53cb76b06093242e085a46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97539298-8ccb-40dc-8fd6-05e4800865ad", "node_type": "1", "metadata": {"window": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  "}, "hash": "4fd29a74e8240deef76cfd940f6f25cc84d86f04a443d1496cd0db765911bd48", "class_name": "RelatedNodeInfo"}}, "text": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n ", "start_char_idx": 1009, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97539298-8ccb-40dc-8fd6-05e4800865ad": {"__data__": {"id_": "97539298-8ccb-40dc-8fd6-05e4800865ad", "embedding": null, "metadata": {"window": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fadea879-ae05-44f9-a8b1-2816e96a9161", "node_type": "1", "metadata": {"window": "SG&A  increased 3% to $1.1 billion.   This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e3007f585ccb63b532acee033ab4343d064e8ceffa73e25e5525429e6f4835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93b7c70d-0f8b-47a2-be4b-001a5dbd197e", "node_type": "1", "metadata": {"window": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n "}, "hash": "369f4aff16b81e0d7e604265a982a3c07af3e670d5bb8febfa2927c6af6be854", "class_name": "RelatedNodeInfo"}}, "text": "Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  ", "start_char_idx": 1134, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93b7c70d-0f8b-47a2-be4b-001a5dbd197e": {"__data__": {"id_": "93b7c70d-0f8b-47a2-be4b-001a5dbd197e", "embedding": null, "metadata": {"window": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97539298-8ccb-40dc-8fd6-05e4800865ad", "node_type": "1", "metadata": {"window": "This increase was driven by higher cost to support sales growth and by \nfluctuations in deferred compensation liabilities.   These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.  ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c5906314b9aa1d72fcd627d4d919b83774a48b58856a2feef68271d63e6b74e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5591788-d47a-4280-9aa1-4f814fc40ccc", "node_type": "1", "metadata": {"window": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n "}, "hash": "a8dc5a8ebb3372dd95fa9e04efa3699db4f203d7d2708f0f4b5622568ddf6639", "class_name": "RelatedNodeInfo"}}, "text": "This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n ", "start_char_idx": 1236, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5591788-d47a-4280-9aa1-4f814fc40ccc": {"__data__": {"id_": "c5591788-d47a-4280-9aa1-4f814fc40ccc", "embedding": null, "metadata": {"window": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e668a104c30b902f0b079e01b91d661d801f2eca72be205ca16a48b3b42367b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93b7c70d-0f8b-47a2-be4b-001a5dbd197e", "node_type": "1", "metadata": {"window": "These items were partially offset by the benefits of enterprise -\nwide cost savings measures.   The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4799ac6693b20869ea8685fad948e68129b82a72f0a0d52c3dfa20dbac22cf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a4d9317-a608-4c80-8602-ea2bbeb0eae6", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "original_text": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.  "}, "hash": "9432c6aa3c1d1f3320ffa5ba1acdbc93e52b6e0ca74b2128dc69fa0d06751769", "class_name": "RelatedNodeInfo"}}, "text": "Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "start_char_idx": 1412, "end_char_idx": 1563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a4d9317-a608-4c80-8602-ea2bbeb0eae6": {"__data__": {"id_": "8a4d9317-a608-4c80-8602-ea2bbeb0eae6", "embedding": null, "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "original_text": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5591788-d47a-4280-9aa1-4f814fc40ccc", "node_type": "1", "metadata": {"window": "The net result for the quarter was consolidated operating earnings of $646 million, a \n1% increase from the prior year.  \n \n  Moving below operating earnings, interest and other income and expense decreased 48% to $51 million.   This \nwas primarily driven by the change i n value of deferred compensation plan investments and lower interest \nexpense as we continue to execute our deleveraging plans.  \n \n  Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "original_text": "Of note in the quarter, we paid down more than $700 million of long -term debt and have now paid down nearly \n$800 million throug h the first half.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60e57f00a3c9313cc1f9071ef3f0410adfaf49ce09fb8fc18a6fc5c54142e660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7665f24c-6ff2-4430-b2db-cb95aeaf3d4a", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n ", "original_text": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n "}, "hash": "8fb00775464f5991e2db277ea2d4fda84646aeeefa701e17b14eda5afaa5e3cf", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.  ", "start_char_idx": 0, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7665f24c-6ff2-4430-b2db-cb95aeaf3d4a": {"__data__": {"id_": "7665f24c-6ff2-4430-b2db-cb95aeaf3d4a", "embedding": null, "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n ", "original_text": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a4d9317-a608-4c80-8602-ea2bbeb0eae6", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "original_text": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9df6b245af84209509abc954cebf451109f6875f2412f419da1ca0b1b75cbe3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c018158f-5d0a-433b-8bed-9f39829de3b6", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.  ", "original_text": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.  "}, "hash": "cdeb22632ce72b02eff3087f4c608215e053874d2a2822d586544195eb04bdd4", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n ", "start_char_idx": 199, "end_char_idx": 296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c018158f-5d0a-433b-8bed-9f39829de3b6": {"__data__": {"id_": "c018158f-5d0a-433b-8bed-9f39829de3b6", "embedding": null, "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.  ", "original_text": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7665f24c-6ff2-4430-b2db-cb95aeaf3d4a", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n ", "original_text": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b719b0cdd644b7bc6c70788ad750f40c584edf923cd05320d7c4293a78aabbd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7a2c38a-6e29-42bc-af46-01beb44b301e", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.  ", "original_text": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  "}, "hash": "4d358f0496d5e3891827e148572fa90de4bc3628f9e18b58740a39ae228bb08e", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.  ", "start_char_idx": 296, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7a2c38a-6e29-42bc-af46-01beb44b301e": {"__data__": {"id_": "c7a2c38a-6e29-42bc-af46-01beb44b301e", "embedding": null, "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.  ", "original_text": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c018158f-5d0a-433b-8bed-9f39829de3b6", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.  ", "original_text": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37d79e22ec2e02eb917596d08f7c1bd368f34df97f214f7f37fc26e3e7ad9bb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edbfe7a8-48e1-48a5-b28a-b719a912c9f3", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  ", "original_text": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n "}, "hash": "6757e7163f437e6916c88d57f577c8d28c6c1fbee520e96101ae93fbbaf62338", "class_name": "RelatedNodeInfo"}}, "text": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "start_char_idx": 401, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edbfe7a8-48e1-48a5-b28a-b719a912c9f3": {"__data__": {"id_": "edbfe7a8-48e1-48a5-b28a-b719a912c9f3", "embedding": null, "metadata": {"window": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  ", "original_text": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7a2c38a-6e29-42bc-af46-01beb44b301e", "node_type": "1", "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.  ", "original_text": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e16a3dd8a65e99295be47801648b50d90cbbd74130df5c39cf955e7d9fd8ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe59a99f-c01d-4299-93b0-d44b54b7e5a1", "node_type": "1", "metadata": {"window": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n ", "original_text": "Moving on to cash flow.  "}, "hash": "6b6e8393500692faef1a55dbbd2fa93360e9efac7c29c143b5fbf4d9db861d50", "class_name": "RelatedNodeInfo"}}, "text": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n ", "start_char_idx": 503, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe59a99f-c01d-4299-93b0-d44b54b7e5a1": {"__data__": {"id_": "fe59a99f-c01d-4299-93b0-d44b54b7e5a1", "embedding": null, "metadata": {"window": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n ", "original_text": "Moving on to cash flow.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edbfe7a8-48e1-48a5-b28a-b719a912c9f3", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  ", "original_text": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35d100ec5bea48d77a80f7b67078267eaf03bc98d90abd95edf728d2a02c72e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95c73c0e-c246-462a-88df-6c67f5ecf8d3", "node_type": "1", "metadata": {"window": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  ", "original_text": "Operating cash flow for the quarter was approximately $700 million.  "}, "hash": "f6a25657f767a3c1353fd1993c440a966c5b4668af11ca98ed86d4d1fe231bdb", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to cash flow.  ", "start_char_idx": 598, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95c73c0e-c246-462a-88df-6c67f5ecf8d3": {"__data__": {"id_": "95c73c0e-c246-462a-88df-6c67f5ecf8d3", "embedding": null, "metadata": {"window": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  ", "original_text": "Operating cash flow for the quarter was approximately $700 million.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe59a99f-c01d-4299-93b0-d44b54b7e5a1", "node_type": "1", "metadata": {"window": "During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n ", "original_text": "Moving on to cash flow.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a19aa39d82363b94f9eed344e19bc1a2d3dfb906ca8f404fc5a5aa3539023a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91cee9b6-16ab-432f-8c2b-957463065708", "node_type": "1", "metadata": {"window": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n ", "original_text": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  "}, "hash": "4a431028970f8977442321c521ac6ea4e50cb0c602cae9d72e059b564cd3a230", "class_name": "RelatedNodeInfo"}}, "text": "Operating cash flow for the quarter was approximately $700 million.  ", "start_char_idx": 623, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91cee9b6-16ab-432f-8c2b-957463065708": {"__data__": {"id_": "91cee9b6-16ab-432f-8c2b-957463065708", "embedding": null, "metadata": {"window": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n ", "original_text": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95c73c0e-c246-462a-88df-6c67f5ecf8d3", "node_type": "1", "metadata": {"window": "We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.   W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  ", "original_text": "Operating cash flow for the quarter was approximately $700 million.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e3bb802c57a7ff169d12fa1b7b23c67d0f12fa63ea939b007e1df9dd740aeb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3676df2-f7fa-45ed-88c4-fdf3a619e3a0", "node_type": "1", "metadata": {"window": "Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  ", "original_text": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n "}, "hash": "e57ec77fafa323f702dec473e849b745c2a7ea1ca1f948fbf15e2226e570bbe8", "class_name": "RelatedNodeInfo"}}, "text": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  ", "start_char_idx": 692, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3676df2-f7fa-45ed-88c4-fdf3a619e3a0": {"__data__": {"id_": "e3676df2-f7fa-45ed-88c4-fdf3a619e3a0", "embedding": null, "metadata": {"window": "Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  ", "original_text": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91cee9b6-16ab-432f-8c2b-957463065708", "node_type": "1", "metadata": {"window": "W e now have \n$943 million remaining under our board authorized share repurchase program.  \n \n  Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n ", "original_text": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e921c8a03b89bb12bd4261d0030649bf16832e09b4dc4f6bb4f2674d7e14848e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d482e3a-9ba6-4682-b227-0f7881ae843f", "node_type": "1", "metadata": {"window": "Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n ", "original_text": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  "}, "hash": "8cc514a7139facaa7f59d2f37052d3f69d5b67d7416032113e70f9fc0b671dbd", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n ", "start_char_idx": 802, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d482e3a-9ba6-4682-b227-0f7881ae843f": {"__data__": {"id_": "3d482e3a-9ba6-4682-b227-0f7881ae843f", "embedding": null, "metadata": {"window": "Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n ", "original_text": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3676df2-f7fa-45ed-88c4-fdf3a619e3a0", "node_type": "1", "metadata": {"window": "Moving on to cash flow.   Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  ", "original_text": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "250a8c6b23e023332dffd87b8507345eb36ae850632744cc2ddec0eb4bd38b5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "915a6a4e-5397-44f6-9b7c-72159c25ca8e", "node_type": "1", "metadata": {"window": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  ", "original_text": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n "}, "hash": "eaeeaef6d63a4bfb0667a3162045d011b4f889fa4ae6f45fe3f2f5a4805084c8", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  ", "start_char_idx": 928, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "915a6a4e-5397-44f6-9b7c-72159c25ca8e": {"__data__": {"id_": "915a6a4e-5397-44f6-9b7c-72159c25ca8e", "embedding": null, "metadata": {"window": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  ", "original_text": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d482e3a-9ba6-4682-b227-0f7881ae843f", "node_type": "1", "metadata": {"window": "Operating cash flow for the quarter was approximately $700 million.   We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n ", "original_text": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f6d522317d4b54eeabfa0775478013633d3aee83ff5ff2a14ca692b6a246005", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d641e702-896e-42c8-8e7f-1f4a0557ce53", "node_type": "1", "metadata": {"window": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  "}, "hash": "2e800ba3dc6fd5c3390545c8b75a418ed667e0f2e4111e3eda078782714ac2a3", "class_name": "RelatedNodeInfo"}}, "text": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n ", "start_char_idx": 1061, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d641e702-896e-42c8-8e7f-1f4a0557ce53": {"__data__": {"id_": "d641e702-896e-42c8-8e7f-1f4a0557ce53", "embedding": null, "metadata": {"window": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "915a6a4e-5397-44f6-9b7c-72159c25ca8e", "node_type": "1", "metadata": {"window": "We ended the \nquarter with a cash balance of $1.7 billion, which included $788 million held outside the U.S.   As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  ", "original_text": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f4fcb9d752a05cba883fed0a3f24ba6dc48d7d13b8f0a305d9cc14cd7dd6f6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9edf9ed-fee5-4d67-94ad-6dba19dbd68f", "node_type": "1", "metadata": {"window": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n "}, "hash": "e4f95071544b5dfd6024909d6fbcc9d020b9dab542b70adaa6ec593a8a35af11", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  ", "start_char_idx": 1201, "end_char_idx": 1300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9edf9ed-fee5-4d67-94ad-6dba19dbd68f": {"__data__": {"id_": "e9edf9ed-fee5-4d67-94ad-6dba19dbd68f", "embedding": null, "metadata": {"window": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d641e702-896e-42c8-8e7f-1f4a0557ce53", "node_type": "1", "metadata": {"window": "As a reminder, \ntiming, in particular, the day of the week in which the quarter ends, affects point -in-time cash flows.  \n \n  Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b1bcc8a8885fb72c6f55466633066b41907ca837ca8ae00d8e451b45e84eb07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b01bc1c-0503-471f-a048-01c5d584b86f", "node_type": "1", "metadata": {"window": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  "}, "hash": "8416aeabab84087a44bed37e3351cfbc69279b71bfdf8b121dd82cebdbd0c725", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n ", "start_char_idx": 1300, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b01bc1c-0503-471f-a048-01c5d584b86f": {"__data__": {"id_": "9b01bc1c-0503-471f-a048-01c5d584b86f", "embedding": null, "metadata": {"window": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9edf9ed-fee5-4d67-94ad-6dba19dbd68f", "node_type": "1", "metadata": {"window": "Moving on to segment results, starting with pharma, we were encouraged to see positive momentum acr oss many \nareas of the segment.   Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f6b567b02651c82dc3ea7dccb8877cf75be967c284483e340e6349083a42a5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad9d15d2-065e-4b98-93f3-98d0ff335382", "node_type": "1", "metadata": {"window": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "At \nthe same time we continue to see strong growth in our specialty solutions business.  \n "}, "hash": "70e8a821cf5c9fe59147faa45c8f28f6a9f9aba7064dd5c2970155ff5f969cf6", "class_name": "RelatedNodeInfo"}}, "text": "For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  ", "start_char_idx": 1431, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad9d15d2-065e-4b98-93f3-98d0ff335382": {"__data__": {"id_": "ad9d15d2-065e-4b98-93f3-98d0ff335382", "embedding": null, "metadata": {"window": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae718e34d51f7a0773c6fddb573fc642bacf366bb2af8bf4f30a953d8074ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b01bc1c-0503-471f-a048-01c5d584b86f", "node_type": "1", "metadata": {"window": "Segment revenue increased 6% to $35.7 billion, driven by growth in our pharmaceutical \ndistribution and specialty solutions divisions.  \n \n  Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c22eac4b993b992c5f7d529edec25bff4fd45c4b9a3d87ca9d3a0634880fa42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e70f41c-210b-4726-b677-330da84243ce", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "original_text": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.  "}, "hash": "ec0d10c65d1fa288144ef03aebc26abc1ec9328ef8d9c1b90ca310e505207ec7", "class_name": "RelatedNodeInfo"}}, "text": "At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "start_char_idx": 1544, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e70f41c-210b-4726-b677-330da84243ce": {"__data__": {"id_": "9e70f41c-210b-4726-b677-330da84243ce", "embedding": null, "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "original_text": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad9d15d2-065e-4b98-93f3-98d0ff335382", "node_type": "1", "metadata": {"window": "Segment profit increased 4% to $462 million, with our generics program being the largest  driver.   As a reminder, \nwhat we refer to as our generics program includes sourcing, sell -side pricing, volume and new item launches.  \n \n  For the first time in several quarters, our generics program reverted from a net earnings headwind to tailwind.   At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "original_text": "At \nthe same time we continue to see strong growth in our specialty solutions business.  \n ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dafbba24e9bf68f30fedd9d99cd3f21b299901c0a23a8363735c8c5021d5fe27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "654a15b8-1a06-4aae-b809-a82a4ef0c1ae", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n ", "original_text": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n "}, "hash": "c58a8585c5e18e5f4811df888ff4c44b2e6107825ebf1d678eeeefaebb3117f2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.  ", "start_char_idx": 0, "end_char_idx": 156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "654a15b8-1a06-4aae-b809-a82a4ef0c1ae": {"__data__": {"id_": "654a15b8-1a06-4aae-b809-a82a4ef0c1ae", "embedding": null, "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n ", "original_text": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e70f41c-210b-4726-b677-330da84243ce", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "original_text": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87a7456941cc63d4b3143c87254ce955a5d0b6fd1d5422269b5eb916f512778a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65541b51-b687-45a2-b299-037fea73e1d8", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.  ", "original_text": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.  "}, "hash": "ef3d8df6b9d926ba755ed6531da016d90006f298569a5d4162fdf75fd5f0ded3", "class_name": "RelatedNodeInfo"}}, "text": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n ", "start_char_idx": 156, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65541b51-b687-45a2-b299-037fea73e1d8": {"__data__": {"id_": "65541b51-b687-45a2-b299-037fea73e1d8", "embedding": null, "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.  ", "original_text": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "654a15b8-1a06-4aae-b809-a82a4ef0c1ae", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n ", "original_text": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "212e75befb7687fc313f68d8ad72fa601854dbe228ea91a67ccf156f63125739", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74606245-fac7-4c2a-b8cb-c5cecf747ab8", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n ", "original_text": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  "}, "hash": "2cae27a5e72712aad4db3b82ca73087375330b0facffab3307c738c4f84a79ed", "class_name": "RelatedNodeInfo"}}, "text": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.  ", "start_char_idx": 251, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74606245-fac7-4c2a-b8cb-c5cecf747ab8": {"__data__": {"id_": "74606245-fac7-4c2a-b8cb-c5cecf747ab8", "embedding": null, "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n ", "original_text": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65541b51-b687-45a2-b299-037fea73e1d8", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.  ", "original_text": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4be71a29c244dee7a0b01753a018a63d5ce1c8ea6d6f7730721dc0a0e99d14b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f48e45-b4af-465c-990d-cd25be88e443", "node_type": "1", "metadata": {"window": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.  ", "original_text": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n "}, "hash": "6a0c6391feb9b5dc8cafef6b6e065f6f60badca935ba74b87c3d3f6772d305d2", "class_name": "RelatedNodeInfo"}}, "text": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "start_char_idx": 340, "end_char_idx": 430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f48e45-b4af-465c-990d-cd25be88e443": {"__data__": {"id_": "f4f48e45-b4af-465c-990d-cd25be88e443", "embedding": null, "metadata": {"window": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.  ", "original_text": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74606245-fac7-4c2a-b8cb-c5cecf747ab8", "node_type": "1", "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n ", "original_text": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa5ed769e8b2dfa8827fd5c7b3beb47720ed5cabcee4e6bb73538b0d99000377", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2241410-6956-47fb-827e-09435c5c62e9", "node_type": "1", "metadata": {"window": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  ", "original_text": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.  "}, "hash": "1872161b2621d771ca4b96838abdfcc841f6ad87ad984a4acaecbf3693d223e0", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n ", "start_char_idx": 430, "end_char_idx": 543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2241410-6956-47fb-827e-09435c5c62e9": {"__data__": {"id_": "a2241410-6956-47fb-827e-09435c5c62e9", "embedding": null, "metadata": {"window": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  ", "original_text": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f48e45-b4af-465c-990d-cd25be88e443", "node_type": "1", "metadata": {"window": "These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.  ", "original_text": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e9a33892cdea08f803d5f9af4651888ff51a5fe8be24c97e70ff51a1cd7e8aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfb532a1-6963-42d3-bf05-8b2895076cb7", "node_type": "1", "metadata": {"window": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.  ", "original_text": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n "}, "hash": "4575012cb4ed1a8c27b7f3f14528bde2c0ec36a53e882cd2f7165dfcd584f9de", "class_name": "RelatedNodeInfo"}}, "text": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.  ", "start_char_idx": 543, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfb532a1-6963-42d3-bf05-8b2895076cb7": {"__data__": {"id_": "cfb532a1-6963-42d3-bf05-8b2895076cb7", "embedding": null, "metadata": {"window": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.  ", "original_text": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2241410-6956-47fb-827e-09435c5c62e9", "node_type": "1", "metadata": {"window": "Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  ", "original_text": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a5fb2c3d4d0056ebb06e77020a0374c05c039d83866e7ec572e6ac9d6dc2c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7abdc2fc-bcd1-4043-b0ca-1f9d712a5f07", "node_type": "1", "metadata": {"window": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n ", "original_text": "Medical segment profit increased 4% to $195 million.  "}, "hash": "af98cde0ea2d87c6db6e76120bb830fc48b87517ae3db742d951036e009f4417", "class_name": "RelatedNodeInfo"}}, "text": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n ", "start_char_idx": 637, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7abdc2fc-bcd1-4043-b0ca-1f9d712a5f07": {"__data__": {"id_": "7abdc2fc-bcd1-4043-b0ca-1f9d712a5f07", "embedding": null, "metadata": {"window": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n ", "original_text": "Medical segment profit increased 4% to $195 million.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfb532a1-6963-42d3-bf05-8b2895076cb7", "node_type": "1", "metadata": {"window": "Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.   As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.  ", "original_text": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a371db99793413a7c544fcfff1df4923bddfa2ba80a375a22cd4a9e8b12cc68f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b6fb996-61f4-456a-9cb9-e2cfb7c1d86b", "node_type": "1", "metadata": {"window": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.  ", "original_text": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  "}, "hash": "822ddd22f7b15dd1aa87361e09826026fd7a2680727292a1a54778fc2bb4ae6a", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment profit increased 4% to $195 million.  ", "start_char_idx": 797, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b6fb996-61f4-456a-9cb9-e2cfb7c1d86b": {"__data__": {"id_": "7b6fb996-61f4-456a-9cb9-e2cfb7c1d86b", "embedding": null, "metadata": {"window": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.  ", "original_text": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7abdc2fc-bcd1-4043-b0ca-1f9d712a5f07", "node_type": "1", "metadata": {"window": "As a reminder, products a nd distribution includes both \nCardinal Health brand and national brand products.  \n \n  Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n ", "original_text": "Medical segment profit increased 4% to $195 million.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9e21c4d32e90986cab04fd580665a15886af5111f4c554bb6e06dc093cdd912", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ee716d-d0f0-4f12-aef4-465847d41e11", "node_type": "1", "metadata": {"window": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  ", "original_text": "These benefits were partially offset by a \ndecline in products and distribution.  "}, "hash": "d57e5f8ba358750b23462074b732063e22e311de575455eaf15c533aa09e2b8e", "class_name": "RelatedNodeInfo"}}, "text": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  ", "start_char_idx": 851, "end_char_idx": 992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ee716d-d0f0-4f12-aef4-465847d41e11": {"__data__": {"id_": "34ee716d-d0f0-4f12-aef4-465847d41e11", "embedding": null, "metadata": {"window": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  ", "original_text": "These benefits were partially offset by a \ndecline in products and distribution.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b6fb996-61f4-456a-9cb9-e2cfb7c1d86b", "node_type": "1", "metadata": {"window": "Overall Cardinal Health brand volumes have lagged their expectations through the first half.   While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.  ", "original_text": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "235fde3837dc781b5a7a07a4f2e9b7d338a0e6cd8dfe1e99beb5872ce48c9c1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2188222-1bb2-4c2e-a64a-e2a083e1b3b7", "node_type": "1", "metadata": {"window": "Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n ", "original_text": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n "}, "hash": "7280785b2531ed32656d7e1a29335e92228ccd1d991e4b9f45eb19aa3fd90619", "class_name": "RelatedNodeInfo"}}, "text": "These benefits were partially offset by a \ndecline in products and distribution.  ", "start_char_idx": 992, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2188222-1bb2-4c2e-a64a-e2a083e1b3b7": {"__data__": {"id_": "a2188222-1bb2-4c2e-a64a-e2a083e1b3b7", "embedding": null, "metadata": {"window": "Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n ", "original_text": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ee716d-d0f0-4f12-aef4-465847d41e11", "node_type": "1", "metadata": {"window": "While we recognize \nwe still have progress to make, this validates the importanc e of our commercial initiatives, which Mike will discuss \nin his remarks.  \n \n  Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  ", "original_text": "These benefits were partially offset by a \ndecline in products and distribution.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92ffefe5e0a73ebb38092033b11bca355aed2a7d0f6961de2dc5e03cf3100fa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecacf74c-d7c8-4e04-b690-2573b50de193", "node_type": "1", "metadata": {"window": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  ", "original_text": "Moving now to our full -year outlook.  "}, "hash": "6e7db8d144380e7700ff5cc3ee65b6b27d967af616b27deb37399233b431d50e", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n ", "start_char_idx": 1074, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecacf74c-d7c8-4e04-b690-2573b50de193": {"__data__": {"id_": "ecacf74c-d7c8-4e04-b690-2573b50de193", "embedding": null, "metadata": {"window": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  ", "original_text": "Moving now to our full -year outlook.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2188222-1bb2-4c2e-a64a-e2a083e1b3b7", "node_type": "1", "metadata": {"window": "Medical segment profit increased 4% to $195 million.   This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n ", "original_text": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35971899ab223a865e144aaad2bf1c726f865a785ee2faa978ffe03e6515c77e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a2284bc-11fa-409c-8765-f0703b8550a5", "node_type": "1", "metadata": {"window": "These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  "}, "hash": "a6160dafb8444a264cf30170d46b1c073311ad52d80333f113b5f5ccb12bda61", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our full -year outlook.  ", "start_char_idx": 1168, "end_char_idx": 1207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a2284bc-11fa-409c-8765-f0703b8550a5": {"__data__": {"id_": "1a2284bc-11fa-409c-8765-f0703b8550a5", "embedding": null, "metadata": {"window": "These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecacf74c-d7c8-4e04-b690-2573b50de193", "node_type": "1", "metadata": {"window": "This reflects the benefits of ongoing initiatives to improve \nour cost structure, including work to optimize freight and IT rela tionships.   These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  ", "original_text": "Moving now to our full -year outlook.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec22dddd60a46eb41f30b9d65a9717c0aaad4fde5c16a1c628c5cec335cac57e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5df2e9a-bfbd-4cf4-b442-e3a814f55868", "node_type": "1", "metadata": {"window": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "I'll call out a few items contributing \nto this increase.  \n \n "}, "hash": "9d0d5e8d384543ceb58e9dcbed77754fabb8c5b1e6d1e7a385f1a7e5efa19aba", "class_name": "RelatedNodeInfo"}}, "text": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  ", "start_char_idx": 1207, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5df2e9a-bfbd-4cf4-b442-e3a814f55868": {"__data__": {"id_": "d5df2e9a-bfbd-4cf4-b442-e3a814f55868", "embedding": null, "metadata": {"window": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "I'll call out a few items contributing \nto this increase.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a2284bc-11fa-409c-8765-f0703b8550a5", "node_type": "1", "metadata": {"window": "These benefits were partially offset by a \ndecline in products and distribution.   Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d3d91b2bf588e1fcb941cbf6f8837398b958145faff8e09677a43c97b09cf27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ba9e8fd-007a-46bd-bcd9-9aed5e72acd7", "node_type": "1", "metadata": {"window": "Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  "}, "hash": "6d76d82ffa6660e6ab581836595c5ebdd84704d1df5cf7ccaa637cf70da6736e", "class_name": "RelatedNodeInfo"}}, "text": "I'll call out a few items contributing \nto this increase.  \n \n ", "start_char_idx": 1365, "end_char_idx": 1428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ba9e8fd-007a-46bd-bcd9-9aed5e72acd7": {"__data__": {"id_": "9ba9e8fd-007a-46bd-bcd9-9aed5e72acd7", "embedding": null, "metadata": {"window": "Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5df2e9a-bfbd-4cf4-b442-e3a814f55868", "node_type": "1", "metadata": {"window": "Medical segment profits are now up 13% compared to fiscal '19 on a year -to-\ndate basis.  \n \n  Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "I'll call out a few items contributing \nto this increase.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d520b8952d5ba44c6b140f512f9c8f2fb10bef0e5322fd44d92348034d33339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4311298d-1d98-4aaa-82df-5a8c7db921ba", "node_type": "1", "metadata": {"window": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  "}, "hash": "28156ede9db53aca5d109979910a6e163b3629842091b501bbbaab807a2dc0b2", "class_name": "RelatedNodeInfo"}}, "text": "First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  ", "start_char_idx": 1428, "end_char_idx": 1612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4311298d-1d98-4aaa-82df-5a8c7db921ba": {"__data__": {"id_": "4311298d-1d98-4aaa-82df-5a8c7db921ba", "embedding": null, "metadata": {"window": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69b4df08978f754bcebf22ba14434d1eb6903893875aa3c3fadab2a6093ae00", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ba9e8fd-007a-46bd-bcd9-9aed5e72acd7", "node_type": "1", "metadata": {"window": "Moving now to our full -year outlook.   With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f4a61cbf3bb2b306500f25bcd04e71ef630897cd5518837ad0a1b339903aacb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d3e7ce-7503-4c02-99eb-fed61ca75d84", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "original_text": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.  "}, "hash": "2483593cbe965f77d257039ec87c411d4d8b880977f8c405c042d3a655d7e34a", "class_name": "RelatedNodeInfo"}}, "text": "Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "start_char_idx": 1612, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d3e7ce-7503-4c02-99eb-fed61ca75d84": {"__data__": {"id_": "d7d3e7ce-7503-4c02-99eb-fed61ca75d84", "embedding": null, "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "original_text": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4311298d-1d98-4aaa-82df-5a8c7db921ba", "node_type": "1", "metadata": {"window": "With half the year behind us, we are  raising our full -year fiscal '20 EPS \nguidance to the range of $5.20 to $5.40 from the prior range of $4.85 to $5.10.   I'll call out a few items contributing \nto this increase.  \n \n  First, we now have additional clarity regarding external factors we mentioned last quarter that affect the \nenterprise, including brand inflation, the medical device tax and tariffs.   Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "original_text": "Also based on the sustained improved \ntrends in our generics program, we now expect the pharma segment to exceed our original expectations for the \nfull year.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a92b14d8ed47f74fd3a2d7c6d3bf1d5a77dc8bba1613ba145d8658f77cdebf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69f956e-1b37-498e-a626-8d46b318d6c8", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n ", "original_text": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.  "}, "hash": "2e816bff16dd28d1bfa9f7715ae35394807ab6526e1984cf66ea139214edac92", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.  ", "start_char_idx": 0, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69f956e-1b37-498e-a626-8d46b318d6c8": {"__data__": {"id_": "b69f956e-1b37-498e-a626-8d46b318d6c8", "embedding": null, "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n ", "original_text": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d3e7ce-7503-4c02-99eb-fed61ca75d84", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "original_text": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d8b2bd6757749c746a0e7c622c881b6eb15818f873316e776fde7a9c06076cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71216225-ff67-451c-a7fc-24a2d3dcec7a", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n ", "original_text": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n "}, "hash": "aa8adaa0b994ff1b09e0efdf3ddcb4b534bc247899230ca217f1e0956292c8ed", "class_name": "RelatedNodeInfo"}}, "text": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.  ", "start_char_idx": 118, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71216225-ff67-451c-a7fc-24a2d3dcec7a": {"__data__": {"id_": "71216225-ff67-451c-a7fc-24a2d3dcec7a", "embedding": null, "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n ", "original_text": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69f956e-1b37-498e-a626-8d46b318d6c8", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n ", "original_text": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb5a8eaf256af3724bd44317fbd05b894a555dbdd5349ab5df44326b6a6431e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1f3ef1d-49af-4630-b718-0f0721d9e423", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  ", "original_text": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  "}, "hash": "6ab42d6d33444ce4efade760d57d98c6dcbe00f5ce46229755c30bbd334419b6", "class_name": "RelatedNodeInfo"}}, "text": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n ", "start_char_idx": 285, "end_char_idx": 367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1f3ef1d-49af-4630-b718-0f0721d9e423": {"__data__": {"id_": "b1f3ef1d-49af-4630-b718-0f0721d9e423", "embedding": null, "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  ", "original_text": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71216225-ff67-451c-a7fc-24a2d3dcec7a", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n ", "original_text": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcb9ea9213b708810f8de9a4ef393f83082190ed2f4cf034d5ee3e2dd11b322f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7b0905-a523-4a12-b460-9700dfcf196c", "node_type": "1", "metadata": {"window": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n ", "original_text": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n "}, "hash": "6e900832c7ceaee10e066228941ccbf43345ccb96d9473718b017e0de6661211", "class_name": "RelatedNodeInfo"}}, "text": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "start_char_idx": 367, "end_char_idx": 575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7b0905-a523-4a12-b460-9700dfcf196c": {"__data__": {"id_": "4f7b0905-a523-4a12-b460-9700dfcf196c", "embedding": null, "metadata": {"window": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n ", "original_text": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1f3ef1d-49af-4630-b718-0f0721d9e423", "node_type": "1", "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  ", "original_text": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca1fe8b1cb6a666c95915a364fcd214a1d3ea8bb2e8df600fb18f97a7d501bec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ab418bb-93ee-4553-bf33-59e3d57b9751", "node_type": "1", "metadata": {"window": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  ", "original_text": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n "}, "hash": "db11481c3f2262b6f46fe78fa0a896386ecdad18ba5dfd695fb916cb85546fa7", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n ", "start_char_idx": 575, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ab418bb-93ee-4553-bf33-59e3d57b9751": {"__data__": {"id_": "2ab418bb-93ee-4553-bf33-59e3d57b9751", "embedding": null, "metadata": {"window": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  ", "original_text": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f7b0905-a523-4a12-b460-9700dfcf196c", "node_type": "1", "metadata": {"window": "First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n ", "original_text": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d3f212814d32d5e4ed259d788a4b61d8b1dc2db529a0791f4e2912f8da679bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e72c1b71-6ee3-4522-884f-c2daace298a0", "node_type": "1", "metadata": {"window": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n", "original_text": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  "}, "hash": "fe451641472f92e86fa1ab22c544e773ba05c31692b3fa2468e6d8626aee4aba", "class_name": "RelatedNodeInfo"}}, "text": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n ", "start_char_idx": 647, "end_char_idx": 846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e72c1b71-6ee3-4522-884f-c2daace298a0": {"__data__": {"id_": "e72c1b71-6ee3-4522-884f-c2daace298a0", "embedding": null, "metadata": {"window": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n", "original_text": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ab418bb-93ee-4553-bf33-59e3d57b9751", "node_type": "1", "metadata": {"window": "That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  ", "original_text": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec3d61bf2b9e6fd980aee99710fe0e11079a12e0a4de36b585185be4ec0ee19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32608809-57d6-40f4-ba57-d68f4c508285", "node_type": "1", "metadata": {"window": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n ", "original_text": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n "}, "hash": "eb821671b89f15a1bec84dd535572781e4f538565a501ba33fb212f90006e31e", "class_name": "RelatedNodeInfo"}}, "text": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  ", "start_char_idx": 846, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32608809-57d6-40f4-ba57-d68f4c508285": {"__data__": {"id_": "32608809-57d6-40f4-ba57-d68f4c508285", "embedding": null, "metadata": {"window": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n ", "original_text": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e72c1b71-6ee3-4522-884f-c2daace298a0", "node_type": "1", "metadata": {"window": "Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.   As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n", "original_text": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f379e43cf2e267d6a0eee22d99ca4de872b5200227884a9853d64ae7a65fd63c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f50dfd06-0867-4383-87d2-161e39bcfea0", "node_type": "1", "metadata": {"window": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  ", "original_text": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  "}, "hash": "abe658c3a91ca2f06380cfb4f456864a0ffa693aaa84a3a81404d747de7804ca", "class_name": "RelatedNodeInfo"}}, "text": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n ", "start_char_idx": 956, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f50dfd06-0867-4383-87d2-161e39bcfea0": {"__data__": {"id_": "f50dfd06-0867-4383-87d2-161e39bcfea0", "embedding": null, "metadata": {"window": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  ", "original_text": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32608809-57d6-40f4-ba57-d68f4c508285", "node_type": "1", "metadata": {"window": "As a reminder, these \nexpenses are recorded in our pharma segment.  \n \n  Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n ", "original_text": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "102505448d9c4bb72fb3557559460a33200da4d23647fa6da201cf4653b0cd8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a937a5e4-b0f4-4ccb-a8ff-35c104a0df40", "node_type": "1", "metadata": {"window": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n"}, "hash": "ffe6510ee82676e4ea1573ed7e70c52847fd8dea92da7a3ea7e61d061d6bdb6e", "class_name": "RelatedNodeInfo"}}, "text": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  ", "start_char_idx": 1047, "end_char_idx": 1205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a937a5e4-b0f4-4ccb-a8ff-35c104a0df40": {"__data__": {"id_": "a937a5e4-b0f4-4ccb-a8ff-35c104a0df40", "embedding": null, "metadata": {"window": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f50dfd06-0867-4383-87d2-161e39bcfea0", "node_type": "1", "metadata": {"window": "Third, on brand inflation, while the January price increases from our contingent vendors fell within the range of our \nexpectations, they continue to be a smaller dollar contribution each year.  \n \n  And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  ", "original_text": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e61e89759389944a84c6f1f759a998c2adde48872c4d57212799f04f2b2070d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4254c6bc-0172-48c4-ac96-a3ba5c2aa51d", "node_type": "1", "metadata": {"window": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n "}, "hash": "a2959e6aa9f8012709cf298ac3840e89c8cf5392d56b69dafd347b1af14e6820", "class_name": "RelatedNodeInfo"}}, "text": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n", "start_char_idx": 1205, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4254c6bc-0172-48c4-ac96-a3ba5c2aa51d": {"__data__": {"id_": "4254c6bc-0172-48c4-ac96-a3ba5c2aa51d", "embedding": null, "metadata": {"window": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a937a5e4-b0f4-4ccb-a8ff-35c104a0df40", "node_type": "1", "metadata": {"window": "And in medical, I'll remind you of the charge we took in the fourth quarter of fiscal '19 related to Cordis.   This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2add93dea82b575d73627c7b21209aa24a9c6fd987775781721dcf32194d683a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89268ee2-1d52-4b33-9ca8-56e7ce1d6149", "node_type": "1", "metadata": {"window": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  "}, "hash": "820ce57dc795de11865e7867a6a292746927a6c0e3754d17c03f05d5d9088cb4", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n ", "start_char_idx": 1393, "end_char_idx": 1497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89268ee2-1d52-4b33-9ca8-56e7ce1d6149": {"__data__": {"id_": "89268ee2-1d52-4b33-9ca8-56e7ce1d6149", "embedding": null, "metadata": {"window": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4254c6bc-0172-48c4-ac96-a3ba5c2aa51d", "node_type": "1", "metadata": {"window": "This will \naffect our year -over-year growth rate in the second half for the segment.  \n \n  Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca480e35561f77a115d3e8d9d888abcb6ea0c8aa00ed0e21163d2b0d549978c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d700dec-30f9-4d56-ab7f-d7f27979d5ee", "node_type": "1", "metadata": {"window": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "Given that we are halfway through the year, we've decided to narrow this range.  \n "}, "hash": "add0d622cd98eff792dd25f39f7701d1ba33b171cda76018940f665d5ad0eba0", "class_name": "RelatedNodeInfo"}}, "text": "Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  ", "start_char_idx": 1497, "end_char_idx": 1624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d700dec-30f9-4d56-ab7f-d7f27979d5ee": {"__data__": {"id_": "8d700dec-30f9-4d56-ab7f-d7f27979d5ee", "embedding": null, "metadata": {"window": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "Given that we are halfway through the year, we've decided to narrow this range.  \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "75493068-a001-47b5-a8af-1f802ca5060e", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63319674449edd0d0a244fa26861f4868bd1b357b7d6a8e964a5b65dd355acce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89268ee2-1d52-4b33-9ca8-56e7ce1d6149", "node_type": "1", "metadata": {"window": "Regarding the rest of our corporate assumptions, we now anticipate FY20 interest and other income and expense \nin the range of $260 million to $280 million.   This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a1d9d657d36f3093eb1db6b56cf63ed230afaf239121e17495eb2d6cc208c46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26bec142-c9e4-480d-9770-453a253474ef", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n", "original_text": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.  "}, "hash": "35a9cbfab4937562f7cf3bd854c3d71d159d178c5b9b4bb66e39d375cecdf566", "class_name": "RelatedNodeInfo"}}, "text": "Given that we are halfway through the year, we've decided to narrow this range.  \n ", "start_char_idx": 1624, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26bec142-c9e4-480d-9770-453a253474ef": {"__data__": {"id_": "26bec142-c9e4-480d-9770-453a253474ef", "embedding": null, "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n", "original_text": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d700dec-30f9-4d56-ab7f-d7f27979d5ee", "node_type": "1", "metadata": {"window": "This improvement is largely due to the favorability we've seen thus far \nwith our deferred compensatio n plan investments and the benefits of debt deleveraging that I mentioned earlier.  \n As a reminder, we plan to reduce outstanding long -term debt by at least $1 billion in fiscal '20.  \n \n  Finally we expect diluted weighted average shares to be in the range of 293 million to 296 million for the full fiscal \nyear.   Given that we are halfway through the year, we've decided to narrow this range.  \n ", "original_text": "Given that we are halfway through the year, we've decided to narrow this range.  \n ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fa5ca5bf35ac050964311ebb12326e911caef30139ecfd5d5b4cb5add19b35a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09d0c0be-5f1e-4107-91f0-7e2b610e95cc", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.  ", "original_text": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.  "}, "hash": "39356ca0a1edb10b2378779bb8ccd8d2536fb947086a4aed3eee926d39e199ec", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.  ", "start_char_idx": 0, "end_char_idx": 81, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09d0c0be-5f1e-4107-91f0-7e2b610e95cc": {"__data__": {"id_": "09d0c0be-5f1e-4107-91f0-7e2b610e95cc", "embedding": null, "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.  ", "original_text": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26bec142-c9e4-480d-9770-453a253474ef", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n", "original_text": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b112bf45146000a80e396c1dd3de942a1622a82c35a2836807d546b144517f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0915d9ea-3a5e-4fbe-86be-4d965c3598c1", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n ", "original_text": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n "}, "hash": "d93541a4d63021905d1aa8f3cd2ab21a1764408ef1194af4604788b9c2f8776b", "class_name": "RelatedNodeInfo"}}, "text": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.  ", "start_char_idx": 81, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0915d9ea-3a5e-4fbe-86be-4d965c3598c1": {"__data__": {"id_": "0915d9ea-3a5e-4fbe-86be-4d965c3598c1", "embedding": null, "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n ", "original_text": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09d0c0be-5f1e-4107-91f0-7e2b610e95cc", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.  ", "original_text": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8e06b7c31a21482550b1d7a9dee43c576508530f747f129acc3ec61a9740de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866a18dd-f803-4fb8-91ed-bfec821fd92c", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n ", "original_text": "With that, let me turn it back over to Mike.  \n \n"}, "hash": "4954a8fda2ab63c21f3aef6afae24fbd5d0948d8160a4bc2de38453fbc35688e", "class_name": "RelatedNodeInfo"}}, "text": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n ", "start_char_idx": 193, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866a18dd-f803-4fb8-91ed-bfec821fd92c": {"__data__": {"id_": "866a18dd-f803-4fb8-91ed-bfec821fd92c", "embedding": null, "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n ", "original_text": "With that, let me turn it back over to Mike.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0915d9ea-3a5e-4fbe-86be-4d965c3598c1", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n ", "original_text": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a30c07d7114860330b63ec0e134e509291ed022ae633e5b77575862994d8e661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aca32458-9f28-4913-bc89-e9d265351181", "node_type": "1", "metadata": {"window": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.  ", "original_text": "Mike Kaufmann :  Thanks, Dave.  "}, "hash": "4d8e9814ded7d5f1346952e0a61f84c6223b3e0386572093a9e575abc77c0c1a", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it back over to Mike.  \n \n", "start_char_idx": 294, "end_char_idx": 343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aca32458-9f28-4913-bc89-e9d265351181": {"__data__": {"id_": "aca32458-9f28-4913-bc89-e9d265351181", "embedding": null, "metadata": {"window": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.  ", "original_text": "Mike Kaufmann :  Thanks, Dave.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866a18dd-f803-4fb8-91ed-bfec821fd92c", "node_type": "1", "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n ", "original_text": "With that, let me turn it back over to Mike.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61b5f2bfd4bc0e818b3ba2b3948d57c7a1bed643b33bd7a7171326be001e03c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e06e0115-3042-4f67-bfd1-f0acdc5238cc", "node_type": "1", "metadata": {"window": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  ", "original_text": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n "}, "hash": "74f616f068b9d35d0b91c3f654727e5e8e7d212c0cb9ffc27c547b2d27c43ab8", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Thanks, Dave.  ", "start_char_idx": 343, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e06e0115-3042-4f67-bfd1-f0acdc5238cc": {"__data__": {"id_": "e06e0115-3042-4f67-bfd1-f0acdc5238cc", "embedding": null, "metadata": {"window": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  ", "original_text": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aca32458-9f28-4913-bc89-e9d265351181", "node_type": "1", "metadata": {"window": "With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.  ", "original_text": "Mike Kaufmann :  Thanks, Dave.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5185b6504190aaf9a8134f4fe32f77e056fd9c1dbd14e75cda5d11ef7ba3154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5867bf86-3498-4864-8c56-5ade1e5fd5d1", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n ", "original_text": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n "}, "hash": "ac8e42fc59b76b66b76f20005cd136919a618b7e8456e7fb566d551ee395aee0", "class_name": "RelatedNodeInfo"}}, "text": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n ", "start_char_idx": 375, "end_char_idx": 597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5867bf86-3498-4864-8c56-5ade1e5fd5d1": {"__data__": {"id_": "5867bf86-3498-4864-8c56-5ade1e5fd5d1", "embedding": null, "metadata": {"window": "With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n ", "original_text": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e06e0115-3042-4f67-bfd1-f0acdc5238cc", "node_type": "1", "metadata": {"window": "This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  ", "original_text": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12cd07e605c0b5f98ff85c9b599326f9c246e0c7c06207573f65343f29ec5a43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de822dce-b180-4539-92af-9e5fc7aa5141", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  ", "original_text": "Overall, we have increased confidence in our work to drive growth across the pharma segment.  "}, "hash": "9622c3df8f14dcb53b52a63af070bd91e8ffd1feec248f42ffc5ba90f8d40c19", "class_name": "RelatedNodeInfo"}}, "text": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n ", "start_char_idx": 597, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de822dce-b180-4539-92af-9e5fc7aa5141": {"__data__": {"id_": "de822dce-b180-4539-92af-9e5fc7aa5141", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  ", "original_text": "Overall, we have increased confidence in our work to drive growth across the pharma segment.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5867bf86-3498-4864-8c56-5ade1e5fd5d1", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to Mike.  \n \n Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n ", "original_text": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af87b061e5458acb68c50576b755c475825aed8723600b4e894899891fbf409a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6b548c2-cc90-4331-907a-ec15ea9d0463", "node_type": "1", "metadata": {"window": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n ", "original_text": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  "}, "hash": "838658160e4135bb0d00cfc1a7437a48c1fcfa0460ae815568077ea14dd89656", "class_name": "RelatedNodeInfo"}}, "text": "Overall, we have increased confidence in our work to drive growth across the pharma segment.  ", "start_char_idx": 812, "end_char_idx": 906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6b548c2-cc90-4331-907a-ec15ea9d0463": {"__data__": {"id_": "e6b548c2-cc90-4331-907a-ec15ea9d0463", "embedding": null, "metadata": {"window": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n ", "original_text": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de822dce-b180-4539-92af-9e5fc7aa5141", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks, Dave.   As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  ", "original_text": "Overall, we have increased confidence in our work to drive growth across the pharma segment.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7469d65fb9054533d0387defc81dcb28ad6b08612fc7c2cc8e30ef6142b2dec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48b6afbd-e585-4e26-a627-46b6d96265fc", "node_type": "1", "metadata": {"window": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  ", "original_text": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n "}, "hash": "a5ec73e9b482932e6d97caa07d8572f2143513543715c6964c9c0c81fd7b8c72", "class_name": "RelatedNodeInfo"}}, "text": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  ", "start_char_idx": 906, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48b6afbd-e585-4e26-a627-46b6d96265fc": {"__data__": {"id_": "48b6afbd-e585-4e26-a627-46b6d96265fc", "embedding": null, "metadata": {"window": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  ", "original_text": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6b548c2-cc90-4331-907a-ec15ea9d0463", "node_type": "1", "metadata": {"window": "As we look to the remainder of  this year and the next few, we will continue to focus on \nenhancing our established core businesses and on fueling sustained growth in evolving areas, including specialty \nand at home.  \n \n  In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n ", "original_text": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c64a8899641e8fba9f27ac9414a41b33a6ab6a1dd16b35cef36f0943a374b970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2c9191a-f5b9-43af-96c6-f3e9a8e4ba44", "node_type": "1", "metadata": {"window": "Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  "}, "hash": "91cfa6206d9d8b67d449b952186281a5f22d43a94acea4deb1c1dee0e86f5fbb", "class_name": "RelatedNodeInfo"}}, "text": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n ", "start_char_idx": 1180, "end_char_idx": 1331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2c9191a-f5b9-43af-96c6-f3e9a8e4ba44": {"__data__": {"id_": "d2c9191a-f5b9-43af-96c6-f3e9a8e4ba44", "embedding": null, "metadata": {"window": "Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48b6afbd-e585-4e26-a627-46b6d96265fc", "node_type": "1", "metadata": {"window": "In pharma let me start by saying we continue to be actively involved i n ongoing negotiations of the terms for a \nglobal settlement and we remain committed to being part of the solution to the opioid epidemic.  \n \n  Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  ", "original_text": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3731ef462eaf03a2cbf6e49f7c52907a7815d9a091396b7a35318c3408db085f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee33cff2-ae3a-41d0-8195-f4f734d1f99c", "node_type": "1", "metadata": {"window": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "Our work in these areas continues.  \n \n "}, "hash": "8882f565edc9f4466638f7312577f60ce2a635c70e72ded1ee1f5cfd4a6d75bd", "class_name": "RelatedNodeInfo"}}, "text": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  ", "start_char_idx": 1331, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee33cff2-ae3a-41d0-8195-f4f734d1f99c": {"__data__": {"id_": "ee33cff2-ae3a-41d0-8195-f4f734d1f99c", "embedding": null, "metadata": {"window": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "Our work in these areas continues.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2c9191a-f5b9-43af-96c6-f3e9a8e4ba44", "node_type": "1", "metadata": {"window": "Overall, we have increased confidence in our work to drive growth across the pharma segment.   Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "376ef5969b42f2de9d5e292415aaea9b7da3d05ac55d10be3832dadf6ee8be07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6c1552a-52bc-44d3-95ec-400f72ed01b7", "node_type": "1", "metadata": {"window": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  "}, "hash": "ad76c09f4e8293b0cd66d45045f2b9cde987f750c1a2baf5d892a0578e4a4e6f", "class_name": "RelatedNodeInfo"}}, "text": "Our work in these areas continues.  \n \n ", "start_char_idx": 1490, "end_char_idx": 1530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6c1552a-52bc-44d3-95ec-400f72ed01b7": {"__data__": {"id_": "c6c1552a-52bc-44d3-95ec-400f72ed01b7", "embedding": null, "metadata": {"window": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee33cff2-ae3a-41d0-8195-f4f734d1f99c", "node_type": "1", "metadata": {"window": "Our investments \nin our  generic pricing and analytics capabilities, as well as continued strong performance from Red Oak and \nimproving market dynamics, are enabling our generics program to now be a tailwind for the year rather than a \nheadwind as we previously expected.   Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "Our work in these areas continues.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d79ea17dfe1fefb093d640d746a61023f67fe4a3295db2ad9e4f78d68b2dd2e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288d0477-ad22-4479-826e-79ee5993fb43", "node_type": "1", "metadata": {"window": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "While we recognize this w ill slow momentum in our "}, "hash": "4f6083bab6aebab5b09d3156756f7fdc55b655d04062dc43114dea1ee668c2eb", "class_name": "RelatedNodeInfo"}}, "text": "However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  ", "start_char_idx": 1530, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288d0477-ad22-4479-826e-79ee5993fb43": {"__data__": {"id_": "288d0477-ad22-4479-826e-79ee5993fb43", "embedding": null, "metadata": {"window": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "While we recognize this w ill slow momentum in our ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01248c14-ddd5-43e7-bddb-21d57408d50b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e57df921dae09a0e8b4900b4d87aa5b752132b0750816390c0e3eeddb70b9896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6c1552a-52bc-44d3-95ec-400f72ed01b7", "node_type": "1", "metadata": {"window": "Also our  investments in both our specialty and connected care businesses \nenable us to capture value in the ever -changing healthcare landscape.  \n \n  Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "664331da8f47f726a44d5731cac2cbaf1471a8e9bcdad89ab5237f84bbfde957", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58848c5e-ff41-41a1-81b7-3d666fcc4b14", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "original_text": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.  "}, "hash": "4f39ee8429f2de71dab79ddfcdd5991fba5b93e04cd5676e483bc77d97c6d682", "class_name": "RelatedNodeInfo"}}, "text": "While we recognize this w ill slow momentum in our ", "start_char_idx": 1688, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58848c5e-ff41-41a1-81b7-3d666fcc4b14": {"__data__": {"id_": "58848c5e-ff41-41a1-81b7-3d666fcc4b14", "embedding": null, "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "original_text": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288d0477-ad22-4479-826e-79ee5993fb43", "node_type": "1", "metadata": {"window": "Moving to medical, I mentioned last quarter that we had multiple initiatives in flight  to enhance our commercial \napproa ch and streamline our supply chain.   Our work in these areas continues.  \n \n  However with the recent recalls, we are currently deploying our medical segment teams to meet the most \nimmediate needs of our customers and their patients.   While we recognize this w ill slow momentum in our ", "original_text": "While we recognize this w ill slow momentum in our ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52cfd08fc519bb477a2419e541ccfb8b759058c4b8f6a8b9daf12feba008f28f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f859c378-15b9-4f46-8bae-753352f5fbda", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.  ", "original_text": "We will provide an update on our next call.  \n \n "}, "hash": "44114b8e48ab81a17ceaa031c087e2b14191ab0d11c50846614c0c3df5346d2b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.  ", "start_char_idx": 0, "end_char_idx": 171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f859c378-15b9-4f46-8bae-753352f5fbda": {"__data__": {"id_": "f859c378-15b9-4f46-8bae-753352f5fbda", "embedding": null, "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.  ", "original_text": "We will provide an update on our next call.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58848c5e-ff41-41a1-81b7-3d666fcc4b14", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "original_text": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23ef61ee00a39543563096282aadf99031e3f28d3cf7e60a3ffff4f746f5f656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bafd2de2-f0a0-40cc-b30b-91573bf79e13", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n ", "original_text": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.  "}, "hash": "33c4605c8bca1d1f1e9a05004b41579bb917516c5f13e3aea9e96ee315fdec9d", "class_name": "RelatedNodeInfo"}}, "text": "We will provide an update on our next call.  \n \n ", "start_char_idx": 171, "end_char_idx": 220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bafd2de2-f0a0-40cc-b30b-91573bf79e13": {"__data__": {"id_": "bafd2de2-f0a0-40cc-b30b-91573bf79e13", "embedding": null, "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n ", "original_text": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f859c378-15b9-4f46-8bae-753352f5fbda", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.  ", "original_text": "We will provide an update on our next call.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49484d299e3c030fb21ce6f4481c6c1a2ef69f4ba75d3a0ef1ecfe2a7dcb5986", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06d1d948-fcf7-4e88-97e7-543f7538f965", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.  ", "original_text": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n "}, "hash": "3c06c8112ecf4af259bb5c6e0b42a41e83dd8f7b6aea0b70095cfce59a8fc503", "class_name": "RelatedNodeInfo"}}, "text": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.  ", "start_char_idx": 220, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06d1d948-fcf7-4e88-97e7-543f7538f965": {"__data__": {"id_": "06d1d948-fcf7-4e88-97e7-543f7538f965", "embedding": null, "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.  ", "original_text": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bafd2de2-f0a0-40cc-b30b-91573bf79e13", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n ", "original_text": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e279527ee76624d675a9854674af01fa196303a49e6ab4a1eebe7410e4ed37ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "682098c2-a4ad-4a65-bc0f-938475347488", "node_type": "1", "metadata": {"window": "We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n ", "original_text": "Across  the company we continue to prudently manage our cost structure.  "}, "hash": "378c778fc9ea8d22a614c0e7e90bf372b6a76374efced13c74f07afc809f311b", "class_name": "RelatedNodeInfo"}}, "text": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "start_char_idx": 429, "end_char_idx": 509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "682098c2-a4ad-4a65-bc0f-938475347488": {"__data__": {"id_": "682098c2-a4ad-4a65-bc0f-938475347488", "embedding": null, "metadata": {"window": "We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n ", "original_text": "Across  the company we continue to prudently manage our cost structure.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06d1d948-fcf7-4e88-97e7-543f7538f965", "node_type": "1", "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.  ", "original_text": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8322eefebbb92b064b74be86e4bf3047ea70685d8d1949276f3b809b99f64dc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c094aa57-8c88-4b93-8e8a-df040a9427b4", "node_type": "1", "metadata": {"window": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n", "original_text": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n "}, "hash": "040304eddc06a24ae092a041a298a4b03944fa15528eba687a481fc26388e663", "class_name": "RelatedNodeInfo"}}, "text": "Across  the company we continue to prudently manage our cost structure.  ", "start_char_idx": 509, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c094aa57-8c88-4b93-8e8a-df040a9427b4": {"__data__": {"id_": "c094aa57-8c88-4b93-8e8a-df040a9427b4", "embedding": null, "metadata": {"window": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n", "original_text": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "682098c2-a4ad-4a65-bc0f-938475347488", "node_type": "1", "metadata": {"window": "We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n ", "original_text": "Across  the company we continue to prudently manage our cost structure.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "784b45560c56710d9147f47633df96f40a5f87fab0735b3ea42cec4dc5f75ed3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5925d02a-260a-4b45-b368-7a52d339738a", "node_type": "1", "metadata": {"window": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.  ", "original_text": "Our goal is to be easier to do business with.  "}, "hash": "9736ce74bcf3dea6daf5b8a2c5b845e00850fcdbe262ca394f4e2218f3f072dd", "class_name": "RelatedNodeInfo"}}, "text": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n ", "start_char_idx": 582, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5925d02a-260a-4b45-b368-7a52d339738a": {"__data__": {"id_": "5925d02a-260a-4b45-b368-7a52d339738a", "embedding": null, "metadata": {"window": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.  ", "original_text": "Our goal is to be easier to do business with.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c094aa57-8c88-4b93-8e8a-df040a9427b4", "node_type": "1", "metadata": {"window": "At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n", "original_text": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1024bea05a80a5db13c1a6d2dec54dbdad6df1451dd849b157d4bad238ca0a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "362a794b-86c9-48e1-8b9e-d1ec39e30a7d", "node_type": "1", "metadata": {"window": "Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n ", "original_text": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n "}, "hash": "635120ee1f77a43a868ca688f709f66b201b41937b657162505800542f414721", "class_name": "RelatedNodeInfo"}}, "text": "Our goal is to be easier to do business with.  ", "start_char_idx": 760, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "362a794b-86c9-48e1-8b9e-d1ec39e30a7d": {"__data__": {"id_": "362a794b-86c9-48e1-8b9e-d1ec39e30a7d", "embedding": null, "metadata": {"window": "Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n ", "original_text": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5925d02a-260a-4b45-b368-7a52d339738a", "node_type": "1", "metadata": {"window": "Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n  Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.  ", "original_text": "Our goal is to be easier to do business with.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "185fbd9449b1ae580645fad7178f73acbdbdf8bac0e1f67b5d79d96322f47bff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02755e37-62d8-45f4-b0a8-22aeb99553d6", "node_type": "1", "metadata": {"window": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n", "original_text": "With that I'll now pause to open it up for questions.  \n \n"}, "hash": "4506e25ba406cf97d017c5e4af36f6195b927192e652c53d6efb3ba2691fcea9", "class_name": "RelatedNodeInfo"}}, "text": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n ", "start_char_idx": 807, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02755e37-62d8-45f4-b0a8-22aeb99553d6": {"__data__": {"id_": "02755e37-62d8-45f4-b0a8-22aeb99553d6", "embedding": null, "metadata": {"window": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n", "original_text": "With that I'll now pause to open it up for questions.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "362a794b-86c9-48e1-8b9e-d1ec39e30a7d", "node_type": "1", "metadata": {"window": "Across  the company we continue to prudently manage our cost structure.   We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n ", "original_text": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c6a53a5bba9662a01268a431373da982f40e452a8a0ab54ce59bd94fdb9c1eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33bedb07-8d84-4e0c-9446-bcb88bc61319", "node_type": "1", "metadata": {"window": "Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.  ", "original_text": "Operator :  Thank you.  "}, "hash": "29750c49374c0cbd3ffbc3f959a9dbab4f96128d2a87111208d4d74b932ec225", "class_name": "RelatedNodeInfo"}}, "text": "With that I'll now pause to open it up for questions.  \n \n", "start_char_idx": 946, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33bedb07-8d84-4e0c-9446-bcb88bc61319": {"__data__": {"id_": "33bedb07-8d84-4e0c-9446-bcb88bc61319", "embedding": null, "metadata": {"window": "Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.  ", "original_text": "Operator :  Thank you.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02755e37-62d8-45f4-b0a8-22aeb99553d6", "node_type": "1", "metadata": {"window": "We're doing this through focusing our \nresources, improving our processes and embracing new technologies that create better visibility and velocity \nthroughout the company.  \n \n  Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n", "original_text": "With that I'll now pause to open it up for questions.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5680c7923f6f187d51db25757684fb3eaf55aa57c4b083f83a6f0f5057c690f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b60b2636-d650-4609-ac16-fa478c1ca248", "node_type": "1", "metadata": {"window": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.  ", "original_text": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n "}, "hash": "4e4d1e583656a94b3a91e450dfb88a2d6fe6c7801bce54e0dbc9bfa398d6d5db", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you.  ", "start_char_idx": 1004, "end_char_idx": 1028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b60b2636-d650-4609-ac16-fa478c1ca248": {"__data__": {"id_": "b60b2636-d650-4609-ac16-fa478c1ca248", "embedding": null, "metadata": {"window": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.  ", "original_text": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33bedb07-8d84-4e0c-9446-bcb88bc61319", "node_type": "1", "metadata": {"window": "Our goal is to be easier to do business with.   As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.  ", "original_text": "Operator :  Thank you.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3851f93d7e01ae106f4b9bc80c3bfc9ebfb94842bc598897ea6aec01b5209f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02ba5a61-8c36-4535-9282-0e8098082ba5", "node_type": "1", "metadata": {"window": "With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n", "original_text": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n"}, "hash": "166a8cabab343be2f999aecb30c377c73160fc490ac2759bf759f5b5ed8fbb88", "class_name": "RelatedNodeInfo"}}, "text": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n ", "start_char_idx": 1028, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02ba5a61-8c36-4535-9282-0e8098082ba5": {"__data__": {"id_": "02ba5a61-8c36-4535-9282-0e8098082ba5", "embedding": null, "metadata": {"window": "With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n", "original_text": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b60b2636-d650-4609-ac16-fa478c1ca248", "node_type": "1", "metadata": {"window": "As this new mindset takes root, we will continue to see a sustainable \nbehavioral shift and ongoing value creation for years to come.  \n \n  With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.  ", "original_text": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "990edd1283d321eac4a1920ba06953a0fde9b05f50dbee359dca4ae386665df9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70829e39-bdb9-4b0b-ad3a-bb8586bf5acc", "node_type": "1", "metadata": {"window": "Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  ", "original_text": "Glen Santangelo :  Oh, yes, thanks.  "}, "hash": "1a5215879a03a4a7175584299bc09326bdf4accbeef2e0b37069ae738d2f1868", "class_name": "RelatedNodeInfo"}}, "text": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n", "start_char_idx": 1128, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70829e39-bdb9-4b0b-ad3a-bb8586bf5acc": {"__data__": {"id_": "70829e39-bdb9-4b0b-ad3a-bb8586bf5acc", "embedding": null, "metadata": {"window": "Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  ", "original_text": "Glen Santangelo :  Oh, yes, thanks.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02ba5a61-8c36-4535-9282-0e8098082ba5", "node_type": "1", "metadata": {"window": "With that I'll now pause to open it up for questions.  \n \n Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n", "original_text": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad634aecb60f66b3b19c859db7b6424b9db8ab75fb2d70d8a7d3374dea99cb6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3adb3f5e-cf99-460d-8fdc-fd6040bb932e", "node_type": "1", "metadata": {"window": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Good morning.  "}, "hash": "3de2a6e556bd7d31856c4f305cf1dda3af0aff066e5df8d8efc7ebf97d4faa35", "class_name": "RelatedNodeInfo"}}, "text": "Glen Santangelo :  Oh, yes, thanks.  ", "start_char_idx": 1204, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3adb3f5e-cf99-460d-8fdc-fd6040bb932e": {"__data__": {"id_": "3adb3f5e-cf99-460d-8fdc-fd6040bb932e", "embedding": null, "metadata": {"window": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Good morning.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70829e39-bdb9-4b0b-ad3a-bb8586bf5acc", "node_type": "1", "metadata": {"window": "Operator :  Thank you.   If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  ", "original_text": "Glen Santangelo :  Oh, yes, thanks.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3842c215098fb52143aa361650acdec6290cc068fbe52c453c66ca2e9c0e562e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45aa2d3e-bd00-483c-b7d2-6a9e3817eec8", "node_type": "1", "metadata": {"window": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Just a quick question  regarding the guidance in the medical segment.  \n"}, "hash": "6e0b729d094b93489a4ffe8d65fec197483737b5ef3d7b7a3b00be4deef21b51", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 1241, "end_char_idx": 1256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45aa2d3e-bd00-483c-b7d2-6a9e3817eec8": {"__data__": {"id_": "45aa2d3e-bd00-483c-b7d2-6a9e3817eec8", "embedding": null, "metadata": {"window": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Just a quick question  regarding the guidance in the medical segment.  \n", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3adb3f5e-cf99-460d-8fdc-fd6040bb932e", "node_type": "1", "metadata": {"window": "If you would like to ask a question, please signal by pressing star 1 on your telephone keypad.   \n  And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Good morning.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c12e1682fcba8fa3cee84e9520f4c9e5784aba3c891f4311dfec8da3bf272a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "843a3f02-2f61-4aeb-aed5-4bd6459ce9fa", "node_type": "1", "metadata": {"window": "Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  "}, "hash": "e8ab02e8ff86a6c6def6e51888cf5c1392f0b577add012d832a864f904927780", "class_name": "RelatedNodeInfo"}}, "text": "Just a quick question  regarding the guidance in the medical segment.  \n", "start_char_idx": 1256, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "843a3f02-2f61-4aeb-aed5-4bd6459ce9fa": {"__data__": {"id_": "843a3f02-2f61-4aeb-aed5-4bd6459ce9fa", "embedding": null, "metadata": {"window": "Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45aa2d3e-bd00-483c-b7d2-6a9e3817eec8", "node_type": "1", "metadata": {"window": "And we'll take our first question from Glen Santangelo with Guggenheim.  \n \n Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Just a quick question  regarding the guidance in the medical segment.  \n", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bf621fa26050434a1390901fd9272248c2914fbd5756f98a6c0d80076e2f037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd9f3734-761f-4f60-9c91-37ff7e03565c", "node_type": "1", "metadata": {"window": "Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n "}, "hash": "332ce44f8d1586221a1341c46e83f414472e9cc93ebf01b11db232918fdbacf6", "class_name": "RelatedNodeInfo"}}, "text": "I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  ", "start_char_idx": 1328, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd9f3734-761f-4f60-9c91-37ff7e03565c": {"__data__": {"id_": "dd9f3734-761f-4f60-9c91-37ff7e03565c", "embedding": null, "metadata": {"window": "Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "135ec149-e16f-48bb-b74e-4297365a398d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6de4e181399effcfcd3ac54edead04f48daca8c2eefedfd62405f655b6ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "843a3f02-2f61-4aeb-aed5-4bd6459ce9fa", "node_type": "1", "metadata": {"window": "Glen Santangelo :  Oh, yes, thanks.   Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "I'm kind of curious does the recall have any implications for the outlook in the second half of the year?  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a80e28f8f541e5a342b1d487c3c1394d7174709c0394e39161b0e5a5654f92f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9b41f07-973c-48a1-800f-1f077c359642", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "original_text": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n"}, "hash": "dfa831d76a1673eecc6b9684f4daaac5f5b13f2dd52681496e361c72e3313085", "class_name": "RelatedNodeInfo"}}, "text": "Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "start_char_idx": 1435, "end_char_idx": 1659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9b41f07-973c-48a1-800f-1f077c359642": {"__data__": {"id_": "a9b41f07-973c-48a1-800f-1f077c359642", "embedding": null, "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "original_text": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd9f3734-761f-4f60-9c91-37ff7e03565c", "node_type": "1", "metadata": {"window": "Good morning.   Just a quick question  regarding the guidance in the medical segment.  \n I'm kind of curious does the recall have any implications for the outlook in the second half of the year?   Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "original_text": "Because if \nyou look through the first six months your operating profit is already up double -digits a nd Dave, as you sort of \nalluded to, you have that easy comp coming in the fourth quarter from that charge last year.  \n ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefe1a135648822e2489c2266050b723df8721f583e20544dcef4612fe5c5731", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69135622-76bb-4c07-9d12-d23848aa0d94", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n ", "original_text": "David Evans :  Yes, Glen, this is Dave.  "}, "hash": "0f376bd30df8f30c93a83c15f67c333af1bda5098fe20f369d627f1d30d1b462", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n", "start_char_idx": 0, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69135622-76bb-4c07-9d12-d23848aa0d94": {"__data__": {"id_": "69135622-76bb-4c07-9d12-d23848aa0d94", "embedding": null, "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n ", "original_text": "David Evans :  Yes, Glen, this is Dave.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9b41f07-973c-48a1-800f-1f077c359642", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "original_text": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d3e52dd7827f53667c3383e800390049bf6915862e716332bd59edbb7f9d2cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a610a38-af97-4076-8a7e-56679d165e07", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n", "original_text": "Good question.  "}, "hash": "74d4576ff3dacd2179163f2353dcc42ed223eec61acd8a7222866a9d008945e6", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Yes, Glen, this is Dave.  ", "start_char_idx": 265, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a610a38-af97-4076-8a7e-56679d165e07": {"__data__": {"id_": "2a610a38-af97-4076-8a7e-56679d165e07", "embedding": null, "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n", "original_text": "Good question.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69135622-76bb-4c07-9d12-d23848aa0d94", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n ", "original_text": "David Evans :  Yes, Glen, this is Dave.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2755592db92c913897c8541774a2222e5b38ae259bdd939e129a22c75ba8517e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fba44f03-928f-43c9-8d9e-3a8fab1fbfac", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.  ", "original_text": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   "}, "hash": "fc10c1cc395517afe14abd82e5909e28bf793e28ac4e3eb5f3a21878b25568d0", "class_name": "RelatedNodeInfo"}}, "text": "Good question.  ", "start_char_idx": 306, "end_char_idx": 322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fba44f03-928f-43c9-8d9e-3a8fab1fbfac": {"__data__": {"id_": "fba44f03-928f-43c9-8d9e-3a8fab1fbfac", "embedding": null, "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.  ", "original_text": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a610a38-af97-4076-8a7e-56679d165e07", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n", "original_text": "Good question.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4acb1462f5fff4bf1aaead938bc33c030b2ce62cccc463666917a298feac182e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feb3193d-6120-4bba-9c4a-26f2a4fb4172", "node_type": "1", "metadata": {"window": "David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  ", "original_text": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n "}, "hash": "1059ca7acbc0eba9227f6d685aa15e9c21fdfbc53c7be665b17b3de24ea12cb1", "class_name": "RelatedNodeInfo"}}, "text": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "start_char_idx": 322, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feb3193d-6120-4bba-9c4a-26f2a4fb4172": {"__data__": {"id_": "feb3193d-6120-4bba-9c4a-26f2a4fb4172", "embedding": null, "metadata": {"window": "David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  ", "original_text": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fba44f03-928f-43c9-8d9e-3a8fab1fbfac", "node_type": "1", "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.  ", "original_text": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5f75259e3539ff08a3a0d3368df757138c37485ffa10d5e3f262a49780c58a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f2d95f2-fd1e-4a52-b007-c84c62916c2d", "node_type": "1", "metadata": {"window": "Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n ", "original_text": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n"}, "hash": "e2f166ecf88aa39f2aa35ec9fbe482bcd9cd7956fa28bd30d61d250f867edbb6", "class_name": "RelatedNodeInfo"}}, "text": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n ", "start_char_idx": 423, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f2d95f2-fd1e-4a52-b007-c84c62916c2d": {"__data__": {"id_": "0f2d95f2-fd1e-4a52-b007-c84c62916c2d", "embedding": null, "metadata": {"window": "Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n ", "original_text": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feb3193d-6120-4bba-9c4a-26f2a4fb4172", "node_type": "1", "metadata": {"window": "David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  ", "original_text": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0833a12329aa889cb60df004e37d5f6984222058eb7f30d43b11fbac86e86f6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5346f73c-acc5-4e54-ac5e-9eadb531be04", "node_type": "1", "metadata": {"window": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.  ", "original_text": "Glen Santangelo :  Okay.  "}, "hash": "c5460ce8a5e31661e27bb5cb0c334ecadbc31436ea3f36aece6e79e7e33410a0", "class_name": "RelatedNodeInfo"}}, "text": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n", "start_char_idx": 593, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5346f73c-acc5-4e54-ac5e-9eadb531be04": {"__data__": {"id_": "5346f73c-acc5-4e54-ac5e-9eadb531be04", "embedding": null, "metadata": {"window": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.  ", "original_text": "Glen Santangelo :  Okay.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f2d95f2-fd1e-4a52-b007-c84c62916c2d", "node_type": "1", "metadata": {"window": "Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n ", "original_text": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d05238a3c20adddea26cb07bd8f1ff787aad70e39d7c1ec6dc945e4adf95eb21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88f03664-ec82-40bb-a27e-c2d9b5114fec", "node_type": "1", "metadata": {"window": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.  ", "original_text": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  "}, "hash": "eca430dcb719db0eb292316c789978141bd2f6024e43d7d9efacc90665e555af", "class_name": "RelatedNodeInfo"}}, "text": "Glen Santangelo :  Okay.  ", "start_char_idx": 764, "end_char_idx": 790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88f03664-ec82-40bb-a27e-c2d9b5114fec": {"__data__": {"id_": "88f03664-ec82-40bb-a27e-c2d9b5114fec", "embedding": null, "metadata": {"window": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.  ", "original_text": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5346f73c-acc5-4e54-ac5e-9eadb531be04", "node_type": "1", "metadata": {"window": "So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.    What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.  ", "original_text": "Glen Santangelo :  Okay.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b23169e0c3e0dcb7b41a05392c814a01272dee490b9cf3e5b6288f613aad685", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a22be1f1-7f01-4a18-b490-a289e80819d6", "node_type": "1", "metadata": {"window": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?  ", "original_text": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n "}, "hash": "e472bc139b4513db40083fc8f75184f9c22acd70922f6ec9c99cc0ad02c4d8bb", "class_name": "RelatedNodeInfo"}}, "text": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  ", "start_char_idx": 790, "end_char_idx": 878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a22be1f1-7f01-4a18-b490-a289e80819d6": {"__data__": {"id_": "a22be1f1-7f01-4a18-b490-a289e80819d6", "embedding": null, "metadata": {"window": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?  ", "original_text": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88f03664-ec82-40bb-a27e-c2d9b5114fec", "node_type": "1", "metadata": {"window": "What we have uncertainty on and frankly at this very early stage is \nimplications to second half in terms of revenue, margin and any disruptions with our customers.  \n \n  So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.  ", "original_text": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1bb9f5a68309f6d6534b6e85ab85911e9e6fa87fe06d8ef873b98bd3b9e3646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ef027db-09e0-48ed-8e67-3d7e679589cf", "node_type": "1", "metadata": {"window": "Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?  ", "original_text": "The framework has been out there for a few months.  "}, "hash": "02e3aa05f57d63756572ab2fa9941a49197bc810f20f938e3ecefdba63aaf0fa", "class_name": "RelatedNodeInfo"}}, "text": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n ", "start_char_idx": 878, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ef027db-09e0-48ed-8e67-3d7e679589cf": {"__data__": {"id_": "3ef027db-09e0-48ed-8e67-3d7e679589cf", "embedding": null, "metadata": {"window": "Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?  ", "original_text": "The framework has been out there for a few months.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a22be1f1-7f01-4a18-b490-a289e80819d6", "node_type": "1", "metadata": {"window": "So I would say that you've read this fairly well and that we've reflected some of that u ncertainty in the guidance \nthat we're providing for the second half for med.  \n \n Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?  ", "original_text": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16f47e6d102ee56d265eca60bad23462a5fa0e96476a98db602dca0c56dd8ad9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11457ac4-6034-4168-801b-209347fceab2", "node_type": "1", "metadata": {"window": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n", "original_text": "It kind of sounds like you're confident.  "}, "hash": "5478529252eb664d18a425dfb74fbf9d1e54e920c65145fbe9e147769795acbf", "class_name": "RelatedNodeInfo"}}, "text": "The framework has been out there for a few months.  ", "start_char_idx": 1042, "end_char_idx": 1094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11457ac4-6034-4168-801b-209347fceab2": {"__data__": {"id_": "11457ac4-6034-4168-801b-209347fceab2", "embedding": null, "metadata": {"window": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n", "original_text": "It kind of sounds like you're confident.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ef027db-09e0-48ed-8e67-3d7e679589cf", "node_type": "1", "metadata": {"window": "Glen Santangelo :  Okay.   And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?  ", "original_text": "The framework has been out there for a few months.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "007e950c42743e5601176529a1a139f5cb7c13f490db7eb2ff6615a793dba0e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e67cc47-5ba9-4bbe-b52f-05c33d906336", "node_type": "1", "metadata": {"window": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "Why the increased \nsort of litigation expense now?  "}, "hash": "80fb9f3b888fe7df4b6033e5ba99b23c96d87ea32e2b71879c55c0df9d1a8b03", "class_name": "RelatedNodeInfo"}}, "text": "It kind of sounds like you're confident.  ", "start_char_idx": 1094, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e67cc47-5ba9-4bbe-b52f-05c33d906336": {"__data__": {"id_": "6e67cc47-5ba9-4bbe-b52f-05c33d906336", "embedding": null, "metadata": {"window": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "Why the increased \nsort of litigation expense now?  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11457ac4-6034-4168-801b-209347fceab2", "node_type": "1", "metadata": {"window": "And then maybe if I could just ask a quick follow -up to Mike with respect to opioids.   I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n", "original_text": "It kind of sounds like you're confident.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "118ae57a9884cfbfa14a777cb69d366d77815e337bff7629144ab3d6619f95b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d677d34d-baca-4f41-aedb-9fde87363ba3", "node_type": "1", "metadata": {"window": "The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.  ", "original_text": "Hopefully we're win ding this down?  "}, "hash": "f4456d68a80f370f5a17d81f6447fb5a3eed383a011eabcd492b627426556790", "class_name": "RelatedNodeInfo"}}, "text": "Why the increased \nsort of litigation expense now?  ", "start_char_idx": 1136, "end_char_idx": 1188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d677d34d-baca-4f41-aedb-9fde87363ba3": {"__data__": {"id_": "d677d34d-baca-4f41-aedb-9fde87363ba3", "embedding": null, "metadata": {"window": "The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.  ", "original_text": "Hopefully we're win ding this down?  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e67cc47-5ba9-4bbe-b52f-05c33d906336", "node_type": "1", "metadata": {"window": "I think you \nwere sort of forecasting about $85 million of expenses  and now you've taken your opioid litigation expenses up to \n$100 million to $125 million.  \n \n  The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "Why the increased \nsort of litigation expense now?  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "666c9e10651769388e2a1aa926871a794ab04f23c92286e9d24d70c7655aaf32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3747ad1-d44d-4d65-b8ec-31a4aecb6a8b", "node_type": "1", "metadata": {"window": "It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.  ", "original_text": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n"}, "hash": "578dbef1380244a66078a44acdd86746040a70065a870b19b5d0e6a2a43b8151", "class_name": "RelatedNodeInfo"}}, "text": "Hopefully we're win ding this down?  ", "start_char_idx": 1188, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3747ad1-d44d-4d65-b8ec-31a4aecb6a8b": {"__data__": {"id_": "e3747ad1-d44d-4d65-b8ec-31a4aecb6a8b", "embedding": null, "metadata": {"window": "It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.  ", "original_text": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d677d34d-baca-4f41-aedb-9fde87363ba3", "node_type": "1", "metadata": {"window": "The framework has been out there for a few months.   It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.  ", "original_text": "Hopefully we're win ding this down?  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a47151d66eaf48bfe3f26a375bd47050a1f503a81c69200d50f366d4226ddb73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d7a1a56-99cb-49de-9b58-319f44af55cd", "node_type": "1", "metadata": {"window": "Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.  ", "original_text": "Mike Kaufmann :  Yes.  "}, "hash": "1d22822422cd3c852bd7d9cb3137aa2c465ead6054bf41931305c24c1b86e515", "class_name": "RelatedNodeInfo"}}, "text": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n", "start_char_idx": 1225, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d7a1a56-99cb-49de-9b58-319f44af55cd": {"__data__": {"id_": "1d7a1a56-99cb-49de-9b58-319f44af55cd", "embedding": null, "metadata": {"window": "Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3747ad1-d44d-4d65-b8ec-31a4aecb6a8b", "node_type": "1", "metadata": {"window": "It kind of sounds like you're confident.   Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.  ", "original_text": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "933527e574509ce22ed003b663cd6f534c3012dd1ec1d8d733f202a5284a07b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b2b517b-3c45-49be-8866-6cf89ca68716", "node_type": "1", "metadata": {"window": "Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "Thanks for the question.  "}, "hash": "1db71398ef284a85b6cbdbe5d6cf87145f643ed6cb677b0531f6bfc7e0f663f2", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes.  ", "start_char_idx": 1328, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b2b517b-3c45-49be-8866-6cf89ca68716": {"__data__": {"id_": "1b2b517b-3c45-49be-8866-6cf89ca68716", "embedding": null, "metadata": {"window": "Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "Thanks for the question.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d7a1a56-99cb-49de-9b58-319f44af55cd", "node_type": "1", "metadata": {"window": "Why the increased \nsort of litigation expense now?   Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb1fd2114efa1f19f174739b8fe4842f351aad830e91d3b23dcb2b9690938e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "842f4863-2504-485e-a658-933101d2c985", "node_type": "1", "metadata": {"window": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "We are still dedicated to the framework and progress does continue.  "}, "hash": "89cc24b0a51de9f4d61d93a7c5f32dc96946b0f7b5516c4f0d49fcdc3866bef0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  ", "start_char_idx": 1351, "end_char_idx": 1377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "842f4863-2504-485e-a658-933101d2c985": {"__data__": {"id_": "842f4863-2504-485e-a658-933101d2c985", "embedding": null, "metadata": {"window": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "We are still dedicated to the framework and progress does continue.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b2b517b-3c45-49be-8866-6cf89ca68716", "node_type": "1", "metadata": {"window": "Hopefully we're win ding this down?   Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "Thanks for the question.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95c81ac0375f9e7ea8d20df582cd98ff17a925655612c321a54b2663a43c601d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "647ac908-8dd8-470d-84c7-614a787ff95c", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "So \nthat's a positive.  "}, "hash": "6c3df6ccbb75a11ada715531367fb23a999ea132cb0049cea6f10632c124d4ef", "class_name": "RelatedNodeInfo"}}, "text": "We are still dedicated to the framework and progress does continue.  ", "start_char_idx": 1377, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "647ac908-8dd8-470d-84c7-614a787ff95c": {"__data__": {"id_": "647ac908-8dd8-470d-84c7-614a787ff95c", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "So \nthat's a positive.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "842f4863-2504-485e-a658-933101d2c985", "node_type": "1", "metadata": {"window": "Could you maybe give us an update on the \ntimeline of maybe what we should be expecting from here?  \n \n Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "We are still dedicated to the framework and progress does continue.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08fd11daf4ebb5fca7739e695c3654229a504bf23fdf3bd6c0417e4db0ded145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab63efff-c51a-461b-900c-116a9b74579a", "node_type": "1", "metadata": {"window": "Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n "}, "hash": "b3325960a0a5db391ab4142e3aa8a3f99a2012c5d90c01f0eef37955c3e1cc5e", "class_name": "RelatedNodeInfo"}}, "text": "So \nthat's a positive.  ", "start_char_idx": 1446, "end_char_idx": 1470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab63efff-c51a-461b-900c-116a9b74579a": {"__data__": {"id_": "ab63efff-c51a-461b-900c-116a9b74579a", "embedding": null, "metadata": {"window": "Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0852aca3-2db5-4fae-b330-9bc9d288a552", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51651ed460f5adf5f979cae6d8ac23da7a41f566d6959986ec6cd78b1854b28a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "647ac908-8dd8-470d-84c7-614a787ff95c", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "So \nthat's a positive.  ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32c6858c88f7586d4f2f587d693e1c52cfa54b6437fd6d833ac8b3f4b4fc27d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9139bcc9-cd17-467f-a667-b7a527ecdeb1", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "original_text": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.  "}, "hash": "7650bb2767c59bf8d840358b6e6e7cf1116e9432a4aa398aa88ca5a589dbdd30", "class_name": "RelatedNodeInfo"}}, "text": "But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "start_char_idx": 1470, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9139bcc9-cd17-467f-a667-b7a527ecdeb1": {"__data__": {"id_": "9139bcc9-cd17-467f-a667-b7a527ecdeb1", "embedding": null, "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "original_text": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab63efff-c51a-461b-900c-116a9b74579a", "node_type": "1", "metadata": {"window": "Thanks for the question.   We are still dedicated to the framework and progress does continue.   So \nthat's a positive.   But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "original_text": "But as you can imagine, these are incredibly complicated arrangements we have to work \nthrough with 50 different states that we're working with.  \n ", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db0c1097eb4c3156649b3da281427c9eb894e39c0948940758d8c904d47a9f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b7d2b29-0adc-4d6e-8638-79692caf018e", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n", "original_text": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n "}, "hash": "81ae98cb4b909825f4f585751ea3a370bc622171598c4a50bc6a6607f1bba646", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.  ", "start_char_idx": 0, "end_char_idx": 175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b7d2b29-0adc-4d6e-8638-79692caf018e": {"__data__": {"id_": "3b7d2b29-0adc-4d6e-8638-79692caf018e", "embedding": null, "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n", "original_text": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9139bcc9-cd17-467f-a667-b7a527ecdeb1", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "original_text": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36c60fa0f5d443db4a0871188c4b499707616e1bb7d1f36cae750247f258ba7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4241d25-04f6-4f69-8bef-667cca67aca8", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n", "original_text": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.  "}, "hash": "b9ed0b6a3e704223f9d8db94cd4448e1e9126ad00545a3f2aa29be06247669b9", "class_name": "RelatedNodeInfo"}}, "text": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n ", "start_char_idx": 175, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4241d25-04f6-4f69-8bef-667cca67aca8": {"__data__": {"id_": "e4241d25-04f6-4f69-8bef-667cca67aca8", "embedding": null, "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n", "original_text": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b7d2b29-0adc-4d6e-8638-79692caf018e", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n", "original_text": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28078085a3076cddee64aa6d04d19b66169a0b87a87f70906f376ba289e38266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5bbaf20-4680-4882-83b9-e52c8b12563d", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.  ", "original_text": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  "}, "hash": "15543665cf9aba775f6318741aa149362b34829aaa8cd6a169fd2974b12d66e1", "class_name": "RelatedNodeInfo"}}, "text": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.  ", "start_char_idx": 318, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5bbaf20-4680-4882-83b9-e52c8b12563d": {"__data__": {"id_": "a5bbaf20-4680-4882-83b9-e52c8b12563d", "embedding": null, "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.  ", "original_text": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4241d25-04f6-4f69-8bef-667cca67aca8", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n", "original_text": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc8c6992d1ca80f7f73c50c7f7fd373d319c4319ee780a1067dd15df9ed0e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a56232b0-7818-43cd-8b97-c9eb9dc06478", "node_type": "1", "metadata": {"window": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  ", "original_text": "Next question, please.  \n \n"}, "hash": "a2a069f598600591091a01b8844ebe3b029bebaff16170dbd2d37b01e53d2bdf", "class_name": "RelatedNodeInfo"}}, "text": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "start_char_idx": 451, "end_char_idx": 609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a56232b0-7818-43cd-8b97-c9eb9dc06478": {"__data__": {"id_": "a56232b0-7818-43cd-8b97-c9eb9dc06478", "embedding": null, "metadata": {"window": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  ", "original_text": "Next question, please.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5bbaf20-4680-4882-83b9-e52c8b12563d", "node_type": "1", "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.  ", "original_text": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50bd7aac4fe965abb626233f382c50777be77bced7d3890c673f81b95d13bcdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "267d19bf-c90d-4fe2-aafa-a282fa485686", "node_type": "1", "metadata": {"window": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n ", "original_text": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n"}, "hash": "26dd8615ecb9024d603f9ee6bdeb9c96af6659b8640f213be0619784bb78115b", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 609, "end_char_idx": 636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "267d19bf-c90d-4fe2-aafa-a282fa485686": {"__data__": {"id_": "267d19bf-c90d-4fe2-aafa-a282fa485686", "embedding": null, "metadata": {"window": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n ", "original_text": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a56232b0-7818-43cd-8b97-c9eb9dc06478", "node_type": "1", "metadata": {"window": "And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  ", "original_text": "Next question, please.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd995664d25158de8df353b2871d2813a61bcb47e7f89d292420f854e96327ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b9b3942-ebe6-4f9c-947b-fa2e87a35057", "node_type": "1", "metadata": {"window": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.  ", "original_text": "Robert Jones :  Thanks for the question.  "}, "hash": "70fadf81870f4f1626e2fa53049e584475de1db77d110a49012d11457029cb8e", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n", "start_char_idx": 636, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b9b3942-ebe6-4f9c-947b-fa2e87a35057": {"__data__": {"id_": "0b9b3942-ebe6-4f9c-947b-fa2e87a35057", "embedding": null, "metadata": {"window": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.  ", "original_text": "Robert Jones :  Thanks for the question.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "267d19bf-c90d-4fe2-aafa-a282fa485686", "node_type": "1", "metadata": {"window": "And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n ", "original_text": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbfd5db04caf3bb94accf6c77c413f64b0b73c45ec3d471d143752e14e30f73d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4930ff8f-271b-4d90-b403-5f7de0dd4365", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n ", "original_text": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  "}, "hash": "2a75dddd222f2046448cb1ef413e3d13f99f04de4bfab801b5f3589b99d4064b", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones :  Thanks for the question.  ", "start_char_idx": 724, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4930ff8f-271b-4d90-b403-5f7de0dd4365": {"__data__": {"id_": "4930ff8f-271b-4d90-b403-5f7de0dd4365", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n ", "original_text": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b9b3942-ebe6-4f9c-947b-fa2e87a35057", "node_type": "1", "metadata": {"window": "The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.   Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.  ", "original_text": "Robert Jones :  Thanks for the question.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc2124cf608f3b2f33616905df505a9f8546505118668893b5f0a0422a9c844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e03189d2-f6e9-468d-af1a-c242bf47a9dd", "node_type": "1", "metadata": {"window": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.  ", "original_text": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n "}, "hash": "4e7dec421ed2c29cff538e5ecac017842ad98971effe95d1ccb1151bd31134b5", "class_name": "RelatedNodeInfo"}}, "text": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  ", "start_char_idx": 766, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e03189d2-f6e9-468d-af1a-c242bf47a9dd": {"__data__": {"id_": "e03189d2-f6e9-468d-af1a-c242bf47a9dd", "embedding": null, "metadata": {"window": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.  ", "original_text": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4930ff8f-271b-4d90-b403-5f7de0dd4365", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n ", "original_text": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd5a7e0c9b01f15ca0eccc7f76894c419efc4ce0b96ea2b8ac9e9ae9bde7ad7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fcaef7d-cda6-47c2-bc97-8cb051f896bb", "node_type": "1", "metadata": {"window": "Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n", "original_text": "You know, you obviously sound incrementally, you know, more positive that this is progressing.  "}, "hash": "f46740999ce9fb8c1198fbfc4e01c949e0c518f67d00463b7fa8a782ff9e9800", "class_name": "RelatedNodeInfo"}}, "text": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n ", "start_char_idx": 885, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fcaef7d-cda6-47c2-bc97-8cb051f896bb": {"__data__": {"id_": "3fcaef7d-cda6-47c2-bc97-8cb051f896bb", "embedding": null, "metadata": {"window": "Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n", "original_text": "You know, you obviously sound incrementally, you know, more positive that this is progressing.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e03189d2-f6e9-468d-af1a-c242bf47a9dd", "node_type": "1", "metadata": {"window": "Operator :  And we'll go to our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.  ", "original_text": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "881b4992a0dcdfce0785728c95b8a225b6ba01786a84afb6bfeffd0bd4ab4333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76638140-c614-426c-bbcd-b4a9bf9904cd", "node_type": "1", "metadata": {"window": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.  ", "original_text": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n "}, "hash": "b4d5385b0da29818f4b89434118178b59fee24fc6bae8f4c2324f561af408b5e", "class_name": "RelatedNodeInfo"}}, "text": "You know, you obviously sound incrementally, you know, more positive that this is progressing.  ", "start_char_idx": 995, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76638140-c614-426c-bbcd-b4a9bf9904cd": {"__data__": {"id_": "76638140-c614-426c-bbcd-b4a9bf9904cd", "embedding": null, "metadata": {"window": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.  ", "original_text": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fcaef7d-cda6-47c2-bc97-8cb051f896bb", "node_type": "1", "metadata": {"window": "Robert Jones :  Thanks for the question.   Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n", "original_text": "You know, you obviously sound incrementally, you know, more positive that this is progressing.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3398a480e64c2b3528fd56b56b82c44aec6365aba689c82318d16104d41a767e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8642afcf-227b-4858-b727-698aa5362d98", "node_type": "1", "metadata": {"window": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "I think the original framework that we had all seen obviously highlighted just four state AGs.  "}, "hash": "47f78d53b4ce361d9055b76e7d7c6768fb2a811b4e9f174769d8b37dab41e429", "class_name": "RelatedNodeInfo"}}, "text": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n ", "start_char_idx": 1091, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8642afcf-227b-4858-b727-698aa5362d98": {"__data__": {"id_": "8642afcf-227b-4858-b727-698aa5362d98", "embedding": null, "metadata": {"window": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "I think the original framework that we had all seen obviously highlighted just four state AGs.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76638140-c614-426c-bbcd-b4a9bf9904cd", "node_type": "1", "metadata": {"window": "Yes, I guess just to stick with that topic, Mike, because obviously it's so important \nto Cardinal and to the  group.   You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.  ", "original_text": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355d691ebfe2f6f4fc89baf703f78b7c79465804f335a5a8146b2b0cbd02ae0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6ef050c-0f9e-42c1-bfa0-f504400198f6", "node_type": "1", "metadata": {"window": "You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n"}, "hash": "b3f18c5524ca76ebac68287512f031bdd7c481f1abcb17da3fd08f3236649aac", "class_name": "RelatedNodeInfo"}}, "text": "I think the original framework that we had all seen obviously highlighted just four state AGs.  ", "start_char_idx": 1289, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6ef050c-0f9e-42c1-bfa0-f504400198f6": {"__data__": {"id_": "b6ef050c-0f9e-42c1-bfa0-f504400198f6", "embedding": null, "metadata": {"window": "You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8642afcf-227b-4858-b727-698aa5362d98", "node_type": "1", "metadata": {"window": "You know, one of your peers t alked about narrowing conversations around a \npotential opioid settlement.  \n \n  You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "I think the original framework that we had all seen obviously highlighted just four state AGs.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1951372fb99b591f6178f72d3aab96b0d11a43cbee997fc351a6ed34a4cf13e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bb7ea52-0f1a-4e5d-8a5d-2d0a14cb8415", "node_type": "1", "metadata": {"window": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "Mike Kaufmann :  Yes, thanks again for the question on this important topic.  "}, "hash": "ca12c1352d50c6d5f013025562f01f54d9ed330fb1a31e556bf3bb7a5ce48b15", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n", "start_char_idx": 1385, "end_char_idx": 1488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bb7ea52-0f1a-4e5d-8a5d-2d0a14cb8415": {"__data__": {"id_": "7bb7ea52-0f1a-4e5d-8a5d-2d0a14cb8415", "embedding": null, "metadata": {"window": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "Mike Kaufmann :  Yes, thanks again for the question on this important topic.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6ef050c-0f9e-42c1-bfa0-f504400198f6", "node_type": "1", "metadata": {"window": "You know, you obviously sound incrementally, you know, more positive that this is progressing.   Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2d50671105319534a5b013c04561a01a6508776840caad905ee68a22efb92e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c052b15-3d54-4d83-844a-7d5baf22c3bb", "node_type": "1", "metadata": {"window": "I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n "}, "hash": "4ff7a3604417b0c06b935ad785be925d53553e4deb8cb1d0846fd8b020097694", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, thanks again for the question on this important topic.  ", "start_char_idx": 1488, "end_char_idx": 1566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c052b15-3d54-4d83-844a-7d5baf22c3bb": {"__data__": {"id_": "9c052b15-3d54-4d83-844a-7d5baf22c3bb", "embedding": null, "metadata": {"window": "I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1ca50656-4b33-4930-8de6-396f6665d59a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11829018d9b8293954d46512395e6b54a3f02b2dfa30da7bfbd0b84a62f39fdc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bb7ea52-0f1a-4e5d-8a5d-2d0a14cb8415", "node_type": "1", "metadata": {"window": "Could you maybe \njust give a little bit more on, you know, how many other states, may be not specifically, but are more states and \nlocal governments and municipalities engaging at this point?  \n \n  I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "Mike Kaufmann :  Yes, thanks again for the question on this important topic.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718f11d1d299b4a066e60ac7d17e89a43569f6bb361fcccd057d9ddc686b5bdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "757b4c50-3704-403e-b355-ba7dac18c0c6", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.  ", "original_text": " \nPage 11 of 32 \n \n They have been working with all 50 states.  "}, "hash": "2a0dc335f46b80abd3e23fc262c56bcffbcf2628bcacf1d31258423007247ab5", "class_name": "RelatedNodeInfo"}}, "text": "As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "start_char_idx": 1566, "end_char_idx": 1699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "757b4c50-3704-403e-b355-ba7dac18c0c6": {"__data__": {"id_": "757b4c50-3704-403e-b355-ba7dac18c0c6", "embedding": null, "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.  ", "original_text": " \nPage 11 of 32 \n \n They have been working with all 50 states.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c052b15-3d54-4d83-844a-7d5baf22c3bb", "node_type": "1", "metadata": {"window": "I think the original framework that we had all seen obviously highlighted just four state AGs.   I'm just curious, \nspecifically are you seeing more p eople coming to the other side of the table?  \n \n Mike Kaufmann :  Yes, thanks again for the question on this important topic.   As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "original_text": "As I said, we remain committed to this \nframework and we're very appreciative of the four AGs that took the initial lead on this.  \n ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9b203f44ff849bcc52a73e37e4802762fbf3fba92b52627f9bb35a9134bb68c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53f46995-dd55-4cbd-b8f5-7cc973cb1e6c", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n", "original_text": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.  "}, "hash": "a89b72a6d25ff30f8d9a9a661d4b5c688dbea555dfb9ef14e680204040490320", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 32 \n \n They have been working with all 50 states.  ", "start_char_idx": 0, "end_char_idx": 64, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53f46995-dd55-4cbd-b8f5-7cc973cb1e6c": {"__data__": {"id_": "53f46995-dd55-4cbd-b8f5-7cc973cb1e6c", "embedding": null, "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n", "original_text": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "757b4c50-3704-403e-b355-ba7dac18c0c6", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.  ", "original_text": " \nPage 11 of 32 \n \n They have been working with all 50 states.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfdece2486837b4c20827f324a2b6456dec68c7f1c82436ac67fb0c7f3626854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "560b7236-5d77-4949-852c-f4c6633404b2", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.  ", "original_text": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n "}, "hash": "8780f36d3d31126366a46799262b75e757f0b2f3647f5c292c6cf157881c944a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.  ", "start_char_idx": 64, "end_char_idx": 184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "560b7236-5d77-4949-852c-f4c6633404b2": {"__data__": {"id_": "560b7236-5d77-4949-852c-f4c6633404b2", "embedding": null, "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.  ", "original_text": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53f46995-dd55-4cbd-b8f5-7cc973cb1e6c", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n", "original_text": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf262cf96838850aba64b97f167a66e19f6f8b89c9e15e65a7d6bbf68423a0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7785220-69e8-4375-b585-2a6ac7f3bdbe", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.  ", "original_text": "But I will tell you that the four AGs that we talked to continue to make progress.  "}, "hash": "4fee6006334e3b96d981a1e28058d5f40503f7ad8ac81ca2b42c15d7821bd4b0", "class_name": "RelatedNodeInfo"}}, "text": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n ", "start_char_idx": 184, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7785220-69e8-4375-b585-2a6ac7f3bdbe": {"__data__": {"id_": "a7785220-69e8-4375-b585-2a6ac7f3bdbe", "embedding": null, "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.  ", "original_text": "But I will tell you that the four AGs that we talked to continue to make progress.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "560b7236-5d77-4949-852c-f4c6633404b2", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.  ", "original_text": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cdd9e725f9d52ec13df523847145b3176d1ec259bcc980e99222dbb24a0a3b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4abbc5af-6ff5-4b4c-97e4-598709476001", "node_type": "1", "metadata": {"window": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n ", "original_text": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n"}, "hash": "10be66a3eac7d1abe5e2878104ee5b825f54bb49057c58c5565d57c6148b60a3", "class_name": "RelatedNodeInfo"}}, "text": "But I will tell you that the four AGs that we talked to continue to make progress.  ", "start_char_idx": 300, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4abbc5af-6ff5-4b4c-97e4-598709476001": {"__data__": {"id_": "4abbc5af-6ff5-4b4c-97e4-598709476001", "embedding": null, "metadata": {"window": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n ", "original_text": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7785220-69e8-4375-b585-2a6ac7f3bdbe", "node_type": "1", "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.  ", "original_text": "But I will tell you that the four AGs that we talked to continue to make progress.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f2cfe92dc755a908fa5348ce529e893a697ae4e46a1900354537c076804266c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8403a479-7333-4e0e-af5c-b3aa28850fe7", "node_type": "1", "metadata": {"window": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.  ", "original_text": "Robert Jones :  No, no.  "}, "hash": "11d57f9ae15a5b96840518f5db62568bf45c8e3a94277e3281b48da247f3dfd4", "class_name": "RelatedNodeInfo"}}, "text": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n", "start_char_idx": 384, "end_char_idx": 767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8403a479-7333-4e0e-af5c-b3aa28850fe7": {"__data__": {"id_": "8403a479-7333-4e0e-af5c-b3aa28850fe7", "embedding": null, "metadata": {"window": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.  ", "original_text": "Robert Jones :  No, no.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4abbc5af-6ff5-4b4c-97e4-598709476001", "node_type": "1", "metadata": {"window": "We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n ", "original_text": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f957832ed6091137cb6d9310ac8e0adf602c4d6cea8f21859db711fb4a06c59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72052fd3-0d33-4663-bce9-9f0f79478738", "node_type": "1", "metadata": {"window": "But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n", "original_text": "I appreciat e that, Mike.  "}, "hash": "225b86fd78f55522c809aeec953a4428e25635b2ff1fab0e9581628818efd73a", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones :  No, no.  ", "start_char_idx": 767, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72052fd3-0d33-4663-bce9-9f0f79478738": {"__data__": {"id_": "72052fd3-0d33-4663-bce9-9f0f79478738", "embedding": null, "metadata": {"window": "But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n", "original_text": "I appreciat e that, Mike.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8403a479-7333-4e0e-af5c-b3aa28850fe7", "node_type": "1", "metadata": {"window": "But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.  ", "original_text": "Robert Jones :  No, no.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a92d929aaaf64bd28f371c83c254394e01f457e0aa3884bd90c5f07b71920a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c140c8f-14d3-4352-9225-3f7f4d53196f", "node_type": "1", "metadata": {"window": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.  ", "original_text": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n "}, "hash": "fa31fb06bc220774d12252962ed6772962e5660d27927c7103da9fa17fde74d7", "class_name": "RelatedNodeInfo"}}, "text": "I appreciat e that, Mike.  ", "start_char_idx": 792, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c140c8f-14d3-4352-9225-3f7f4d53196f": {"__data__": {"id_": "2c140c8f-14d3-4352-9225-3f7f4d53196f", "embedding": null, "metadata": {"window": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.  ", "original_text": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72052fd3-0d33-4663-bce9-9f0f79478738", "node_type": "1", "metadata": {"window": "But I will tell you that the four AGs that we talked to continue to make progress.   And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n", "original_text": "I appreciat e that, Mike.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "595e472d548b64354c9a46058414ec3b92f331e3df1136a6686967f19a3c6531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4866f63-1e66-438b-95e4-8f79aa63405b", "node_type": "1", "metadata": {"window": "Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  ", "original_text": "You guys talked specifically about four components that I guess compri se your generic program.  "}, "hash": "9cf9111b72ec7b65df50895fd3c0d7e3294961d5b63896a0072dfaf9efa15ccd", "class_name": "RelatedNodeInfo"}}, "text": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n ", "start_char_idx": 819, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4866f63-1e66-438b-95e4-8f79aa63405b": {"__data__": {"id_": "f4866f63-1e66-438b-95e4-8f79aa63405b", "embedding": null, "metadata": {"window": "Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  ", "original_text": "You guys talked specifically about four components that I guess compri se your generic program.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c140c8f-14d3-4352-9225-3f7f4d53196f", "node_type": "1", "metadata": {"window": "And I think we all believe that this \nis the right thing to do for the companies and for the country to help get some relief to the people that need it with  \nnot only the dollars we're talking about, which are important, but equally the other components, which are \ndistributing the free goods and working with them on programs to improve the overall monitoring of the opioids.  \n \n Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.  ", "original_text": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcb203ee322d50cfd02643b6b414c93790e854309bdfe91e8306aad1e29d833e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "451a16de-a0de-4f31-bb4a-4af1094d1000", "node_type": "1", "metadata": {"window": "I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  ", "original_text": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n"}, "hash": "b99664faf4e1e3012bcff9023651077f4ce2af5fd4c9a6e6da3911ea927d1bc5", "class_name": "RelatedNodeInfo"}}, "text": "You guys talked specifically about four components that I guess compri se your generic program.  ", "start_char_idx": 994, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "451a16de-a0de-4f31-bb4a-4af1094d1000": {"__data__": {"id_": "451a16de-a0de-4f31-bb4a-4af1094d1000", "embedding": null, "metadata": {"window": "I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  ", "original_text": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4866f63-1e66-438b-95e4-8f79aa63405b", "node_type": "1", "metadata": {"window": "Robert Jones :  No, no.   I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  ", "original_text": "You guys talked specifically about four components that I guess compri se your generic program.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "441791558dd34d6ef99ab04b199330f402a0b6da346a62db5135a778bc090b56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf30973d-1d9c-4768-9c62-4ec9ce74d4f0", "node_type": "1", "metadata": {"window": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n ", "original_text": "Mike Kaufmann :  Yes, I think a couple of things.  "}, "hash": "43afc4e780f11e58e5a398ce3c65d932a2198b29c798a4d9d20710e323bf8276", "class_name": "RelatedNodeInfo"}}, "text": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n", "start_char_idx": 1091, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf30973d-1d9c-4768-9c62-4ec9ce74d4f0": {"__data__": {"id_": "bf30973d-1d9c-4768-9c62-4ec9ce74d4f0", "embedding": null, "metadata": {"window": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n ", "original_text": "Mike Kaufmann :  Yes, I think a couple of things.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "451a16de-a0de-4f31-bb4a-4af1094d1000", "node_type": "1", "metadata": {"window": "I appreciat e that, Mike.   And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  ", "original_text": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ffcbcf5e7cbafa4db4ed231b21ddf467d14325c89b793b81623bda7cef8838e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc07711a-ba64-41d4-a2de-6b8e39627208", "node_type": "1", "metadata": {"window": "You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.  ", "original_text": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  "}, "hash": "c15b6d61ed86ae17076ce397b6f90fca503fc53e34dbd7eb8b3fa70f0b1f39b0", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, I think a couple of things.  ", "start_char_idx": 1243, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc07711a-ba64-41d4-a2de-6b8e39627208": {"__data__": {"id_": "bc07711a-ba64-41d4-a2de-6b8e39627208", "embedding": null, "metadata": {"window": "You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.  ", "original_text": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf30973d-1d9c-4768-9c62-4ec9ce74d4f0", "node_type": "1", "metadata": {"window": "And I guess just to go back to this generic program dynamic, you know, \nyou highlighted this is the first time in several quarters it went from a headwind to a tailwind.  \n \n  You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n ", "original_text": "Mike Kaufmann :  Yes, I think a couple of things.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adc003513a8ff322c1eb4cae3f04bd578d0b2dd58836a5f4beb9b2135a1c6240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9c55f4d-c08f-4dc4-9d5b-a736c6ae0925", "node_type": "1", "metadata": {"window": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.  ", "original_text": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  "}, "hash": "a50ceb75d8c8d8b4a0b6ef55967eb5564e35b0bf53045ba4bd0a19272f1a368d", "class_name": "RelatedNodeInfo"}}, "text": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  ", "start_char_idx": 1294, "end_char_idx": 1423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9c55f4d-c08f-4dc4-9d5b-a736c6ae0925": {"__data__": {"id_": "c9c55f4d-c08f-4dc4-9d5b-a736c6ae0925", "embedding": null, "metadata": {"window": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.  ", "original_text": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc07711a-ba64-41d4-a2de-6b8e39627208", "node_type": "1", "metadata": {"window": "You guys talked specifically about four components that I guess compri se your generic program.   Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.  ", "original_text": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10f8c584e883c8767cac0fc7fffe77323014f92804b52737f85683c2bc073472", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a6224e-0095-4708-8602-aecc94271eb5", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "But this was the big driver.  \n \n "}, "hash": "b9d56416851543cc964fc83b12ada3b86451456e8d6e49d91e128a4c578bdbaa", "class_name": "RelatedNodeInfo"}}, "text": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  ", "start_char_idx": 1423, "end_char_idx": 1524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a6224e-0095-4708-8602-aecc94271eb5": {"__data__": {"id_": "33a6224e-0095-4708-8602-aecc94271eb5", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "But this was the big driver.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9c55f4d-c08f-4dc4-9d5b-a736c6ae0925", "node_type": "1", "metadata": {"window": "Could you \nmaybe just dive a little deeper into what exactly changed, you know, to flip the generics from a headwind to a \ntailwind in the quarter?  \n \n Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.  ", "original_text": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ed1b1581f5406b8517b5d9da08de456bf8b3a9486c940b819d4a5b181b8eb8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53444d06-f00f-4e01-a226-1a1c4f56d1a1", "node_type": "1", "metadata": {"window": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "And it's really good performan ce across all of the components.  "}, "hash": "5e33e2a7b9d5674382a90f26857f9ad8c59a295b85550460971e00d2d9b78bae", "class_name": "RelatedNodeInfo"}}, "text": "But this was the big driver.  \n \n ", "start_char_idx": 1524, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53444d06-f00f-4e01-a226-1a1c4f56d1a1": {"__data__": {"id_": "53444d06-f00f-4e01-a226-1a1c4f56d1a1", "embedding": null, "metadata": {"window": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "And it's really good performan ce across all of the components.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a6224e-0095-4708-8602-aecc94271eb5", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, I think a couple of things.   I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "But this was the big driver.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f38173ee11abc7e91ba331bddf310436bfd6ecccf471c70f1c751fe1f425a3b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26816b8e-429f-45c2-be8d-4cf2085c7b3e", "node_type": "1", "metadata": {"window": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "We're very happy with Red Oak.  "}, "hash": "8fabe0e38b121e52c4aae4ebcc614fe3ed7e9173621ae87f770c86778d52ac9c", "class_name": "RelatedNodeInfo"}}, "text": "And it's really good performan ce across all of the components.  ", "start_char_idx": 1558, "end_char_idx": 1623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26816b8e-429f-45c2-be8d-4cf2085c7b3e": {"__data__": {"id_": "26816b8e-429f-45c2-be8d-4cf2085c7b3e", "embedding": null, "metadata": {"window": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "We're very happy with Red Oak.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53444d06-f00f-4e01-a226-1a1c4f56d1a1", "node_type": "1", "metadata": {"window": "I think first of all by far this is the item that drove the difference in our \nexpectations for the quarter, as Dave mentioned.   Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "And it's really good performan ce across all of the components.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57f0800f9cadabdd34f6bb8f87251b46d9e8b574dc695ecc6ed90c4e2ce20ca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e40b9e18-03e5-4ac6-ac7b-478172d0f0ca", "node_type": "1", "metadata": {"window": "But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n "}, "hash": "4f205147a8580048d5f9b7619da2e16e872fc1ac02579d7c469e0936887450ff", "class_name": "RelatedNodeInfo"}}, "text": "We're very happy with Red Oak.  ", "start_char_idx": 1623, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e40b9e18-03e5-4ac6-ac7b-478172d0f0ca": {"__data__": {"id_": "e40b9e18-03e5-4ac6-ac7b-478172d0f0ca", "embedding": null, "metadata": {"window": "But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb11f40c9d1ea2f0aa6b67b2b589af5f3c8e48238f7684021aa775daa4e8f12e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26816b8e-429f-45c2-be8d-4cf2085c7b3e", "node_type": "1", "metadata": {"window": "Pretty much everything else was right there where we expected \nit to be, maybe a little bit better.   But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "We're very happy with Red Oak.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2c9e4c8e40b80a579cbe56ed6c7a881c64b17038ada0c986c971dc537c4c85b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7981e866-9b63-4902-bbe2-3301aefb25ae", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "original_text": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.  "}, "hash": "e3bedb0620a0c72a0b21138f02befad60d09542a7cbffeab13987457abc995a6", "class_name": "RelatedNodeInfo"}}, "text": "They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "start_char_idx": 1655, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7981e866-9b63-4902-bbe2-3301aefb25ae": {"__data__": {"id_": "7981e866-9b63-4902-bbe2-3301aefb25ae", "embedding": null, "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "original_text": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e40b9e18-03e5-4ac6-ac7b-478172d0f0ca", "node_type": "1", "metadata": {"window": "But this was the big driver.  \n \n  And it's really good performan ce across all of the components.   We're very happy with Red Oak.   They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "original_text": "They continue \nto perform at a very high level not only in getting after cost for us but also just doing an excellent job on service \nlevel.  \n ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "854eed273e93b125286c72b5aa6776315e4ba17cf18e0e14c0ca4d8f34093d6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4dbab9d-2233-4e54-8f26-f57d53c874a9", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n", "original_text": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n "}, "hash": "fa80b920e4ae87356a8bfed2d21340c5be1dea871d85d67697faa5a18a7e4104", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.  ", "start_char_idx": 0, "end_char_idx": 183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4dbab9d-2233-4e54-8f26-f57d53c874a9": {"__data__": {"id_": "a4dbab9d-2233-4e54-8f26-f57d53c874a9", "embedding": null, "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n", "original_text": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7981e866-9b63-4902-bbe2-3301aefb25ae", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "original_text": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "462d15696d4df4e277f40440ebbfa6ef21a0bc0b275c5b85b3b25ea2a65f34d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61b64baf-7e35-4342-b773-882c372c1f61", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.  ", "original_text": "And then the other big factor is going to be just market dynamics.  "}, "hash": "c618054ba622c437457e3b92eb30a73da13a2cc88ccbb2a01b5380e87dfc7344", "class_name": "RelatedNodeInfo"}}, "text": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n ", "start_char_idx": 183, "end_char_idx": 437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61b64baf-7e35-4342-b773-882c372c1f61": {"__data__": {"id_": "61b64baf-7e35-4342-b773-882c372c1f61", "embedding": null, "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.  ", "original_text": "And then the other big factor is going to be just market dynamics.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4dbab9d-2233-4e54-8f26-f57d53c874a9", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n", "original_text": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40253ab4b40eb3bf278712d851b8b9db2f0f4127f62dd7a26faa84ed32fe5b5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ebe255c-cb01-46ec-bfe3-08dd13de60fc", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.  ", "original_text": "We've seen significant improvement in the \noverall market dynamics on the pricing side .  "}, "hash": "1e064952e64d96675305cc30e675a3fbe474a61a145354ed18fe213f2d1063c7", "class_name": "RelatedNodeInfo"}}, "text": "And then the other big factor is going to be just market dynamics.  ", "start_char_idx": 437, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ebe255c-cb01-46ec-bfe3-08dd13de60fc": {"__data__": {"id_": "1ebe255c-cb01-46ec-bfe3-08dd13de60fc", "embedding": null, "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.  ", "original_text": "We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61b64baf-7e35-4342-b773-882c372c1f61", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.  ", "original_text": "And then the other big factor is going to be just market dynamics.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b93a1187bda003b56fb0c1b26e7bb85605403cb794cd391b3324c593f565c26b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2df2aa94-1b10-427a-8f12-901b78206eaa", "node_type": "1", "metadata": {"window": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.  ", "original_text": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n"}, "hash": "0d667b6b3614d1836c91bce8661f0287196a90b810721a68e63ddda1b782482f", "class_name": "RelatedNodeInfo"}}, "text": "We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "start_char_idx": 505, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2df2aa94-1b10-427a-8f12-901b78206eaa": {"__data__": {"id_": "2df2aa94-1b10-427a-8f12-901b78206eaa", "embedding": null, "metadata": {"window": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.  ", "original_text": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ebe255c-cb01-46ec-bfe3-08dd13de60fc", "node_type": "1", "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.  ", "original_text": "We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce1e47a12cc22da2e495aa8045eb640d12b91da7df62c2a89c8943126931c152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8933b933-08ca-4f35-bd86-eb7a9b0356de", "node_type": "1", "metadata": {"window": "And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.  ", "original_text": "David Evans :  Yes.  "}, "hash": "fbd91f5b2c5578ffcf1e93acb3383a92c094efd2171d8492228700c3dfbe407d", "class_name": "RelatedNodeInfo"}}, "text": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n", "start_char_idx": 595, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8933b933-08ca-4f35-bd86-eb7a9b0356de": {"__data__": {"id_": "8933b933-08ca-4f35-bd86-eb7a9b0356de", "embedding": null, "metadata": {"window": "And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.  ", "original_text": "David Evans :  Yes.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2df2aa94-1b10-427a-8f12-901b78206eaa", "node_type": "1", "metadata": {"window": "So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.  ", "original_text": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88dd8ddac0361bf491cfc6b08f9fc313bcefb97fbf99dc92ed49192ec4c0c475", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f2a0c80-1474-4372-8cfc-65097240cfd8", "node_type": "1", "metadata": {"window": "We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n", "original_text": "Just, hey, Mike, you hit it on the head there.  "}, "hash": "c361415fdb7dad0156dc179cc8841d78114663ac1224258e20cfa59bed87afe2", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Yes.  ", "start_char_idx": 776, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f2a0c80-1474-4372-8cfc-65097240cfd8": {"__data__": {"id_": "8f2a0c80-1474-4372-8cfc-65097240cfd8", "embedding": null, "metadata": {"window": "We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n", "original_text": "Just, hey, Mike, you hit it on the head there.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8933b933-08ca-4f35-bd86-eb7a9b0356de", "node_type": "1", "metadata": {"window": "And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.  ", "original_text": "David Evans :  Yes.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2b76059b77949f13a657cf0e4c68769b6a6eaf1d72a7684857d018b052e6a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c779f519-6d40-42ef-ba08-7ede125c22d7", "node_type": "1", "metadata": {"window": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n", "original_text": "I think w e did have an earlier than expected launch of \nsome new items.  "}, "hash": "e4b9a3a60228f6a05d44b739b7533490247f06a8eee4c3694e54edf4713bb93c", "class_name": "RelatedNodeInfo"}}, "text": "Just, hey, Mike, you hit it on the head there.  ", "start_char_idx": 797, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c779f519-6d40-42ef-ba08-7ede125c22d7": {"__data__": {"id_": "c779f519-6d40-42ef-ba08-7ede125c22d7", "embedding": null, "metadata": {"window": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n", "original_text": "I think w e did have an earlier than expected launch of \nsome new items.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f2a0c80-1474-4372-8cfc-65097240cfd8", "node_type": "1", "metadata": {"window": "We've seen significant improvement in the \noverall market dynamics on the pricing side .   So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n", "original_text": "Just, hey, Mike, you hit it on the head there.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39e9673698fc09d2c0e595d819b1c0e815cae35802ec1274e53386b641a367c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef8f4ec5-588f-43e2-b8c4-92f820d9b865", "node_type": "1", "metadata": {"window": "David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "That was helpful for the quarter.  "}, "hash": "a8c5f6122d8354038e9da42f4586e721cfd035daca291063e1b0691c6b111a61", "class_name": "RelatedNodeInfo"}}, "text": "I think w e did have an earlier than expected launch of \nsome new items.  ", "start_char_idx": 845, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef8f4ec5-588f-43e2-b8c4-92f820d9b865": {"__data__": {"id_": "ef8f4ec5-588f-43e2-b8c4-92f820d9b865", "embedding": null, "metadata": {"window": "David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "That was helpful for the quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c779f519-6d40-42ef-ba08-7ede125c22d7", "node_type": "1", "metadata": {"window": "So when you put all of the components together and we had a \nstrong quarter on launches, it was really strength across all of the components that made the program \noverperform.  \n \n David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n", "original_text": "I think w e did have an earlier than expected launch of \nsome new items.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ced9e5c1140ae5a93a6e350ec8a003d57427e3aa6a859a2cfa28113b3a837949", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "818d1d59-1697-4ef9-be27-fdcd7dcec32f", "node_type": "1", "metadata": {"window": "Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.  ", "original_text": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n"}, "hash": "0ccac662f48329a1370a1f8df0518306e71df368e271b1cfc8ba4bd6788522df", "class_name": "RelatedNodeInfo"}}, "text": "That was helpful for the quarter.  ", "start_char_idx": 919, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "818d1d59-1697-4ef9-be27-fdcd7dcec32f": {"__data__": {"id_": "818d1d59-1697-4ef9-be27-fdcd7dcec32f", "embedding": null, "metadata": {"window": "Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.  ", "original_text": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef8f4ec5-588f-43e2-b8c4-92f820d9b865", "node_type": "1", "metadata": {"window": "David Evans :  Yes.   Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "That was helpful for the quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70bb81d7925f12556ac2a4d58dcc316420159a2a285e0f8721a196dfb76d37b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f5fd2e8-e803-4aeb-970f-381af58a464b", "node_type": "1", "metadata": {"window": "I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.  ", "original_text": "Kevin Moran :  Next question please.  \n \n"}, "hash": "de7bb5a5b983dce47cdb2de0195e51e84a38971a8070944261f72b783731b5a4", "class_name": "RelatedNodeInfo"}}, "text": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n", "start_char_idx": 954, "end_char_idx": 1062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f5fd2e8-e803-4aeb-970f-381af58a464b": {"__data__": {"id_": "1f5fd2e8-e803-4aeb-970f-381af58a464b", "embedding": null, "metadata": {"window": "I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.  ", "original_text": "Kevin Moran :  Next question please.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "818d1d59-1697-4ef9-be27-fdcd7dcec32f", "node_type": "1", "metadata": {"window": "Just, hey, Mike, you hit it on the head there.   I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.  ", "original_text": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5195df4a8e38c46fef8c6e7e251191b2647ea309e82dfb68f32392bc933b17f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97e54a2a-72a8-4c19-9568-747ce271bc48", "node_type": "1", "metadata": {"window": "That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n ", "original_text": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n"}, "hash": "e7603da61c351ac80b9e144295bd4d234547ea7cf3e7339388bcd6aad1dbad75", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Next question please.  \n \n", "start_char_idx": 1062, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97e54a2a-72a8-4c19-9568-747ce271bc48": {"__data__": {"id_": "97e54a2a-72a8-4c19-9568-747ce271bc48", "embedding": null, "metadata": {"window": "That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n ", "original_text": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f5fd2e8-e803-4aeb-970f-381af58a464b", "node_type": "1", "metadata": {"window": "I think w e did have an earlier than expected launch of \nsome new items.   That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.  ", "original_text": "Kevin Moran :  Next question please.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cec259e6a8bdb0e471c302e0d81b2ac01cd8091dce7cfeed9ff2a1b275aa086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "227fb644-4d79-4521-aefe-d3ef6338b30b", "node_type": "1", "metadata": {"window": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.  ", "original_text": "Ricky Goldwasser :  Yes, hi.  "}, "hash": "f32634c9fc48cfc31836312adc70fa54b208c70c0f7f2daaa83afeae2b2fbc07", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n", "start_char_idx": 1103, "end_char_idx": 1174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "227fb644-4d79-4521-aefe-d3ef6338b30b": {"__data__": {"id_": "227fb644-4d79-4521-aefe-d3ef6338b30b", "embedding": null, "metadata": {"window": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.  ", "original_text": "Ricky Goldwasser :  Yes, hi.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97e54a2a-72a8-4c19-9568-747ce271bc48", "node_type": "1", "metadata": {"window": "That was helpful for the quarter.   In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n ", "original_text": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05316ebcb9b727ec42642c1c3a93e5adf2039e38f996fe564741d2a6799e0021", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64217d82-5c7d-4879-bb97-8493b6452dd8", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "Good morning and congrats on a very good quarter.  "}, "hash": "a1bd6c5b797f0a869d731678fef5a49f965ec8fd883a94fb62d78ced65ef7521", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser :  Yes, hi.  ", "start_char_idx": 1174, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64217d82-5c7d-4879-bb97-8493b6452dd8": {"__data__": {"id_": "64217d82-5c7d-4879-bb97-8493b6452dd8", "embedding": null, "metadata": {"window": "Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "Good morning and congrats on a very good quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "227fb644-4d79-4521-aefe-d3ef6338b30b", "node_type": "1", "metadata": {"window": "In addition, we had a fairly favorable mix that helped drive the \nresults we saw in the second quarter.  \n \n Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.  ", "original_text": "Ricky Goldwasser :  Yes, hi.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "504d79541deb306bcd4fc9aabdde8b76a36441fafed1a9de8b8b4143d865d3ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc72b49d-2a08-418f-9114-3c384440f2dd", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n "}, "hash": "5e8a79096421b9a2d285fb58b3d3cb9b96b43207f3750fb32099860c66dbe3d3", "class_name": "RelatedNodeInfo"}}, "text": "Good morning and congrats on a very good quarter.  ", "start_char_idx": 1204, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc72b49d-2a08-418f-9114-3c384440f2dd": {"__data__": {"id_": "cc72b49d-2a08-418f-9114-3c384440f2dd", "embedding": null, "metadata": {"window": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64217d82-5c7d-4879-bb97-8493b6452dd8", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question please.  \n \n Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "Good morning and congrats on a very good quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "402813d0d5fdd13c74ce8fee026f6bcbd1dbb81908c8984af174460593c86f6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75fa039d-b4f6-43bc-8f05-60bf6f1182c9", "node_type": "1", "metadata": {"window": "Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "And focusing on the buy side, you know, China is an important source of generic API supply.  "}, "hash": "4d4b027ec57064e644255ccf34d5df6d4c61313a132065cb3923e6104394695d", "class_name": "RelatedNodeInfo"}}, "text": "You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n ", "start_char_idx": 1255, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75fa039d-b4f6-43bc-8f05-60bf6f1182c9": {"__data__": {"id_": "75fa039d-b4f6-43bc-8f05-60bf6f1182c9", "embedding": null, "metadata": {"window": "Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "And focusing on the buy side, you know, China is an important source of generic API supply.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc72b49d-2a08-418f-9114-3c384440f2dd", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c62bdf9ce22ed1a41e35fdc7ea5b440bdb05d453aebd9fc36fff6980bd44ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f87dd4d-50ed-441d-9265-af165d926d31", "node_type": "1", "metadata": {"window": "Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and "}, "hash": "d21bf322f5b45a3b8ed50f6289615a29e191b1a34072b10cf366d35ec2ed2b01", "class_name": "RelatedNodeInfo"}}, "text": "And focusing on the buy side, you know, China is an important source of generic API supply.  ", "start_char_idx": 1490, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f87dd4d-50ed-441d-9265-af165d926d31": {"__data__": {"id_": "6f87dd4d-50ed-441d-9265-af165d926d31", "embedding": null, "metadata": {"window": "Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fe8a54-832b-4185-a72b-e8c072e46848", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195f5c944874b3988b08649138c243817b95cf9931233ebe8b52d9fbd91dbff7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75fa039d-b4f6-43bc-8f05-60bf6f1182c9", "node_type": "1", "metadata": {"window": "Ricky Goldwasser :  Yes, hi.   Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "And focusing on the buy side, you know, China is an important source of generic API supply.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d96e9101a92afffec079c0cd428d7975902e8fe8fb4c723255dc80f6c0a1af46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6ea48b1-5929-4d10-8fe9-dc7b26b483ae", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "original_text": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?  "}, "hash": "75b42b8f42a03ffcd857222cec387fb0335d6ab0917a520e11a48f11fb4e270a", "class_name": "RelatedNodeInfo"}}, "text": "Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "start_char_idx": 1583, "end_char_idx": 1712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6ea48b1-5929-4d10-8fe9-dc7b26b483ae": {"__data__": {"id_": "d6ea48b1-5929-4d10-8fe9-dc7b26b483ae", "embedding": null, "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "original_text": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f87dd4d-50ed-441d-9265-af165d926d31", "node_type": "1", "metadata": {"window": "Good morning and congrats on a very good quarter.   You know, Mike, going back to your \ncomments on market dynamics and just improved pricing, digging a little bit deeper into that, when we think about \npricing, are you seeing improved pricing on the sell side versus the buy side?  \n \n  And focusing on the buy side, you know, China is an important source of generic API supply.   Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "original_text": "Given what we're \nseeing there with the coron avirus, how does that impact supply, overall global supply, in the marketplace and ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20920278fdbe8fec63ea8313f0b1222562f62688351cfaa5edf0bbca9ebbec94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88eb73c2-a272-49f9-8e65-821dec52e323", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  ", "original_text": "And is any of that in your second \nhalf outlook?  \n \n"}, "hash": "23ec108234160d6f75fa1fc42b1372663f8c5492e5b9bced0f917908a73f1035", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?  ", "start_char_idx": 0, "end_char_idx": 103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88eb73c2-a272-49f9-8e65-821dec52e323": {"__data__": {"id_": "88eb73c2-a272-49f9-8e65-821dec52e323", "embedding": null, "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  ", "original_text": "And is any of that in your second \nhalf outlook?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6ea48b1-5929-4d10-8fe9-dc7b26b483ae", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "original_text": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e815027fd9c4feda6ac1b47b12075523442c465d62da4da6c9951f74fddccf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2b9a854-bb63-400b-8a7c-2e10c89737a4", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n ", "original_text": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.  "}, "hash": "4689dff3236613670d5de069487efb7bc00ec4b6a4661d6f9edd31b2f75499c4", "class_name": "RelatedNodeInfo"}}, "text": "And is any of that in your second \nhalf outlook?  \n \n", "start_char_idx": 103, "end_char_idx": 156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2b9a854-bb63-400b-8a7c-2e10c89737a4": {"__data__": {"id_": "e2b9a854-bb63-400b-8a7c-2e10c89737a4", "embedding": null, "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n ", "original_text": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88eb73c2-a272-49f9-8e65-821dec52e323", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  ", "original_text": "And is any of that in your second \nhalf outlook?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0fdb0f2d41d0f6bfcc0d62195fa1d4b75709047066cd0651d65180379877d19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e55b871e-bd86-483b-8b3b-b8e3b9f30747", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  ", "original_text": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n "}, "hash": "7e29d178afca01740cc117af8752d94bc961d1b4ce427f13cffc41da873af71f", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.  ", "start_char_idx": 156, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e55b871e-bd86-483b-8b3b-b8e3b9f30747": {"__data__": {"id_": "e55b871e-bd86-483b-8b3b-b8e3b9f30747", "embedding": null, "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  ", "original_text": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2b9a854-bb63-400b-8a7c-2e10c89737a4", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n ", "original_text": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5537e524b6b53e8fa4c0fb3a3528661441afefc95c181982072219fbd0eaab20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "254283ee-98f2-4535-bcbf-99cd87554ba1", "node_type": "1", "metadata": {"window": "And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n ", "original_text": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  "}, "hash": "3452fa838336721a337c92852a346211e327e2443152c8af654ed29d85efb9ac", "class_name": "RelatedNodeInfo"}}, "text": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "start_char_idx": 340, "end_char_idx": 513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "254283ee-98f2-4535-bcbf-99cd87554ba1": {"__data__": {"id_": "254283ee-98f2-4535-bcbf-99cd87554ba1", "embedding": null, "metadata": {"window": "And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n ", "original_text": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e55b871e-bd86-483b-8b3b-b8e3b9f30747", "node_type": "1", "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  ", "original_text": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "beb0281b83c85411bf77523307f8fb75ab7495d847474b25372dc8a4dbc69a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "402d9b26-09c0-4343-9c14-9a103f1fa406", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n ", "original_text": "That is clearly the biggest item.  \n \n "}, "hash": "6dc203b0505dc34b8773847533c8b03a587b34cc7385bd30625f2b16a0ea04ad", "class_name": "RelatedNodeInfo"}}, "text": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  ", "start_char_idx": 513, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "402d9b26-09c0-4343-9c14-9a103f1fa406": {"__data__": {"id_": "402d9b26-09c0-4343-9c14-9a103f1fa406", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n ", "original_text": "That is clearly the biggest item.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "254283ee-98f2-4535-bcbf-99cd87554ba1", "node_type": "1", "metadata": {"window": "And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n ", "original_text": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cadc4b7b25e3f5e0cd0611ac6b28758351b761e6cd6d34301e5d04ba6b3b9f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96000cfe-76c1-466b-931f-7890651ab0a2", "node_type": "1", "metadata": {"window": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.  ", "original_text": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  "}, "hash": "6579f8f604c0c60ee8696eb325a2e786fce6b1648e2f906c9ce5632d6b78154a", "class_name": "RelatedNodeInfo"}}, "text": "That is clearly the biggest item.  \n \n ", "start_char_idx": 819, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96000cfe-76c1-466b-931f-7890651ab0a2": {"__data__": {"id_": "96000cfe-76c1-466b-931f-7890651ab0a2", "embedding": null, "metadata": {"window": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.  ", "original_text": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "402d9b26-09c0-4343-9c14-9a103f1fa406", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n ", "original_text": "That is clearly the biggest item.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25a61114b7e67a200785bcafe46f1bd8cb8932e2ad4924b03311210d87a144f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b801e7-8d1d-4c14-ac3b-51325e29083f", "node_type": "1", "metadata": {"window": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n ", "original_text": "And it's really about driving margin per unit.  \n \n "}, "hash": "0898596dc7c00624b217ecc4808741c44cbb0dcd2d94c6174080ced4eaffe244", "class_name": "RelatedNodeInfo"}}, "text": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  ", "start_char_idx": 858, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b801e7-8d1d-4c14-ac3b-51325e29083f": {"__data__": {"id_": "81b801e7-8d1d-4c14-ac3b-51325e29083f", "embedding": null, "metadata": {"window": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n ", "original_text": "And it's really about driving margin per unit.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96000cfe-76c1-466b-931f-7890651ab0a2", "node_type": "1", "metadata": {"window": "The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n  It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.  ", "original_text": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b68ccb45a1162323f478ee6ccb75eaf070eb2e1fb641fafb5480bfd17a0eb0a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "307b87af-d5b8-46e0-af50-5688a48850b2", "node_type": "1", "metadata": {"window": "That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.  ", "original_text": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n "}, "hash": "59f3cd60bb3b659adb3cdb7538a8d5d9e2a31bdbccacc52a729420cc87631803", "class_name": "RelatedNodeInfo"}}, "text": "And it's really about driving margin per unit.  \n \n ", "start_char_idx": 1024, "end_char_idx": 1076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "307b87af-d5b8-46e0-af50-5688a48850b2": {"__data__": {"id_": "307b87af-d5b8-46e0-af50-5688a48850b2", "embedding": null, "metadata": {"window": "That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.  ", "original_text": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b801e7-8d1d-4c14-ac3b-51325e29083f", "node_type": "1", "metadata": {"window": "It's just really about being more confident that what we're seeing now that we have roughly eight months of \nactivity versus five last quarter, which it just felt a little too early to call it, we feel l ike we've had enough activity \nhere that we feel good about increasing our guidance related to that.   That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n ", "original_text": "And it's really about driving margin per unit.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ae34d8115ef6a5556ee0b34007f9803b31eb8fd86d2ad60822c635097e59c83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78021071-210c-4bed-bac8-f516ea87ef0d", "node_type": "1", "metadata": {"window": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n", "original_text": "And as Dave said, the units and the overall launch has helped for that t oo.  "}, "hash": "162a6bcade9fc21608d434a4fc2efe1be7765fff0eb63d1e3db8aa807807a50e", "class_name": "RelatedNodeInfo"}}, "text": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n ", "start_char_idx": 1076, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78021071-210c-4bed-bac8-f516ea87ef0d": {"__data__": {"id_": "78021071-210c-4bed-bac8-f516ea87ef0d", "embedding": null, "metadata": {"window": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n", "original_text": "And as Dave said, the units and the overall launch has helped for that t oo.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "307b87af-d5b8-46e0-af50-5688a48850b2", "node_type": "1", "metadata": {"window": "That is clearly the biggest item.  \n \n  As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.  ", "original_text": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e1b088dbe21567b83d73e35311ae255e77839775fb3e401e920424b825ec53e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24757615-fb62-40ba-ad27-432476c65eec", "node_type": "1", "metadata": {"window": "And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "And so that's really how we look at it.  \n \n "}, "hash": "d95aa9390c2efe46d3f07d1cbdcefa062202f28fb9de73db6c8cbf55cc5c549f", "class_name": "RelatedNodeInfo"}}, "text": "And as Dave said, the units and the overall launch has helped for that t oo.  ", "start_char_idx": 1429, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24757615-fb62-40ba-ad27-432476c65eec": {"__data__": {"id_": "24757615-fb62-40ba-ad27-432476c65eec", "embedding": null, "metadata": {"window": "And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "And so that's really how we look at it.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78021071-210c-4bed-bac8-f516ea87ef0d", "node_type": "1", "metadata": {"window": "As far as some color on it, I think the important thing is it's hard to really get focused on just the buy side or just  \nthe sell side because they work in tandem.   And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n", "original_text": "And as Dave said, the units and the overall launch has helped for that t oo.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92782adb8685d8fce5f3cd3a2c8ce19211ee290ab28b83fdd5680d774fdbbeb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f386b0ea-8f8e-41c4-8e93-733fa9a7d10b", "node_type": "1", "metadata": {"window": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "As far as the China API, as you can imagine, this is something that we monitor.  "}, "hash": "c7cd2d14414eec615bbd51d36fb2a034dde5e48d122898f881227b9fcce7c604", "class_name": "RelatedNodeInfo"}}, "text": "And so that's really how we look at it.  \n \n ", "start_char_idx": 1507, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f386b0ea-8f8e-41c4-8e93-733fa9a7d10b": {"__data__": {"id_": "f386b0ea-8f8e-41c4-8e93-733fa9a7d10b", "embedding": null, "metadata": {"window": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "As far as the China API, as you can imagine, this is something that we monitor.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24757615-fb62-40ba-ad27-432476c65eec", "node_type": "1", "metadata": {"window": "And it's really about driving margin per unit.  \n \n  And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "And so that's really how we look at it.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc21c6bdc734d05f4a25ffa904bc661564d2d6e8918e4b93fadfe9d71d0f94cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dde51aa-0197-4175-9166-111348bbd62b", "node_type": "1", "metadata": {"window": "And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n"}, "hash": "553388888c83da095a6ee107def4ea221d27352f78f9bf85ff2a7f77f0791852", "class_name": "RelatedNodeInfo"}}, "text": "As far as the China API, as you can imagine, this is something that we monitor.  ", "start_char_idx": 1552, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dde51aa-0197-4175-9166-111348bbd62b": {"__data__": {"id_": "7dde51aa-0197-4175-9166-111348bbd62b", "embedding": null, "metadata": {"window": "And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f386b0ea-8f8e-41c4-8e93-733fa9a7d10b", "node_type": "1", "metadata": {"window": "And what we're seeing is a much better balance between what's happening on the sell side in terms of the \namount of inflation being less than historical but also b eing able to balance any decreases there with good \nperformance at Red Oak so that we can continue to manage our margin per unit in a way to be able to have the \noverall program grow.  \n \n  And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "As far as the China API, as you can imagine, this is something that we monitor.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e2ab5065aec599900448425262cf3d9d174eb90277692478963c6dfb228eb68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7739945-19f0-44b1-ac4a-bedb17d559d8", "node_type": "1", "metadata": {"window": "And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  "}, "hash": "e94aabac49e018ccce14a9dc5dff41e66ff52a1eeb05f0fde016107d3a3f9277", "class_name": "RelatedNodeInfo"}}, "text": "Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n", "start_char_idx": 1633, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7739945-19f0-44b1-ac4a-bedb17d559d8": {"__data__": {"id_": "d7739945-19f0-44b1-ac4a-bedb17d559d8", "embedding": null, "metadata": {"window": "And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71d93dea97fee97218b66b77b9ff696630b87a50202c834ab59d586e192d135b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dde51aa-0197-4175-9166-111348bbd62b", "node_type": "1", "metadata": {"window": "And as Dave said, the units and the overall launch has helped for that t oo.   And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25fbaaf21b9458d770845184b7090a4f46af3d07fceced14e0df4947c0eadc9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae6dd3f7-d504-47c8-81bf-11aa10822b53", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "original_text": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.  "}, "hash": "759e3feee4955dc7c5c9884bf326e81a6fd47aac34c6ddbb1ffb1b7ce628392f", "class_name": "RelatedNodeInfo"}}, "text": "And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "start_char_idx": 1778, "end_char_idx": 1888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae6dd3f7-d504-47c8-81bf-11aa10822b53": {"__data__": {"id_": "ae6dd3f7-d504-47c8-81bf-11aa10822b53", "embedding": null, "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "original_text": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7739945-19f0-44b1-ac4a-bedb17d559d8", "node_type": "1", "metadata": {"window": "And so that's really how we look at it.  \n \n  As far as the China API, as you can imagine, this is something that we monitor.   Red Oak is in charge of that for \nus and they do a great job of understanding where raw materials are coming from, where they're manufactured.  \n And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "original_text": "And you're right, there are a decent amount of API manufactured over in China in some of the affected areas.  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fa8d00702a06d62ff2572f96668a96b5b757def1cb4325a214f49d6cbc816ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "255a3bcd-80db-4df9-908d-d023349da887", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.  ", "original_text": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.  "}, "hash": "26e2fd3523b95a4de7d4c3e2c49a97cdaa940ea06ca9dd0ffbb1ba4702bdbc54", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.  ", "start_char_idx": 0, "end_char_idx": 113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "255a3bcd-80db-4df9-908d-d023349da887": {"__data__": {"id_": "255a3bcd-80db-4df9-908d-d023349da887", "embedding": null, "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.  ", "original_text": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae6dd3f7-d504-47c8-81bf-11aa10822b53", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "original_text": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c77e5eadc4f69687a442fc609177f60d0727ddde795e3b756c3561124adbd45a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a4e3f57-1d22-48b7-a85c-1d0a71f884d7", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.  ", "original_text": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n"}, "hash": "9a8fb7c0a11c502a00388c47adc6622c9923c6cd4db7d782c547af098ec0c5f4", "class_name": "RelatedNodeInfo"}}, "text": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.  ", "start_char_idx": 113, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a4e3f57-1d22-48b7-a85c-1d0a71f884d7": {"__data__": {"id_": "5a4e3f57-1d22-48b7-a85c-1d0a71f884d7", "embedding": null, "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.  ", "original_text": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "255a3bcd-80db-4df9-908d-d023349da887", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.  ", "original_text": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4285d0155f035b3efb71aed6d72108031dd5d0ba0a6a992f145e0bfa3173a109", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15a718c4-1bc6-41eb-acb3-b01a6280e957", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.  ", "original_text": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n"}, "hash": "611888f58f44ae23581c6f2070f6e43fe05591522bfb48b78c67e45d7ee98347", "class_name": "RelatedNodeInfo"}}, "text": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n", "start_char_idx": 256, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15a718c4-1bc6-41eb-acb3-b01a6280e957": {"__data__": {"id_": "15a718c4-1bc6-41eb-acb3-b01a6280e957", "embedding": null, "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.  ", "original_text": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a4e3f57-1d22-48b7-a85c-1d0a71f884d7", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.  ", "original_text": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e18aeb5258854e7377c90d0b394feeeb20a24a844cb48c48922b3bfbc6daab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cce5d40c-404e-4ff7-8465-5697bf7bf6ce", "node_type": "1", "metadata": {"window": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.  ", "original_text": "Lisa Gill :  Hi.  "}, "hash": "84aaae814204c70df644547d2f6f6ad739100316f959c350bb5b0934e6af5786", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "start_char_idx": 381, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cce5d40c-404e-4ff7-8465-5697bf7bf6ce": {"__data__": {"id_": "cce5d40c-404e-4ff7-8465-5697bf7bf6ce", "embedding": null, "metadata": {"window": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.  ", "original_text": "Lisa Gill :  Hi.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15a718c4-1bc6-41eb-acb3-b01a6280e957", "node_type": "1", "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.  ", "original_text": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7f28ac7d319aa7304080ede758716707ef48536e629fd0b2c6f419c673de175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e38bab70-e75c-4ed7-a462-903b2311e90a", "node_type": "1", "metadata": {"window": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n ", "original_text": "Thanks very much.  "}, "hash": "54abd862f39b43489529fd169b50b641da9b5c652076b2be4ad02fd46c583c3c", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill :  Hi.  ", "start_char_idx": 499, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e38bab70-e75c-4ed7-a462-903b2311e90a": {"__data__": {"id_": "e38bab70-e75c-4ed7-a462-903b2311e90a", "embedding": null, "metadata": {"window": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n ", "original_text": "Thanks very much.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cce5d40c-404e-4ff7-8465-5697bf7bf6ce", "node_type": "1", "metadata": {"window": "I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.  ", "original_text": "Lisa Gill :  Hi.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81e06fb4acd082e614576973bc2f25fce9c91461b9c9dcc531604a65a0a30d97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c99a5412-9fb3-4fc5-9dee-5605c3b66d25", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n", "original_text": "Good morning.  "}, "hash": "427373752d05a2ac7446ef4609435a34113993c7aaf4d3f6ad01a8ad63d3c537", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  ", "start_char_idx": 517, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c99a5412-9fb3-4fc5-9dee-5605c3b66d25": {"__data__": {"id_": "c99a5412-9fb3-4fc5-9dee-5605c3b66d25", "embedding": null, "metadata": {"window": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n", "original_text": "Good morning.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e38bab70-e75c-4ed7-a462-903b2311e90a", "node_type": "1", "metadata": {"window": "But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n ", "original_text": "Thanks very much.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fac7d2a7d182e23139f35f32175537f146e5944e30db42662c2795fcf6052fa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d9b6061-5c28-4d2c-9bb3-c0a0b27e6924", "node_type": "1", "metadata": {"window": "Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.  ", "original_text": "Mike, you called out specialty as being a growth area again in the \nquarter.  "}, "hash": "095a99a702c37c61a4116f1f063cf2c3f55fcdcb1017bee492797b489635de1e", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 536, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d9b6061-5c28-4d2c-9bb3-c0a0b27e6924": {"__data__": {"id_": "5d9b6061-5c28-4d2c-9bb3-c0a0b27e6924", "embedding": null, "metadata": {"window": "Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.  ", "original_text": "Mike, you called out specialty as being a growth area again in the \nquarter.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c99a5412-9fb3-4fc5-9dee-5605c3b66d25", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n", "original_text": "Good morning.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66e85272ba238213bd74a55633ccd01c41bf55c5e1e3dd15de5d5547db2aa541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f04ae789-293e-4c39-b281-512683403ccc", "node_type": "1", "metadata": {"window": "Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  ", "original_text": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n "}, "hash": "75fdf91d773697d53cc873f35593b41fe6785df40bba15d8793c83df994bd261", "class_name": "RelatedNodeInfo"}}, "text": "Mike, you called out specialty as being a growth area again in the \nquarter.  ", "start_char_idx": 551, "end_char_idx": 629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f04ae789-293e-4c39-b281-512683403ccc": {"__data__": {"id_": "f04ae789-293e-4c39-b281-512683403ccc", "embedding": null, "metadata": {"window": "Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  ", "original_text": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d9b6061-5c28-4d2c-9bb3-c0a0b27e6924", "node_type": "1", "metadata": {"window": "Lisa Gill :  Hi.   Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.  ", "original_text": "Mike, you called out specialty as being a growth area again in the \nquarter.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "471c5fd833caa3bf04e671057d48198f8f7a6f9cfc2e425774a8dea1453a6744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00996555-1e67-46f7-bea6-295ca42ce203", "node_type": "1", "metadata": {"window": "Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n ", "original_text": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n"}, "hash": "fb6d164b7e65e7e6db1959126c6fefd4d08f518443c63a635f06ad2b4b2c4381", "class_name": "RelatedNodeInfo"}}, "text": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n ", "start_char_idx": 629, "end_char_idx": 743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00996555-1e67-46f7-bea6-295ca42ce203": {"__data__": {"id_": "00996555-1e67-46f7-bea6-295ca42ce203", "embedding": null, "metadata": {"window": "Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n ", "original_text": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f04ae789-293e-4c39-b281-512683403ccc", "node_type": "1", "metadata": {"window": "Thanks very much.   Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  ", "original_text": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd5fcb6346d0b3f49992faef97140ecf5bc56a969635c8c8b274694c03a848a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65ee96bb-bc55-4e07-8b8b-10f6bbd23b49", "node_type": "1", "metadata": {"window": "Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "Mike Kaufmann :  Yes, thanks for the question.  "}, "hash": "e080b58b761851ebd60fa5263354d01c74fddfe602ada09f1ff8ce9787cd6f53", "class_name": "RelatedNodeInfo"}}, "text": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n", "start_char_idx": 743, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65ee96bb-bc55-4e07-8b8b-10f6bbd23b49": {"__data__": {"id_": "65ee96bb-bc55-4e07-8b8b-10f6bbd23b49", "embedding": null, "metadata": {"window": "Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "Mike Kaufmann :  Yes, thanks for the question.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00996555-1e67-46f7-bea6-295ca42ce203", "node_type": "1", "metadata": {"window": "Good morning.   Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n ", "original_text": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "893b0de1a93c9372186b5f7cbc114865abffea89d8f65c47c9d4fd3e5fad7bdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6fab380-2411-4dcf-8eed-d85b5afb3fa1", "node_type": "1", "metadata": {"window": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  "}, "hash": "df9e3d4932873191f08ea9818ab2f026ac6ec408027d1e35fb3b68bbd28c2103", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, thanks for the question.  ", "start_char_idx": 956, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6fab380-2411-4dcf-8eed-d85b5afb3fa1": {"__data__": {"id_": "a6fab380-2411-4dcf-8eed-d85b5afb3fa1", "embedding": null, "metadata": {"window": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65ee96bb-bc55-4e07-8b8b-10f6bbd23b49", "node_type": "1", "metadata": {"window": "Mike, you called out specialty as being a growth area again in the \nquarter.   Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "Mike Kaufmann :  Yes, thanks for the question.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e8af7508d6c23b9b2c5ed19de04d9b5f70fca29d73da2446bb4405c59f53221", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47bfd398-9d27-4d2e-be59-5b1665212573", "node_type": "1", "metadata": {"window": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "And so that's where that business is.  \n \n "}, "hash": "c4aabc17ec180a1d82b283826501d6bb5779111f700bc516967bce3753c45cd7", "class_name": "RelatedNodeInfo"}}, "text": "Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  ", "start_char_idx": 1004, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47bfd398-9d27-4d2e-be59-5b1665212573": {"__data__": {"id_": "47bfd398-9d27-4d2e-be59-5b1665212573", "embedding": null, "metadata": {"window": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "And so that's where that business is.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6fab380-2411-4dcf-8eed-d85b5afb3fa1", "node_type": "1", "metadata": {"window": "Can you just remind us, you know, the size of that business and the capabilities versus some of your \npeers?  \n \n  And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22a4870857dbe61a2172a8336f10f9938672ae5f229b616bf4fc70657e1a15fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe3729d5-f085-4d53-962b-67247e9bc35b", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n "}, "hash": "f857e12c6102c8281b2c5e6e49ba95ea578025c54f1dd7958435bd9434efc196", "class_name": "RelatedNodeInfo"}}, "text": "And so that's where that business is.  \n \n ", "start_char_idx": 1126, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe3729d5-f085-4d53-962b-67247e9bc35b": {"__data__": {"id_": "fe3729d5-f085-4d53-962b-67247e9bc35b", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0582efa88c5c010c14d31e31f509870a947cf81760c5f9bf7af7bccc732fd9ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47bfd398-9d27-4d2e-be59-5b1665212573", "node_type": "1", "metadata": {"window": "And then as we think about the potential for IPI and potential changes around reimbursement, can you talk about, \nyou know, your thoughts on that and any impact that you could see in your speci alty business?  \n \n Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "And so that's where that business is.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cec3469c699231990ef8be097eea2d1455df4e1fb6d8db9686793259382218c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6d6d7c7-d442-41d2-8363-df549ed9ca92", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "original_text": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.  "}, "hash": "1a480147485e778706d6a401e9941a24b8d7c63ae31128b115fca320b40e9c07", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "start_char_idx": 1169, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6d6d7c7-d442-41d2-8363-df549ed9ca92": {"__data__": {"id_": "b6d6d7c7-d442-41d2-8363-df549ed9ca92", "embedding": null, "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "original_text": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe3729d5-f085-4d53-962b-67247e9bc35b", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, thanks for the question.   Our specialty business, the last number that we publicly gave for FY19 is \nthat we finished around $19 billion in sales.   And so that's where that business is.  \n \n  We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "original_text": "We continue to expect that busin ess to have significant growth this year across all of its areas, its sales into the \nactual downstream providers in the acute space as well as upstream services to manufacturers.  \n ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3030897ea4f94e227a21a62ff517070150f738ddae215a25df2fdce64585eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20b90c31-5a02-4fdd-8f5b-aacf41f8fbef", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.  ", "original_text": "So we continue to be excited \nabout the specialty area.  \n \n "}, "hash": "95d3294def1e68ee160774948fa921f0a489f4df026ab011ca8ed3c7bec63168", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.  ", "start_char_idx": 0, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20b90c31-5a02-4fdd-8f5b-aacf41f8fbef": {"__data__": {"id_": "20b90c31-5a02-4fdd-8f5b-aacf41f8fbef", "embedding": null, "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.  ", "original_text": "So we continue to be excited \nabout the specialty area.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6d6d7c7-d442-41d2-8363-df549ed9ca92", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "original_text": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f487ae5e4da6af848d1c918015b7949c2e9398093b199af275f6f02bec97db43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35188314-ccbf-4a1a-a482-897cd167aafa", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.  ", "original_text": "As far as it relates to IPI, I would say this.  "}, "hash": "6370853f891a9fc08f229542ad7d2f6f19eea9df845c6cfed636d00b01fe222b", "class_name": "RelatedNodeInfo"}}, "text": "So we continue to be excited \nabout the specialty area.  \n \n ", "start_char_idx": 442, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35188314-ccbf-4a1a-a482-897cd167aafa": {"__data__": {"id_": "35188314-ccbf-4a1a-a482-897cd167aafa", "embedding": null, "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.  ", "original_text": "As far as it relates to IPI, I would say this.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20b90c31-5a02-4fdd-8f5b-aacf41f8fbef", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.  ", "original_text": "So we continue to be excited \nabout the specialty area.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "060bb920f5d0fb4bed843a8156126c84e6aaf0561b183c130893245dff2b8eea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2d44571-d7f6-4613-86da-1e660b2187b5", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n ", "original_text": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  "}, "hash": "b48fdd30af2df8b175e071cad6e6a4a605b883f24faf3eb4bb68dd84fbaeb56b", "class_name": "RelatedNodeInfo"}}, "text": "As far as it relates to IPI, I would say this.  ", "start_char_idx": 503, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2d44571-d7f6-4613-86da-1e660b2187b5": {"__data__": {"id_": "f2d44571-d7f6-4613-86da-1e660b2187b5", "embedding": null, "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n ", "original_text": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35188314-ccbf-4a1a-a482-897cd167aafa", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.  ", "original_text": "As far as it relates to IPI, I would say this.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3ae8b39b2e3d573d759e69bd23cc0091afc6a54c1621d660c760f8ef3fc7e5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f4fb5b3-5bd3-425f-8916-23ce7c614e90", "node_type": "1", "metadata": {"window": "So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n ", "original_text": "We know that's important.  "}, "hash": "70887fe8c6b91fb050815957aeaf45b60bf0b92b18a62ebf6fa3514a637f712b", "class_name": "RelatedNodeInfo"}}, "text": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "start_char_idx": 551, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f4fb5b3-5bd3-425f-8916-23ce7c614e90": {"__data__": {"id_": "6f4fb5b3-5bd3-425f-8916-23ce7c614e90", "embedding": null, "metadata": {"window": "So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n ", "original_text": "We know that's important.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2d44571-d7f6-4613-86da-1e660b2187b5", "node_type": "1", "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n ", "original_text": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc64e9e8a8768a8356da12705d0f2b95318d1305c29c42e66dc546dbcdfde3d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c97cc2ce-73e1-404c-b99a-33c6b228f246", "node_type": "1", "metadata": {"window": "As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?  ", "original_text": "We hope and look to folks to be able to find \nways to reduce costs for folks.  "}, "hash": "1377d23498c64cb44ce37cf1ecc23627fc90aa4c5c09d04451db16ea89d50380", "class_name": "RelatedNodeInfo"}}, "text": "We know that's important.  ", "start_char_idx": 667, "end_char_idx": 694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c97cc2ce-73e1-404c-b99a-33c6b228f246": {"__data__": {"id_": "c97cc2ce-73e1-404c-b99a-33c6b228f246", "embedding": null, "metadata": {"window": "As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?  ", "original_text": "We hope and look to folks to be able to find \nways to reduce costs for folks.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f4fb5b3-5bd3-425f-8916-23ce7c614e90", "node_type": "1", "metadata": {"window": "So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n ", "original_text": "We know that's important.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba49fb795d8058fb2a68036265f8772fda811bf3020d76224b1f1edbccaa5023", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6b76e01-b458-47e5-824f-cd85a12a8e97", "node_type": "1", "metadata": {"window": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?  ", "original_text": "So that's important to us.  \n \n "}, "hash": "b794c5b71b7f21eacaa7ee996dbbdcb3a7d1de92049b95f19e995f07e4cba767", "class_name": "RelatedNodeInfo"}}, "text": "We hope and look to folks to be able to find \nways to reduce costs for folks.  ", "start_char_idx": 694, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6b76e01-b458-47e5-824f-cd85a12a8e97": {"__data__": {"id_": "b6b76e01-b458-47e5-824f-cd85a12a8e97", "embedding": null, "metadata": {"window": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?  ", "original_text": "So that's important to us.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c97cc2ce-73e1-404c-b99a-33c6b228f246", "node_type": "1", "metadata": {"window": "As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?  ", "original_text": "We hope and look to folks to be able to find \nways to reduce costs for folks.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12897165c66c857df9c80405e5bf5551707e0ee4b4a18b030cf1f59f215dc08d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c160d19-064a-4310-9907-3e0c34ec2919", "node_type": "1", "metadata": {"window": "We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n ", "original_text": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n "}, "hash": "bc827b77f5ddb39442e03cecb8e6cafdeede79a9a0a9cf3dc1a9609108eb19b1", "class_name": "RelatedNodeInfo"}}, "text": "So that's important to us.  \n \n ", "start_char_idx": 773, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c160d19-064a-4310-9907-3e0c34ec2919": {"__data__": {"id_": "6c160d19-064a-4310-9907-3e0c34ec2919", "embedding": null, "metadata": {"window": "We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n ", "original_text": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6b76e01-b458-47e5-824f-cd85a12a8e97", "node_type": "1", "metadata": {"window": "First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.   We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?  ", "original_text": "So that's important to us.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70b204cfc5b11870c9b14fbbea6409ff29372d85e01f2ca0cd070ca4fcce3f77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "684b31a3-e88a-43e6-b479-78953ff2d83d", "node_type": "1", "metadata": {"window": "We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n ", "original_text": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?  "}, "hash": "8be5990ca57743c363255cf514667720d8503f6bafea3b7f3f3085463939ff57", "class_name": "RelatedNodeInfo"}}, "text": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n ", "start_char_idx": 805, "end_char_idx": 1041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "684b31a3-e88a-43e6-b479-78953ff2d83d": {"__data__": {"id_": "684b31a3-e88a-43e6-b479-78953ff2d83d", "embedding": null, "metadata": {"window": "We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n ", "original_text": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c160d19-064a-4310-9907-3e0c34ec2919", "node_type": "1", "metadata": {"window": "We know that's important.   We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n ", "original_text": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2970154834fb5b1ddaf70327acabf60a7c91a60fae110c138653b7a2ea3b285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04ef5d15-0e03-43db-90ba-eb5e691a9810", "node_type": "1", "metadata": {"window": "So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "Do they have to \nreduce their price increases?  "}, "hash": "4b937d4f067cf7315496360aac184be211a62aefc65c28521ad0a047d977e826", "class_name": "RelatedNodeInfo"}}, "text": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?  ", "start_char_idx": 1041, "end_char_idx": 1138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04ef5d15-0e03-43db-90ba-eb5e691a9810": {"__data__": {"id_": "04ef5d15-0e03-43db-90ba-eb5e691a9810", "embedding": null, "metadata": {"window": "So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "Do they have to \nreduce their price increases?  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "684b31a3-e88a-43e6-b479-78953ff2d83d", "node_type": "1", "metadata": {"window": "We hope and look to folks to be able to find \nways to reduce costs for folks.   So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n ", "original_text": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df06c4fb3b5f0358e971e9cacd1feda59f32178bebfb5fcbfbb1cb19a54eb319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e58e92c-ec9f-454e-ab88-fbd5831b43bb", "node_type": "1", "metadata": {"window": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n "}, "hash": "0b3f2fa3f95cd9c784c2954e0c1fd949f4d2645ff788b59033f1754bc3d24b88", "class_name": "RelatedNodeInfo"}}, "text": "Do they have to \nreduce their price increases?  ", "start_char_idx": 1138, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e58e92c-ec9f-454e-ab88-fbd5831b43bb": {"__data__": {"id_": "1e58e92c-ec9f-454e-ab88-fbd5831b43bb", "embedding": null, "metadata": {"window": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04ef5d15-0e03-43db-90ba-eb5e691a9810", "node_type": "1", "metadata": {"window": "So that's important to us.  \n \n  The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "Do they have to \nreduce their price increases?  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e064a957589efc8efecdbcb416ca029c5defaa18ff081340fe7bdd9163fe8e25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96ed7c18-d5e7-4b2b-84e7-21279ce811ff", "node_type": "1", "metadata": {"window": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n "}, "hash": "32c70d74d0b604676bb5be59b04b87860395e17bbc2ab5be39cccf2406909ad0", "class_name": "RelatedNodeInfo"}}, "text": "Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n ", "start_char_idx": 1186, "end_char_idx": 1277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96ed7c18-d5e7-4b2b-84e7-21279ce811ff": {"__data__": {"id_": "96ed7c18-d5e7-4b2b-84e7-21279ce811ff", "embedding": null, "metadata": {"window": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e58e92c-ec9f-454e-ab88-fbd5831b43bb", "node_type": "1", "metadata": {"window": "The second thing I would say is that when you think about IPI or any of these programs that folks are looking at, \nthe impact to us, I think, is generally where it could impact us in the first order is, does it change list prices?  \n \n  Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0dd985d1742ee3948570012f9fa8b7e1ee97ee44beb2afa420b9e11a019665c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05cca7e8-1b47-4cfc-ba1e-0e9f249c7ed5", "node_type": "1", "metadata": {"window": "Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n "}, "hash": "da8bb73a9363642dd2a5e43d1f77402cc759e84b7a85a2ca9c16e0a7065d1557", "class_name": "RelatedNodeInfo"}}, "text": "And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n ", "start_char_idx": 1277, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05cca7e8-1b47-4cfc-ba1e-0e9f249c7ed5": {"__data__": {"id_": "05cca7e8-1b47-4cfc-ba1e-0e9f249c7ed5", "embedding": null, "metadata": {"window": "Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e57e945e4defcb8c0e3d570ab24fb3a84687ffa21d5580a90aef6d2665c4b68", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96ed7c18-d5e7-4b2b-84e7-21279ce811ff", "node_type": "1", "metadata": {"window": "Does it mean that the way that manufacturers establish list prices, do they have to lower them?   Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd38d4ff4d6d3bf00440f68984b356faf70373cd6100241bf4b49b9e145a2d95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94e30b10-cdc9-4788-9b5b-4fd99ea92f7f", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n", "original_text": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.  "}, "hash": "bcb08fd522c024a34072756289fa7f359bf2fae62c04cf0d308e03b32824d876", "class_name": "RelatedNodeInfo"}}, "text": "And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "start_char_idx": 1657, "end_char_idx": 1913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94e30b10-cdc9-4788-9b5b-4fd99ea92f7f": {"__data__": {"id_": "94e30b10-cdc9-4788-9b5b-4fd99ea92f7f", "embedding": null, "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n", "original_text": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05cca7e8-1b47-4cfc-ba1e-0e9f249c7ed5", "node_type": "1", "metadata": {"window": "Do they have to \nreduce their price increases?   Those are the types of first order of kind of magnitude impact to us that we look at.  \n \n  And as you and the others have heard me say, I think that we as a company and as an industry have really \nworked well ove r the years in the fee for service model to first of all make anything that's - the part that's \ndependent on inflation to be less than 5% of our overall margin rate so that helps protect us from any impact on \nwhat folks might do with inflation rates.  \n \n  And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "original_text": "And secondly the way we've been able to demonstrate our ability to renegotiate DSAs over time as WAC prices \nfluctuate, we still feel very confident that any impact to list prices we can manage through very effectively as a \ncompany and as an industry.  \n ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b084258e44d2265cac721b606c9bbf02c828d5c165a78e5f0eede527b5b51336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6f792d9-f482-44fc-aceb-2d6926a9649f", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n", "original_text": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.  "}, "hash": "808afe1b2c3efdf4569bfb1719dd241546fd205ae2b6d398775730eb00386b56", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.  ", "start_char_idx": 0, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6f792d9-f482-44fc-aceb-2d6926a9649f": {"__data__": {"id_": "f6f792d9-f482-44fc-aceb-2d6926a9649f", "embedding": null, "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n", "original_text": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94e30b10-cdc9-4788-9b5b-4fd99ea92f7f", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n", "original_text": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "155237e22d803bdae6578e288104f3267e20847f5fe4a0b5a42a4059a63cb980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45f449eb-ec3d-4cf7-98fc-cea3a66899f9", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n", "original_text": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n"}, "hash": "bdf62622ad65d1de00821a8251ed38374195ba346a1dc19bae3da548ca9caa88", "class_name": "RelatedNodeInfo"}}, "text": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.  ", "start_char_idx": 101, "end_char_idx": 203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45f449eb-ec3d-4cf7-98fc-cea3a66899f9": {"__data__": {"id_": "45f449eb-ec3d-4cf7-98fc-cea3a66899f9", "embedding": null, "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n", "original_text": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6f792d9-f482-44fc-aceb-2d6926a9649f", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n", "original_text": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93ecf349c6aa0832d5643d05515007762e27ac716aa8e5536fb8a8f92162bb13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "295a929e-56ae-43c7-8650-265c20d01e8b", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.  ", "original_text": "Lisa Gill :  Thank you.  \n \n"}, "hash": "8b15bd627dab38fc1cd9e87aaea720cd7d538dc346c7526d8aa6a944b3126bc0", "class_name": "RelatedNodeInfo"}}, "text": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n", "start_char_idx": 203, "end_char_idx": 537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "295a929e-56ae-43c7-8650-265c20d01e8b": {"__data__": {"id_": "295a929e-56ae-43c7-8650-265c20d01e8b", "embedding": null, "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.  ", "original_text": "Lisa Gill :  Thank you.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45f449eb-ec3d-4cf7-98fc-cea3a66899f9", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n", "original_text": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8341d693741705d6f65450d3642552d33415057ba8fb45955802241895d9ae5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8a1b89c-6431-4176-a4fc-62de7df92215", "node_type": "1", "metadata": {"window": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.  ", "original_text": "Mike Kaufmann :  Thanks, Lisa.  \n \n"}, "hash": "e59dcb9e8b231234bd94bee4e207b8afe8d6e29d7a6bcb04c749aed45a86e53c", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill :  Thank you.  \n \n", "start_char_idx": 537, "end_char_idx": 565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8a1b89c-6431-4176-a4fc-62de7df92215": {"__data__": {"id_": "f8a1b89c-6431-4176-a4fc-62de7df92215", "embedding": null, "metadata": {"window": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.  ", "original_text": "Mike Kaufmann :  Thanks, Lisa.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "295a929e-56ae-43c7-8650-265c20d01e8b", "node_type": "1", "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.  ", "original_text": "Lisa Gill :  Thank you.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d410011f47e2a42317dbaa3150694e0cd5a2a1ea0a6a0835da4b8aa9804a325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c10ff758-2e20-4e71-a1cf-9b27675ad14a", "node_type": "1", "metadata": {"window": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  ", "original_text": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n"}, "hash": "3e0874ca08d7f5efba985f2754ec2b6f44bf9ce925a40201f80bf385717de0f6", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Thanks, Lisa.  \n \n", "start_char_idx": 565, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c10ff758-2e20-4e71-a1cf-9b27675ad14a": {"__data__": {"id_": "c10ff758-2e20-4e71-a1cf-9b27675ad14a", "embedding": null, "metadata": {"window": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  ", "original_text": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8a1b89c-6431-4176-a4fc-62de7df92215", "node_type": "1", "metadata": {"window": "We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.  ", "original_text": "Mike Kaufmann :  Thanks, Lisa.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c061bd3f067e8f5a769b76bf6bf2bd114cf3df13b35835ed6ea0b8b06863cd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1a61136-1608-436c-bbda-31f5a2b20004", "node_type": "1", "metadata": {"window": "Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n ", "original_text": "George Hill :  Hey, good morning, guys.  "}, "hash": "bfba2deee052549a2ad67ecf017c3df954f74cf3238757335ddfcc40fd65a207", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n", "start_char_idx": 600, "end_char_idx": 669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1a61136-1608-436c-bbda-31f5a2b20004": {"__data__": {"id_": "f1a61136-1608-436c-bbda-31f5a2b20004", "embedding": null, "metadata": {"window": "Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n ", "original_text": "George Hill :  Hey, good morning, guys.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c10ff758-2e20-4e71-a1cf-9b27675ad14a", "node_type": "1", "metadata": {"window": "And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  ", "original_text": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e8143037e941ca4abf6e1faccda14d1597c3b3d0d71d79318e1cdc67fac7026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "299d962e-c365-4ea3-a702-2225f497f587", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  ", "original_text": "Thanks for taking the question.  "}, "hash": "16e592460036635ccdd74374a9bc2d260eb3c0385cbdafa07d7ee47a0fd33b24", "class_name": "RelatedNodeInfo"}}, "text": "George Hill :  Hey, good morning, guys.  ", "start_char_idx": 669, "end_char_idx": 710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "299d962e-c365-4ea3-a702-2225f497f587": {"__data__": {"id_": "299d962e-c365-4ea3-a702-2225f497f587", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  ", "original_text": "Thanks for taking the question.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1a61136-1608-436c-bbda-31f5a2b20004", "node_type": "1", "metadata": {"window": "Lisa Gill :  Thank you.  \n \n Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n ", "original_text": "George Hill :  Hey, good morning, guys.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64ba18f8414da9cb1c9a0d35cd05ba328a98af97e2f586ba42aab43664266a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74406c4b-bb67-4ba3-81a8-07f194f0e5c2", "node_type": "1", "metadata": {"window": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.  ", "original_text": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  "}, "hash": "83c22a51fdbeb75e68ed7dd3ad761017182d35663e685c3898be7a7bff235351", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question.  ", "start_char_idx": 710, "end_char_idx": 743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74406c4b-bb67-4ba3-81a8-07f194f0e5c2": {"__data__": {"id_": "74406c4b-bb67-4ba3-81a8-07f194f0e5c2", "embedding": null, "metadata": {"window": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.  ", "original_text": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "299d962e-c365-4ea3-a702-2225f497f587", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks, Lisa.  \n \n Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  ", "original_text": "Thanks for taking the question.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdec9d87bdf8349b8166666ece521fbc03ee66e0278679cd204955603108cdd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0bdaa90-d446-4368-b307-b7bd5ab3c703", "node_type": "1", "metadata": {"window": "George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n", "original_text": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n "}, "hash": "6d8b65cd9683b47bf96fe4f4351e8679a75753b30e81eea6f85ac382cf040ada", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  ", "start_char_idx": 743, "end_char_idx": 860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0bdaa90-d446-4368-b307-b7bd5ab3c703": {"__data__": {"id_": "c0bdaa90-d446-4368-b307-b7bd5ab3c703", "embedding": null, "metadata": {"window": "George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n", "original_text": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74406c4b-bb67-4ba3-81a8-07f194f0e5c2", "node_type": "1", "metadata": {"window": "Operator :  And we'll go next to George Hill with Deutsche Bank.  \n \n George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.  ", "original_text": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c77f656634d53d13b2255a6c9f2234cb7e5aad29e3434d63c1027000703023d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2d43ad5-30cf-41cf-ac65-3d354b709b2d", "node_type": "1", "metadata": {"window": "Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.  ", "original_text": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  "}, "hash": "87141a5c8354ae11de3747b09a64f83381b65500b85a7936eb456664c38d2f65", "class_name": "RelatedNodeInfo"}}, "text": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n ", "start_char_idx": 860, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2d43ad5-30cf-41cf-ac65-3d354b709b2d": {"__data__": {"id_": "a2d43ad5-30cf-41cf-ac65-3d354b709b2d", "embedding": null, "metadata": {"window": "Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.  ", "original_text": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0bdaa90-d446-4368-b307-b7bd5ab3c703", "node_type": "1", "metadata": {"window": "George Hill :  Hey, good morning, guys.   Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n", "original_text": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681a8b13e1d29136f3b6205e11e8a4f3d2d76072a6b85b5c565f8a1bcbbb2049", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d44b464b-2a4f-4fa9-bc0a-23ea87329b84", "node_type": "1", "metadata": {"window": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.  ", "original_text": "I know that's a lot.  "}, "hash": "88f2b61c177ec55fc2fa4286dcc1ca67946a21b06da07a854a7f61bcc72e04dd", "class_name": "RelatedNodeInfo"}}, "text": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  ", "start_char_idx": 1135, "end_char_idx": 1468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d44b464b-2a4f-4fa9-bc0a-23ea87329b84": {"__data__": {"id_": "d44b464b-2a4f-4fa9-bc0a-23ea87329b84", "embedding": null, "metadata": {"window": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.  ", "original_text": "I know that's a lot.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2d43ad5-30cf-41cf-ac65-3d354b709b2d", "node_type": "1", "metadata": {"window": "Thanks for taking the question.   I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.  ", "original_text": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6aa4a26cdaddc90b5a5db7de547322e5bbee38ae14025b7150db3128db5a31c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56c74a56-6d44-4f0e-bde2-e9aa2df2ef14", "node_type": "1", "metadata": {"window": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  ", "original_text": "Thanks.  \n \n"}, "hash": "8348d3533fd8cac067e5c71cb94d2fb0bbf6ec5b38b1b5b27e74cf7c23ea6800", "class_name": "RelatedNodeInfo"}}, "text": "I know that's a lot.  ", "start_char_idx": 1468, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56c74a56-6d44-4f0e-bde2-e9aa2df2ef14": {"__data__": {"id_": "56c74a56-6d44-4f0e-bde2-e9aa2df2ef14", "embedding": null, "metadata": {"window": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  ", "original_text": "Thanks.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d44b464b-2a4f-4fa9-bc0a-23ea87329b84", "node_type": "1", "metadata": {"window": "I guess, Mike and Dave, I'd ask you guys a little \nbit more about the generics program contribution in the quarter.   And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.  ", "original_text": "I know that's a lot.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3de68f23092c0b7833279c262dbe4b5f46e07d909453846c2cb9bf5b2c147fe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "599953d0-521e-4c46-b502-6597b7771269", "node_type": "1", "metadata": {"window": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "David Evans :  Yes, George.  "}, "hash": "6839baeb71b2abfdda62ac4691c8a7175d0309fe9c3ccad3da9550969a528227", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1490, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "599953d0-521e-4c46-b502-6597b7771269": {"__data__": {"id_": "599953d0-521e-4c46-b502-6597b7771269", "embedding": null, "metadata": {"window": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "David Evans :  Yes, George.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56c74a56-6d44-4f0e-bde2-e9aa2df2ef14", "node_type": "1", "metadata": {"window": "And I guess, what I'm looking at is, you guys and \nyour friends in Texas kind of highlighted - you demonstrated big beats in earnings this quarter that were generics \nrelated that don't seem repeatable either in  the next quarter or in the balance of your fiscal years.  \n \n  So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  ", "original_text": "Thanks.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dce496050de8e77b46df8769e317e46d18f1fc90f20a8356d86c6fb3d8d7235", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a178da4-a655-4036-b4fe-b64bbf19e36b", "node_type": "1", "metadata": {"window": "I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "Let me answer that.  "}, "hash": "f405d7de93c73ab04072d63925b55feba597c1c91e39e8149c8c909d0b3c799f", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Yes, George.  ", "start_char_idx": 1502, "end_char_idx": 1531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a178da4-a655-4036-b4fe-b64bbf19e36b": {"__data__": {"id_": "4a178da4-a655-4036-b4fe-b64bbf19e36b", "embedding": null, "metadata": {"window": "I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "Let me answer that.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "599953d0-521e-4c46-b502-6597b7771269", "node_type": "1", "metadata": {"window": "So maybe could you provide a little bit more color on the earlier than expected launch of the new items that was \nhighlighted and maybe the contribution in the quarter and maybe some more commentar y around what was \ndelivered in the quarter that might seem more one -time versus what might seem repeatable on a go -forward \nbasis?   I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "David Evans :  Yes, George.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9574fdf6a8f479c88b5aa72f8bb9783ab1db05a959f17f4b934de6bedd01f5a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef383a25-32c8-490f-84ea-60d67a5b1d58", "node_type": "1", "metadata": {"window": "Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  "}, "hash": "64f9eb1f2b4fb4ae210f708f8b57188a8041677e6a3f7ccea1ea2a02d688540c", "class_name": "RelatedNodeInfo"}}, "text": "Let me answer that.  ", "start_char_idx": 1531, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef383a25-32c8-490f-84ea-60d67a5b1d58": {"__data__": {"id_": "ef383a25-32c8-490f-84ea-60d67a5b1d58", "embedding": null, "metadata": {"window": "Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a178da4-a655-4036-b4fe-b64bbf19e36b", "node_type": "1", "metadata": {"window": "I know that's a lot.   Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "Let me answer that.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0959c6e35747603218d64b5820eec8b0654701c7faedbc7eb255d5376e2abce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "902d7723-1edf-4ac6-8449-6039fc18b448", "node_type": "1", "metadata": {"window": "David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "So we'd "}, "hash": "f7d1b862f2f9ff0475b9be3537fb0cd4b5a8527543f8c2a58504b5c73b369058", "class_name": "RelatedNodeInfo"}}, "text": "Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  ", "start_char_idx": 1552, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "902d7723-1edf-4ac6-8449-6039fc18b448": {"__data__": {"id_": "902d7723-1edf-4ac6-8449-6039fc18b448", "embedding": null, "metadata": {"window": "David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "So we'd ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea5c4abc9480f41f7236666b3c56ea39681d517769877f05e01365fc7e25a3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef383a25-32c8-490f-84ea-60d67a5b1d58", "node_type": "1", "metadata": {"window": "Thanks.  \n \n David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "051ee9e68c1af0b78808287d55a4260ad8ce45267b5a0eae8ad4088588d2b1f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad08b168-8ee0-441f-85ad-1fbad50ffa08", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "original_text": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.  "}, "hash": "d32ec5a433696e7aa6f7bb9f332aea2e1197a78de7c93fa9a7738e2c65e70d77", "class_name": "RelatedNodeInfo"}}, "text": "So we'd ", "start_char_idx": 1723, "end_char_idx": 1731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad08b168-8ee0-441f-85ad-1fbad50ffa08": {"__data__": {"id_": "ad08b168-8ee0-441f-85ad-1fbad50ffa08", "embedding": null, "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "original_text": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "902d7723-1edf-4ac6-8449-6039fc18b448", "node_type": "1", "metadata": {"window": "David Evans :  Yes, George.   Let me answer that.   Look, when we talk about the four elements of  what we described as \nthe generic dynamic, those are a continuation of trends that we would expect to see in Q3 and in Q4.   So we'd ", "original_text": "So we'd ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44dbdef46fb91c8e3ceeaaf53077099ed2c8d681dbd77f3892aad73409d0cfa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8b3b53d-3661-4942-b9d2-fa3ebbefb1c4", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.  ", "original_text": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.  "}, "hash": "9073066d0f71427d0419ec1c4131f23a00964689186390547becc32ca1f82d90", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.  ", "start_char_idx": 0, "end_char_idx": 82, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8b3b53d-3661-4942-b9d2-fa3ebbefb1c4": {"__data__": {"id_": "e8b3b53d-3661-4942-b9d2-fa3ebbefb1c4", "embedding": null, "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.  ", "original_text": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad08b168-8ee0-441f-85ad-1fbad50ffa08", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "original_text": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd78e994c5920b97433e1714632d34d27f0fe40ba16dddc4110adf0ec7d3177a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "105ade8e-c668-4b07-a548-1b2ddbcba761", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  ", "original_text": "And so we have a much more challenging comp in \nQ4. \n \n "}, "hash": "48a5d8c470e9aadb60287485e4fa9e35b2a0b9c60bc7b7588a8271c8b88dd9c5", "class_name": "RelatedNodeInfo"}}, "text": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.  ", "start_char_idx": 82, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "105ade8e-c668-4b07-a548-1b2ddbcba761": {"__data__": {"id_": "105ade8e-c668-4b07-a548-1b2ddbcba761", "embedding": null, "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  ", "original_text": "And so we have a much more challenging comp in \nQ4. \n \n ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8b3b53d-3661-4942-b9d2-fa3ebbefb1c4", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.  ", "original_text": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6fff9208f6f02bcd2338fde238dee3505062a5985477d47c2c7ed8f80f307a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05094f87-96c5-42a9-86c7-3291ea7ca06a", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n", "original_text": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.  "}, "hash": "109aa75603a525cb229cba729748c3ce98c1571c62dcb92330445b967b04cd25", "class_name": "RelatedNodeInfo"}}, "text": "And so we have a much more challenging comp in \nQ4. \n \n ", "start_char_idx": 314, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05094f87-96c5-42a9-86c7-3291ea7ca06a": {"__data__": {"id_": "05094f87-96c5-42a9-86c7-3291ea7ca06a", "embedding": null, "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n", "original_text": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "105ade8e-c668-4b07-a548-1b2ddbcba761", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  ", "original_text": "And so we have a much more challenging comp in \nQ4. \n \n ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "850e2fbc9ece5c220f04f0de3886c0dfd71af9e7f54820be308e450ecae736c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfcb524b-f829-4720-ae6f-44f9d855feaa", "node_type": "1", "metadata": {"window": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.  ", "original_text": "It's just a pull forward of \nsomething that was anticipated later in the year.  "}, "hash": "9cc3455a95d66790ea6cc4238ea188f4625d28ce12fc88517c80ae699fe5410e", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "start_char_idx": 370, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfcb524b-f829-4720-ae6f-44f9d855feaa": {"__data__": {"id_": "dfcb524b-f829-4720-ae6f-44f9d855feaa", "embedding": null, "metadata": {"window": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.  ", "original_text": "It's just a pull forward of \nsomething that was anticipated later in the year.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05094f87-96c5-42a9-86c7-3291ea7ca06a", "node_type": "1", "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n", "original_text": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df863d32273eaa29a868c51a5a95d981fb0ae706407218af46f099fd423441f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38c6c671-caeb-45b3-831d-06f72bee23b2", "node_type": "1", "metadata": {"window": "And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n", "original_text": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  "}, "hash": "88eff34ecb3d25511afdcb06ef78b23fbe7a60278aa96015aa5c37251cd4708a", "class_name": "RelatedNodeInfo"}}, "text": "It's just a pull forward of \nsomething that was anticipated later in the year.  ", "start_char_idx": 461, "end_char_idx": 541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38c6c671-caeb-45b3-831d-06f72bee23b2": {"__data__": {"id_": "38c6c671-caeb-45b3-831d-06f72bee23b2", "embedding": null, "metadata": {"window": "And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n", "original_text": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfcb524b-f829-4720-ae6f-44f9d855feaa", "node_type": "1", "metadata": {"window": "Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.  ", "original_text": "It's just a pull forward of \nsomething that was anticipated later in the year.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8629719620152ea9c12fcca54b3a7bf34b457b517dc8415ee600fc6093e12584", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde3dc5e-2b3e-4dce-a845-a4af822168d7", "node_type": "1", "metadata": {"window": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n", "original_text": "Does that help answer your question, George?  \n \n"}, "hash": "586c624d34827d2941e273f10df3bc7653e7de9c2a5327b1ed477f0ec1789e7c", "class_name": "RelatedNodeInfo"}}, "text": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  ", "start_char_idx": 541, "end_char_idx": 780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde3dc5e-2b3e-4dce-a845-a4af822168d7": {"__data__": {"id_": "fde3dc5e-2b3e-4dce-a845-a4af822168d7", "embedding": null, "metadata": {"window": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n", "original_text": "Does that help answer your question, George?  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38c6c671-caeb-45b3-831d-06f72bee23b2", "node_type": "1", "metadata": {"window": "And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n", "original_text": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5074b97598849072aa498a6479f351c0a74eb3b8f03dad245e36dbbc1da62ee3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20853244-e1c4-40f3-bc7b-cdce8be1b513", "node_type": "1", "metadata": {"window": "It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n", "original_text": "George Hill :  Yes, I think you covered it clearly.  "}, "hash": "de4867d8a8200d71cd31b0bdee23bec98de57cfdbb5cf567b8279203dfc7ba88", "class_name": "RelatedNodeInfo"}}, "text": "Does that help answer your question, George?  \n \n", "start_char_idx": 780, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20853244-e1c4-40f3-bc7b-cdce8be1b513": {"__data__": {"id_": "20853244-e1c4-40f3-bc7b-cdce8be1b513", "embedding": null, "metadata": {"window": "It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n", "original_text": "George Hill :  Yes, I think you covered it clearly.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde3dc5e-2b3e-4dce-a845-a4af822168d7", "node_type": "1", "metadata": {"window": "With respect to the accelerated launc h of new items, that's not necessarily a one timer.   It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n", "original_text": "Does that help answer your question, George?  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "566289e5866282e0e724fec856bf6f3b6b25d88174f7c771d8a4f263720dd5ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd8b48b6-ef9a-46b9-923f-f7e108fb1d08", "node_type": "1", "metadata": {"window": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.  ", "original_text": "Thank you.  \n \n"}, "hash": "f185f8cdf7ebceb07668cdc00e05e52395a1721b762a594c2b6709bda9a5a138", "class_name": "RelatedNodeInfo"}}, "text": "George Hill :  Yes, I think you covered it clearly.  ", "start_char_idx": 829, "end_char_idx": 882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd8b48b6-ef9a-46b9-923f-f7e108fb1d08": {"__data__": {"id_": "bd8b48b6-ef9a-46b9-923f-f7e108fb1d08", "embedding": null, "metadata": {"window": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.  ", "original_text": "Thank you.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20853244-e1c4-40f3-bc7b-cdce8be1b513", "node_type": "1", "metadata": {"window": "It's just a pull forward of \nsomething that was anticipated later in the year.   So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n", "original_text": "George Hill :  Yes, I think you covered it clearly.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fa1554a2c77a16105e45e5e177d3d806e1fab571cc4951d790b095931d55a89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77e8de5d-c94e-4677-9876-976cdd1e7218", "node_type": "1", "metadata": {"window": "Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.  ", "original_text": "Kevin Moran :  Next question.  \n \n"}, "hash": "c7dbd4bed13030d4a44d87bedea6b7bf2b60a6f090533ea1ed578d1e8ef84f28", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 882, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77e8de5d-c94e-4677-9876-976cdd1e7218": {"__data__": {"id_": "77e8de5d-c94e-4677-9876-976cdd1e7218", "embedding": null, "metadata": {"window": "Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.  ", "original_text": "Kevin Moran :  Next question.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd8b48b6-ef9a-46b9-923f-f7e108fb1d08", "node_type": "1", "metadata": {"window": "So I think you can expect, which is why we call our guidance up \nspecific to pharma, we expect to see some positive results i n Q3 and then possibly today based on what we see \nsomewhat moderation in the year -over-year comparison in Q4.   Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.  ", "original_text": "Thank you.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13c9bbd592b9dc693412a3d09fb9a5cb900b743597219c84d2aebccc898ac383", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "843e9acf-63d7-4258-87fa-f636cfb57cf5", "node_type": "1", "metadata": {"window": "George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  ", "original_text": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n"}, "hash": "f71a4da583c9e010422e3d46b2082e080762ffd7b61fd7a7a261b716e47eb9d1", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Next question.  \n \n", "start_char_idx": 897, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "843e9acf-63d7-4258-87fa-f636cfb57cf5": {"__data__": {"id_": "843e9acf-63d7-4258-87fa-f636cfb57cf5", "embedding": null, "metadata": {"window": "George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  ", "original_text": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77e8de5d-c94e-4677-9876-976cdd1e7218", "node_type": "1", "metadata": {"window": "Does that help answer your question, George?  \n \n George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.  ", "original_text": "Kevin Moran :  Next question.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e617d2c6d0b9d362cf2fc85a3158cad30736af932f2aee84ff92fc4ef168222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb1ee752-a26f-4830-9675-ba5b3dbfe7ce", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n", "original_text": "Elizabeth Anderson :  Hi.  "}, "hash": "1cc58de2c6faea181dac08f1bc8a6c8111ff73efc67d2908034d2c74dbcb3d2c", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n", "start_char_idx": 931, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb1ee752-a26f-4830-9675-ba5b3dbfe7ce": {"__data__": {"id_": "bb1ee752-a26f-4830-9675-ba5b3dbfe7ce", "embedding": null, "metadata": {"window": "Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n", "original_text": "Elizabeth Anderson :  Hi.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "843e9acf-63d7-4258-87fa-f636cfb57cf5", "node_type": "1", "metadata": {"window": "George Hill :  Yes, I think you covered it clearly.   Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  ", "original_text": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e563ba85fd259311401cfb3ab6d0eac35dbc3f488d606e994da19f0db5ea5f20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2625f123-df23-454a-a934-b90848cfaa9d", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n", "original_text": "Good morning, guys.  "}, "hash": "8258966c6cc59df3a84cd0374362a138b870d17a7f38bd671d2f73bcb13f15ad", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson :  Hi.  ", "start_char_idx": 1019, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2625f123-df23-454a-a934-b90848cfaa9d": {"__data__": {"id_": "2625f123-df23-454a-a934-b90848cfaa9d", "embedding": null, "metadata": {"window": "Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n", "original_text": "Good morning, guys.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb1ee752-a26f-4830-9675-ba5b3dbfe7ce", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n", "original_text": "Elizabeth Anderson :  Hi.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d883a41845744cd9b61cdcd1a6b313bac3f2581c91b9bd882bfae9e532b78eee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb980769-7cf2-4148-9c40-a08475e340f3", "node_type": "1", "metadata": {"window": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  ", "original_text": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  "}, "hash": "833701442e664619f57005902f6f239d5a0a7f2adf9daa378b13fbb655d26a72", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys.  ", "start_char_idx": 1046, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb980769-7cf2-4148-9c40-a08475e340f3": {"__data__": {"id_": "eb980769-7cf2-4148-9c40-a08475e340f3", "embedding": null, "metadata": {"window": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  ", "original_text": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2625f123-df23-454a-a934-b90848cfaa9d", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question.  \n \n Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n", "original_text": "Good morning, guys.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6755b5d41a15f1238e29b70de9ef22ea3f013b2ae9446cd3e3d63c524ae57fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54bebece-4b12-43fe-9dee-ff56a4c35e34", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  ", "original_text": "You know, is it sort of an increase in services?  \n"}, "hash": "4c408f20e45b1d28adacc4fa42384c8982952653a98b9cece97b2cf1c3f6afb3", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  ", "start_char_idx": 1067, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54bebece-4b12-43fe-9dee-ff56a4c35e34": {"__data__": {"id_": "54bebece-4b12-43fe-9dee-ff56a4c35e34", "embedding": null, "metadata": {"window": "Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  ", "original_text": "You know, is it sort of an increase in services?  \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb980769-7cf2-4148-9c40-a08475e340f3", "node_type": "1", "metadata": {"window": "Operator :  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  ", "original_text": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c137b3284353f01f22b0d5db08385e8420bfa8aec1cd4fb9b41314e009cf85c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc35fc73-2f9c-4bc0-b857-209bef4d1a32", "node_type": "1", "metadata": {"window": "Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n"}, "hash": "61bb3ee4ab7273d7cbf420ccf0812d2f9d6f656c6be59324687ba70c6767ed4a", "class_name": "RelatedNodeInfo"}}, "text": "You know, is it sort of an increase in services?  \n", "start_char_idx": 1210, "end_char_idx": 1261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc35fc73-2f9c-4bc0-b857-209bef4d1a32": {"__data__": {"id_": "fc35fc73-2f9c-4bc0-b857-209bef4d1a32", "embedding": null, "metadata": {"window": "Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54bebece-4b12-43fe-9dee-ff56a4c35e34", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi.   Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  ", "original_text": "You know, is it sort of an increase in services?  \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae4bd9735f7c0bbf6a3d1d58200bb5bbd78ac303b2ad200e782b9c16c3622fd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08e53813-e661-4eb8-97e6-a59474d9f1e2", "node_type": "1", "metadata": {"window": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  "}, "hash": "260ea2d45a60e28a69397de783d99d407b52118d62083e250f02c11782153b51", "class_name": "RelatedNodeInfo"}}, "text": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n", "start_char_idx": 1261, "end_char_idx": 1362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e53813-e661-4eb8-97e6-a59474d9f1e2": {"__data__": {"id_": "08e53813-e661-4eb8-97e6-a59474d9f1e2", "embedding": null, "metadata": {"window": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc35fc73-2f9c-4bc0-b857-209bef4d1a32", "node_type": "1", "metadata": {"window": "Good morning, guys.   I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74a655273c6913cee84e0a8a40c633e747955d7e2bb3ade72af1153e01a1c960", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cbdbf80-7488-45f6-8511-0eff77b022aa", "node_type": "1", "metadata": {"window": "You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  "}, "hash": "81cd91031c51f40c8d6fd6e66fc329c73ebdeca8db5f934e20e9295368ba379c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  ", "start_char_idx": 1362, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cbdbf80-7488-45f6-8511-0eff77b022aa": {"__data__": {"id_": "7cbdbf80-7488-45f6-8511-0eff77b022aa", "embedding": null, "metadata": {"window": "You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e53813-e661-4eb8-97e6-a59474d9f1e2", "node_type": "1", "metadata": {"window": "I was hoping you could talk a little bit more about some of the specialty \nprofit drivers in the quarter and maybe more broadl y beyond that.   You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f0717e61d761a3c0f8dccfbd06dfa278b8ef4f12b38bf32334db8f0064a97c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2c138c-f7e4-4154-9ec1-a7ef3a99b3c9", "node_type": "1", "metadata": {"window": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "That's a really big piece of it.  \n "}, "hash": "8ac926573b70cdbfc51761e3af406bde1f739e4cc6b46c614c436ca2b90c6cbc", "class_name": "RelatedNodeInfo"}}, "text": "We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  ", "start_char_idx": 1467, "end_char_idx": 1643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2c138c-f7e4-4154-9ec1-a7ef3a99b3c9": {"__data__": {"id_": "af2c138c-f7e4-4154-9ec1-a7ef3a99b3c9", "embedding": null, "metadata": {"window": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "That's a really big piece of it.  \n ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26d39df9-9910-4a9d-a829-04e3781d6c12", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c00d2d93ca49bbbc02163ef03ea300eb15f20c27820cddfaaf77baa937a35b3e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cbdbf80-7488-45f6-8511-0eff77b022aa", "node_type": "1", "metadata": {"window": "You know, is it sort of an increase in services?  \n Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3c7a7171ba64b2be58e9cf15a068e1772d30a48aeefb0f73d51cbdc0c7ad853", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2501271f-fdb2-456f-82c2-a2c34399c6e3", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "original_text": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.  "}, "hash": "cb978fd46f380bb020d42fc54a52659b103350beb4dcc54ee15d5ab521bd4fce", "class_name": "RelatedNodeInfo"}}, "text": "That's a really big piece of it.  \n ", "start_char_idx": 1643, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2501271f-fdb2-456f-82c2-a2c34399c6e3": {"__data__": {"id_": "2501271f-fdb2-456f-82c2-a2c34399c6e3", "embedding": null, "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "original_text": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2c138c-f7e4-4154-9ec1-a7ef3a99b3c9", "node_type": "1", "metadata": {"window": "Is this just a launch calendar, any additional color you could provide on that would be helpful.  \n \n Mike Kaufmann :  I think in specialty a lot of this just has to do with the normal growth of specialty.   We are continuing to \nsee certain drugs grow in the marketplace because of their success, particularly in the oncology space, getting \nnew indications and just normal growth.   That's a really big piece of it.  \n ", "original_text": "That's a really big piece of it.  \n ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b88d21e402287769c3ba835dced280e03ffb44c2c7468e1d088c77e661edf99a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc6fe74c-ea8a-4301-9fa0-a2db1e27b452", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  ", "original_text": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .  "}, "hash": "086ff86afe46d037e363b4f11d0b729c606677895ced36e67d4aa74aba74b452", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.  ", "start_char_idx": 0, "end_char_idx": 123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc6fe74c-ea8a-4301-9fa0-a2db1e27b452": {"__data__": {"id_": "cc6fe74c-ea8a-4301-9fa0-a2db1e27b452", "embedding": null, "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  ", "original_text": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2501271f-fdb2-456f-82c2-a2c34399c6e3", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "original_text": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25ef134aeb317f8f9205108106d1efda4b1844e363bf61f34fbba366ec69fd58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "339bac2f-7588-432a-964c-121398d2aec4", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n", "original_text": "That's been a piece of it.  \n \n "}, "hash": "bba109dd7b4a6fa8eda4dd6a90411fd6917133d7e57c9d37bed4de1cf033ffa3", "class_name": "RelatedNodeInfo"}}, "text": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .  ", "start_char_idx": 123, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "339bac2f-7588-432a-964c-121398d2aec4": {"__data__": {"id_": "339bac2f-7588-432a-964c-121398d2aec4", "embedding": null, "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n", "original_text": "That's been a piece of it.  \n \n ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc6fe74c-ea8a-4301-9fa0-a2db1e27b452", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  ", "original_text": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d00a33537f22fca03dc091d078b64dfbc343467fb8847b4b5fcedeb992034471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bb266a0-8815-42af-9bd4-1a981f02fd38", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n", "original_text": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  "}, "hash": "fc17a7676ed16bcccffdbed08d2b34d01c65ffdc89df542c03bb301fa8c1d225", "class_name": "RelatedNodeInfo"}}, "text": "That's been a piece of it.  \n \n ", "start_char_idx": 318, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bb266a0-8815-42af-9bd4-1a981f02fd38": {"__data__": {"id_": "8bb266a0-8815-42af-9bd4-1a981f02fd38", "embedding": null, "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n", "original_text": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "339bac2f-7588-432a-964c-121398d2aec4", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n", "original_text": "That's been a piece of it.  \n \n ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef73cb97fde1f0339fd08bca8cc1c0b7f3a7ec787a1a55e448cca991ef14720d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb56aff1-5d62-40f8-b293-bda010f39b3a", "node_type": "1", "metadata": {"window": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n", "original_text": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  "}, "hash": "d053ab3edf48c2efe0b6ceba7e6cd7620d42894c30396754e327198a4ba58ee0", "class_name": "RelatedNodeInfo"}}, "text": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "start_char_idx": 350, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb56aff1-5d62-40f8-b293-bda010f39b3a": {"__data__": {"id_": "eb56aff1-5d62-40f8-b293-bda010f39b3a", "embedding": null, "metadata": {"window": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n", "original_text": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bb266a0-8815-42af-9bd4-1a981f02fd38", "node_type": "1", "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n", "original_text": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cf98c51f1e32c6d5c513e46aefa5eca6e35a3fa3582892e2a7277514205f9e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d53faa94-a61a-40a7-97b4-e986016501ca", "node_type": "1", "metadata": {"window": "That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n", "original_text": "It's just nice solid growth with volumes across the board.  \n \n"}, "hash": "4442243749972176c469c7bb6c8fc5f96744bf4e20b52950aed49724174d10dc", "class_name": "RelatedNodeInfo"}}, "text": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  ", "start_char_idx": 514, "end_char_idx": 627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d53faa94-a61a-40a7-97b4-e986016501ca": {"__data__": {"id_": "d53faa94-a61a-40a7-97b4-e986016501ca", "embedding": null, "metadata": {"window": "That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n", "original_text": "It's just nice solid growth with volumes across the board.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb56aff1-5d62-40f8-b293-bda010f39b3a", "node_type": "1", "metadata": {"window": "While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n", "original_text": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0e260856b85b52ea50e49bfae58e8813ee9ee8d44a8bd49fe6c52b42f61f2b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "343a2eba-ffe5-423a-813d-02e908b8f148", "node_type": "1", "metadata": {"window": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.  ", "original_text": "Elizabeth Anderson :  Thank you.  \n \n"}, "hash": "63ab60ddf07a771b7fb635751057de3aa835024b39952a184ee5f0c6947411a2", "class_name": "RelatedNodeInfo"}}, "text": "It's just nice solid growth with volumes across the board.  \n \n", "start_char_idx": 627, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "343a2eba-ffe5-423a-813d-02e908b8f148": {"__data__": {"id_": "343a2eba-ffe5-423a-813d-02e908b8f148", "embedding": null, "metadata": {"window": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.  ", "original_text": "Elizabeth Anderson :  Thank you.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d53faa94-a61a-40a7-97b4-e986016501ca", "node_type": "1", "metadata": {"window": "That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n", "original_text": "It's just nice solid growth with volumes across the board.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21095c720604e01f9a4fd33d468a6aa415561afd27674b5ceb9d0927e61f2d47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e49ffea-c28d-4119-9fa8-0d2ec7202b8e", "node_type": "1", "metadata": {"window": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n ", "original_text": "Mike Kaufmann :  Next question.  \n \n"}, "hash": "5188e5fef85e808ba34a8ed1b8e5c710b5c31a4f45a02946b7908ff3ff0b0c7d", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson :  Thank you.  \n \n", "start_char_idx": 690, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e49ffea-c28d-4119-9fa8-0d2ec7202b8e": {"__data__": {"id_": "4e49ffea-c28d-4119-9fa8-0d2ec7202b8e", "embedding": null, "metadata": {"window": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n ", "original_text": "Mike Kaufmann :  Next question.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "343a2eba-ffe5-423a-813d-02e908b8f148", "node_type": "1", "metadata": {"window": "We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.   So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.  ", "original_text": "Elizabeth Anderson :  Thank you.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b28559d6d0a4dec70fee88aec7013bece7d91fca1d2c7c2ebef0b2571138a745", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73a5b421-43ff-47cc-bbb2-aa5fbbe317c4", "node_type": "1", "metadata": {"window": "It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.  ", "original_text": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n"}, "hash": "426cd510470e891af20af88378586863ad515c31d0ed3b216bfab6d9efa7e960", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Next question.  \n \n", "start_char_idx": 727, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73a5b421-43ff-47cc-bbb2-aa5fbbe317c4": {"__data__": {"id_": "73a5b421-43ff-47cc-bbb2-aa5fbbe317c4", "embedding": null, "metadata": {"window": "It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.  ", "original_text": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e49ffea-c28d-4119-9fa8-0d2ec7202b8e", "node_type": "1", "metadata": {"window": "So nothing unique about like large pieces of movement, a \nbusiness or anything, you know, one timers like that.   It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n ", "original_text": "Mike Kaufmann :  Next question.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dbebec22a907e3c81d3030152c463a14bd162bbd7980993b06e800ef41e8006", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe8ed9c-e507-4c7a-8f9e-fe1ce5bb5fb6", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "Stephen Baxter :  Hey, thanks for the question.  "}, "hash": "3f9be26426cb538951990597795a8ead2d3c281264ce4adae88bfa464980088c", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n", "start_char_idx": 763, "end_char_idx": 832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe8ed9c-e507-4c7a-8f9e-fe1ce5bb5fb6": {"__data__": {"id_": "ebe8ed9c-e507-4c7a-8f9e-fe1ce5bb5fb6", "embedding": null, "metadata": {"window": "Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "Stephen Baxter :  Hey, thanks for the question.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73a5b421-43ff-47cc-bbb2-aa5fbbe317c4", "node_type": "1", "metadata": {"window": "It's just nice solid growth with volumes across the board.  \n \n Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.  ", "original_text": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7abe651951c0d456e3ba5848fda4786e5e54b6ad0dc82ee45e195e7034a1352", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb01aa35-ed44-4ce6-8c62-954166bc3551", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n "}, "hash": "d43e3a091dcfa14575c9209fd84a2848d565c044787b075c5f2e5a27efbd9c55", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Baxter :  Hey, thanks for the question.  ", "start_char_idx": 832, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb01aa35-ed44-4ce6-8c62-954166bc3551": {"__data__": {"id_": "fb01aa35-ed44-4ce6-8c62-954166bc3551", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe8ed9c-e507-4c7a-8f9e-fe1ce5bb5fb6", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Thank you.  \n \n Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "Stephen Baxter :  Hey, thanks for the question.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5808d0375988167a8e07167454d3aee40ceb294971567d777a17001036cbbbf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3b419a-5e52-4db4-8f0e-4381c9cd5b16", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "I assume the renewal impact hasn't changed.  "}, "hash": "7b9eeb35c283cb9277881fb4181ad74ebd887d3c555c2686fffc255e83162570", "class_name": "RelatedNodeInfo"}}, "text": "So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n ", "start_char_idx": 881, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3b419a-5e52-4db4-8f0e-4381c9cd5b16": {"__data__": {"id_": "3d3b419a-5e52-4db4-8f0e-4381c9cd5b16", "embedding": null, "metadata": {"window": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "I assume the renewal impact hasn't changed.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb01aa35-ed44-4ce6-8c62-954166bc3551", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Next question.  \n \n Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c144eca4f52561ba23e30f46fe1f2ca6d8ce24095f2a1aaa0d4660914dea1550", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54094481-35a7-4cac-99c8-eca9e755921a", "node_type": "1", "metadata": {"window": "Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n "}, "hash": "75616a2403be1552b72023cc33c72a604ea3b0504190454540e7a6bab64b610e", "class_name": "RelatedNodeInfo"}}, "text": "I assume the renewal impact hasn't changed.  ", "start_char_idx": 1112, "end_char_idx": 1157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54094481-35a7-4cac-99c8-eca9e755921a": {"__data__": {"id_": "54094481-35a7-4cac-99c8-eca9e755921a", "embedding": null, "metadata": {"window": "Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9942db7f-1c27-41eb-83a6-1b4802668146", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749391ff9a6f5e7876f961d497b6ff4fa407e16041d769d28a541ec0d4406155", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3b419a-5e52-4db4-8f0e-4381c9cd5b16", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Stephen Baxter with Wolfe Research.  \n \n Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "I assume the renewal impact hasn't changed.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a566ecd244f00197b114c2a100f9a02bc50ad9e9159d32033b062d8638448d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de02a0f4-3afd-40d5-a9f6-b279de812e21", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.  ", "original_text": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.  "}, "hash": "7b149057e9c0f56801c29a80058f0504b4a7732c4e29c275cff9a9765380a038", "class_name": "RelatedNodeInfo"}}, "text": "So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "start_char_idx": 1157, "end_char_idx": 1364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de02a0f4-3afd-40d5-a9f6-b279de812e21": {"__data__": {"id_": "de02a0f4-3afd-40d5-a9f6-b279de812e21", "embedding": null, "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.  ", "original_text": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54094481-35a7-4cac-99c8-eca9e755921a", "node_type": "1", "metadata": {"window": "Stephen Baxter :  Hey, thanks for the question.   So based on how you sized the relative components of the pharma \nguidance coming into the year, it seemed like renewals were driving at least half of the high single digit to low \ndouble digit profit decline you're ass uming.  \n \n  I assume the renewal impact hasn't changed.   So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "original_text": "So the revised guidance for the low single digit percent decline \nwould seem to indicate a decent amount of underlying growth, excluding the renewals and opioid expenses, \nwhich has now moved higher too.  \n ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd60b71118917088e56feb3d8937f8b94acb0e27784afa323448a5ddafa164eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a86bcf23-8c1a-4147-b6ed-a80cb69b6e03", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  ", "original_text": "Thanks.  \n \n"}, "hash": "97f88e664bc8ff3a11d97b228cc40f0fa45d9431de6843aca326a2b6cf646512", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.  ", "start_char_idx": 0, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a86bcf23-8c1a-4147-b6ed-a80cb69b6e03": {"__data__": {"id_": "a86bcf23-8c1a-4147-b6ed-a80cb69b6e03", "embedding": null, "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  ", "original_text": "Thanks.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de02a0f4-3afd-40d5-a9f6-b279de812e21", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.  ", "original_text": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd9a0662444680cfcc3da9277af67f9bbc97f1119badcf6e4fb5d294d09ca45e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27c0aecb-0711-45dc-9580-1a49b89432c0", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n", "original_text": "David Evans :  Well, Stephen, this Dave.  "}, "hash": "5687185e259fd2232fba3062a3c24195947e61618008ed68e7b80cb029f8c666", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 317, "end_char_idx": 329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c0aecb-0711-45dc-9580-1a49b89432c0": {"__data__": {"id_": "27c0aecb-0711-45dc-9580-1a49b89432c0", "embedding": null, "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n", "original_text": "David Evans :  Well, Stephen, this Dave.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a86bcf23-8c1a-4147-b6ed-a80cb69b6e03", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  ", "original_text": "Thanks.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9d301af71572d626a4eb781887dc6ae23aad0d34c51494d79029fcb80cb6ad8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dae5c380-4a08-4164-9877-b1d9f901c318", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n", "original_text": "So I'd say your assumptions are all pretty spot on.  "}, "hash": "8b94416049b77c740d00d901a5f700aade737536f5c847bdac4b457bfa5067f3", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Well, Stephen, this Dave.  ", "start_char_idx": 329, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dae5c380-4a08-4164-9877-b1d9f901c318": {"__data__": {"id_": "dae5c380-4a08-4164-9877-b1d9f901c318", "embedding": null, "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n", "original_text": "So I'd say your assumptions are all pretty spot on.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27c0aecb-0711-45dc-9580-1a49b89432c0", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n", "original_text": "David Evans :  Well, Stephen, this Dave.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8fdaae197e33bc96526932353429430e0f9d2e621b9ba0c5f9a683160ad51d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ded71b0a-019d-43c8-b2ff-258338975827", "node_type": "1", "metadata": {"window": "Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n", "original_text": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  "}, "hash": "52c4bc742d633045fbab261239a25047223775c3e5279278a7c8a90c0b4b1483", "class_name": "RelatedNodeInfo"}}, "text": "So I'd say your assumptions are all pretty spot on.  ", "start_char_idx": 371, "end_char_idx": 424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ded71b0a-019d-43c8-b2ff-258338975827": {"__data__": {"id_": "ded71b0a-019d-43c8-b2ff-258338975827", "embedding": null, "metadata": {"window": "Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n", "original_text": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dae5c380-4a08-4164-9877-b1d9f901c318", "node_type": "1", "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n", "original_text": "So I'd say your assumptions are all pretty spot on.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c1a63feecb41c9cb3db6275f87c929f512d8e2b5525ed0d479ecd7a17bac3a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c56f52d-7ab2-463f-8215-189536592707", "node_type": "1", "metadata": {"window": "David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.  ", "original_text": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n"}, "hash": "3f9425f21a03fc95a0a7f26a4b3b9826f20a1ac091dff011d467dc527c552ef5", "class_name": "RelatedNodeInfo"}}, "text": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  ", "start_char_idx": 424, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c56f52d-7ab2-463f-8215-189536592707": {"__data__": {"id_": "7c56f52d-7ab2-463f-8215-189536592707", "embedding": null, "metadata": {"window": "David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.  ", "original_text": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ded71b0a-019d-43c8-b2ff-258338975827", "node_type": "1", "metadata": {"window": "Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n", "original_text": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f6b5ed820384269c83f1c88320df0a1cd0edc546b4b0fd0e82f8a0919e5a0fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31f6feab-2d45-41a2-8c44-f8aea272f6d6", "node_type": "1", "metadata": {"window": "So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?  ", "original_text": "Kevin Moran :  Next question.  \n \n"}, "hash": "dc59b93dbf0ec325c20a617a512ffc6fdbe33d2c8e9103ee6655af84ab7b2d1c", "class_name": "RelatedNodeInfo"}}, "text": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n", "start_char_idx": 562, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31f6feab-2d45-41a2-8c44-f8aea272f6d6": {"__data__": {"id_": "31f6feab-2d45-41a2-8c44-f8aea272f6d6", "embedding": null, "metadata": {"window": "So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?  ", "original_text": "Kevin Moran :  Next question.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c56f52d-7ab2-463f-8215-189536592707", "node_type": "1", "metadata": {"window": "David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.  ", "original_text": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "843c16528a10876a2ed062919700fbec182d9262ba099e3087692247d253accd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d6a03a-b675-4227-8274-ab9d04554815", "node_type": "1", "metadata": {"window": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n", "original_text": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n"}, "hash": "af9ba5e34d7b1b9d51fd19ad63e1de950dca539ae0bb8ee2bc91c9afa225dd75", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Next question.  \n \n", "start_char_idx": 668, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5d6a03a-b675-4227-8274-ab9d04554815": {"__data__": {"id_": "d5d6a03a-b675-4227-8274-ab9d04554815", "embedding": null, "metadata": {"window": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n", "original_text": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31f6feab-2d45-41a2-8c44-f8aea272f6d6", "node_type": "1", "metadata": {"window": "So I'd say your assumptions are all pretty spot on.   I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?  ", "original_text": "Kevin Moran :  Next question.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9f1dc34303cb917bfe6be18271c9c87934b08a7a80cdbda003b603dfb4d52ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fd614ce-b15e-4ecf-aab2-36d0fb467ddd", "node_type": "1", "metadata": {"window": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "Erin Wright :  Great, thanks.  "}, "hash": "614e56a5eee8974e08be9c6498bfde174763b28ba59df65d004a183876fe644c", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n", "start_char_idx": 702, "end_char_idx": 767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fd614ce-b15e-4ecf-aab2-36d0fb467ddd": {"__data__": {"id_": "3fd614ce-b15e-4ecf-aab2-36d0fb467ddd", "embedding": null, "metadata": {"window": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "Erin Wright :  Great, thanks.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d6a03a-b675-4227-8274-ab9d04554815", "node_type": "1", "metadata": {"window": "I would say though that we're \nreally, you know, per our usual practice, we are not in a position to comment on '2 1 at this early date.   But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n", "original_text": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67c80f1848e8cc8676db5bd7a0828afaf76ab65c9a171e223e0de14d0a2fbe11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5ec56c5-63d5-42d0-bc68-7f54960eec53", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.  ", "original_text": "Does your guidance assume any meaningful contribution from biosimilars?  "}, "hash": "09b6d9d75d72f43ff31be9e73da6570fe5e17bf60458160aedaf0caa61754b6a", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wright :  Great, thanks.  ", "start_char_idx": 767, "end_char_idx": 798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5ec56c5-63d5-42d0-bc68-7f54960eec53": {"__data__": {"id_": "d5ec56c5-63d5-42d0-bc68-7f54960eec53", "embedding": null, "metadata": {"window": "Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.  ", "original_text": "Does your guidance assume any meaningful contribution from biosimilars?  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fd614ce-b15e-4ecf-aab2-36d0fb467ddd", "node_type": "1", "metadata": {"window": "But overall, \nI think you've got a good handle on it and can understand what we've been articulating.  \n \n Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "Erin Wright :  Great, thanks.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57be24201ab0e2ae59b14de828ea2d7f1c37a3ccc0bc856142db9bfe6f61a65d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1c6bcc0-0888-49c1-bebf-9b9bab26acba", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.  ", "original_text": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n"}, "hash": "ff8e930c5840e77d1b2c9868517dcd38b16feee9b046e46b1b7475b25e6ca6ec", "class_name": "RelatedNodeInfo"}}, "text": "Does your guidance assume any meaningful contribution from biosimilars?  ", "start_char_idx": 798, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1c6bcc0-0888-49c1-bebf-9b9bab26acba": {"__data__": {"id_": "a1c6bcc0-0888-49c1-bebf-9b9bab26acba", "embedding": null, "metadata": {"window": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.  ", "original_text": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5ec56c5-63d5-42d0-bc68-7f54960eec53", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question.  \n \n Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.  ", "original_text": "Does your guidance assume any meaningful contribution from biosimilars?  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dbad75c5d2b2713e9cbe024363c0e6ce8be8de09092e4a39637a5873e4c6693", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51eb2f4a-71b9-4c8c-b88b-4a0a5a134309", "node_type": "1", "metadata": {"window": "Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.  ", "original_text": "Mike Kaufmann :  Yes.  "}, "hash": "2899d8f7b478ba606e9cbad65f351efa25ba95cd028ec499fdd3174b293ea0d1", "class_name": "RelatedNodeInfo"}}, "text": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n", "start_char_idx": 871, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51eb2f4a-71b9-4c8c-b88b-4a0a5a134309": {"__data__": {"id_": "51eb2f4a-71b9-4c8c-b88b-4a0a5a134309", "embedding": null, "metadata": {"window": "Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1c6bcc0-0888-49c1-bebf-9b9bab26acba", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Erin Wright with Credit Suisse.  \n \n Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.  ", "original_text": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b68be30718f0f6aaf27d15a26d1e69c6a2492cf5adfdf823b950401cde6338f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9760cdc-1a0c-4e2b-8abc-66ccc6e5624d", "node_type": "1", "metadata": {"window": "Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n ", "original_text": "Our guidance, you know, would assume any of the normal type related stuff.  "}, "hash": "692c7d65db8897dc0ed94dbd029cac19f015e9c4c8220ab42150fa2642d7aa80", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes.  ", "start_char_idx": 952, "end_char_idx": 975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9760cdc-1a0c-4e2b-8abc-66ccc6e5624d": {"__data__": {"id_": "d9760cdc-1a0c-4e2b-8abc-66ccc6e5624d", "embedding": null, "metadata": {"window": "Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n ", "original_text": "Our guidance, you know, would assume any of the normal type related stuff.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51eb2f4a-71b9-4c8c-b88b-4a0a5a134309", "node_type": "1", "metadata": {"window": "Erin Wright :  Great, thanks.   Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0001bcd0d2b511b5824a2d5898e3bf1094534cb73099f12d5839684ac4a0e883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b591e5d1-2791-4876-ba14-74eba6bc9834", "node_type": "1", "metadata": {"window": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  ", "original_text": "But there is nothi ng \nnew.  "}, "hash": "ce9c8891341636a7b60e3fea7bcaf611d74ce269ed5d786b0d4e1cdad9fa78cc", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance, you know, would assume any of the normal type related stuff.  ", "start_char_idx": 975, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b591e5d1-2791-4876-ba14-74eba6bc9834": {"__data__": {"id_": "b591e5d1-2791-4876-ba14-74eba6bc9834", "embedding": null, "metadata": {"window": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  ", "original_text": "But there is nothi ng \nnew.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9760cdc-1a0c-4e2b-8abc-66ccc6e5624d", "node_type": "1", "metadata": {"window": "Does your guidance assume any meaningful contribution from biosimilars?   Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n ", "original_text": "Our guidance, you know, would assume any of the normal type related stuff.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1b81d8d7fc7fe0956c2649368d86bd43a83c36cf535dbf9cb27cdc8d391a9f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a10928-c403-4ca6-9100-5ec10bbea583", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "No new launches that created the increase related to biosimilars.  "}, "hash": "c15d25ab1ae27e35d0f328591c1d2154fdc917c17bc8f69f8c63c30359a52b81", "class_name": "RelatedNodeInfo"}}, "text": "But there is nothi ng \nnew.  ", "start_char_idx": 1051, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84a10928-c403-4ca6-9100-5ec10bbea583": {"__data__": {"id_": "84a10928-c403-4ca6-9100-5ec10bbea583", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "No new launches that created the increase related to biosimilars.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b591e5d1-2791-4876-ba14-74eba6bc9834", "node_type": "1", "metadata": {"window": "Do you continue \nto view that as sort of an opportunity for you longer term?  \n \n Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  ", "original_text": "But there is nothi ng \nnew.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d04e1c71a07d245081296d365c397751ff322e516318bc9c6918f80b8a797ed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac0cde38-927e-42df-95bc-b4e90b7f293b", "node_type": "1", "metadata": {"window": "Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "We continue to think that something that \nwe'll keep an eye on.  \n \n "}, "hash": "1f4a1945275ab45c03139c82469fdf260bfd94435a4b88373decc0a092769b6e", "class_name": "RelatedNodeInfo"}}, "text": "No new launches that created the increase related to biosimilars.  ", "start_char_idx": 1080, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac0cde38-927e-42df-95bc-b4e90b7f293b": {"__data__": {"id_": "ac0cde38-927e-42df-95bc-b4e90b7f293b", "embedding": null, "metadata": {"window": "Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "We continue to think that something that \nwe'll keep an eye on.  \n \n ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84a10928-c403-4ca6-9100-5ec10bbea583", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "No new launches that created the increase related to biosimilars.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bfe501c50a7ff621dfa3e07c3505a317f9d981ce21beaecbce36a35bc18f54e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec031a4-1601-4905-8aec-c53f59974b2d", "node_type": "1", "metadata": {"window": "But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  "}, "hash": "71f1a76eb9ecf3a6ed49dc15c972243404ad331eb630f56c17b2501867be8ab9", "class_name": "RelatedNodeInfo"}}, "text": "We continue to think that something that \nwe'll keep an eye on.  \n \n ", "start_char_idx": 1147, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec031a4-1601-4905-8aec-c53f59974b2d": {"__data__": {"id_": "5ec031a4-1601-4905-8aec-c53f59974b2d", "embedding": null, "metadata": {"window": "But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac0cde38-927e-42df-95bc-b4e90b7f293b", "node_type": "1", "metadata": {"window": "Our guidance, you know, would assume any of the normal type related stuff.   But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "We continue to think that something that \nwe'll keep an eye on.  \n \n ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2de4029b5896f60a5aa61489cf5f698870622dc10a725e8ca4b905fee4daa93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6851d501-2b04-42fd-94ca-a1ef9ae4dc1b", "node_type": "1", "metadata": {"window": "No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n "}, "hash": "64f643ce1e83ec6a1c3b7a06548aee67aa76d5cef82ca568fae2cec8b131c635", "class_name": "RelatedNodeInfo"}}, "text": "I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  ", "start_char_idx": 1216, "end_char_idx": 1380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6851d501-2b04-42fd-94ca-a1ef9ae4dc1b": {"__data__": {"id_": "6851d501-2b04-42fd-94ca-a1ef9ae4dc1b", "embedding": null, "metadata": {"window": "No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0cd5095065c4a30426319ade00333579552c959934cec8af81a65d7b85a112", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec031a4-1601-4905-8aec-c53f59974b2d", "node_type": "1", "metadata": {"window": "But there is nothi ng \nnew.   No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59f0e396c0c682df73fb525cf8edcb05185306008a26249b78c1c2e319471333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9b0f526-f7d6-4d0a-b4c3-e38f893559b0", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.  ", "original_text": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.  "}, "hash": "147be92c0d1753489287866f3ee01dc108900db65f1fd2f7c946354e70e8517a", "class_name": "RelatedNodeInfo"}}, "text": "There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "start_char_idx": 1380, "end_char_idx": 1551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9b0f526-f7d6-4d0a-b4c3-e38f893559b0": {"__data__": {"id_": "d9b0f526-f7d6-4d0a-b4c3-e38f893559b0", "embedding": null, "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.  ", "original_text": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6851d501-2b04-42fd-94ca-a1ef9ae4dc1b", "node_type": "1", "metadata": {"window": "No new launches that created the increase related to biosimilars.   We continue to think that something that \nwe'll keep an eye on.  \n \n  I don't believe it will be a big driver for us in the short term because right now, they act more like branded drug s \nand their overall margin rates are similar.   There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "original_text": "There is a little bit of opportunity to make a little bit more money on \nsome of the biosimilars depending on programs we might be able to put in place with customers.  \n ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96d32fee2263a0a3ee9ca70d881771858dfacbd023078f7e469da3dc9eea2e56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea511c25-49f8-4c50-bacf-ebc152380625", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  ", "original_text": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.  "}, "hash": "59d20cb8eb55cc5994de4f7e3e48bab6f9fbcaea584310819968de8d87d5fb9d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.  ", "start_char_idx": 0, "end_char_idx": 152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea511c25-49f8-4c50-bacf-ebc152380625": {"__data__": {"id_": "ea511c25-49f8-4c50-bacf-ebc152380625", "embedding": null, "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  ", "original_text": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9b0f526-f7d6-4d0a-b4c3-e38f893559b0", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.  ", "original_text": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3651bd24087831898935d7e3296201b62ff36b723df9f1505fe47e5593ec887c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05e4e85-7d80-49b0-a085-73db6b921014", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n ", "original_text": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n"}, "hash": "1e13da9c6b7199b32008182e0546ef097bd6a4817ff7fbe8aea1aa86170a7962", "class_name": "RelatedNodeInfo"}}, "text": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.  ", "start_char_idx": 152, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05e4e85-7d80-49b0-a085-73db6b921014": {"__data__": {"id_": "b05e4e85-7d80-49b0-a085-73db6b921014", "embedding": null, "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n ", "original_text": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea511c25-49f8-4c50-bacf-ebc152380625", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  ", "original_text": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37999181e6be777a683a8a0ba4dbea8ffec36fb21039146d3394f2a6100ca4a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "737e6a60-b3ae-4e46-ae74-6b6740831163", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.  ", "original_text": "Erin Wright :  Okay, great.  "}, "hash": "123a5114c00bb8026f3844b48a55c5b017367111f7a07e059d64cf36a96c0813", "class_name": "RelatedNodeInfo"}}, "text": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n", "start_char_idx": 265, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "737e6a60-b3ae-4e46-ae74-6b6740831163": {"__data__": {"id_": "737e6a60-b3ae-4e46-ae74-6b6740831163", "embedding": null, "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.  ", "original_text": "Erin Wright :  Okay, great.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05e4e85-7d80-49b0-a085-73db6b921014", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n ", "original_text": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d64ca8d38aaf0967c0c8a3706c9d732ac90e9c5a47dcb424e6601c1e877eed7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d458441c-6d55-486f-a37b-2230925750ca", "node_type": "1", "metadata": {"window": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n", "original_text": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  "}, "hash": "4637dbfa72f0b65e23a0ffca1d0d5bd4bf92f64bf16fb8010cb8a3b3f46f6400", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wright :  Okay, great.  ", "start_char_idx": 378, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d458441c-6d55-486f-a37b-2230925750ca": {"__data__": {"id_": "d458441c-6d55-486f-a37b-2230925750ca", "embedding": null, "metadata": {"window": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n", "original_text": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "737e6a60-b3ae-4e46-ae74-6b6740831163", "node_type": "1", "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.  ", "original_text": "Erin Wright :  Okay, great.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acd0028dcfcb97654cbd6178413b430aac588ffd2f5e3f51d8e45d1dcfd1b6ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4814a69-4fdc-4c76-a913-d5295357e60a", "node_type": "1", "metadata": {"window": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.  ", "original_text": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n "}, "hash": "334cd18449dff22e85648cafc3948fe37a4c70eebf0f6c59e58c0a9fec8fc88f", "class_name": "RelatedNodeInfo"}}, "text": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  ", "start_char_idx": 407, "end_char_idx": 546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4814a69-4fdc-4c76-a913-d5295357e60a": {"__data__": {"id_": "d4814a69-4fdc-4c76-a913-d5295357e60a", "embedding": null, "metadata": {"window": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.  ", "original_text": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d458441c-6d55-486f-a37b-2230925750ca", "node_type": "1", "metadata": {"window": "It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n", "original_text": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e776e8fae8d83f3cdac714d136c7fd47cfda7f9f474efc51397b9e30fca5d224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ed62eb-03f2-4130-b00e-256b42825af4", "node_type": "1", "metadata": {"window": "Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  ", "original_text": "And also if you could break out the recent Cordis trends specifically, that would be helpful.  "}, "hash": "1639bc5f5f78b80aae88f613238178d18d18828d3eb748ebc4b785b2be07d7d9", "class_name": "RelatedNodeInfo"}}, "text": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n ", "start_char_idx": 546, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ed62eb-03f2-4130-b00e-256b42825af4": {"__data__": {"id_": "90ed62eb-03f2-4130-b00e-256b42825af4", "embedding": null, "metadata": {"window": "Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  ", "original_text": "And also if you could break out the recent Cordis trends specifically, that would be helpful.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4814a69-4fdc-4c76-a913-d5295357e60a", "node_type": "1", "metadata": {"window": "And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.  ", "original_text": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83538b877485d0312ba3301fd4140d524b9dbe4d7a232a7d398541f6070649c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "284bde84-9f2f-4965-a766-a727a7f864f1", "node_type": "1", "metadata": {"window": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.  ", "original_text": "Thanks.  \n \n"}, "hash": "dfa64c4ea7eedb6d0c116dd16d616bfa43919c5068e60802a24bb60af8270686", "class_name": "RelatedNodeInfo"}}, "text": "And also if you could break out the recent Cordis trends specifically, that would be helpful.  ", "start_char_idx": 727, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "284bde84-9f2f-4965-a766-a727a7f864f1": {"__data__": {"id_": "284bde84-9f2f-4965-a766-a727a7f864f1", "embedding": null, "metadata": {"window": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.  ", "original_text": "Thanks.  \n \n", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ed62eb-03f2-4130-b00e-256b42825af4", "node_type": "1", "metadata": {"window": "Erin Wright :  Okay, great.   And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  ", "original_text": "And also if you could break out the recent Cordis trends specifically, that would be helpful.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83e75819e32251c301a9128d4005dc26896d4cf129f626fd8fcd818ed8a9a771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "686f4b8d-6bbb-4d62-b47f-764f849a4b32", "node_type": "1", "metadata": {"window": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n ", "original_text": "Mike Kaufmann :  Yes.  "}, "hash": "17cc8dceb81114c166081f9b1f3ff36467b07f2a1c34f712b9c73e96e6a557b5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 822, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "686f4b8d-6bbb-4d62-b47f-764f849a4b32": {"__data__": {"id_": "686f4b8d-6bbb-4d62-b47f-764f849a4b32", "embedding": null, "metadata": {"window": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "284bde84-9f2f-4965-a766-a727a7f864f1", "node_type": "1", "metadata": {"window": "And then where are you in terms of the streamlining of your commercial and supply chain \ninitiatives on the medical side of the business?   You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.  ", "original_text": "Thanks.  \n \n", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a31a6ddc8d9f22b30fc7efcb62efaf30b2d3a746c27b1842d6fd06b37706fe41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e4b760d-8e8a-4427-b3d7-3a0c01efca4a", "node_type": "1", "metadata": {"window": "And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  ", "original_text": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  "}, "hash": "a063ea43ebb742f1889b4f2d1311625633e9e1b93f5208f659968fbd257684f9", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes.  ", "start_char_idx": 834, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e4b760d-8e8a-4427-b3d7-3a0c01efca4a": {"__data__": {"id_": "6e4b760d-8e8a-4427-b3d7-3a0c01efca4a", "embedding": null, "metadata": {"window": "And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  ", "original_text": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "686f4b8d-6bbb-4d62-b47f-764f849a4b32", "node_type": "1", "metadata": {"window": "You suggested that maybe you face a li ttle bit of a setback here in \nterms of the recent recalls, but would you say you're still seeing some progress and focus on that front?  \n \n  And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34573aba2300e0ee5001f28da1baec87d288886d4c18dce4d23093b97396ecab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a46435d2-6fc6-4952-8062-af3523be6204", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n ", "original_text": "The business is continuing to grow.  "}, "hash": "ebe7fa7000bea2413c4f3bc2dd529a745b0ffe6b81132d4447669565334d5390", "class_name": "RelatedNodeInfo"}}, "text": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  ", "start_char_idx": 857, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a46435d2-6fc6-4952-8062-af3523be6204": {"__data__": {"id_": "a46435d2-6fc6-4952-8062-af3523be6204", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n ", "original_text": "The business is continuing to grow.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e4b760d-8e8a-4427-b3d7-3a0c01efca4a", "node_type": "1", "metadata": {"window": "And also if you could break out the recent Cordis trends specifically, that would be helpful.   Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  ", "original_text": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68fff916267cbdf7501c7b13c361aa0de0ec212870dd46aea49e54bc6234dce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22bc21fb-b6a9-457b-92da-a1e0def3f434", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.  ", "original_text": "We're seeing growth in our profit there.  \n \n "}, "hash": "539d764a8790c20541641f01e9fed6f52850490f664877a3042a049aadac8287", "class_name": "RelatedNodeInfo"}}, "text": "The business is continuing to grow.  ", "start_char_idx": 977, "end_char_idx": 1014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22bc21fb-b6a9-457b-92da-a1e0def3f434": {"__data__": {"id_": "22bc21fb-b6a9-457b-92da-a1e0def3f434", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.  ", "original_text": "We're seeing growth in our profit there.  \n \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a46435d2-6fc6-4952-8062-af3523be6204", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n ", "original_text": "The business is continuing to grow.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05bb962e8cb8c8edd6e63426e50293f85d6d02bd7fdb30464c51b81b9cf52c88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d2cfcaf-cbd5-4b53-b525-ee556a5245c2", "node_type": "1", "metadata": {"window": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  "}, "hash": "981aa41893ddd609947a8fa0027588e59f8e1e84163dd378f10955324e03efb3", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing growth in our profit there.  \n \n ", "start_char_idx": 1014, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d2cfcaf-cbd5-4b53-b525-ee556a5245c2": {"__data__": {"id_": "9d2cfcaf-cbd5-4b53-b525-ee556a5245c2", "embedding": null, "metadata": {"window": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22bc21fb-b6a9-457b-92da-a1e0def3f434", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.  ", "original_text": "We're seeing growth in our profit there.  \n \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3fb0818ca23b96dbff9c718a5e34cca8fc6e6157035273896bbe9f022371d96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c04234e-5c3b-4d00-bdf6-0468a29af4b1", "node_type": "1", "metadata": {"window": "The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n "}, "hash": "97eedec74381686d34079381df3d9b648e910ce307b35b33283e93ab63e99caf", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  ", "start_char_idx": 1060, "end_char_idx": 1217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c04234e-5c3b-4d00-bdf6-0468a29af4b1": {"__data__": {"id_": "9c04234e-5c3b-4d00-bdf6-0468a29af4b1", "embedding": null, "metadata": {"window": "The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d2cfcaf-cbd5-4b53-b525-ee556a5245c2", "node_type": "1", "metadata": {"window": "On Cordis, I'll just handle that real quick, nothing really to report on Cordis outside of what our \nexpectations are.   The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97e95888e8aa4be09059efb56ce4a46194c57e86d8a461b7b02d22415d2fc36d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36fdec5d-4d22-4d0b-825a-94e48a7bc21e", "node_type": "1", "metadata": {"window": "We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "As far as the initiatives in medical, we remain i ncredibly committed to both of them.  "}, "hash": "cd7940728b4f8d4cba4d9ebffa02e4f04c5505508f5bd1bd3cc2243a6ad65316", "class_name": "RelatedNodeInfo"}}, "text": "We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n ", "start_char_idx": 1217, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36fdec5d-4d22-4d0b-825a-94e48a7bc21e": {"__data__": {"id_": "36fdec5d-4d22-4d0b-825a-94e48a7bc21e", "embedding": null, "metadata": {"window": "We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "As far as the initiatives in medical, we remain i ncredibly committed to both of them.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c04234e-5c3b-4d00-bdf6-0468a29af4b1", "node_type": "1", "metadata": {"window": "The business is continuing to grow.   We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68f86adca9063dfbec3c81f7dadb0158bdfeb5ff7a09a6e71416d3fb1d8bfe51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61b8b572-a94a-4f85-a9f3-300a53cae88d", "node_type": "1", "metadata": {"window": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n "}, "hash": "a8145904e7c2e1ef46547d97c412e42d4923adaedd9c0180a90264d8e0c54e20", "class_name": "RelatedNodeInfo"}}, "text": "As far as the initiatives in medical, we remain i ncredibly committed to both of them.  ", "start_char_idx": 1317, "end_char_idx": 1405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61b8b572-a94a-4f85-a9f3-300a53cae88d": {"__data__": {"id_": "61b8b572-a94a-4f85-a9f3-300a53cae88d", "embedding": null, "metadata": {"window": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "798df53f-049d-4a69-9e12-285cc64ea53d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54642ac983cb175a8f0374a3ec0b7717d86e94598fcb17d6322f2c47e47a2710", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36fdec5d-4d22-4d0b-825a-94e48a7bc21e", "node_type": "1", "metadata": {"window": "We're seeing growth in our profit there.  \n \n  And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "As far as the initiatives in medical, we remain i ncredibly committed to both of them.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc8b55b1a867ef36ffb4a37c36f2559d0c105e6d53fae045672e4f06725360f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35613848-d4a5-4eb1-88ea-ecf60370383d", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n ", "original_text": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.  "}, "hash": "817ad7e54f92b38c26541c004a8690a7b482bd3b577f38582d45ada27695489e", "class_name": "RelatedNodeInfo"}}, "text": "There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "start_char_idx": 1405, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35613848-d4a5-4eb1-88ea-ecf60370383d": {"__data__": {"id_": "35613848-d4a5-4eb1-88ea-ecf60370383d", "embedding": null, "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n ", "original_text": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61b8b572-a94a-4f85-a9f3-300a53cae88d", "node_type": "1", "metadata": {"window": "And we continue to be really happy with what the team is doing there to meet or slightly exceed the expectations \nthat we have for that business this year.   We don't see it being a driver outside of what we expected for the year \none way or the other.  \n \n  As far as the initiatives in medical, we remain i ncredibly committed to both of them.   There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "original_text": "There is nothing about the \nunderlying strategies of our commercial realignment or our supply chain initiatives that at this time, I would say, \nmake me feel any differently than we have been talking about.  \n ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "469cf559c4c0f50d6b1735867a01290da386be52a0ecf9ef887d3c36e7aa897f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c311a21-4ba7-4191-b45b-aa9823541bb3", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  ", "original_text": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n "}, "hash": "239906c4fbc6af1743d41b85ec7fd5dfbcca09460575c91d4fda0ab22e0662f2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.  ", "start_char_idx": 0, "end_char_idx": 175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c311a21-4ba7-4191-b45b-aa9823541bb3": {"__data__": {"id_": "7c311a21-4ba7-4191-b45b-aa9823541bb3", "embedding": null, "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  ", "original_text": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35613848-d4a5-4eb1-88ea-ecf60370383d", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n ", "original_text": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51197bdd851975786d9651ad0426c5806669ced6c015aa460f9f58c64bb12e8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d626230-71c2-45c1-9eb7-f8128b944094", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.  ", "original_text": "And it's really important to us that we take care of our customers and our patients.  "}, "hash": "ccbc6eb02dd22dae9e337098377a7f9e2bd08ac27b89215a0d49431847674789", "class_name": "RelatedNodeInfo"}}, "text": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n ", "start_char_idx": 175, "end_char_idx": 372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d626230-71c2-45c1-9eb7-f8128b944094": {"__data__": {"id_": "0d626230-71c2-45c1-9eb7-f8128b944094", "embedding": null, "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.  ", "original_text": "And it's really important to us that we take care of our customers and our patients.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c311a21-4ba7-4191-b45b-aa9823541bb3", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  ", "original_text": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bcc9f161fbb9c1d3ec4833e3ce5292e1b80801cf9ce384431693fbf9883c19a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ee2e620-c3b0-4697-b8cf-bb57f0f31cca", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n ", "original_text": "So because of that, it would \nslow down where we expect to be.  \n \n "}, "hash": "8a146d4cf027cbe2440682afd9cf39884d4c1b79fbafbd265f33c7b5dd47e88c", "class_name": "RelatedNodeInfo"}}, "text": "And it's really important to us that we take care of our customers and our patients.  ", "start_char_idx": 372, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ee2e620-c3b0-4697-b8cf-bb57f0f31cca": {"__data__": {"id_": "1ee2e620-c3b0-4697-b8cf-bb57f0f31cca", "embedding": null, "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n ", "original_text": "So because of that, it would \nslow down where we expect to be.  \n \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d626230-71c2-45c1-9eb7-f8128b944094", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.  ", "original_text": "And it's really important to us that we take care of our customers and our patients.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62bddda2f089ddd1c438acec14dfbd0ec26352790f48089a0040b729ea70096d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "733f9f72-a98b-4d71-8f48-764c3dca75dd", "node_type": "1", "metadata": {"window": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n", "original_text": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  "}, "hash": "003c44fcd4b6d0cd50d65ea864b56196b75ae688032ce4c37d7682870978410e", "class_name": "RelatedNodeInfo"}}, "text": "So because of that, it would \nslow down where we expect to be.  \n \n ", "start_char_idx": 458, "end_char_idx": 526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "733f9f72-a98b-4d71-8f48-764c3dca75dd": {"__data__": {"id_": "733f9f72-a98b-4d71-8f48-764c3dca75dd", "embedding": null, "metadata": {"window": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n", "original_text": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ee2e620-c3b0-4697-b8cf-bb57f0f31cca", "node_type": "1", "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n ", "original_text": "So because of that, it would \nslow down where we expect to be.  \n \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6453bedafa00f522d23286a68999075e77c5c10165af3af36b9ab9283e494bd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4baf248-b2cb-460d-9abf-51c3015fde55", "node_type": "1", "metadata": {"window": "And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n", "original_text": "That \nplan was done.  "}, "hash": "a2de972a2bb3c5bcddafa3596e95041b487cdfca9074a39ffc34111d6596335c", "class_name": "RelatedNodeInfo"}}, "text": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  ", "start_char_idx": 526, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4baf248-b2cb-460d-9abf-51c3015fde55": {"__data__": {"id_": "f4baf248-b2cb-460d-9abf-51c3015fde55", "embedding": null, "metadata": {"window": "And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n", "original_text": "That \nplan was done.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "733f9f72-a98b-4d71-8f48-764c3dca75dd", "node_type": "1", "metadata": {"window": "We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n", "original_text": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcaac53d7e7daa2c5bd5696475449b423e6e4233ba6fcda0e3f3175d3c897163", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f64f4b-16ed-4e59-970e-9a1a1c1e25b9", "node_type": "1", "metadata": {"window": "So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.  ", "original_text": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n "}, "hash": "09c078cd5912fc2b5b37469a723b6caa599d99934eed68332d45959c0f342b91", "class_name": "RelatedNodeInfo"}}, "text": "That \nplan was done.  ", "start_char_idx": 628, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f64f4b-16ed-4e59-970e-9a1a1c1e25b9": {"__data__": {"id_": "c5f64f4b-16ed-4e59-970e-9a1a1c1e25b9", "embedding": null, "metadata": {"window": "So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.  ", "original_text": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4baf248-b2cb-460d-9abf-51c3015fde55", "node_type": "1", "metadata": {"window": "And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n", "original_text": "That \nplan was done.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68ff97048eb9227c577e939c4e60cb70fe08f29c94f0d7528945e36989da5886", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3369c22-7b53-40f9-b291-c1e21938cee6", "node_type": "1", "metadata": {"window": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  ", "original_text": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n"}, "hash": "5fd43294428d4ffc5c88a814ea1c3ae72259622a7b34e05e46401c549f0c1544", "class_name": "RelatedNodeInfo"}}, "text": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n ", "start_char_idx": 650, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3369c22-7b53-40f9-b291-c1e21938cee6": {"__data__": {"id_": "d3369c22-7b53-40f9-b291-c1e21938cee6", "embedding": null, "metadata": {"window": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  ", "original_text": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f64f4b-16ed-4e59-970e-9a1a1c1e25b9", "node_type": "1", "metadata": {"window": "So because of that, it would \nslow down where we expect to be.  \n \n  So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.  ", "original_text": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4143fc290b9c5f78648b57f7ea741fa14f3d9d4d9c8940d0b3c3268bf030c9d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27d7da06-3302-4d72-ae87-777fcd503494", "node_type": "1", "metadata": {"window": "That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n"}, "hash": "f3320a195d1e30c8d94b6068c9f132040f08ef4b7413f1239b5d5445989355d2", "class_name": "RelatedNodeInfo"}}, "text": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n", "start_char_idx": 942, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27d7da06-3302-4d72-ae87-777fcd503494": {"__data__": {"id_": "27d7da06-3302-4d72-ae87-777fcd503494", "embedding": null, "metadata": {"window": "That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3369c22-7b53-40f9-b291-c1e21938cee6", "node_type": "1", "metadata": {"window": "So we have said and committe d that on our supply chain, we would have a plan done by the end of Q2.   That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  ", "original_text": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00df753ef35b0765fbd98d4de99e7d1941da0ed7b26e5c2932924f60d256f085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87fa3cf2-640a-4b47-8764-47065b9b2751", "node_type": "1", "metadata": {"window": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Michael Cherny :  Good morning and thanks for all the details so far.  "}, "hash": "c8e1d2bb34aad8470451f25b5b1da350a1e6cedc04f78dea0f02760a26891f0e", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n", "start_char_idx": 1124, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87fa3cf2-640a-4b47-8764-47065b9b2751": {"__data__": {"id_": "87fa3cf2-640a-4b47-8764-47065b9b2751", "embedding": null, "metadata": {"window": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Michael Cherny :  Good morning and thanks for all the details so far.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27d7da06-3302-4d72-ae87-777fcd503494", "node_type": "1", "metadata": {"window": "That \nplan was done.   But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "564555c4ddac5212843077b1b98e1ffa053eaed686f7baf584a465b91edbd88a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e74c2955-cdfe-47bc-9fa4-74fa314ef399", "node_type": "1", "metadata": {"window": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  "}, "hash": "7ea57f44569579309ccff2f7a686a5112f60e987b44e14ee6bb680f7366d5bfa", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny :  Good morning and thanks for all the details so far.  ", "start_char_idx": 1194, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e74c2955-cdfe-47bc-9fa4-74fa314ef399": {"__data__": {"id_": "e74c2955-cdfe-47bc-9fa4-74fa314ef399", "embedding": null, "metadata": {"window": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87fa3cf2-640a-4b47-8764-47065b9b2751", "node_type": "1", "metadata": {"window": "But as we look at implementation of that plan, we're taking into account this disruption that we're \nworking on and just overall reevaluating and make sure we look  at the overall global supply chain to make sure \nthere's no changes we would make based on some of the recent challenges.  \n \n  And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Michael Cherny :  Good morning and thanks for all the details so far.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd2ba6d45682f42f0fe25549b587dff2396ae395997e8ddf2ccb39df5d3ec64a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a17d907-f364-419e-9600-5ed2d824782c", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Obviously you're performing well so far in areas of \nmedical.  \n "}, "hash": "bf79fc778835ed57948458aad02e60a06d30e0397d8688976b7622a29057aa72", "class_name": "RelatedNodeInfo"}}, "text": "So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  ", "start_char_idx": 1265, "end_char_idx": 1376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a17d907-f364-419e-9600-5ed2d824782c": {"__data__": {"id_": "0a17d907-f364-419e-9600-5ed2d824782c", "embedding": null, "metadata": {"window": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Obviously you're performing well so far in areas of \nmedical.  \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00bad821ca8b0147b7d9bdf4e8a3e362e03c87cff514877526dfeca5076d3016", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e74c2955-cdfe-47bc-9fa4-74fa314ef399", "node_type": "1", "metadata": {"window": "And then again on the commercial piece, we're on track to get the jobs hired and all that, but we do have folks \ndeployed to customer s. \n \nKevin Moran :  Next question, please.  \n \n Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82e6e0b6d20946119fbd9c2a73a392793284139387ebd0c40fac922826cc22c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d39feec-6c57-4be1-bafa-2295eee99be6", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "original_text": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?  "}, "hash": "83a0478914f4489a57b1b8a4644c979783d734b7eb1da9ab02a937263c00d940", "class_name": "RelatedNodeInfo"}}, "text": "Obviously you're performing well so far in areas of \nmedical.  \n ", "start_char_idx": 1376, "end_char_idx": 1441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d39feec-6c57-4be1-bafa-2295eee99be6": {"__data__": {"id_": "2d39feec-6c57-4be1-bafa-2295eee99be6", "embedding": null, "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "original_text": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a17d907-f364-419e-9600-5ed2d824782c", "node_type": "1", "metadata": {"window": "Operator :  We'll go next to Michael Cherny with BofA Securities.  \n \n Michael Cherny :  Good morning and thanks for all the details so far.   So as you think about the opportunities that you \nhave, you've highlighted specialty as a growth opportunity.   Obviously you're performing well so far in areas of \nmedical.  \n ", "original_text": "Obviously you're performing well so far in areas of \nmedical.  \n ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "715cac1867385e50f343b9490d97517797cf728daf33b475ae76713b842f1b2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd3eb872-fdbc-4aca-9ddc-49d9cc4a215b", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n ", "original_text": "How do you think about areas where \nyou think your customers are asking f or you to do more?  "}, "hash": "1b4fb09c0ffe5689ffedc5650f429686ed7d6dd935e636bd85f3138df086bc00", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?  ", "start_char_idx": 0, "end_char_idx": 93, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd3eb872-fdbc-4aca-9ddc-49d9cc4a215b": {"__data__": {"id_": "dd3eb872-fdbc-4aca-9ddc-49d9cc4a215b", "embedding": null, "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n ", "original_text": "How do you think about areas where \nyou think your customers are asking f or you to do more?  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d39feec-6c57-4be1-bafa-2295eee99be6", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "original_text": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5da7e30b39b62afdfd1081a6d4cd75db27bd36df902710efb43faef5ab71030f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae2b5eb0-14f0-4f79-90c3-95ce51f53514", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.  ", "original_text": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n"}, "hash": "e4b696e065cba3e9236a738a9d98841bd155bb6de5409e9d01a658a39eced2fa", "class_name": "RelatedNodeInfo"}}, "text": "How do you think about areas where \nyou think your customers are asking f or you to do more?  ", "start_char_idx": 93, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae2b5eb0-14f0-4f79-90c3-95ce51f53514": {"__data__": {"id_": "ae2b5eb0-14f0-4f79-90c3-95ce51f53514", "embedding": null, "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.  ", "original_text": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd3eb872-fdbc-4aca-9ddc-49d9cc4a215b", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n ", "original_text": "How do you think about areas where \nyou think your customers are asking f or you to do more?  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e486cbbf66a761702ab13bdd15926d4b1bcb477439a340d76e72a9aeb34a1ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "562be8e2-101e-4b53-8847-1a2cb2e088a4", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.  ", "original_text": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  "}, "hash": "818329a2b5e258363c76573483af827242623a5f5c2d57f77189df85d4ec34d8", "class_name": "RelatedNodeInfo"}}, "text": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n", "start_char_idx": 187, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "562be8e2-101e-4b53-8847-1a2cb2e088a4": {"__data__": {"id_": "562be8e2-101e-4b53-8847-1a2cb2e088a4", "embedding": null, "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.  ", "original_text": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae2b5eb0-14f0-4f79-90c3-95ce51f53514", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.  ", "original_text": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14f71c9e7e88478b511a4c81cb6480524db691c14e990ec15353b9a5423b25b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bba7ffe8-b580-4f16-8ce0-aec02583a1dd", "node_type": "1", "metadata": {"window": "How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  ", "original_text": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n "}, "hash": "411bbf4790c149811389a02b848d29cab0f95912934850e6d6b4414733a95477", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "start_char_idx": 361, "end_char_idx": 502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bba7ffe8-b580-4f16-8ce0-aec02583a1dd": {"__data__": {"id_": "bba7ffe8-b580-4f16-8ce0-aec02583a1dd", "embedding": null, "metadata": {"window": "How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  ", "original_text": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "562be8e2-101e-4b53-8847-1a2cb2e088a4", "node_type": "1", "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.  ", "original_text": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2eb3f73ff90bbdc645c459bf5ae660929f866a747993f4897f5f36be5070a1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5cdd403-3c64-48b5-bfa9-ee46c9b7392a", "node_type": "1", "metadata": {"window": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n ", "original_text": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.  "}, "hash": "a117007ac6499e7554fbf50c99ef26af3029cbc085ac6b3ce04720a263022e59", "class_name": "RelatedNodeInfo"}}, "text": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n ", "start_char_idx": 502, "end_char_idx": 686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5cdd403-3c64-48b5-bfa9-ee46c9b7392a": {"__data__": {"id_": "d5cdd403-3c64-48b5-bfa9-ee46c9b7392a", "embedding": null, "metadata": {"window": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n ", "original_text": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bba7ffe8-b580-4f16-8ce0-aec02583a1dd", "node_type": "1", "metadata": {"window": "How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  ", "original_text": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecf270d2649f43126a873950f6cd0c7757411d38e4bcd53a057e4ba221c5fbcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "850add53-64d7-4493-aaf7-03a746affb77", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  ", "original_text": "And they are also \nbusinesses that are really right on trend.  "}, "hash": "73180f7cb0afd797ffdfdb54d980157bc1847950f5357d086e042ca1291508f3", "class_name": "RelatedNodeInfo"}}, "text": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.  ", "start_char_idx": 686, "end_char_idx": 785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "850add53-64d7-4493-aaf7-03a746affb77": {"__data__": {"id_": "850add53-64d7-4493-aaf7-03a746affb77", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  ", "original_text": "And they are also \nbusinesses that are really right on trend.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5cdd403-3c64-48b5-bfa9-ee46c9b7392a", "node_type": "1", "metadata": {"window": "And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n ", "original_text": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3770bf1ab9938a9d0531706b2b7433168c8a1f16f2b2a2283f7f04101c24a432", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d21f253-56e5-4d04-864d-6426da5a1d3b", "node_type": "1", "metadata": {"window": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n ", "original_text": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  "}, "hash": "48a62538eb29f2be5e0ac98bc8577ad2efb1c81b83c1d0d6695ddeefbf05b89c", "class_name": "RelatedNodeInfo"}}, "text": "And they are also \nbusinesses that are really right on trend.  ", "start_char_idx": 785, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d21f253-56e5-4d04-864d-6426da5a1d3b": {"__data__": {"id_": "1d21f253-56e5-4d04-864d-6426da5a1d3b", "embedding": null, "metadata": {"window": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n ", "original_text": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "850add53-64d7-4493-aaf7-03a746affb77", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.   I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  ", "original_text": "And they are also \nbusinesses that are really right on trend.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eb383524d2b813d642a86bb30e3bc89b2e0e9cc796d048d01e7c230c9ddf29f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a382d9d5-fd41-4b96-ac71-f6bc678e4636", "node_type": "1", "metadata": {"window": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n", "original_text": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n "}, "hash": "fc2476d692b7cddc696e84c11d749f2d243f08d14add0e5e8dff69769ed0adc9", "class_name": "RelatedNodeInfo"}}, "text": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  ", "start_char_idx": 848, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a382d9d5-fd41-4b96-ac71-f6bc678e4636": {"__data__": {"id_": "a382d9d5-fd41-4b96-ac71-f6bc678e4636", "embedding": null, "metadata": {"window": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n", "original_text": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d21f253-56e5-4d04-864d-6426da5a1d3b", "node_type": "1", "metadata": {"window": "I would highlight four of them, specialty being one of them, at home that we've talked \nabout, our connected care services business in pharma and our medical services businesses.  \n \n  These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n ", "original_text": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ca6d34079cc8a23e517693d20b4d36e4f20dec18a7ad000e90c3532eb711a20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46115c72-61a6-48b3-8b14-d939e5f4b04a", "node_type": "1", "metadata": {"window": "And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.  ", "original_text": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  "}, "hash": "6b9797008307f89fdac64e80ef169a0535c452b2aee990d357cc10651e910f58", "class_name": "RelatedNodeInfo"}}, "text": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n ", "start_char_idx": 970, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46115c72-61a6-48b3-8b14-d939e5f4b04a": {"__data__": {"id_": "46115c72-61a6-48b3-8b14-d939e5f4b04a", "embedding": null, "metadata": {"window": "And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.  ", "original_text": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a382d9d5-fd41-4b96-ac71-f6bc678e4636", "node_type": "1", "metadata": {"window": "These  are all businesses we're seeing significant growth on the top line and on the bottom line.   And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n", "original_text": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5845e07b948cc218fd42ffc912d4ee287b7869af9f6902b1af3bf200c1f2f8aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbc19273-4191-4b38-8aff-6ce27d6a5a76", "node_type": "1", "metadata": {"window": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  ", "original_text": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n "}, "hash": "c70206b32f8a9022091aab482e8b72d65a55e96ed783b201fda96bf57c01440a", "class_name": "RelatedNodeInfo"}}, "text": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  ", "start_char_idx": 1103, "end_char_idx": 1230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbc19273-4191-4b38-8aff-6ce27d6a5a76": {"__data__": {"id_": "fbc19273-4191-4b38-8aff-6ce27d6a5a76", "embedding": null, "metadata": {"window": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  ", "original_text": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46115c72-61a6-48b3-8b14-d939e5f4b04a", "node_type": "1", "metadata": {"window": "And they are also \nbusinesses that are really right on trend.   You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.  ", "original_text": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18d1e77ad7d9e4b4406405ce8bbbe19ed23ee6fd490d8f6e53f16ff5bf7e5cd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ebfa653-b085-47b4-a396-ef7a986630d5", "node_type": "1", "metadata": {"window": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n"}, "hash": "aa6dedaf86b151ecc255bf91abb7d846a5df6c021dc7bff69c52ec6de93f4e94", "class_name": "RelatedNodeInfo"}}, "text": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n ", "start_char_idx": 1230, "end_char_idx": 1372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ebfa653-b085-47b4-a396-ef7a986630d5": {"__data__": {"id_": "5ebfa653-b085-47b4-a396-ef7a986630d5", "embedding": null, "metadata": {"window": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbc19273-4191-4b38-8aff-6ce27d6a5a76", "node_type": "1", "metadata": {"window": "You know, care moving towards the home and the various things that go \nalong with specialty and the se rvice businesses.   So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  ", "original_text": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fb8957a47d969ae703527ff5f43799ddefe294cf8f8b91a7e0d5298cd11f54b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31258b32-0cef-4d97-81fa-852d7588ba29", "node_type": "1", "metadata": {"window": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "David Evans :  Yes, Michael, if I can add.  "}, "hash": "99d5ec0513743a57a23772ffe4a0e0b806fa1c725d9db7325a42da997455eb32", "class_name": "RelatedNodeInfo"}}, "text": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n", "start_char_idx": 1372, "end_char_idx": 1518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31258b32-0cef-4d97-81fa-852d7588ba29": {"__data__": {"id_": "31258b32-0cef-4d97-81fa-852d7588ba29", "embedding": null, "metadata": {"window": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "David Evans :  Yes, Michael, if I can add.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ebfa653-b085-47b4-a396-ef7a986630d5", "node_type": "1", "metadata": {"window": "So these are areas where we are prioritizing our capital \nexpenditures to those areas so we can really focus on organic growth.  \n \n  And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51b045236eb66241c772fee469029fb5351908100d7dd8471a8ee4a64780b364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4baab8e-5db7-4dcb-a597-a63be7ee2c26", "node_type": "1", "metadata": {"window": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  "}, "hash": "0bc962aebe47f6ba360fb02ef18ac4b9c0feefa9bfacd5e02e5e832c5e57d768", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Yes, Michael, if I can add.  ", "start_char_idx": 1518, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4baab8e-5db7-4dcb-a597-a63be7ee2c26": {"__data__": {"id_": "c4baab8e-5db7-4dcb-a597-a63be7ee2c26", "embedding": null, "metadata": {"window": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31258b32-0cef-4d97-81fa-852d7588ba29", "node_type": "1", "metadata": {"window": "And if there are M&A opportunities out there that would make sense, those would be the areas that you would see \nus focus on.   Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "David Evans :  Yes, Michael, if I can add.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65204cfb87bff0117cc1cc5682d6a52c19bc59b9baa0ed4f91b83724fd1d9983", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c0d699c-3b98-4628-abac-21edf8d57314", "node_type": "1", "metadata": {"window": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n "}, "hash": "8984ac8518b3e9a6eb49cca2d310132fc0267755e353ea97be3601cdad7397f4", "class_name": "RelatedNodeInfo"}}, "text": "So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  ", "start_char_idx": 1562, "end_char_idx": 1692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c0d699c-3b98-4628-abac-21edf8d57314": {"__data__": {"id_": "7c0d699c-3b98-4628-abac-21edf8d57314", "embedding": null, "metadata": {"window": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc3b790b-6695-439b-97a4-376d5825da86", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e539a26615490a866c1b0af6e3eaa6e58b1d87cd31322b639038ca93895570b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4baab8e-5db7-4dcb-a597-a63be7ee2c26", "node_type": "1", "metadata": {"window": "Now that being said, we're going to continue to do all the right things in our core businesses to make \nsure we maintain and grow those.  \n \n  But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fa13fd42b0750bb3ae7f170e5964290240c61d0cf61bb1ceaa2472727c94128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a65603c-d79e-43fc-9b09-09dee68feb3a", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "original_text": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.  "}, "hash": "bacc02e3aa7cfb51126ca579f7bc915bee2d01179307556b46697fc69c094b28", "class_name": "RelatedNodeInfo"}}, "text": "And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "start_char_idx": 1692, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a65603c-d79e-43fc-9b09-09dee68feb3a": {"__data__": {"id_": "1a65603c-d79e-43fc-9b09-09dee68feb3a", "embedding": null, "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "original_text": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c0d699c-3b98-4628-abac-21edf8d57314", "node_type": "1", "metadata": {"window": "But for what I would say extra allocation of capital, those are going to be key areas that we're going to focus our \ncapital expenditures on.  \n \n David Evans :  Yes, Michael, if I can add.   So really, you know, I'd say we're focusing as well on partnerships in a way that \nis probably more so than we have in the past.   And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "original_text": "And when we do think about our in ternal capital, we're really \nthinking about it in four different categories.  \n ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fdb4699dc35c9d5927840d4173eb9fad57dbdecee4f4675590bc0412eadf96f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03b46831-827b-4b04-a4b0-1ece90f1c094", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n", "original_text": "We are focusing \non deploying capital to cost out projects.  "}, "hash": "d4f615e3c8e92957f3fd32a1605ae848c188f39f1304317e4ca13a38fb60777c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.  ", "start_char_idx": 0, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03b46831-827b-4b04-a4b0-1ece90f1c094": {"__data__": {"id_": "03b46831-827b-4b04-a4b0-1ece90f1c094", "embedding": null, "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n", "original_text": "We are focusing \non deploying capital to cost out projects.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a65603c-d79e-43fc-9b09-09dee68feb3a", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "original_text": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c2fea77969c138504ee50ad6539b7b7eef551a3ccd222fefcb279de36b211fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "541a1f17-d5aa-4311-97f4-82609c4bc11a", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n", "original_text": "We're providing cap ital in areas where we need capacity for growth.  "}, "hash": "ba8abe94a3d9481cc0d3fba5aaf8644842182c733afce112b7d7f00e907ed8ed", "class_name": "RelatedNodeInfo"}}, "text": "We are focusing \non deploying capital to cost out projects.  ", "start_char_idx": 118, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "541a1f17-d5aa-4311-97f4-82609c4bc11a": {"__data__": {"id_": "541a1f17-d5aa-4311-97f4-82609c4bc11a", "embedding": null, "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n", "original_text": "We're providing cap ital in areas where we need capacity for growth.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03b46831-827b-4b04-a4b0-1ece90f1c094", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n", "original_text": "We are focusing \non deploying capital to cost out projects.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e9f2651512c7c5a95c1cf92498a1faf9aab6299bdf84c92b063f9d8a55164b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ea96f33-3e66-4c2b-8a02-6a7b23349c6b", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.  ", "original_text": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n "}, "hash": "fef57628e414dc90ca92e603a2c5da94d10001504594b20340b49f9c6b9de636", "class_name": "RelatedNodeInfo"}}, "text": "We're providing cap ital in areas where we need capacity for growth.  ", "start_char_idx": 179, "end_char_idx": 249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ea96f33-3e66-4c2b-8a02-6a7b23349c6b": {"__data__": {"id_": "9ea96f33-3e66-4c2b-8a02-6a7b23349c6b", "embedding": null, "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.  ", "original_text": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "541a1f17-d5aa-4311-97f4-82609c4bc11a", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n", "original_text": "We're providing cap ital in areas where we need capacity for growth.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9d159af01beed17a862b48954aff7bcf5fecbd7015a9951b2007901fee27ab1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f054ad45-4e7d-4a17-91ac-6ddd1956d261", "node_type": "1", "metadata": {"window": "We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n", "original_text": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n"}, "hash": "020a80754237b3fd2eb82a42e4e6afd6729d8de017c727dc50861e8bd397ad28", "class_name": "RelatedNodeInfo"}}, "text": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "start_char_idx": 249, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f054ad45-4e7d-4a17-91ac-6ddd1956d261": {"__data__": {"id_": "f054ad45-4e7d-4a17-91ac-6ddd1956d261", "embedding": null, "metadata": {"window": "We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n", "original_text": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ea96f33-3e66-4c2b-8a02-6a7b23349c6b", "node_type": "1", "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.  ", "original_text": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "988092c2a7fe905e278aafba8955f6c24d2d79a9e8f6ef3625ba64ae803fbd9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7dd3d00-9209-4e8c-b2d8-703b1594b54c", "node_type": "1", "metadata": {"window": "We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n", "original_text": "Michael Cherny :  Okay, thanks.  \n \n"}, "hash": "719eaf98fb620a6820042e3b11958d9f815be330e029e1a55aef8078163bddfe", "class_name": "RelatedNodeInfo"}}, "text": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n", "start_char_idx": 328, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7dd3d00-9209-4e8c-b2d8-703b1594b54c": {"__data__": {"id_": "d7dd3d00-9209-4e8c-b2d8-703b1594b54c", "embedding": null, "metadata": {"window": "We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n", "original_text": "Michael Cherny :  Okay, thanks.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f054ad45-4e7d-4a17-91ac-6ddd1956d261", "node_type": "1", "metadata": {"window": "We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n", "original_text": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ef910da40b9614cb7a78f85184eb53fcd4a27d2cdd308940737bbf094a277f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a42a454a-ce65-4a57-9fb3-abaf0da27563", "node_type": "1", "metadata": {"window": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.  ", "original_text": "Mike Ka ufmann :  Thanks, Michael.  "}, "hash": "a3df38825c5e1fc11489bcdd8e404421e9a509fc93969017534a54d8eaee1b6a", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny :  Okay, thanks.  \n \n", "start_char_idx": 423, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a42a454a-ce65-4a57-9fb3-abaf0da27563": {"__data__": {"id_": "a42a454a-ce65-4a57-9fb3-abaf0da27563", "embedding": null, "metadata": {"window": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.  ", "original_text": "Mike Ka ufmann :  Thanks, Michael.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7dd3d00-9209-4e8c-b2d8-703b1594b54c", "node_type": "1", "metadata": {"window": "We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n", "original_text": "Michael Cherny :  Okay, thanks.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a85ce459cc4baaa45bdcbd5d17b05f482699bb05d0cca01eca2d6b142d915da2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96dff063-4046-47b0-8b5f-0761f2157f41", "node_type": "1", "metadata": {"window": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.  ", "original_text": "Next question.  \n \n"}, "hash": "42653fab7e6a7a752292117afadb73eb2e698910e9f2a98d84a5c1bf811c2d6b", "class_name": "RelatedNodeInfo"}}, "text": "Mike Ka ufmann :  Thanks, Michael.  ", "start_char_idx": 459, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96dff063-4046-47b0-8b5f-0761f2157f41": {"__data__": {"id_": "96dff063-4046-47b0-8b5f-0761f2157f41", "embedding": null, "metadata": {"window": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.  ", "original_text": "Next question.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a42a454a-ce65-4a57-9fb3-abaf0da27563", "node_type": "1", "metadata": {"window": "But \nthen we are also deploying some capital to explore new growth areas.  \n \n  So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.  ", "original_text": "Mike Ka ufmann :  Thanks, Michael.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fe5d07702ca13b2f7672cb1d0d9100b1f50a1508b0644c5d10c44273ed97106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "495114a6-aebb-4b46-b0a3-ed14a6c22fa3", "node_type": "1", "metadata": {"window": "Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.  ", "original_text": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n"}, "hash": "197b10f78995e2d48c2c7e428279a5d28a925d033731420522376e101f82a0b2", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 495, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "495114a6-aebb-4b46-b0a3-ed14a6c22fa3": {"__data__": {"id_": "495114a6-aebb-4b46-b0a3-ed14a6c22fa3", "embedding": null, "metadata": {"window": "Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.  ", "original_text": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96dff063-4046-47b0-8b5f-0761f2157f41", "node_type": "1", "metadata": {"window": "So it's a pretty balanced approach, disciplined approach to getting a return on our CAPEX.  \n \n Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.  ", "original_text": "Next question.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed017067ad10eda3de83da7643f1bf2f905d12b441004b6803a8f8e0e29db2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a30562a-e7f6-4503-a136-959613fe0a8e", "node_type": "1", "metadata": {"window": "Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.  ", "original_text": "Steven Valiquette :  Great.  "}, "hash": "b34dbb7b1619e947f20555647016881c3d9d0bf1404093ed6c3c999b7b7bb892", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n", "start_char_idx": 514, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a30562a-e7f6-4503-a136-959613fe0a8e": {"__data__": {"id_": "1a30562a-e7f6-4503-a136-959613fe0a8e", "embedding": null, "metadata": {"window": "Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.  ", "original_text": "Steven Valiquette :  Great.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "495114a6-aebb-4b46-b0a3-ed14a6c22fa3", "node_type": "1", "metadata": {"window": "Michael Cherny :  Okay, thanks.  \n \n Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.  ", "original_text": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adc63af0b3343dfb85498051a31d2a892927c9366e521cbad9532630d96fef9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "538b2475-375f-44cf-9ee4-3b5fc962e2d0", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n ", "original_text": "Thanks and good morning, everyone.  "}, "hash": "857777295fd9048d1bb3efa18e3948410228bb6b6e68bfd139847105c8883774", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette :  Great.  ", "start_char_idx": 582, "end_char_idx": 611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "538b2475-375f-44cf-9ee4-3b5fc962e2d0": {"__data__": {"id_": "538b2475-375f-44cf-9ee4-3b5fc962e2d0", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n ", "original_text": "Thanks and good morning, everyone.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a30562a-e7f6-4503-a136-959613fe0a8e", "node_type": "1", "metadata": {"window": "Mike Ka ufmann :  Thanks, Michael.   Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.  ", "original_text": "Steven Valiquette :  Great.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21b138550f953b5cac369ef7b2b3cf26baaea1cfe2b6de26bea6def2c15596f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc88419c-bf97-41b5-895b-e79dc6715f60", "node_type": "1", "metadata": {"window": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  ", "original_text": "So just to follow -up a little bit on specialty.  "}, "hash": "91d9d2e45a44178973ccc4995ba806474510815f5ef6f77e9b6dc015d895ad44", "class_name": "RelatedNodeInfo"}}, "text": "Thanks and good morning, everyone.  ", "start_char_idx": 611, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc88419c-bf97-41b5-895b-e79dc6715f60": {"__data__": {"id_": "cc88419c-bf97-41b5-895b-e79dc6715f60", "embedding": null, "metadata": {"window": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  ", "original_text": "So just to follow -up a little bit on specialty.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "538b2475-375f-44cf-9ee4-3b5fc962e2d0", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n ", "original_text": "Thanks and good morning, everyone.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec2cb50b992b1f82957cdb14f37d6f26d2350a7c583dc0cccdb8d29629ea929a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f6fef0-8158-45b9-b778-8325cfb5c81b", "node_type": "1", "metadata": {"window": "Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n", "original_text": "Two things I \nwanted to just get done  real quick.  "}, "hash": "b6e576353ec896da83acb28111bd9e4d119a6b3777e38fbc88a32de46718df6f", "class_name": "RelatedNodeInfo"}}, "text": "So just to follow -up a little bit on specialty.  ", "start_char_idx": 647, "end_char_idx": 697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f6fef0-8158-45b9-b778-8325cfb5c81b": {"__data__": {"id_": "66f6fef0-8158-45b9-b778-8325cfb5c81b", "embedding": null, "metadata": {"window": "Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n", "original_text": "Two things I \nwanted to just get done  real quick.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc88419c-bf97-41b5-895b-e79dc6715f60", "node_type": "1", "metadata": {"window": "Operator :  We will go next to Steven Valiquette with Barclays.  \n \n Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  ", "original_text": "So just to follow -up a little bit on specialty.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29dfd6ddb1b6d595eab2987072e20601ec011971fecc84b2525f00739efdb20a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a717fb2-4592-4493-b87d-05e184527667", "node_type": "1", "metadata": {"window": "Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.  ", "original_text": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n "}, "hash": "c8b3e5943216359009745040c7eeb1f59f668d19e12d35fa2b7771bdaedfd703", "class_name": "RelatedNodeInfo"}}, "text": "Two things I \nwanted to just get done  real quick.  ", "start_char_idx": 697, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a717fb2-4592-4493-b87d-05e184527667": {"__data__": {"id_": "0a717fb2-4592-4493-b87d-05e184527667", "embedding": null, "metadata": {"window": "Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.  ", "original_text": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f6fef0-8158-45b9-b778-8325cfb5c81b", "node_type": "1", "metadata": {"window": "Steven Valiquette :  Great.   Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n", "original_text": "Two things I \nwanted to just get done  real quick.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e6a66f6c981e2cc32810dc2dd6353bcfbab44581a490603dfacbcfc6f1a7d79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e1fc756-6a11-4ffb-a71f-1c594ac1319d", "node_type": "1", "metadata": {"window": "So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.  ", "original_text": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  "}, "hash": "506f4ed324e3ca8f44abb1bbc7b5940b6756e003b075e011bcd8f344b9b1b797", "class_name": "RelatedNodeInfo"}}, "text": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n ", "start_char_idx": 749, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e1fc756-6a11-4ffb-a71f-1c594ac1319d": {"__data__": {"id_": "4e1fc756-6a11-4ffb-a71f-1c594ac1319d", "embedding": null, "metadata": {"window": "So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.  ", "original_text": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a717fb2-4592-4493-b87d-05e184527667", "node_type": "1", "metadata": {"window": "Thanks and good morning, everyone.   So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.  ", "original_text": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6f7eb53cf6da09c47a99dfecde7c34833dca0df6d54259026f7a28572535375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "344d25a2-f424-45f0-83de-b435832563bb", "node_type": "1", "metadata": {"window": "Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.  ", "original_text": "Thanks.  \n \n"}, "hash": "5b65c8bcbcd1a6681f8f5cdff350ed3c2f590748ce598b7a2d4c0a5f45a14d7d", "class_name": "RelatedNodeInfo"}}, "text": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  ", "start_char_idx": 920, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344d25a2-f424-45f0-83de-b435832563bb": {"__data__": {"id_": "344d25a2-f424-45f0-83de-b435832563bb", "embedding": null, "metadata": {"window": "Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.  ", "original_text": "Thanks.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e1fc756-6a11-4ffb-a71f-1c594ac1319d", "node_type": "1", "metadata": {"window": "So just to follow -up a little bit on specialty.   Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.  ", "original_text": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b1565150f642ba6e364b8fa734f57c125da1d583bd4594b3ee7369fee434852", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4036d46-6ca1-4e8a-b143-2e6f36974be3", "node_type": "1", "metadata": {"window": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.  ", "original_text": "Mike Kaufmann :  Thanks.  "}, "hash": "586cd8016bc574abf94b5fd79914f9366b1e396523459144188c0a0711fb1b19", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1204, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4036d46-6ca1-4e8a-b143-2e6f36974be3": {"__data__": {"id_": "e4036d46-6ca1-4e8a-b143-2e6f36974be3", "embedding": null, "metadata": {"window": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.  ", "original_text": "Mike Kaufmann :  Thanks.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344d25a2-f424-45f0-83de-b435832563bb", "node_type": "1", "metadata": {"window": "Two things I \nwanted to just get done  real quick.   First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.  ", "original_text": "Thanks.  \n \n", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff2b68b126a4d832795932e289b2959d357ace5b498883b6dc539b06956dde24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0945c749-88d6-4e0b-8492-222e996332ed", "node_type": "1", "metadata": {"window": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "I think I picked the m up.  "}, "hash": "dc2f217420714249430f1a02e32ba39cc2f32ede0da148a027d379a7587fea60", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Thanks.  ", "start_char_idx": 1216, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0945c749-88d6-4e0b-8492-222e996332ed": {"__data__": {"id_": "0945c749-88d6-4e0b-8492-222e996332ed", "embedding": null, "metadata": {"window": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "I think I picked the m up.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4036d46-6ca1-4e8a-b143-2e6f36974be3", "node_type": "1", "metadata": {"window": "First, I was a little bit surprised about biosimilars because there actually had \nbeen a bunch of biosimilars  launched into the  channel  worth billions of dollars . \n \n  But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.  ", "original_text": "Mike Kaufmann :  Thanks.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8dfa9b70dee87a0ca26721b18ed40f65af192d1cb851c16d799d57778e7d3a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd65cd7-f116-47f2-8da6-ff66f0354e19", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "It was a little spotty on being able to hear.  "}, "hash": "a75cf16b9d439ff660eb6ca526734cbad424d0b3652ad254bf556c8861a0fd85", "class_name": "RelatedNodeInfo"}}, "text": "I think I picked the m up.  ", "start_char_idx": 1242, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd65cd7-f116-47f2-8da6-ff66f0354e19": {"__data__": {"id_": "bbd65cd7-f116-47f2-8da6-ff66f0354e19", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "It was a little spotty on being able to hear.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0945c749-88d6-4e0b-8492-222e996332ed", "node_type": "1", "metadata": {"window": "But that was not the only driver  up front just changes in the price experience  with either customers or suppliers \nand that separating specialty pricing from traditional brand pricing, whether that may have played a role in some \nof the better pharma distribution segment results.   Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "I think I picked the m up.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e29c52a4101e72b569b7d4787f37be85be065d5f7ee433d54e160324715e8fd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e01d9b04-fd65-443e-a2da-074e63ac1c7d", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "But I think I got all your \npieces.  "}, "hash": "96bf3749974b104718cdbcef5db82d7e484fd9af733f1f30ef2587fe64213dae", "class_name": "RelatedNodeInfo"}}, "text": "It was a little spotty on being able to hear.  ", "start_char_idx": 1270, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e01d9b04-fd65-443e-a2da-074e63ac1c7d": {"__data__": {"id_": "e01d9b04-fd65-443e-a2da-074e63ac1c7d", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "But I think I got all your \npieces.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd65cd7-f116-47f2-8da6-ff66f0354e19", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "It was a little spotty on being able to hear.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5f70bc39e0470cb0c3d0cb3f6feef8d1084198126a8f9f9863d6dd24464864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c3af8b7-b806-4b4e-bde6-e0133a196ff1", "node_type": "1", "metadata": {"window": "I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "So let me see if I can walk through them all.  \n "}, "hash": "f1ddc2d00c0c909f3cf329dd55caa1df3aa173f0efbacc2b5359635c3874ede9", "class_name": "RelatedNodeInfo"}}, "text": "But I think I got all your \npieces.  ", "start_char_idx": 1317, "end_char_idx": 1354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c3af8b7-b806-4b4e-bde6-e0133a196ff1": {"__data__": {"id_": "9c3af8b7-b806-4b4e-bde6-e0133a196ff1", "embedding": null, "metadata": {"window": "I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "So let me see if I can walk through them all.  \n ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b249afb974a02ff44951f22b62fbe313d404412610d4aa3b0a3394e213ee9c13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e01d9b04-fd65-443e-a2da-074e63ac1c7d", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks.   I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "But I think I got all your \npieces.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54dabc6bef8411d69cd6e8e5f72b9647c610039d4eec0a213d336e0191936851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7b5e996-8975-4f9f-8423-48d9d5241106", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.  ", "original_text": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.  "}, "hash": "f4b674b4899b57273832eef9646ad6ba4c1181ca7191cda7a05fd105ca9853f5", "class_name": "RelatedNodeInfo"}}, "text": "So let me see if I can walk through them all.  \n ", "start_char_idx": 1354, "end_char_idx": 1403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7b5e996-8975-4f9f-8423-48d9d5241106": {"__data__": {"id_": "c7b5e996-8975-4f9f-8423-48d9d5241106", "embedding": null, "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.  ", "original_text": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c3af8b7-b806-4b4e-bde6-e0133a196ff1", "node_type": "1", "metadata": {"window": "I think I picked the m up.   It was a little spotty on being able to hear.   But I think I got all your \npieces.   So let me see if I can walk through them all.  \n ", "original_text": "So let me see if I can walk through them all.  \n ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2f044163d9cdc9f97cc1353a4286e6333ce04216c4b07f62f894d53600d3098", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cb7682e-c286-4fcf-a59e-fc99cc63e538", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n ", "original_text": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n "}, "hash": "235ff0d2171b3755183cd3e82606a417e89a89bbc8ca3aadd76f086a758a6f28", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.  ", "start_char_idx": 0, "end_char_idx": 73, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cb7682e-c286-4fcf-a59e-fc99cc63e538": {"__data__": {"id_": "2cb7682e-c286-4fcf-a59e-fc99cc63e538", "embedding": null, "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n ", "original_text": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7b5e996-8975-4f9f-8423-48d9d5241106", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.  ", "original_text": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "347893306434a04a2774195bd5b0827801ee9914e5e8608f21d13fe860d343b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddf2ef2c-5da9-484a-87f0-bd3148b8767a", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.  ", "original_text": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n "}, "hash": "c9d8a6e936934898312a570cff413bcbabaf1bb6da6a218494c9065735b9b768", "class_name": "RelatedNodeInfo"}}, "text": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n ", "start_char_idx": 73, "end_char_idx": 363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddf2ef2c-5da9-484a-87f0-bd3148b8767a": {"__data__": {"id_": "ddf2ef2c-5da9-484a-87f0-bd3148b8767a", "embedding": null, "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.  ", "original_text": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cb7682e-c286-4fcf-a59e-fc99cc63e538", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n ", "original_text": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72c1fbe5050f3bbdec15796d627574956b64aec0c354730aec3f45121ef3c643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d98c31d8-9b7b-4b6b-b486-bf9b51ff71bd", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  ", "original_text": "So we continue to be very focused on that in the PD area.  "}, "hash": "d4189a0bc04c47c456f500b577748525bb2cb321af5afd7a34b1c08d4e72444c", "class_name": "RelatedNodeInfo"}}, "text": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n ", "start_char_idx": 363, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d98c31d8-9b7b-4b6b-b486-bf9b51ff71bd": {"__data__": {"id_": "d98c31d8-9b7b-4b6b-b486-bf9b51ff71bd", "embedding": null, "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  ", "original_text": "So we continue to be very focused on that in the PD area.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddf2ef2c-5da9-484a-87f0-bd3148b8767a", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.  ", "original_text": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe056fb9d98eff85c7f09291e259fb034e27738bbf9ae175cb05b7c03c8dae02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0828968b-7ed0-4988-9503-1d2340e2fb6c", "node_type": "1", "metadata": {"window": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n ", "original_text": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n "}, "hash": "5e43e8b53b0b1c9597c936bb51850c1c4f59d2fc5468285b9f86581c1b74ba66", "class_name": "RelatedNodeInfo"}}, "text": "So we continue to be very focused on that in the PD area.  ", "start_char_idx": 682, "end_char_idx": 741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0828968b-7ed0-4988-9503-1d2340e2fb6c": {"__data__": {"id_": "0828968b-7ed0-4988-9503-1d2340e2fb6c", "embedding": null, "metadata": {"window": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n ", "original_text": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d98c31d8-9b7b-4b6b-b486-bf9b51ff71bd", "node_type": "1", "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  ", "original_text": "So we continue to be very focused on that in the PD area.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e15daa05dfc8c1b63ad08b17c33130419b68dbf217e237ab7068ee6fcc5e7205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fb08a09-0650-49b7-8a7a-4714d6627ea5", "node_type": "1", "metadata": {"window": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.  ", "original_text": "And, again, we remain very disciplined in that area to be careful.  "}, "hash": "71dd1634ba693a3306c977c90e069a3430b23ab3bd74e33430a6b18cfc5ca24c", "class_name": "RelatedNodeInfo"}}, "text": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n ", "start_char_idx": 741, "end_char_idx": 895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fb08a09-0650-49b7-8a7a-4714d6627ea5": {"__data__": {"id_": "3fb08a09-0650-49b7-8a7a-4714d6627ea5", "embedding": null, "metadata": {"window": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.  ", "original_text": "And, again, we remain very disciplined in that area to be careful.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0828968b-7ed0-4988-9503-1d2340e2fb6c", "node_type": "1", "metadata": {"window": "You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n ", "original_text": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8750b831b22b11fa423904f244e34962b7785bf07f99cc2beb8719dd6cadaf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "199fa66e-de93-40de-805f-cb88e3504e30", "node_type": "1", "metadata": {"window": "So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n ", "original_text": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  "}, "hash": "5a8017297ffe554e92476859afbefaf6013be176aac1f7d4dca3f9621f02575a", "class_name": "RelatedNodeInfo"}}, "text": "And, again, we remain very disciplined in that area to be careful.  ", "start_char_idx": 895, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "199fa66e-de93-40de-805f-cb88e3504e30": {"__data__": {"id_": "199fa66e-de93-40de-805f-cb88e3504e30", "embedding": null, "metadata": {"window": "So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n ", "original_text": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fb08a09-0650-49b7-8a7a-4714d6627ea5", "node_type": "1", "metadata": {"window": "And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.  ", "original_text": "And, again, we remain very disciplined in that area to be careful.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3dc8b999a3e932237eefdce960bb78a0eaaba14e1e293bdc55e796656053395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a563560-abba-40dc-ba87-c85edda19865", "node_type": "1", "metadata": {"window": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n ", "original_text": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n "}, "hash": "9a69af3ffd7a64163d816832fea1aeb6cd66ceb569e0fbe7b7bd187231e9debf", "class_name": "RelatedNodeInfo"}}, "text": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  ", "start_char_idx": 963, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a563560-abba-40dc-ba87-c85edda19865": {"__data__": {"id_": "1a563560-abba-40dc-ba87-c85edda19865", "embedding": null, "metadata": {"window": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n ", "original_text": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "199fa66e-de93-40de-805f-cb88e3504e30", "node_type": "1", "metadata": {"window": "So we continue to be very focused on that in the PD area.   And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n ", "original_text": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f59f8a8749b2c26194385dc64f0e196de5f0edb126e43de4e10f0a67311e525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f4ad125-6e51-4490-92bc-43c73b77af26", "node_type": "1", "metadata": {"window": "And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.  ", "original_text": "As far as growth in specialty, overall I would say it really comes from market growth.  "}, "hash": "06286036bc89f09f1182ed29e7e08efda7ac87f6d62c573e4dbc6879b75e9380", "class_name": "RelatedNodeInfo"}}, "text": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n ", "start_char_idx": 1044, "end_char_idx": 1149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f4ad125-6e51-4490-92bc-43c73b77af26": {"__data__": {"id_": "3f4ad125-6e51-4490-92bc-43c73b77af26", "embedding": null, "metadata": {"window": "And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.  ", "original_text": "As far as growth in specialty, overall I would say it really comes from market growth.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a563560-abba-40dc-ba87-c85edda19865", "node_type": "1", "metadata": {"window": "And also in the overall specialty business, since there \nis very little generics in that space, that is priced on a more individual drug standpoint.  \n \n  And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n ", "original_text": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04ccdb484263654409355e2cbbc10968164d0d12474323700cc9179a9baae36f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99cfcae4-8f95-4889-bd08-0c0bafc14765", "node_type": "1", "metadata": {"window": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n "}, "hash": "b4f89b15c127dbd7a8a15333fc97b149ab6ad83d9b880b4d985a967dca9f6556", "class_name": "RelatedNodeInfo"}}, "text": "As far as growth in specialty, overall I would say it really comes from market growth.  ", "start_char_idx": 1149, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99cfcae4-8f95-4889-bd08-0c0bafc14765": {"__data__": {"id_": "99cfcae4-8f95-4889-bd08-0c0bafc14765", "embedding": null, "metadata": {"window": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f4ad125-6e51-4490-92bc-43c73b77af26", "node_type": "1", "metadata": {"window": "And, again, we remain very disciplined in that area to be careful.   So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.  ", "original_text": "As far as growth in specialty, overall I would say it really comes from market growth.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21c41cbeb9a26cfa1bc0357b8555afbb5d69c664fab26d2c2c15277be422c891", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6677bd44-06c6-4044-bac3-e30e28d9a489", "node_type": "1", "metadata": {"window": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n "}, "hash": "b12e9d935752b35fe155472710d1b1135cd3f1c66ecbc614bc208c3ea938ea80", "class_name": "RelatedNodeInfo"}}, "text": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n ", "start_char_idx": 1237, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6677bd44-06c6-4044-bac3-e30e28d9a489": {"__data__": {"id_": "6677bd44-06c6-4044-bac3-e30e28d9a489", "embedding": null, "metadata": {"window": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99cfcae4-8f95-4889-bd08-0c0bafc14765", "node_type": "1", "metadata": {"window": "So I wouldn't say that pricing changes is a driver \nof our growth in specialty.   But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "932b708f3356dda30cc84be4e457190757a4fca4be9e7fb8985022fb061b0a82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f13d60e-acb3-41ae-815e-c6a90f4e893b", "node_type": "1", "metadata": {"window": "As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "So overall your volume doesn't generally go up because of a biosimilar.  "}, "hash": "c6d14cf02db277bc2bd2e7d674a1a6113dea5f1df1ea53ac8134581fde27f365", "class_name": "RelatedNodeInfo"}}, "text": "Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n ", "start_char_idx": 1327, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f13d60e-acb3-41ae-815e-c6a90f4e893b": {"__data__": {"id_": "0f13d60e-acb3-41ae-815e-c6a90f4e893b", "embedding": null, "metadata": {"window": "As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "So overall your volume doesn't generally go up because of a biosimilar.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6677bd44-06c6-4044-bac3-e30e28d9a489", "node_type": "1", "metadata": {"window": "But it's also not something that we're ignoring or I would say is a headwind from that \nstandpoint.  \n \n  As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2662ac49f763d6a1f8be17953c29a9657b560c5a60fb8f9b23cada8d3e70179e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41f45016-fbb7-47a7-98c2-c25f322124b5", "node_type": "1", "metadata": {"window": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  "}, "hash": "77bcbfe43c77ee715d889b9cc5781bcd2df6c77ca8351769514d69a22804c9d6", "class_name": "RelatedNodeInfo"}}, "text": "So overall your volume doesn't generally go up because of a biosimilar.  ", "start_char_idx": 1579, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41f45016-fbb7-47a7-98c2-c25f322124b5": {"__data__": {"id_": "41f45016-fbb7-47a7-98c2-c25f322124b5", "embedding": null, "metadata": {"window": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef4a0d09c3b9a6770b7bef0f00e6d2cd345d1a1aa6fea7a56369a816ff90b84a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f13d60e-acb3-41ae-815e-c6a90f4e893b", "node_type": "1", "metadata": {"window": "As far as growth in specialty, overall I would say it really comes from market growth.   The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "So overall your volume doesn't generally go up because of a biosimilar.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "158066cc3bd30287c6ddd79d686e1d5078dde199fe7adc038fd7cd25a49a2e6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56b83ecc-f865-48b3-9577-2532f4912d8b", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n", "original_text": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.  "}, "hash": "e96a1d6c52e0d591d300c890a647be87ea61f6160f40441c1035cdc59343e21b", "class_name": "RelatedNodeInfo"}}, "text": "It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "start_char_idx": 1652, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56b83ecc-f865-48b3-9577-2532f4912d8b": {"__data__": {"id_": "56b83ecc-f865-48b3-9577-2532f4912d8b", "embedding": null, "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n", "original_text": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41f45016-fbb7-47a7-98c2-c25f322124b5", "node_type": "1", "metadata": {"window": "The market itself is growing \nsignificantly with new indications, new drug launches.  \n \n  Your question on biosimilars, the thing about the biosimilars the way to think about it is when the bi osimilar \nlaunches, you're not necessarily getting new volume to speak up because you're replacing a current branded drug \nwith the biosimilar.  \n \n  So overall your volume doesn't generally go up because of a biosimilar.   It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "original_text": "It's just an opportunity to potentially  be \nable to have some market movement capabilities to have customers prefer one over the other.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f53359d87cf9abc5445f6649b8af6363bd9bdfcaa2dbb468bdd61a4ce718bfac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a176b7f-94e8-4c65-accd-2f2ba884348d", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n", "original_text": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.  "}, "hash": "5b29caf4f6328deb94bb46b7a6ebafb93eb0a1db9a17e6244254ff12ef02b264", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.  ", "start_char_idx": 0, "end_char_idx": 175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a176b7f-94e8-4c65-accd-2f2ba884348d": {"__data__": {"id_": "2a176b7f-94e8-4c65-accd-2f2ba884348d", "embedding": null, "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n", "original_text": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56b83ecc-f865-48b3-9577-2532f4912d8b", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n", "original_text": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "306d2c994d9057bc4150950b9d4134cc5199ddb8f3c4b7d7c0de3e460f596f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1754cff-ee70-4483-bb55-b079bd2de45a", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.  ", "original_text": "But I think over time, it will get to be a more and more potential driver for specialty.  \n"}, "hash": "04620ca9ec82eb577c3fb8c124377b9d22bfc30536bdb27d47e65a094a43cc1b", "class_name": "RelatedNodeInfo"}}, "text": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.  ", "start_char_idx": 175, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1754cff-ee70-4483-bb55-b079bd2de45a": {"__data__": {"id_": "f1754cff-ee70-4483-bb55-b079bd2de45a", "embedding": null, "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.  ", "original_text": "But I think over time, it will get to be a more and more potential driver for specialty.  \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a176b7f-94e8-4c65-accd-2f2ba884348d", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n", "original_text": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "076aae1afe3c89533639c26c08db627bb57194c7f0fe7ae3b305521ad4046188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1439cb7c-9496-471d-a3ec-e147ffc9dd2f", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?  ", "original_text": "Next question please.  \n \n"}, "hash": "5d3cfed659999593c4d05fd310ed132d2891676c5e8f48f369362edc2b72d73b", "class_name": "RelatedNodeInfo"}}, "text": "But I think over time, it will get to be a more and more potential driver for specialty.  \n", "start_char_idx": 290, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1439cb7c-9496-471d-a3ec-e147ffc9dd2f": {"__data__": {"id_": "1439cb7c-9496-471d-a3ec-e147ffc9dd2f", "embedding": null, "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?  ", "original_text": "Next question please.  \n \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1754cff-ee70-4483-bb55-b079bd2de45a", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.  ", "original_text": "But I think over time, it will get to be a more and more potential driver for specialty.  \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fde5e798797aaa68a5a5a9b1dd1abf3d56bc15fc180b0dd3d7a2fcd21b24e90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0022580f-2889-4860-b406-37f6c3882093", "node_type": "1", "metadata": {"window": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  ", "original_text": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n"}, "hash": "6a72b096d941a174d3f8710be5955091c4c618ba5972571ad54d491eb37b4b9a", "class_name": "RelatedNodeInfo"}}, "text": "Next question please.  \n \n", "start_char_idx": 381, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0022580f-2889-4860-b406-37f6c3882093": {"__data__": {"id_": "0022580f-2889-4860-b406-37f6c3882093", "embedding": null, "metadata": {"window": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  ", "original_text": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1439cb7c-9496-471d-a3ec-e147ffc9dd2f", "node_type": "1", "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?  ", "original_text": "Next question please.  \n \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ccb18dcc6218de4b677033efb14ec786e86c7d954310f54e5cedd4d307c3003", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b33fb33c-06e1-4e14-bd21-ec1bd4436a94", "node_type": "1", "metadata": {"window": "But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?  ", "original_text": "James Auh :  Hey, it's James Auh for Charles.  "}, "hash": "19adbe4f602a9a235a734e12ce905d144cf8b2a473ff7e249059ef0b08f422c9", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n", "start_char_idx": 407, "end_char_idx": 497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b33fb33c-06e1-4e14-bd21-ec1bd4436a94": {"__data__": {"id_": "b33fb33c-06e1-4e14-bd21-ec1bd4436a94", "embedding": null, "metadata": {"window": "But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?  ", "original_text": "James Auh :  Hey, it's James Auh for Charles.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0022580f-2889-4860-b406-37f6c3882093", "node_type": "1", "metadata": {"window": "But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  ", "original_text": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03a17007618ca9a18d2c51d2ccea44f32dab16caa621db84d27a0b2aa6b1bc40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35dc6362-2284-43a2-9240-3d151158979f", "node_type": "1", "metadata": {"window": "Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n", "original_text": "Can you give us a quick update on the cost savings program?  "}, "hash": "d05e40de206d4e5c9db9399be38e5cec6a5da932e9057a8f8b2cd89034a7fedf", "class_name": "RelatedNodeInfo"}}, "text": "James Auh :  Hey, it's James Auh for Charles.  ", "start_char_idx": 497, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35dc6362-2284-43a2-9240-3d151158979f": {"__data__": {"id_": "35dc6362-2284-43a2-9240-3d151158979f", "embedding": null, "metadata": {"window": "Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n", "original_text": "Can you give us a quick update on the cost savings program?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b33fb33c-06e1-4e14-bd21-ec1bd4436a94", "node_type": "1", "metadata": {"window": "But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?  ", "original_text": "James Auh :  Hey, it's James Auh for Charles.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "029f0f5cddb91c1631abd8bfed7d5ac7c86da8f17daaea282b1c0e3c885393a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25fc5cf5-26aa-41e9-876e-8f1d0f4e0283", "node_type": "1", "metadata": {"window": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.  ", "original_text": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  "}, "hash": "273ad979f8a1308dce7fab09e3fda95e36a43851c1cc3ed8dd174b2b8e0a01d0", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a quick update on the cost savings program?  ", "start_char_idx": 544, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25fc5cf5-26aa-41e9-876e-8f1d0f4e0283": {"__data__": {"id_": "25fc5cf5-26aa-41e9-876e-8f1d0f4e0283", "embedding": null, "metadata": {"window": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.  ", "original_text": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35dc6362-2284-43a2-9240-3d151158979f", "node_type": "1", "metadata": {"window": "Next question please.  \n \n Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n", "original_text": "Can you give us a quick update on the cost savings program?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b338ceffb3cefd7ac16ce461a82fd1b05a012888711bc8e27bca1d43332b2921", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f844d6-99d3-4fbd-a4d0-fc49df12aa07", "node_type": "1", "metadata": {"window": "James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.  ", "original_text": "You know, is it \ntracking in line with expectations?  "}, "hash": "b37a152e86256345e52f956c720defede952c74451c99bd63e6582e432fdd4c6", "class_name": "RelatedNodeInfo"}}, "text": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  ", "start_char_idx": 605, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f844d6-99d3-4fbd-a4d0-fc49df12aa07": {"__data__": {"id_": "e1f844d6-99d3-4fbd-a4d0-fc49df12aa07", "embedding": null, "metadata": {"window": "James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.  ", "original_text": "You know, is it \ntracking in line with expectations?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25fc5cf5-26aa-41e9-876e-8f1d0f4e0283", "node_type": "1", "metadata": {"window": "Operator :  We'll go to our next ques tion from Charles Rhyee with Cowen and Company.  \n \n James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.  ", "original_text": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aab61f0946fe43783c84883c5c163d72ff370d2892e45275564ec99522d913c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "562d4300-84de-4844-afb4-5f800588d763", "node_type": "1", "metadata": {"window": "Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n ", "original_text": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n"}, "hash": "800cb6b182902316f3b36de2b54a4483e9a20a115efd8f7e840c299571e4af52", "class_name": "RelatedNodeInfo"}}, "text": "You know, is it \ntracking in line with expectations?  ", "start_char_idx": 707, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "562d4300-84de-4844-afb4-5f800588d763": {"__data__": {"id_": "562d4300-84de-4844-afb4-5f800588d763", "embedding": null, "metadata": {"window": "Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n ", "original_text": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f844d6-99d3-4fbd-a4d0-fc49df12aa07", "node_type": "1", "metadata": {"window": "James Auh :  Hey, it's James Auh for Charles.   Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.  ", "original_text": "You know, is it \ntracking in line with expectations?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbc2e9c64be55b8a4ef9f0e1dbd85f5dc702f87cbe9f5d7edc633c11fa1528e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4acb5999-5bce-4fda-92c4-5269b52da6b7", "node_type": "1", "metadata": {"window": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.  ", "original_text": "David Evans :  Yes, James.  "}, "hash": "350054fe2481b19510fb35deb699accaa06cbffe77400f450e0b2d7d38d282bd", "class_name": "RelatedNodeInfo"}}, "text": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n", "start_char_idx": 761, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4acb5999-5bce-4fda-92c4-5269b52da6b7": {"__data__": {"id_": "4acb5999-5bce-4fda-92c4-5269b52da6b7", "embedding": null, "metadata": {"window": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.  ", "original_text": "David Evans :  Yes, James.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "562d4300-84de-4844-afb4-5f800588d763", "node_type": "1", "metadata": {"window": "Can you give us a quick update on the cost savings program?   Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n ", "original_text": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c12c348b8a397093e8ac7c71a0b47202c00684c6dce4ea634d30398e255d826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f911b390-8197-48b8-b0fb-5640620aa71e", "node_type": "1", "metadata": {"window": "You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.  ", "original_text": "Thanks for  the question.  "}, "hash": "03e68e63ee0d54d2989869b851a801a04681774401c332538303c9762bad6b81", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Yes, James.  ", "start_char_idx": 868, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f911b390-8197-48b8-b0fb-5640620aa71e": {"__data__": {"id_": "f911b390-8197-48b8-b0fb-5640620aa71e", "embedding": null, "metadata": {"window": "You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.  ", "original_text": "Thanks for  the question.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4acb5999-5bce-4fda-92c4-5269b52da6b7", "node_type": "1", "metadata": {"window": "Maybe, you \nknow, how much of the $130M of incremental savings expected this year has been achieved?   You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.  ", "original_text": "David Evans :  Yes, James.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e734dae3d07a805ed284e30605bc1381bf844f75051347fdabb55187a4ac7635", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81c2e082-e3e6-4808-936b-1f3e5f723765", "node_type": "1", "metadata": {"window": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.  ", "original_text": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n "}, "hash": "1a7e10bb7444ddef6f88fecf70d15fddbb7688cb368752a94e4e8942d1f9647b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for  the question.  ", "start_char_idx": 896, "end_char_idx": 923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81c2e082-e3e6-4808-936b-1f3e5f723765": {"__data__": {"id_": "81c2e082-e3e6-4808-936b-1f3e5f723765", "embedding": null, "metadata": {"window": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.  ", "original_text": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f911b390-8197-48b8-b0fb-5640620aa71e", "node_type": "1", "metadata": {"window": "You know, is it \ntracking in line with expectations?   And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.  ", "original_text": "Thanks for  the question.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcc02a6e2490ed82c3630999416d871e7d5f4cff530f73ce97ab4bb2827840ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d78ce1d1-e97e-49a7-8391-ece5dcc2a8ac", "node_type": "1", "metadata": {"window": "David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n ", "original_text": "And I would also say we're on track to realize the $130 million or more this fiscal year.  "}, "hash": "973c77cb355678d5c6b17992010c836f7cdf2c38ebc21241aa3e0f072191ccdc", "class_name": "RelatedNodeInfo"}}, "text": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n ", "start_char_idx": 923, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d78ce1d1-e97e-49a7-8391-ece5dcc2a8ac": {"__data__": {"id_": "d78ce1d1-e97e-49a7-8391-ece5dcc2a8ac", "embedding": null, "metadata": {"window": "David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n ", "original_text": "And I would also say we're on track to realize the $130 million or more this fiscal year.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81c2e082-e3e6-4808-936b-1f3e5f723765", "node_type": "1", "metadata": {"window": "And perhaps how much of that's been reinvested as opposed to, you know,  \ndropping to the bottom line?  \n \n David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.  ", "original_text": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8f2fa65998e7beace1bcf52faa78265f60f9a506f1bb983de9278c0dcb8b267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51cf7232-b00f-46f7-8144-58a5cd9794ab", "node_type": "1", "metadata": {"window": "Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  ", "original_text": "So we're making good \nprogress.  "}, "hash": "925447fa692fdaa7df3ac7ee9eb97cca9fb2bb49fe5454d84f2648c08394973b", "class_name": "RelatedNodeInfo"}}, "text": "And I would also say we're on track to realize the $130 million or more this fiscal year.  ", "start_char_idx": 1077, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51cf7232-b00f-46f7-8144-58a5cd9794ab": {"__data__": {"id_": "51cf7232-b00f-46f7-8144-58a5cd9794ab", "embedding": null, "metadata": {"window": "Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  ", "original_text": "So we're making good \nprogress.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d78ce1d1-e97e-49a7-8391-ece5dcc2a8ac", "node_type": "1", "metadata": {"window": "David Evans :  Yes, James.   Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n ", "original_text": "And I would also say we're on track to realize the $130 million or more this fiscal year.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4880bb61d585e4fb68c85be388b686682330d3443dcf798a3eecbf469eb54ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01491980-f2e2-48ec-920f-e85b06711aac", "node_type": "1", "metadata": {"window": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "We've got a pipeline.  "}, "hash": "6d2cc633d99c51ea935370278c40891292e68db312cc541e707091b50916f865", "class_name": "RelatedNodeInfo"}}, "text": "So we're making good \nprogress.  ", "start_char_idx": 1168, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01491980-f2e2-48ec-920f-e85b06711aac": {"__data__": {"id_": "01491980-f2e2-48ec-920f-e85b06711aac", "embedding": null, "metadata": {"window": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "We've got a pipeline.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51cf7232-b00f-46f7-8144-58a5cd9794ab", "node_type": "1", "metadata": {"window": "Thanks for  the question.   You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  ", "original_text": "So we're making good \nprogress.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f132d78f8c48da3ec7659164d524f52dc876723ae0263f81243eaa858a99776", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "876acda1-c0e7-483a-b489-96d07cce638f", "node_type": "1", "metadata": {"window": "And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n "}, "hash": "7296301d3168228fe3740e536b1bef0b38a2c6c3887f767d06cdb6d10b86ad6a", "class_name": "RelatedNodeInfo"}}, "text": "We've got a pipeline.  ", "start_char_idx": 1201, "end_char_idx": 1224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "876acda1-c0e7-483a-b489-96d07cce638f": {"__data__": {"id_": "876acda1-c0e7-483a-b489-96d07cce638f", "embedding": null, "metadata": {"window": "And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01491980-f2e2-48ec-920f-e85b06711aac", "node_type": "1", "metadata": {"window": "You know, we're making great progress against that program, and \nwe're still on track to achieve the $500 million target as previously communicated.  \n \n  And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "We've got a pipeline.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c88e312cc0c8122c4fc2dfa3c62b2cd58359f895f154f06ac495947d9f763c36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1134666d-fd17-4c34-9fe3-c3a718b36304", "node_type": "1", "metadata": {"window": "So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  "}, "hash": "21042d10528bbef79307d37d2c9d79477933540a5fb39ffc663a10b959714327", "class_name": "RelatedNodeInfo"}}, "text": "As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n ", "start_char_idx": 1224, "end_char_idx": 1343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1134666d-fd17-4c34-9fe3-c3a718b36304": {"__data__": {"id_": "1134666d-fd17-4c34-9fe3-c3a718b36304", "embedding": null, "metadata": {"window": "So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "876acda1-c0e7-483a-b489-96d07cce638f", "node_type": "1", "metadata": {"window": "And I would also say we're on track to realize the $130 million or more this fiscal year.   So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d073e31f6290fd8cca7718083693ebe246aeb8bf4848a32fd6d3d98d70019359", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b5f1e4-4803-4e07-9074-d62a12048737", "node_type": "1", "metadata": {"window": "We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  "}, "hash": "c375b32e1136c251e250142031bcbff4b6aeee3f5a466f76e300f1e18923e347", "class_name": "RelatedNodeInfo"}}, "text": "And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  ", "start_char_idx": 1343, "end_char_idx": 1447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b5f1e4-4803-4e07-9074-d62a12048737": {"__data__": {"id_": "d8b5f1e4-4803-4e07-9074-d62a12048737", "embedding": null, "metadata": {"window": "We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69ee837e00133f3759772787c5a0d73c9054a30f3d218ccd51277a49b5b8c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1134666d-fd17-4c34-9fe3-c3a718b36304", "node_type": "1", "metadata": {"window": "So we're making good \nprogress.   We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2225bfc647e83bf9f408afbff54558098c3144e0ae2546542af45b12602d0c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03fd2ccb-8aff-4d0b-b474-8db3870282c7", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.  ", "original_text": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n "}, "hash": "88e13adce12df33e6fc5fa2dbfbb071b22fd6e4b8bc335d4949c6bb12add2662", "class_name": "RelatedNodeInfo"}}, "text": "So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "start_char_idx": 1447, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03fd2ccb-8aff-4d0b-b474-8db3870282c7": {"__data__": {"id_": "03fd2ccb-8aff-4d0b-b474-8db3870282c7", "embedding": null, "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.  ", "original_text": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b5f1e4-4803-4e07-9074-d62a12048737", "node_type": "1", "metadata": {"window": "We've got a pipeline.   As you can imagine, we're tracking all sorts of opportunities and working through \nkind of stages and maturation.  \n \n  And we're seeing with, you know, strong confidence now our ability to obtain the enti re $500 million.   So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "original_text": "So we're \nreally continuing to focus more on not just simply cost out, but how do we try to drive improved value, speed \nthroughout the organization, increase our capabilities with the belief that that will continue to drive more savings \nthroughout the future?  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b7859ed7991aff0c01aacc11bd1d86be1bffa44c5c86c8b13f8b4232845545e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "416ad303-a2a4-463f-8369-c8ded4317e1b", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.  ", "original_text": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.  "}, "hash": "8fdb6feccf17e1da4801fb8f0d38db9990dfe8dfcd3467add7c56dc717dec518", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n ", "start_char_idx": 0, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "416ad303-a2a4-463f-8369-c8ded4317e1b": {"__data__": {"id_": "416ad303-a2a4-463f-8369-c8ded4317e1b", "embedding": null, "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.  ", "original_text": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03fd2ccb-8aff-4d0b-b474-8db3870282c7", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.  ", "original_text": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "166704fae387a1a09d91e4ce8bbe56488eafb079826138bd7b41c960cf792b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b5b7a1c-4f20-404d-af60-d5f2397d7bcb", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n", "original_text": "So I think the program is one that we should \ndeem as a real success.  \n \n"}, "hash": "4048ef439d4cea6aaf787d7100b87b6d38db66f70e64025fa02f2bd9bbfeeb2f", "class_name": "RelatedNodeInfo"}}, "text": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.  ", "start_char_idx": 233, "end_char_idx": 527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b5b7a1c-4f20-404d-af60-d5f2397d7bcb": {"__data__": {"id_": "1b5b7a1c-4f20-404d-af60-d5f2397d7bcb", "embedding": null, "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n", "original_text": "So I think the program is one that we should \ndeem as a real success.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "416ad303-a2a4-463f-8369-c8ded4317e1b", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.  ", "original_text": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9364fe369dd9b9ea76d0aec0e68237dca0957d206b61cd782943454c4d58e49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "193912fc-f10d-4d71-b1eb-43985214e884", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.  ", "original_text": "James Auh :  Okay.  "}, "hash": "46ba20797ad169dcbb7e1edbc13547dd404f042ecc47cd5fd00d12d52af5730f", "class_name": "RelatedNodeInfo"}}, "text": "So I think the program is one that we should \ndeem as a real success.  \n \n", "start_char_idx": 527, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "193912fc-f10d-4d71-b1eb-43985214e884": {"__data__": {"id_": "193912fc-f10d-4d71-b1eb-43985214e884", "embedding": null, "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.  ", "original_text": "James Auh :  Okay.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b5b7a1c-4f20-404d-af60-d5f2397d7bcb", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n", "original_text": "So I think the program is one that we should \ndeem as a real success.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87f0575f1e47c9a37d931d301141ed7c612d4e8b672ef71b097d243c2f68a4b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eda82a6c-5b19-44c2-a117-70a20ea56873", "node_type": "1", "metadata": {"window": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n", "original_text": "And just another technical question.  "}, "hash": "8727b5ce25584b481e18ca555a2e760fe1997b9f47fe54e198536bc68561e77e", "class_name": "RelatedNodeInfo"}}, "text": "James Auh :  Okay.  ", "start_char_idx": 601, "end_char_idx": 621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eda82a6c-5b19-44c2-a117-70a20ea56873": {"__data__": {"id_": "eda82a6c-5b19-44c2-a117-70a20ea56873", "embedding": null, "metadata": {"window": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n", "original_text": "And just another technical question.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "193912fc-f10d-4d71-b1eb-43985214e884", "node_type": "1", "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.  ", "original_text": "James Auh :  Okay.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8093fa4334cafb80ed135020a27dba940437c51891865f13ce2b0fffb8f514", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b3eb4e4-0d14-41c8-aafc-8a86d0a50c44", "node_type": "1", "metadata": {"window": "So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.  ", "original_text": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n"}, "hash": "a5381d84607e38fdeb39d93371a00c7d8df04c53bf0e331b5e0d9c1e7548e3eb", "class_name": "RelatedNodeInfo"}}, "text": "And just another technical question.  ", "start_char_idx": 621, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b3eb4e4-0d14-41c8-aafc-8a86d0a50c44": {"__data__": {"id_": "9b3eb4e4-0d14-41c8-aafc-8a86d0a50c44", "embedding": null, "metadata": {"window": "So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.  ", "original_text": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eda82a6c-5b19-44c2-a117-70a20ea56873", "node_type": "1", "metadata": {"window": "I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n", "original_text": "And just another technical question.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62965038fa8eff2d37869e4bb356635da58f97c80b01aa28537e85ecac0e3559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e69173e-fbfc-44c3-9f9d-6f8d22eb4991", "node_type": "1", "metadata": {"window": "James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n", "original_text": "David Evan s:  No, James.  "}, "hash": "88dcf99530d2c12a8363c789328e720d3cc27049fdf2b8328d70f9375c566c82", "class_name": "RelatedNodeInfo"}}, "text": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n", "start_char_idx": 659, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e69173e-fbfc-44c3-9f9d-6f8d22eb4991": {"__data__": {"id_": "4e69173e-fbfc-44c3-9f9d-6f8d22eb4991", "embedding": null, "metadata": {"window": "James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n", "original_text": "David Evan s:  No, James.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b3eb4e4-0d14-41c8-aafc-8a86d0a50c44", "node_type": "1", "metadata": {"window": "So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.  ", "original_text": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cd48f2830270297b5fb3f09cd8624aa68ed4cc24a1c04f1687bf09318d4955a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7766d183-a5b0-44d8-8a95-695dc7515602", "node_type": "1", "metadata": {"window": "And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.  ", "original_text": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n"}, "hash": "0690a434f64e9d20bed7a073d68652fe4467b33f478a2d2b4c0b3da7b1acc3bc", "class_name": "RelatedNodeInfo"}}, "text": "David Evan s:  No, James.  ", "start_char_idx": 775, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7766d183-a5b0-44d8-8a95-695dc7515602": {"__data__": {"id_": "7766d183-a5b0-44d8-8a95-695dc7515602", "embedding": null, "metadata": {"window": "And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.  ", "original_text": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e69173e-fbfc-44c3-9f9d-6f8d22eb4991", "node_type": "1", "metadata": {"window": "James Auh :  Okay.   And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n", "original_text": "David Evan s:  No, James.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aec7e2ebb55175fd00a468e40bd7fad8f4020ab63a84cfa84b113b611df624c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e314057-9a2b-45b2-8de4-c71cfb602aa8", "node_type": "1", "metadata": {"window": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n", "original_text": "James Auh :  Okay, great.  "}, "hash": "404137dd67654eb55cc6b25e8138a5a2f095cbcc8711fb3c040c8ff1de11321e", "class_name": "RelatedNodeInfo"}}, "text": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n", "start_char_idx": 802, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e314057-9a2b-45b2-8de4-c71cfb602aa8": {"__data__": {"id_": "6e314057-9a2b-45b2-8de4-c71cfb602aa8", "embedding": null, "metadata": {"window": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n", "original_text": "James Auh :  Okay, great.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7766d183-a5b0-44d8-8a95-695dc7515602", "node_type": "1", "metadata": {"window": "And just another technical question.   In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.  ", "original_text": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0daf01eef800e32bb5f1b43b64293b068957294a27de93f6b4226542e93d7e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7b7f40e-6fe6-45a2-a27e-573096cb6bb5", "node_type": "1", "metadata": {"window": "David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n", "original_text": "Thank you.  \n \n"}, "hash": "ad3e679e023d8bb4a847d1823964f6f1424583dd5856cf7bbc0af7cc9b0068b8", "class_name": "RelatedNodeInfo"}}, "text": "James Auh :  Okay, great.  ", "start_char_idx": 943, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7b7f40e-6fe6-45a2-a27e-573096cb6bb5": {"__data__": {"id_": "a7b7f40e-6fe6-45a2-a27e-573096cb6bb5", "embedding": null, "metadata": {"window": "David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n", "original_text": "Thank you.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e314057-9a2b-45b2-8de4-c71cfb602aa8", "node_type": "1", "metadata": {"window": "In the share count guidance, does that include any additional \nshare repo beyond the $350 million from the ASR?  \n \n David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n", "original_text": "James Auh :  Okay, great.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "552736545743454fe84e862cb142918e54da3b0f94b07c22b9f3aea562faf101", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a72d2e27-4adb-4ec0-a011-361111b74011", "node_type": "1", "metadata": {"window": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.  ", "original_text": "Mike Kaufmann:  Thanks for the question.  "}, "hash": "5b343126c30bd0f97269647b8b6c271324ac65a8b9576f0aa165ca80ffabc810", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 970, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a72d2e27-4adb-4ec0-a011-361111b74011": {"__data__": {"id_": "a72d2e27-4adb-4ec0-a011-361111b74011", "embedding": null, "metadata": {"window": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.  ", "original_text": "Mike Kaufmann:  Thanks for the question.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7b7f40e-6fe6-45a2-a27e-573096cb6bb5", "node_type": "1", "metadata": {"window": "David Evan s:  No, James.   That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n", "original_text": "Thank you.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83331b43b047ca5d9f883af0125aa9df45e5cc1e89a6c3e5f127c143160f2777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82627fe5-a223-4037-a5ce-c70da964f9e3", "node_type": "1", "metadata": {"window": "James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  ", "original_text": "Next question please.  \n \n"}, "hash": "53e7fa8f3ca670b5d1d4bcaee9093d4afb7778da89ddb871bfebf282a06aed13", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks for the question.  ", "start_char_idx": 985, "end_char_idx": 1027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82627fe5-a223-4037-a5ce-c70da964f9e3": {"__data__": {"id_": "82627fe5-a223-4037-a5ce-c70da964f9e3", "embedding": null, "metadata": {"window": "James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  ", "original_text": "Next question please.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a72d2e27-4adb-4ec0-a011-361111b74011", "node_type": "1", "metadata": {"window": "That assumes that we completed $350 million and there would be no further purchases for this \nfiscal year contemplated in that guidance.  \n \n James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.  ", "original_text": "Mike Kaufmann:  Thanks for the question.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1da21529c7bd00510a652a6ba4ff1677923eb3518c39f29e891b6c089d7bf8d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "201d8a04-fa5e-4f35-9a84-fb16a3ee9a62", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n"}, "hash": "ba1fbc7bcf8daa92565c67a0199ba96d006584dbd455ea65cb5ab89883ebf2b0", "class_name": "RelatedNodeInfo"}}, "text": "Next question please.  \n \n", "start_char_idx": 1027, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "201d8a04-fa5e-4f35-9a84-fb16a3ee9a62": {"__data__": {"id_": "201d8a04-fa5e-4f35-9a84-fb16a3ee9a62", "embedding": null, "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82627fe5-a223-4037-a5ce-c70da964f9e3", "node_type": "1", "metadata": {"window": "James Auh :  Okay, great.   Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  ", "original_text": "Next question please.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4c022c4bc50bbacbc6e7bbc4636c9cec5a54dc738dc2c83ae916678889a0e49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ff659a-52e4-40ea-bad8-bba3d71b700a", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "Eric Percher :  Thank you.  "}, "hash": "851e6929c98da09e8d213294e5bfbdd80be01a5bca664ba2db4419e04e6df96e", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n", "start_char_idx": 1053, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ff659a-52e4-40ea-bad8-bba3d71b700a": {"__data__": {"id_": "34ff659a-52e4-40ea-bad8-bba3d71b700a", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "Eric Percher :  Thank you.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "201d8a04-fa5e-4f35-9a84-fb16a3ee9a62", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a34cdaebf4dfa8485db6a9e35ff0b04fded6c4626f8b8d8db2c1aa61de1b8e9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7945270a-63ed-4494-9047-8de4e458da96", "node_type": "1", "metadata": {"window": "Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  "}, "hash": "8d88e346361dbc663f6af26bfe7efd1fa97d862a67cee84aeb88147b89a377be", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :  Thank you.  ", "start_char_idx": 1134, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7945270a-63ed-4494-9047-8de4e458da96": {"__data__": {"id_": "7945270a-63ed-4494-9047-8de4e458da96", "embedding": null, "metadata": {"window": "Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ff659a-52e4-40ea-bad8-bba3d71b700a", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks for the question.   Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "Eric Percher :  Thank you.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "019bc4b1beec7b9f9ceb8039589d9488146ccd542781f820f11668cb7592225d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bf2ccfa-3a73-4315-b14c-f4e884d8486b", "node_type": "1", "metadata": {"window": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "But could you provide us some context for how surgical gowns and kits fit into medical "}, "hash": "43ce65c8c39c8d697e2fe496d94b6e893655c47aba1c29239cc9f56a41b817b6", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  ", "start_char_idx": 1162, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bf2ccfa-3a73-4315-b14c-f4e884d8486b": {"__data__": {"id_": "2bf2ccfa-3a73-4315-b14c-f4e884d8486b", "embedding": null, "metadata": {"window": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "But could you provide us some context for how surgical gowns and kits fit into medical ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fea0a7373c1f2a34520e1c5a67915e10aa0e0faa0c943894b85c0372cd7399f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7945270a-63ed-4494-9047-8de4e458da96", "node_type": "1", "metadata": {"window": "Next question please.  \n \n Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.  ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5223bf136e1e78b1b5c75786babbe8df8e45a816659a5d93acf19e4ff73de72a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f3f0622-2405-4149-b525-8d9dd1453c3b", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n ", "original_text": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n"}, "hash": "c239303c48f309a04b2e2f5e3ec917c4848ef8655e0468051ce81aef2d012ced", "class_name": "RelatedNodeInfo"}}, "text": "But could you provide us some context for how surgical gowns and kits fit into medical ", "start_char_idx": 1284, "end_char_idx": 1371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f3f0622-2405-4149-b525-8d9dd1453c3b": {"__data__": {"id_": "1f3f0622-2405-4149-b525-8d9dd1453c3b", "embedding": null, "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n ", "original_text": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bf2ccfa-3a73-4315-b14c-f4e884d8486b", "node_type": "1", "metadata": {"window": "Operator :  Our next question comes from Eric Percher with Nephron Research.  \n \n Eric Percher :  Thank you.   I'd like to return to the medical recall, I recognize, you're still working through the potential \nimpact going forward.   But could you provide us some context for how surgical gowns and kits fit into medical ", "original_text": "But could you provide us some context for how surgical gowns and kits fit into medical ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e99ba8334ca3ead70c7ff60c8a039ec7067df2c2e8c16186754f6e78cf3c345b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b33a8a8-a392-452e-bb20-450051e0f9a2", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n ", "original_text": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.  "}, "hash": "d78ed394c0b0ce542e5fc0480b448f0374b722727395d8070af60e3d3cd193d0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n", "start_char_idx": 0, "end_char_idx": 145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b33a8a8-a392-452e-bb20-450051e0f9a2": {"__data__": {"id_": "7b33a8a8-a392-452e-bb20-450051e0f9a2", "embedding": null, "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n ", "original_text": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f3f0622-2405-4149-b525-8d9dd1453c3b", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n ", "original_text": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f18202aae336ca1b53b844e31c2de0353a4c2369efa898a7dd846a446d4fcf97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690517dc-ee93-41e4-b29f-6e2bb97e01a8", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S. ", "original_text": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S. "}, "hash": "5aecdc97c850b439697dbdf515baa0dd9072304f290a2fb76545ae999468ef52", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.  ", "start_char_idx": 145, "end_char_idx": 239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690517dc-ee93-41e4-b29f-6e2bb97e01a8": {"__data__": {"id_": "690517dc-ee93-41e4-b29f-6e2bb97e01a8", "embedding": null, "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S. ", "original_text": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S. ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b33a8a8-a392-452e-bb20-450051e0f9a2", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n ", "original_text": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bb7d59826d1ccb9350ad140c8f26d76489c8adfb95a95e0d3a9af089d2710e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edf1cca1-fe7e-41f5-b8fb-d1b731047a6f", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.  ", "original_text": "use kits.  \n \n "}, "hash": "4df275c41f6676a73c1f0b4acb391f56a803ba0ccd15583701b620bfe16498fd", "class_name": "RelatedNodeInfo"}}, "text": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S. ", "start_char_idx": 239, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edf1cca1-fe7e-41f5-b8fb-d1b731047a6f": {"__data__": {"id_": "edf1cca1-fe7e-41f5-b8fb-d1b731047a6f", "embedding": null, "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.  ", "original_text": "use kits.  \n \n ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690517dc-ee93-41e4-b29f-6e2bb97e01a8", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S. ", "original_text": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S. ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b1852b63f70861e4cdea1d8c887c01e7fed0b40b2b7d89a67c2e475cb2f6ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59dc3930-7e19-4dbf-b934-70ab993d540a", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n", "original_text": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n "}, "hash": "3c04f574d6c3858c7c49fdbc95d7b4a5b318542f71a113b4cfdbfb6fdc82625e", "class_name": "RelatedNodeInfo"}}, "text": "use kits.  \n \n ", "start_char_idx": 380, "end_char_idx": 395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59dc3930-7e19-4dbf-b934-70ab993d540a": {"__data__": {"id_": "59dc3930-7e19-4dbf-b934-70ab993d540a", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n", "original_text": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edf1cca1-fe7e-41f5-b8fb-d1b731047a6f", "node_type": "1", "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.  ", "original_text": "use kits.  \n \n ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac38d932064abeacaee822d327e77cd5fb43119734f1bad8a652e11d6a26f295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84be6d16-7f20-475b-9bad-726ff4da4bbd", "node_type": "1", "metadata": {"window": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n ", "original_text": "So the idea here is that a lot of surgeries in the U.S. "}, "hash": "8a774092ee91719f610264cee9c7199ee1afbd6154718c79ae4cb2cf5c1175c3", "class_name": "RelatedNodeInfo"}}, "text": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n ", "start_char_idx": 395, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84be6d16-7f20-475b-9bad-726ff4da4bbd": {"__data__": {"id_": "84be6d16-7f20-475b-9bad-726ff4da4bbd", "embedding": null, "metadata": {"window": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n ", "original_text": "So the idea here is that a lot of surgeries in the U.S. ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59dc3930-7e19-4dbf-b934-70ab993d540a", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n", "original_text": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "576a4333fe5bc95737752a8bd507740a212bf93e4140c7daf63eba74830c50a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "548b6aed-0bd4-4775-91e9-e59823c248f8", "node_type": "1", "metadata": {"window": "use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n", "original_text": "do use kits.  "}, "hash": "f4ac8045fe8b23a210689449716a761db48a088802a730b056f627b95c622f08", "class_name": "RelatedNodeInfo"}}, "text": "So the idea here is that a lot of surgeries in the U.S. ", "start_char_idx": 650, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "548b6aed-0bd4-4775-91e9-e59823c248f8": {"__data__": {"id_": "548b6aed-0bd4-4775-91e9-e59823c248f8", "embedding": null, "metadata": {"window": "use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n", "original_text": "do use kits.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84be6d16-7f20-475b-9bad-726ff4da4bbd", "node_type": "1", "metadata": {"window": "But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n ", "original_text": "So the idea here is that a lot of surgeries in the U.S. ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9206080f06c2cc3a28cddfbc0755f5c404f7d10fae0bebdd66e5bee663bc0243", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c92dac4-e8be-4309-a8cd-57c22eb28df0", "node_type": "1", "metadata": {"window": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  ", "original_text": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n"}, "hash": "f9c9d933fecead580392edafe6ada402dac36120a0ebe6df904547b8a02f202b", "class_name": "RelatedNodeInfo"}}, "text": "do use kits.  ", "start_char_idx": 706, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c92dac4-e8be-4309-a8cd-57c22eb28df0": {"__data__": {"id_": "8c92dac4-e8be-4309-a8cd-57c22eb28df0", "embedding": null, "metadata": {"window": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  ", "original_text": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "548b6aed-0bd4-4775-91e9-e59823c248f8", "node_type": "1", "metadata": {"window": "use kits.  \n \n  There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n", "original_text": "do use kits.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed8f959f8769088052a4e4a95a1d17f66bbce566998ac3aac5a567aa66a05f3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e699b969-1269-465d-ab4c-69b7718dad7c", "node_type": "1", "metadata": {"window": "So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n", "original_text": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n "}, "hash": "9e3329c76654927a5d9a43a4c50ea2aef65950f8e663da3641e4fd1ddafb658c", "class_name": "RelatedNodeInfo"}}, "text": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n", "start_char_idx": 720, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e699b969-1269-465d-ab4c-69b7718dad7c": {"__data__": {"id_": "e699b969-1269-465d-ab4c-69b7718dad7c", "embedding": null, "metadata": {"window": "So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n", "original_text": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c92dac4-e8be-4309-a8cd-57c22eb28df0", "node_type": "1", "metadata": {"window": "There are several different folks that compete in that space, but we do compete v ery effectively, we think, with \nmarket -leading type of quality and services tied to those kits, the ability to design and price those kits \nappropriately, et cetera.  \n \n  So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  ", "original_text": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2223a88818693c5219152521d4225ad98267b9e0c65fd1626f595fa8820a399b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abf5f1b5-3358-4283-b96d-7a782e100c80", "node_type": "1", "metadata": {"window": "do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  ", "original_text": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n"}, "hash": "369d9ead66ba2f23aac2573d55de89c1873bfeb3cb41d6792a5fa1722e580889", "class_name": "RelatedNodeInfo"}}, "text": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n ", "start_char_idx": 872, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abf5f1b5-3358-4283-b96d-7a782e100c80": {"__data__": {"id_": "abf5f1b5-3358-4283-b96d-7a782e100c80", "embedding": null, "metadata": {"window": "do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  ", "original_text": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e699b969-1269-465d-ab4c-69b7718dad7c", "node_type": "1", "metadata": {"window": "So the idea here is that a lot of surgeries in the U.S.  do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n", "original_text": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "add71aaad8cff5cb1cdb9c59bc1bcf5ca59fa053276236925b5dc712ea058a70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b95c2b70-d216-4666-8699-32133fd76e0b", "node_type": "1", "metadata": {"window": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  "}, "hash": "c83025b276ffff381a08f5d8f03b830d734dac5a059d3d797347448886526188", "class_name": "RelatedNodeInfo"}}, "text": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n", "start_char_idx": 965, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b95c2b70-d216-4666-8699-32133fd76e0b": {"__data__": {"id_": "b95c2b70-d216-4666-8699-32133fd76e0b", "embedding": null, "metadata": {"window": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abf5f1b5-3358-4283-b96d-7a782e100c80", "node_type": "1", "metadata": {"window": "do use kits.   And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  ", "original_text": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c7d6f72f16987258031de87d7268b889227918cb121cddbc5dd77dcb2c9fe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06edd1cd-601f-4916-beeb-3eebe084cf12", "node_type": "1", "metadata": {"window": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n"}, "hash": "052ec117297e6d2c94b64929cf54d8aa6f807d03cac9dcd361dc5f144cad4af4", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  ", "start_char_idx": 1115, "end_char_idx": 1302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06edd1cd-601f-4916-beeb-3eebe084cf12": {"__data__": {"id_": "06edd1cd-601f-4916-beeb-3eebe084cf12", "embedding": null, "metadata": {"window": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b95c2b70-d216-4666-8699-32133fd76e0b", "node_type": "1", "metadata": {"window": "And because gowns a re in almost every kit, \neven though when you look at this as an overall relatively small percentage of gowns sold across the U.S. \n because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0de5bcc48048f2b039a8fdad03d29778cf61cd5f2922949390b5df0c10c272b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de0b621d-b918-4be0-b26c-ef03d753469d", "node_type": "1", "metadata": {"window": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  "}, "hash": "eb90efc2affc32fadc5cd16c7f4525907c68df35e7de0601c57230059202d480", "class_name": "RelatedNodeInfo"}}, "text": "But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n", "start_char_idx": 1302, "end_char_idx": 1437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de0b621d-b918-4be0-b26c-ef03d753469d": {"__data__": {"id_": "de0b621d-b918-4be0-b26c-ef03d753469d", "embedding": null, "metadata": {"window": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06edd1cd-601f-4916-beeb-3eebe084cf12", "node_type": "1", "metadata": {"window": "because they are in kits, that's why it's having a larger impact than you might expect.  \n \n  And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd0d82511b49ed13cd608eff90b560908913f1643c0b438222b84c7c02112db7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42dc7c66-8399-438d-bcc0-c0f0e38c1152", "node_type": "1", "metadata": {"window": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and "}, "hash": "9e50dc1f57f78c1ea67ac803303b2546efab5332e171e1c842336c93e9b0829c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  ", "start_char_idx": 1437, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42dc7c66-8399-438d-bcc0-c0f0e38c1152": {"__data__": {"id_": "42dc7c66-8399-438d-bcc0-c0f0e38c1152", "embedding": null, "metadata": {"window": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5e85b94-6264-4b17-a195-3eb3f253987d", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9c3bb77aeef3e76d4869c7c4b7f377e5c90ff648b4dd9ae8ce7a6e00d1a2d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de0b621d-b918-4be0-b26c-ef03d753469d", "node_type": "1", "metadata": {"window": "And so, I'll just stop there and see  what your follow -up question might be beyond that just to make sure I'm hitting \nthe right things for you.  \n \n Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.  ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46c055924424f31e251539c2df3bf1450ce5a49bbcc5d1f080e572c30e5c77a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93206f79-2940-432f-9f21-00a94801254e", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "original_text": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n "}, "hash": "e70cded5e88336c2eacc086461b72f78e08c43c45711eaa3047288c03ee28a6e", "class_name": "RelatedNodeInfo"}}, "text": "And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "start_char_idx": 1583, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93206f79-2940-432f-9f21-00a94801254e": {"__data__": {"id_": "93206f79-2940-432f-9f21-00a94801254e", "embedding": null, "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "original_text": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42dc7c66-8399-438d-bcc0-c0f0e38c1152", "node_type": "1", "metadata": {"window": "Eric Percher :  So I think concerns from the hospital purchasers around impacts on utilization and impacts on their \nbusiness, you started with an apo logy and are taking that head -on.   But what is your take on the ability to remedy \nthis and any impact on the business from what this has done to relationships here?  \n \n Mike Kaufmann :  Yes, I think, you know, anytime you have a challenge in any business, it's  often the way you respond \nthat makes a difference.   And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "original_text": "And I couldn't be more impressed with how our medical team from the leader, Steve  \n(Mason) , all the way down to people in the distribution centers have responded taken accountability and ", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb3a9e4f7a9dd908aa15edefd6a466e57475932846ad06d06126143db9772308", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b58757b-c0f0-461a-b85d-660f235cd215", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  ", "original_text": "So we have deployed hundreds of people.  "}, "hash": "e10a1e1fca04393d0e4d4771f5ce5114501c35ba70a66456c7a1b0d8cfc01fbe", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n ", "start_char_idx": 0, "end_char_idx": 163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b58757b-c0f0-461a-b85d-660f235cd215": {"__data__": {"id_": "2b58757b-c0f0-461a-b85d-660f235cd215", "embedding": null, "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  ", "original_text": "So we have deployed hundreds of people.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93206f79-2940-432f-9f21-00a94801254e", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "original_text": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "501707820ebbff1a77a3bff0ed2f5f07258f6d0a5fd0132efcd3973b7c112d8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f1af34f-c395-499b-810a-92bc6ed64735", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n ", "original_text": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.  "}, "hash": "87acd516b42825ccc621d3cc239b24a048ca9e8c5d92cbace3e045a59c8f5619", "class_name": "RelatedNodeInfo"}}, "text": "So we have deployed hundreds of people.  ", "start_char_idx": 163, "end_char_idx": 204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f1af34f-c395-499b-810a-92bc6ed64735": {"__data__": {"id_": "0f1af34f-c395-499b-810a-92bc6ed64735", "embedding": null, "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n ", "original_text": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b58757b-c0f0-461a-b85d-660f235cd215", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  ", "original_text": "So we have deployed hundreds of people.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c93138df851f37eaa2843392f26e767e8e1c4ccc6361e0a0a0c9deb2d6359bf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96233ab0-4db1-44d1-96a7-678d7aecdbd1", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n ", "original_text": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n "}, "hash": "22233f4c0ec5c278d2edf26b9ca4cbbd483ac368b65a4546bd0a555ff2992c8a", "class_name": "RelatedNodeInfo"}}, "text": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.  ", "start_char_idx": 204, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96233ab0-4db1-44d1-96a7-678d7aecdbd1": {"__data__": {"id_": "96233ab0-4db1-44d1-96a7-678d7aecdbd1", "embedding": null, "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n ", "original_text": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f1af34f-c395-499b-810a-92bc6ed64735", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n ", "original_text": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c222efcef79e6f25feb64130acf31336480f1f272de3d7235c96fb2821fe432", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7ed85ca-a46f-488e-994b-2b49bb7c7610", "node_type": "1", "metadata": {"window": "So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.  ", "original_text": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  "}, "hash": "200eaa49c942b465638e8f1268b21719dc59e4776911fcea5c2708f7777e67d3", "class_name": "RelatedNodeInfo"}}, "text": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "start_char_idx": 477, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7ed85ca-a46f-488e-994b-2b49bb7c7610": {"__data__": {"id_": "c7ed85ca-a46f-488e-994b-2b49bb7c7610", "embedding": null, "metadata": {"window": "So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.  ", "original_text": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96233ab0-4db1-44d1-96a7-678d7aecdbd1", "node_type": "1", "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n ", "original_text": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77c4ca14ceb1b55e654371b0122b3ee2fee981884de848092cb9e8a818f578", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "873b4896-6f16-49a9-b586-007207ea64dd", "node_type": "1", "metadata": {"window": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  ", "original_text": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n "}, "hash": "8770e25aac1fcb0c09c0eba547ead0c8a5ab0593101af3dbf33c98ff92c0526b", "class_name": "RelatedNodeInfo"}}, "text": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  ", "start_char_idx": 568, "end_char_idx": 744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "873b4896-6f16-49a9-b586-007207ea64dd": {"__data__": {"id_": "873b4896-6f16-49a9-b586-007207ea64dd", "embedding": null, "metadata": {"window": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  ", "original_text": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7ed85ca-a46f-488e-994b-2b49bb7c7610", "node_type": "1", "metadata": {"window": "So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.  ", "original_text": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8562da3bf83864e274cb691464dc7e6b5a6f49677349154a958a7d87073f45f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "145ed10a-2d6d-4dd5-b0a7-f05aa520a63b", "node_type": "1", "metadata": {"window": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  ", "original_text": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n "}, "hash": "cc83fea640887a344aafb0dff6e6dda2f0f5eb151d036c1bd2385478eae1be04", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n ", "start_char_idx": 744, "end_char_idx": 900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "145ed10a-2d6d-4dd5-b0a7-f05aa520a63b": {"__data__": {"id_": "145ed10a-2d6d-4dd5-b0a7-f05aa520a63b", "embedding": null, "metadata": {"window": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  ", "original_text": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "873b4896-6f16-49a9-b586-007207ea64dd", "node_type": "1", "metadata": {"window": "We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  ", "original_text": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bafadfcf8aba9257edf2f2845b4d12f6cf7a1ad5926694ae1c3776ed92581fe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20431225-30c0-4fcf-a822-67fe2c8b6975", "node_type": "1", "metadata": {"window": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.  ", "original_text": "We're also taking a lot of other specific actions too.  "}, "hash": "d18554f3f77434a125ec5a8b33ca8a6c8d129dab2f354196b43c6554f1f5fcf3", "class_name": "RelatedNodeInfo"}}, "text": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n ", "start_char_idx": 900, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20431225-30c0-4fcf-a822-67fe2c8b6975": {"__data__": {"id_": "20431225-30c0-4fcf-a822-67fe2c8b6975", "embedding": null, "metadata": {"window": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.  ", "original_text": "We're also taking a lot of other specific actions too.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "145ed10a-2d6d-4dd5-b0a7-f05aa520a63b", "node_type": "1", "metadata": {"window": "And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n  And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  ", "original_text": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "802a6275416ea976930ff0d433c7edddf30f14591782cac8e030c4b70bf8d962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e45aff6c-3461-4529-9adb-e7df4521577a", "node_type": "1", "metadata": {"window": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n ", "original_text": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  "}, "hash": "1fb01921aa20bd37c771cb8d2097de6e330efa8323bbd395aa2785afb61471e8", "class_name": "RelatedNodeInfo"}}, "text": "We're also taking a lot of other specific actions too.  ", "start_char_idx": 1123, "end_char_idx": 1179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e45aff6c-3461-4529-9adb-e7df4521577a": {"__data__": {"id_": "e45aff6c-3461-4529-9adb-e7df4521577a", "embedding": null, "metadata": {"window": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n ", "original_text": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20431225-30c0-4fcf-a822-67fe2c8b6975", "node_type": "1", "metadata": {"window": "And I think that our feedback so far from the majority of customers is they understand things like this can happen, \nbut they respect and appreciate the way we're responding.   It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.  ", "original_text": "We're also taking a lot of other specific actions too.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eafe5c9219f0f868fa63282db5cccae4d55e68a3cc9fc0a11740cc229b0621bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8cf7963-f85e-4dc1-a275-33c5a3ac90f7", "node_type": "1", "metadata": {"window": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  ", "original_text": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  "}, "hash": "11079926536d9279d85e9cacd61bb3691d45b4499de0691c090051bcc3720155", "class_name": "RelatedNodeInfo"}}, "text": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  ", "start_char_idx": 1179, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8cf7963-f85e-4dc1-a275-33c5a3ac90f7": {"__data__": {"id_": "c8cf7963-f85e-4dc1-a275-33c5a3ac90f7", "embedding": null, "metadata": {"window": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  ", "original_text": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e45aff6c-3461-4529-9adb-e7df4521577a", "node_type": "1", "metadata": {"window": "It's hard to say how this ultimately, as Dave said, we \ndon't know how this  could affect our business going forward and we're hoping that it doesn't.  \n \n  But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n ", "original_text": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49d365dd02cf277392cdceafe42fc81bed934becaa024e53bb807fd29d304411", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4d8e325-174f-4660-a3ce-ba45ac03dd3a", "node_type": "1", "metadata": {"window": "We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  ", "original_text": "We've ramped up production, because we do \nsource these gowns in multiple locations.  "}, "hash": "8f83fa63ccd2434156df20fd381ecfba0a4ebf33fc48dbbfbe446ab2d43bef4d", "class_name": "RelatedNodeInfo"}}, "text": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  ", "start_char_idx": 1329, "end_char_idx": 1426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4d8e325-174f-4660-a3ce-ba45ac03dd3a": {"__data__": {"id_": "d4d8e325-174f-4660-a3ce-ba45ac03dd3a", "embedding": null, "metadata": {"window": "We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  ", "original_text": "We've ramped up production, because we do \nsource these gowns in multiple locations.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8cf7963-f85e-4dc1-a275-33c5a3ac90f7", "node_type": "1", "metadata": {"window": "But we know that we have created some pain and the most important thing to us is that our customers know that \nwe are focused on them first and foremost so that they can treat the patients that they take care of that.  \n \n  We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  ", "original_text": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1afc1441617d706e6e939ae88708d04af410b36ce20f21f194e769b834711b09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70471d16-2ae5-49c8-9c14-b03e7f8ca07a", "node_type": "1", "metadata": {"window": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "And so, we're ramping up sourcing elsewhere.  \n \n "}, "hash": "fbf62c1b9e35714fca03ddeb55e25d66957a88249f57470028c87834a8f71274", "class_name": "RelatedNodeInfo"}}, "text": "We've ramped up production, because we do \nsource these gowns in multiple locations.  ", "start_char_idx": 1426, "end_char_idx": 1512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70471d16-2ae5-49c8-9c14-b03e7f8ca07a": {"__data__": {"id_": "70471d16-2ae5-49c8-9c14-b03e7f8ca07a", "embedding": null, "metadata": {"window": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "And so, we're ramping up sourcing elsewhere.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4d8e325-174f-4660-a3ce-ba45ac03dd3a", "node_type": "1", "metadata": {"window": "We're also taking a lot of other specific actions too.   It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  ", "original_text": "We've ramped up production, because we do \nsource these gowns in multiple locations.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efe5d4212312e60635c9fdd26eef82a1f7f2d6ae5ffd18066a84665cc807fe88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce307d13-8402-4436-a510-02ad7076eb90", "node_type": "1", "metadata": {"window": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  "}, "hash": "0406b75514fcabd97276949f066857e4062e79fa61b49061771f7de9011469c3", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're ramping up sourcing elsewhere.  \n \n ", "start_char_idx": 1512, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce307d13-8402-4436-a510-02ad7076eb90": {"__data__": {"id_": "ce307d13-8402-4436-a510-02ad7076eb90", "embedding": null, "metadata": {"window": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70471d16-2ae5-49c8-9c14-b03e7f8ca07a", "node_type": "1", "metadata": {"window": "It's not only deploying people into the field to make things \nbetter, but it is also about increasing production of similar or replacement products.   For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "And so, we're ramping up sourcing elsewhere.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f848bea9ad32d4c8bede62eb79327780c58a15cdfac03e73eb59df8693498fad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "463fabf5-2946-42c4-a574-1e1f99b5f1ca", "node_type": "1", "metadata": {"window": "We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  "}, "hash": "326d53dcd8d88f890785e479274344355d3ace578cce036b30c1e0ad576b3785", "class_name": "RelatedNodeInfo"}}, "text": "We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  ", "start_char_idx": 1562, "end_char_idx": 1752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "463fabf5-2946-42c4-a574-1e1f99b5f1ca": {"__data__": {"id_": "463fabf5-2946-42c4-a574-1e1f99b5f1ca", "embedding": null, "metadata": {"window": "We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce307d13-8402-4436-a510-02ad7076eb90", "node_type": "1", "metadata": {"window": "For instanc e, we're offering \nour more protective Level 4 gowns to help bridge the supply gap.   We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e5ad186157028ae4e01bd10c0acdcca722a754068e4c04e7551907dbe1e12bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbdac471-e097-45b2-bafb-de390dd4e04f", "node_type": "1", "metadata": {"window": "And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "Next question, please.  \n "}, "hash": "f01f759c83813b68648b39b81d8e8c5c22e5a6f11f8ece7bc5f79aa57a013d5c", "class_name": "RelatedNodeInfo"}}, "text": "So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  ", "start_char_idx": 1752, "end_char_idx": 1943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbdac471-e097-45b2-bafb-de390dd4e04f": {"__data__": {"id_": "cbdac471-e097-45b2-bafb-de390dd4e04f", "embedding": null, "metadata": {"window": "And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "Next question, please.  \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c231b2ec9b31306895edc17647a244f6a2b61bcf7aebc027ae7d05f2aa19f17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "463fabf5-2946-42c4-a574-1e1f99b5f1ca", "node_type": "1", "metadata": {"window": "We've ramped up production, because we do \nsource these gowns in multiple locations.   And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.  ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2df683a3ee4a1a6739a69d3e30269b9b1a5a5d54c95f66c4d78b976dda785c79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51ccc4ba-02e9-40c4-a77a-b916486e3bf6", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "original_text": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n"}, "hash": "491cde8681a99333e2c0d8afc1ae608c4da7c3a5b1ee696ae13251cc6feaf553", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n ", "start_char_idx": 1943, "end_char_idx": 1969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51ccc4ba-02e9-40c4-a77a-b916486e3bf6": {"__data__": {"id_": "51ccc4ba-02e9-40c4-a77a-b916486e3bf6", "embedding": null, "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "original_text": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbdac471-e097-45b2-bafb-de390dd4e04f", "node_type": "1", "metadata": {"window": "And so, we're ramping up sourcing elsewhere.  \n \n  We're working with folks that make similar products, both brand and I'd say, private -label products to ramp those \nup to get them going so we have those that go in through with surgeries.   So it's really important that we look at all \nof these actions to make sure that we're keeping surgeries  going and keeping our customers - the pain for our \ncustomers as small as possible.   Next question, please.  \n ", "original_text": "Next question, please.  \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "233ad3d9670a33542052c88b21848f15faaab951a429498ae8dcb377e3feb141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53b9c76d-a53a-4393-8044-a4ebc3fefb15", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n", "original_text": "Kevin Caliendo :  Hi, thanks for taking my question.  "}, "hash": "2209a78953f8cbad2fe39fbf586830813dfc62111c5ed629a980abdef300c4d0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n", "start_char_idx": 0, "end_char_idx": 94, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53b9c76d-a53a-4393-8044-a4ebc3fefb15": {"__data__": {"id_": "53b9c76d-a53a-4393-8044-a4ebc3fefb15", "embedding": null, "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n", "original_text": "Kevin Caliendo :  Hi, thanks for taking my question.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51ccc4ba-02e9-40c4-a77a-b916486e3bf6", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "original_text": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c02abcc06122b0e786439f08c2612d500c0f30e86fdd0f6e4f384f8835c35164", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb05c82f-3bdb-4f66-b5ce-32c8fe3ca049", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "I just want to go back to the opioid comment.  "}, "hash": "4942b6502c677adb4f2586dbf1d09f568d73efac017570703ac3099869174022", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :  Hi, thanks for taking my question.  ", "start_char_idx": 94, "end_char_idx": 148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb05c82f-3bdb-4f66-b5ce-32c8fe3ca049": {"__data__": {"id_": "fb05c82f-3bdb-4f66-b5ce-32c8fe3ca049", "embedding": null, "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "I just want to go back to the opioid comment.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53b9c76d-a53a-4393-8044-a4ebc3fefb15", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n", "original_text": "Kevin Caliendo :  Hi, thanks for taking my question.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb909a548ce25614196527ace9d6c587ffd66ae1ff9ad3ca393973eb1c2551ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed4236b6-a90a-434c-b595-b3ffaa28fb48", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  ", "original_text": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n "}, "hash": "855aa8bcccc32b9f6aa36eb8df6e48e76cf4c6b8116696ae60826dbde1f96680", "class_name": "RelatedNodeInfo"}}, "text": "I just want to go back to the opioid comment.  ", "start_char_idx": 148, "end_char_idx": 195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed4236b6-a90a-434c-b595-b3ffaa28fb48": {"__data__": {"id_": "ed4236b6-a90a-434c-b595-b3ffaa28fb48", "embedding": null, "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  ", "original_text": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb05c82f-3bdb-4f66-b5ce-32c8fe3ca049", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "I just want to go back to the opioid comment.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45c9036dfab53a8bc8f88e9fdfc23d8d470fb2d0d67832b7a37a5a148835c9a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e65fce5-1360-477d-8ba7-d2edb0c6f424", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.  ", "original_text": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n"}, "hash": "17ba0f372e75fb3af0a64a89168eba4549d6f1739368f4af8b9b292e073317ee", "class_name": "RelatedNodeInfo"}}, "text": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "start_char_idx": 195, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e65fce5-1360-477d-8ba7-d2edb0c6f424": {"__data__": {"id_": "3e65fce5-1360-477d-8ba7-d2edb0c6f424", "embedding": null, "metadata": {"window": "Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.  ", "original_text": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed4236b6-a90a-434c-b595-b3ffaa28fb48", "node_type": "1", "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  ", "original_text": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ae68acbb436ca4ef54b743d24cad5576b357341a20b77ac4bb2db81266d5a82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f0d8291-9867-4bfd-902a-8f38b4814874", "node_type": "1", "metadata": {"window": "I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.  ", "original_text": "Mike Kaufmann :  Yes.  "}, "hash": "1cd934f82930f4fbdd511120391c270e80136e4f74f8789162d383c38fc1204c", "class_name": "RelatedNodeInfo"}}, "text": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n", "start_char_idx": 360, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f0d8291-9867-4bfd-902a-8f38b4814874": {"__data__": {"id_": "4f0d8291-9867-4bfd-902a-8f38b4814874", "embedding": null, "metadata": {"window": "I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e65fce5-1360-477d-8ba7-d2edb0c6f424", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.  ", "original_text": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e58a11620755512eb447a287aeeee9590a437494e8bb4af3ece61233e6e6e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d4df627-14d3-4c90-8144-b63e0ec72b37", "node_type": "1", "metadata": {"window": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.  ", "original_text": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  "}, "hash": "f7bc40990f1b1c6465ae37491f80fe8c38a8c78ea053c446ee15f375ae75d693", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes.  ", "start_char_idx": 589, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d4df627-14d3-4c90-8144-b63e0ec72b37": {"__data__": {"id_": "1d4df627-14d3-4c90-8144-b63e0ec72b37", "embedding": null, "metadata": {"window": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.  ", "original_text": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f0d8291-9867-4bfd-902a-8f38b4814874", "node_type": "1", "metadata": {"window": "I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "708d73e78f897e0d260569ce7eecb81bd81deea3c9015fa0249a392ed8e3cc67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b925084-bd1c-4693-b67c-009f3c56569c", "node_type": "1", "metadata": {"window": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n ", "original_text": "We're not \ntrying to indicate that they will or they won't.  "}, "hash": "f57e7cbbac4cb767fb6ad75091554bfe694b28e147ec886fd26923f79641b72f", "class_name": "RelatedNodeInfo"}}, "text": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  ", "start_char_idx": 612, "end_char_idx": 701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b925084-bd1c-4693-b67c-009f3c56569c": {"__data__": {"id_": "1b925084-bd1c-4693-b67c-009f3c56569c", "embedding": null, "metadata": {"window": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n ", "original_text": "We're not \ntrying to indicate that they will or they won't.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d4df627-14d3-4c90-8144-b63e0ec72b37", "node_type": "1", "metadata": {"window": "I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n  This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.  ", "original_text": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f77928009ba7babcfbc40fb453bd5ed5a8b0206990e7f7fa922acc9cd2edf93d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81fbe40e-a6bf-48a2-98de-45f6192c766b", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n", "original_text": "We just know they're out there.  "}, "hash": "5655e1bec74d4a319e3c7ff5e451bad9c5d3f41acfbf6c28b0c4d2f92d53d6d3", "class_name": "RelatedNodeInfo"}}, "text": "We're not \ntrying to indicate that they will or they won't.  ", "start_char_idx": 701, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81fbe40e-a6bf-48a2-98de-45f6192c766b": {"__data__": {"id_": "81fbe40e-a6bf-48a2-98de-45f6192c766b", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n", "original_text": "We just know they're out there.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b925084-bd1c-4693-b67c-009f3c56569c", "node_type": "1", "metadata": {"window": "This increase in spending does it have anything to do with maybe a longer  timeline or how should we think about \nthose two state trials coming up in terms of the context of your expected spend now versus what it was before?  \n \n Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n ", "original_text": "We're not \ntrying to indicate that they will or they won't.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87ae3bfbd17515c4e8be3c826fcb786ca9c29b6419ba395d4cb953d73c8fd8fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86521992-99e6-4ec1-b5c5-a44f57c1eeb7", "node_type": "1", "metadata": {"window": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  ", "original_text": "We intend to vigorously defend \nourselves.  "}, "hash": "be22f404168718c35429e5137735a0555d90068aa704f4c968ea5adb2fde5fe9", "class_name": "RelatedNodeInfo"}}, "text": "We just know they're out there.  ", "start_char_idx": 762, "end_char_idx": 795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86521992-99e6-4ec1-b5c5-a44f57c1eeb7": {"__data__": {"id_": "86521992-99e6-4ec1-b5c5-a44f57c1eeb7", "embedding": null, "metadata": {"window": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  ", "original_text": "We intend to vigorously defend \nourselves.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81fbe40e-a6bf-48a2-98de-45f6192c766b", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n", "original_text": "We just know they're out there.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26a530821a13b14d63301a0133590df3027b172c8adad30a1b4a1318b13559be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "141f9779-abad-483f-a8f4-1a01e986c669", "node_type": "1", "metadata": {"window": "We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n ", "original_text": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n "}, "hash": "3bb19105b8188f54486a3af6e3aab43729cc0b77db1cb8def9d2c73d86ea28b2", "class_name": "RelatedNodeInfo"}}, "text": "We intend to vigorously defend \nourselves.  ", "start_char_idx": 795, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "141f9779-abad-483f-a8f4-1a01e986c669": {"__data__": {"id_": "141f9779-abad-483f-a8f4-1a01e986c669", "embedding": null, "metadata": {"window": "We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n ", "original_text": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86521992-99e6-4ec1-b5c5-a44f57c1eeb7", "node_type": "1", "metadata": {"window": "Clearly if those trials do happen, our spending goes up, which is why we gave a ran ge.   We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  ", "original_text": "We intend to vigorously defend \nourselves.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f31e01d67f7195592ab610a0a76350a05be5df89cfc1686b861eade233a063c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eab65f11-0e33-45b3-b247-8b1e0a631143", "node_type": "1", "metadata": {"window": "We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.  ", "original_text": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n"}, "hash": "ed22b515f2bcc9c49019e52ea720035c4e7bd04cdf77c469bd6525c78f9c00f0", "class_name": "RelatedNodeInfo"}}, "text": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n ", "start_char_idx": 839, "end_char_idx": 929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eab65f11-0e33-45b3-b247-8b1e0a631143": {"__data__": {"id_": "eab65f11-0e33-45b3-b247-8b1e0a631143", "embedding": null, "metadata": {"window": "We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.  ", "original_text": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "141f9779-abad-483f-a8f4-1a01e986c669", "node_type": "1", "metadata": {"window": "We're not \ntrying to indicate that they will or they won't.   We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n ", "original_text": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d77899cdec5db3a6efc0bbc6f1df686a8438d2fe0396b712976e1da79a1477ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f22db9c5-ee23-4ca8-89c2-b331ae4c305a", "node_type": "1", "metadata": {"window": "We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.  ", "original_text": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  "}, "hash": "3ff11d04122302fc7bea795726c4ab70d00be1be69457314fd016987ce6fd7f7", "class_name": "RelatedNodeInfo"}}, "text": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n", "start_char_idx": 929, "end_char_idx": 1045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f22db9c5-ee23-4ca8-89c2-b331ae4c305a": {"__data__": {"id_": "f22db9c5-ee23-4ca8-89c2-b331ae4c305a", "embedding": null, "metadata": {"window": "We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.  ", "original_text": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eab65f11-0e33-45b3-b247-8b1e0a631143", "node_type": "1", "metadata": {"window": "We just know they're out there.   We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.  ", "original_text": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6da86c17c37475484dbe7a83841505fe18ec63a62c209727e5319a8dde8d1da1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a948380-558d-45dc-8f94-db31e54f6f8a", "node_type": "1", "metadata": {"window": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n ", "original_text": "It's still our goal.  \n \n "}, "hash": "84c314a98168967d6cf530f5935cef587ea7d083a85baac81492d51179b33a5a", "class_name": "RelatedNodeInfo"}}, "text": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  ", "start_char_idx": 1045, "end_char_idx": 1167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a948380-558d-45dc-8f94-db31e54f6f8a": {"__data__": {"id_": "9a948380-558d-45dc-8f94-db31e54f6f8a", "embedding": null, "metadata": {"window": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n ", "original_text": "It's still our goal.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f22db9c5-ee23-4ca8-89c2-b331ae4c305a", "node_type": "1", "metadata": {"window": "We intend to vigorously defend \nourselves.   We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.  ", "original_text": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e005ccfdee16d2cd9483a12d95db35a5b7ce3cc3cb4410e0e379cbba174722dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ececa927-4528-4579-902d-a2b435a90571", "node_type": "1", "metadata": {"window": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  ", "original_text": "But I wouldn't look at the increased spending around - particularly related to the trials.  "}, "hash": "196e80e42136b9cb52e74e2195375dbc23b67a8786a25b316cf3ca7afb692e0d", "class_name": "RelatedNodeInfo"}}, "text": "It's still our goal.  \n \n ", "start_char_idx": 1167, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ececa927-4528-4579-902d-a2b435a90571": {"__data__": {"id_": "ececa927-4528-4579-902d-a2b435a90571", "embedding": null, "metadata": {"window": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  ", "original_text": "But I wouldn't look at the increased spending around - particularly related to the trials.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a948380-558d-45dc-8f94-db31e54f6f8a", "node_type": "1", "metadata": {"window": "We feel really good that we are, and w ill be prepared for those trials that happen.  \n \n  We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n ", "original_text": "It's still our goal.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ca7ba751d9e3b7fbc50307af2c4968363573e13d2ae936fd9c95b7455dc1a3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcd76bc8-c6b3-43dd-ba65-bf49cb61bfff", "node_type": "1", "metadata": {"window": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  ", "original_text": "Again there is a range, but \nit's more around finishing up the negotiations.  "}, "hash": "d8f2f59a6f24b305201067ff05636799b21f7e70cc282763d32d7560fad68899", "class_name": "RelatedNodeInfo"}}, "text": "But I wouldn't look at the increased spending around - particularly related to the trials.  ", "start_char_idx": 1193, "end_char_idx": 1285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcd76bc8-c6b3-43dd-ba65-bf49cb61bfff": {"__data__": {"id_": "dcd76bc8-c6b3-43dd-ba65-bf49cb61bfff", "embedding": null, "metadata": {"window": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  ", "original_text": "Again there is a range, but \nit's more around finishing up the negotiations.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ececa927-4528-4579-902d-a2b435a90571", "node_type": "1", "metadata": {"window": "We're not going to use those trials or have those trials cause us panic and do something that doesn't make sense.  \n And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  ", "original_text": "But I wouldn't look at the increased spending around - particularly related to the trials.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8a0454480afca197265e6180ebaad78462431bccbc7d55c1dfb0fbcb36e0a1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "508f5b5e-f3c1-4886-9ca0-33e38c87c950", "node_type": "1", "metadata": {"window": "It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "And then you have got to go through a documentation process like \nactually papering it.  \n \n "}, "hash": "eb55f576abfa7e791e29d24160b91cf9d6c3dc712fea7578d251aa867c7f94ef", "class_name": "RelatedNodeInfo"}}, "text": "Again there is a range, but \nit's more around finishing up the negotiations.  ", "start_char_idx": 1285, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "508f5b5e-f3c1-4886-9ca0-33e38c87c950": {"__data__": {"id_": "508f5b5e-f3c1-4886-9ca0-33e38c87c950", "embedding": null, "metadata": {"window": "It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "And then you have got to go through a documentation process like \nactually papering it.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcd76bc8-c6b3-43dd-ba65-bf49cb61bfff", "node_type": "1", "metadata": {"window": "And so we're going to continue to work with the four AGs and the rest of the states to get this initial framework \ndone.   It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  ", "original_text": "Again there is a range, but \nit's more around finishing up the negotiations.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a5e9352c8e62b40d0d58457f245997633e9a9219709d9dc2d400727c23e352d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56f09357-15e8-4b44-9ac3-8017c3618bd8", "node_type": "1", "metadata": {"window": "But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  "}, "hash": "2d47515ea9ff2570df59ef078551403d03f914eda102723051a0a8a9a3442668", "class_name": "RelatedNodeInfo"}}, "text": "And then you have got to go through a documentation process like \nactually papering it.  \n \n ", "start_char_idx": 1363, "end_char_idx": 1456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56f09357-15e8-4b44-9ac3-8017c3618bd8": {"__data__": {"id_": "56f09357-15e8-4b44-9ac3-8017c3618bd8", "embedding": null, "metadata": {"window": "But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "508f5b5e-f3c1-4886-9ca0-33e38c87c950", "node_type": "1", "metadata": {"window": "It's still our goal.  \n \n  But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "And then you have got to go through a documentation process like \nactually papering it.  \n \n ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c059cca8f5a11c52e1266caf6c93961dbd28ab48b8944c467ab519e225bb0fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5509037-39f3-40bb-90e9-2e1ed4ec36a3", "node_type": "1", "metadata": {"window": "Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  "}, "hash": "d01a791bba744520991dd08f1fc952d8e0237608bfb469cf6b05c14459965905", "class_name": "RelatedNodeInfo"}}, "text": "And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  ", "start_char_idx": 1456, "end_char_idx": 1577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5509037-39f3-40bb-90e9-2e1ed4ec36a3": {"__data__": {"id_": "d5509037-39f3-40bb-90e9-2e1ed4ec36a3", "embedding": null, "metadata": {"window": "Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56f09357-15e8-4b44-9ac3-8017c3618bd8", "node_type": "1", "metadata": {"window": "But I wouldn't look at the increased spending around - particularly related to the trials.   Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b61a05b53798849206a96154ecd58938b3bccf844da727a529fbe03e7bc71ee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dcb3f19-fd43-477d-8783-aa30ec0e1752", "node_type": "1", "metadata": {"window": "And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "What changes can we make in the overall monitoring systems?  "}, "hash": "378aa3505eb168d5565c2c68c7a4fd52e293d1ae7c700dedd3a909d8d04d70b3", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  ", "start_char_idx": 1577, "end_char_idx": 1715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dcb3f19-fd43-477d-8783-aa30ec0e1752": {"__data__": {"id_": "6dcb3f19-fd43-477d-8783-aa30ec0e1752", "embedding": null, "metadata": {"window": "And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "What changes can we make in the overall monitoring systems?  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f1e0a2f7aae119b1866d2c6431fe255706d5ff4e5f5cb844970f7ca77a5990", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5509037-39f3-40bb-90e9-2e1ed4ec36a3", "node_type": "1", "metadata": {"window": "Again there is a range, but \nit's more around finishing up the negotiations.   And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67e02070f02252d6bb749973412f67995921a8e9bdae6656f892deff0f865d31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb37b972-4b77-486a-b0ee-378e2a9004f4", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.  ", "original_text": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.  "}, "hash": "a425f8bb8dfa9e89e6a1d055ac7885a5c106c2549dc8c12414e65ff458bab953", "class_name": "RelatedNodeInfo"}}, "text": "What changes can we make in the overall monitoring systems?  ", "start_char_idx": 1715, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb37b972-4b77-486a-b0ee-378e2a9004f4": {"__data__": {"id_": "bb37b972-4b77-486a-b0ee-378e2a9004f4", "embedding": null, "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.  ", "original_text": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dcb3f19-fd43-477d-8783-aa30ec0e1752", "node_type": "1", "metadata": {"window": "And then you have got to go through a documentation process like \nactually papering it.  \n \n  And that takes - that will take some significant lawyer time to get things papered and work through all those \ndetails.   So I think it's more things like those and then an implementation process working through the - how \nwould we distribute the free goods?   What changes can we make in the overall monitoring systems?  ", "original_text": "What changes can we make in the overall monitoring systems?  ", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc7df8aa8030f69ef28229e140f6d13a5a2347502d075acbcfe94d454b38ab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5330d980-0ee7-40a6-a07f-b3573d7ce12d", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?  ", "original_text": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n"}, "hash": "ed451fb8ebd3e78d2b972483152c9ed4ad669a55a88e7a89325c163fa193dd9b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.  ", "start_char_idx": 0, "end_char_idx": 84, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5330d980-0ee7-40a6-a07f-b3573d7ce12d": {"__data__": {"id_": "5330d980-0ee7-40a6-a07f-b3573d7ce12d", "embedding": null, "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?  ", "original_text": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb37b972-4b77-486a-b0ee-378e2a9004f4", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.  ", "original_text": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a88ec84678be93e9676443fd311e566773e6c694a741b129cdda59907866bb8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128f275d-0abd-469f-ac6e-0440b8fae149", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n", "original_text": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.  "}, "hash": "1c7efbe33044c96615829a7db1b5508bae0253254c1da57abf2515ba86e2f3d7", "class_name": "RelatedNodeInfo"}}, "text": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n", "start_char_idx": 84, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128f275d-0abd-469f-ac6e-0440b8fae149": {"__data__": {"id_": "128f275d-0abd-469f-ac6e-0440b8fae149", "embedding": null, "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n", "original_text": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5330d980-0ee7-40a6-a07f-b3573d7ce12d", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?  ", "original_text": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c422c16a985c4e8bddde575d5a2d56ca19e23b5ef574fc3f28bbe7effa243678", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "244f0af6-2fba-4a0e-8c1d-6de94e36c45a", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "You said that \nyou thought there was enough supply in the chain to manage it.  "}, "hash": "9b22199fbb14723ea2c32a8d10bc1fbf3a82b8d13cd6566b26d7cb66ab476044", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.  ", "start_char_idx": 165, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "244f0af6-2fba-4a0e-8c1d-6de94e36c45a": {"__data__": {"id_": "244f0af6-2fba-4a0e-8c1d-6de94e36c45a", "embedding": null, "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "You said that \nyou thought there was enough supply in the chain to manage it.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128f275d-0abd-469f-ac6e-0440b8fae149", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n", "original_text": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e750c8f9ca52d78bb27f0c2c5003979a8cd409df98f5f9a0fcc339dd021e8d5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d4fe2c9-b4ef-4719-ba3f-747a71e422f7", "node_type": "1", "metadata": {"window": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.  ", "original_text": "Can you quantify like how much is actually in the \nsupply chain in terms of product?  "}, "hash": "3d101cd61df5861154d5b59af03f0aba50912a6990ebf9fd5f886e5c899a4d13", "class_name": "RelatedNodeInfo"}}, "text": "You said that \nyou thought there was enough supply in the chain to manage it.  ", "start_char_idx": 281, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d4fe2c9-b4ef-4719-ba3f-747a71e422f7": {"__data__": {"id_": "3d4fe2c9-b4ef-4719-ba3f-747a71e422f7", "embedding": null, "metadata": {"window": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.  ", "original_text": "Can you quantify like how much is actually in the \nsupply chain in terms of product?  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "244f0af6-2fba-4a0e-8c1d-6de94e36c45a", "node_type": "1", "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.  ", "original_text": "You said that \nyou thought there was enough supply in the chain to manage it.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1527ddf67202005ab7cabab72f16ffb6b495f10b28b658cbd690947f39f8d0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19487790-9ef4-4231-ace6-428225e6c4b2", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.  ", "original_text": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n"}, "hash": "9d6b0b21a78581af9017ca07b2424a246cc4721f00148b70aac438ac063ee2db", "class_name": "RelatedNodeInfo"}}, "text": "Can you quantify like how much is actually in the \nsupply chain in terms of product?  ", "start_char_idx": 360, "end_char_idx": 446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19487790-9ef4-4231-ace6-428225e6c4b2": {"__data__": {"id_": "19487790-9ef4-4231-ace6-428225e6c4b2", "embedding": null, "metadata": {"window": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.  ", "original_text": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d4fe2c9-b4ef-4719-ba3f-747a71e422f7", "node_type": "1", "metadata": {"window": "And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.  ", "original_text": "Can you quantify like how much is actually in the \nsupply chain in terms of product?  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cfe56325d9b9cacfd90d5a584f937c32d776a5d1c0a00dc424fd85d32fa6854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b911d4c-30cd-40fb-95c1-1a1998a579e7", "node_type": "1", "metadata": {"window": "You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.  ", "original_text": "Mike Kaufmann :  Yes.  "}, "hash": "a770ce93b9fb81a5cdd3b058b56ea54ba595e2fd4878da596ad688254b157a0b", "class_name": "RelatedNodeInfo"}}, "text": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n", "start_char_idx": 446, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b911d4c-30cd-40fb-95c1-1a1998a579e7": {"__data__": {"id_": "6b911d4c-30cd-40fb-95c1-1a1998a579e7", "embedding": null, "metadata": {"window": "You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19487790-9ef4-4231-ace6-428225e6c4b2", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.  ", "original_text": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb17085d1b5d8a2773035dd8bc0ee5972ccdb66abf2bf62b7181d2f5e93a59c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e1ab682-3cc1-4017-ba33-685c092f5824", "node_type": "1", "metadata": {"window": "Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n ", "original_text": "It's a great question.  "}, "hash": "e0e4872880d317db4f4ffeead8957f7593f20dd60beb5d7d45801fce6d1c4030", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yes.  ", "start_char_idx": 585, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e1ab682-3cc1-4017-ba33-685c092f5824": {"__data__": {"id_": "2e1ab682-3cc1-4017-ba33-685c092f5824", "embedding": null, "metadata": {"window": "Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n ", "original_text": "It's a great question.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b911d4c-30cd-40fb-95c1-1a1998a579e7", "node_type": "1", "metadata": {"window": "You said that \nyou thought there was enough supply in the chain to manage it.   Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.  ", "original_text": "Mike Kaufmann :  Yes.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "724f9aac4d6e321ddbc1da2d71daa8f51e119bc6bd6750ca6713b9a645e47cbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd5a9f82-4afa-42c5-a19d-68bbccd24469", "node_type": "1", "metadata": {"window": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.  ", "original_text": "You know, I can't really give you that level of detail.  "}, "hash": "e3cef0fdb4d4ed8d02349c8fe6a1be39259318ec4257d6c58faa26f8f9473215", "class_name": "RelatedNodeInfo"}}, "text": "It's a great question.  ", "start_char_idx": 608, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd5a9f82-4afa-42c5-a19d-68bbccd24469": {"__data__": {"id_": "dd5a9f82-4afa-42c5-a19d-68bbccd24469", "embedding": null, "metadata": {"window": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.  ", "original_text": "You know, I can't really give you that level of detail.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e1ab682-3cc1-4017-ba33-685c092f5824", "node_type": "1", "metadata": {"window": "Can you quantify like how much is actually in the \nsupply chain in terms of product?   If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n ", "original_text": "It's a great question.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b114880d56d5afca724c615bd85982fdd0671532eb6acfb54bb4418945312d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7e2da8e-6535-498b-94d0-9e52f524d091", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.  ", "original_text": "I don't really know where \nour competitors are.  "}, "hash": "118d29e920882c71df8ac88d229d5d820b93d72cf8f7b621f8b54c5ee3d8bd52", "class_name": "RelatedNodeInfo"}}, "text": "You know, I can't really give you that level of detail.  ", "start_char_idx": 632, "end_char_idx": 689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7e2da8e-6535-498b-94d0-9e52f524d091": {"__data__": {"id_": "a7e2da8e-6535-498b-94d0-9e52f524d091", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.  ", "original_text": "I don't really know where \nour competitors are.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd5a9f82-4afa-42c5-a19d-68bbccd24469", "node_type": "1", "metadata": {"window": "If China were to be a six -week issue or an eight -week issue, would that still be - \nwould you just still feel comfortable with that?  \n \n Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.  ", "original_text": "You know, I can't really give you that level of detail.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95f5c0412d2acaeab1f253522a21e488577faff089a8b87ca0221438b9664665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01339826-2bbe-474c-ae84-3902e5598353", "node_type": "1", "metadata": {"window": "It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n", "original_text": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n "}, "hash": "668002e0baca9d86fc7c4da0869b9c9cf81c99401bb8de1ace251c4c6f39020a", "class_name": "RelatedNodeInfo"}}, "text": "I don't really know where \nour competitors are.  ", "start_char_idx": 689, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01339826-2bbe-474c-ae84-3902e5598353": {"__data__": {"id_": "01339826-2bbe-474c-ae84-3902e5598353", "embedding": null, "metadata": {"window": "It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n", "original_text": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7e2da8e-6535-498b-94d0-9e52f524d091", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yes.   It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.  ", "original_text": "I don't really know where \nour competitors are.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f392ff242d6561a7d12ec390ea5157cde6a168fa8ab3270587baebc45371b2b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1740f898-ca85-41cf-bcf7-e0a6c1549032", "node_type": "1", "metadata": {"window": "You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.  ", "original_text": "And we have been working to ramp up supply in a few of those to carry a little bit extra.  "}, "hash": "59f47df3c0272e2af17aad22c5da5e5dc197c44da38fdf5922463afa8e358616", "class_name": "RelatedNodeInfo"}}, "text": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n ", "start_char_idx": 738, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1740f898-ca85-41cf-bcf7-e0a6c1549032": {"__data__": {"id_": "1740f898-ca85-41cf-bcf7-e0a6c1549032", "embedding": null, "metadata": {"window": "You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.  ", "original_text": "And we have been working to ramp up supply in a few of those to carry a little bit extra.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01339826-2bbe-474c-ae84-3902e5598353", "node_type": "1", "metadata": {"window": "It's a great question.   You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n", "original_text": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6233ef48d1efb91551d3d6e70a5b761febb83327f95d5bb80f7d58dc6fbb4335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b892a56-e671-42e0-a8fc-a52afdbcbd28", "node_type": "1", "metadata": {"window": "I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n", "original_text": "So for right now from \nwhat we see, we are not anticipating any problems.  "}, "hash": "4cb8189c2b24295fc6037f2a19e41b72975d180ff80162c33e8f58a990f8f7c1", "class_name": "RelatedNodeInfo"}}, "text": "And we have been working to ramp up supply in a few of those to carry a little bit extra.  ", "start_char_idx": 1018, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b892a56-e671-42e0-a8fc-a52afdbcbd28": {"__data__": {"id_": "1b892a56-e671-42e0-a8fc-a52afdbcbd28", "embedding": null, "metadata": {"window": "I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n", "original_text": "So for right now from \nwhat we see, we are not anticipating any problems.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1740f898-ca85-41cf-bcf7-e0a6c1549032", "node_type": "1", "metadata": {"window": "You know, I can't really give you that level of detail.   I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.  ", "original_text": "And we have been working to ramp up supply in a few of those to carry a little bit extra.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90b4a943e06425b3ae0114823d672958da687c72b39a45c196eceb5370d0f20f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3abab5cb-4794-4f82-a1af-41020eadc6d7", "node_type": "1", "metadata": {"window": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n"}, "hash": "d78630b366544b7b2154046eb4333df65f882eb833ded3a81e197df54209a8b3", "class_name": "RelatedNodeInfo"}}, "text": "So for right now from \nwhat we see, we are not anticipating any problems.  ", "start_char_idx": 1109, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3abab5cb-4794-4f82-a1af-41020eadc6d7": {"__data__": {"id_": "3abab5cb-4794-4f82-a1af-41020eadc6d7", "embedding": null, "metadata": {"window": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b892a56-e671-42e0-a8fc-a52afdbcbd28", "node_type": "1", "metadata": {"window": "I don't really know where \nour competitors are.   I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n", "original_text": "So for right now from \nwhat we see, we are not anticipating any problems.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34ba01f6c8dab6189b29f98173524396b64e30dfdb047945bcc3d55da7a8eb99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "313d8acf-67be-4f3c-8182-815235cc00b7", "node_type": "1", "metadata": {"window": "And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Kevin Caliendo :  That's really helpful.  "}, "hash": "ea29166a77dfe285eb8a88c2d11b432b8a1eda0e60b1a9b424caab8327d16c3b", "class_name": "RelatedNodeInfo"}}, "text": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n", "start_char_idx": 1184, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "313d8acf-67be-4f3c-8182-815235cc00b7": {"__data__": {"id_": "313d8acf-67be-4f3c-8182-815235cc00b7", "embedding": null, "metadata": {"window": "And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Kevin Caliendo :  That's really helpful.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3abab5cb-4794-4f82-a1af-41020eadc6d7", "node_type": "1", "metadata": {"window": "I know that this is some thing that we've looked at specifically product -by-product, looked at \nproducts that we think have a more potential risk of supply challenges because of where the raw materials are at \nand the importance of those products to the health care system.  \n \n  And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6144071f811f19bcdb8870ab1171cef6639975a5b689311a967e89b5312acdc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5eb1019f-28a5-4ccd-b544-95e744155529", "node_type": "1", "metadata": {"window": "So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Thanks so much.  \n \n"}, "hash": "8a2b2551d9c48f120c6d44e5943d1571beaba53e3c06f1de6e2eb53428d0a684", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :  That's really helpful.  ", "start_char_idx": 1414, "end_char_idx": 1456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5eb1019f-28a5-4ccd-b544-95e744155529": {"__data__": {"id_": "5eb1019f-28a5-4ccd-b544-95e744155529", "embedding": null, "metadata": {"window": "So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Thanks so much.  \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "313d8acf-67be-4f3c-8182-815235cc00b7", "node_type": "1", "metadata": {"window": "And we have been working to ramp up supply in a few of those to carry a little bit extra.   So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Kevin Caliendo :  That's really helpful.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "483d3c188f58b93c48524085b5c49d7f1f326aad1f0b7fe80f099786cd6d9691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "956e5429-69f4-48a6-b220-68c1fb1d87d3", "node_type": "1", "metadata": {"window": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n "}, "hash": "e286a4703afe406009a8f915ade6f23dee9882c0310d5114825e4fb29d234338", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much.  \n \n", "start_char_idx": 1456, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "956e5429-69f4-48a6-b220-68c1fb1d87d3": {"__data__": {"id_": "956e5429-69f4-48a6-b220-68c1fb1d87d3", "embedding": null, "metadata": {"window": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9915696b-dd41-40f0-ae0c-71bb342359de", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712f1c378a059eedc48674f70023267e259e405100e75d732e8f7f792cca81cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5eb1019f-28a5-4ccd-b544-95e744155529", "node_type": "1", "metadata": {"window": "So for right now from \nwhat we see, we are not anticipating any problems.   But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Thanks so much.  \n \n", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf6dbf12970090cc810948b98505c99ab941c1b540fd4b57c32f3a2d8d079033", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c45c1e83-a512-4a1e-80e4-0c6a83b5c0dd", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.  ", "original_text": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.  "}, "hash": "3580cbe26ace9c866cb5101c5c6e5efa73ec2aa430311a200dad2d523e669856", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "start_char_idx": 1476, "end_char_idx": 1581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c45c1e83-a512-4a1e-80e4-0c6a83b5c0dd": {"__data__": {"id_": "c45c1e83-a512-4a1e-80e4-0c6a83b5c0dd", "embedding": null, "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.  ", "original_text": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "956e5429-69f4-48a6-b220-68c1fb1d87d3", "node_type": "1", "metadata": {"window": "But if the shutdowns in China were to go longer or it spreads \nand creates other challenges, it's j ust hard to know at this point in time, but we think we're managing it to the best \nof our abilities at this point in time.  \n \n \n Kevin Caliendo :  That's really helpful.   Thanks so much.  \n \n Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "original_text": "Operator :  And we'll go to our last -- we will take our last question from Eric Coldwell with Baird.  \n ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f0e093e554bc0e91ab614823b29f4862766ab3b18a6237fefe020e203b620de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4a9a024-2edc-43e3-adfb-c17ec81f7aa8", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  ", "original_text": "Good morning.  "}, "hash": "1fe3db36fe3ba2ad4805ff713da2fbaa3cca4bb651ff68ba2569db9c251d2f48", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.  ", "start_char_idx": 0, "end_char_idx": 50, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4a9a024-2edc-43e3-adfb-c17ec81f7aa8": {"__data__": {"id_": "c4a9a024-2edc-43e3-adfb-c17ec81f7aa8", "embedding": null, "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  ", "original_text": "Good morning.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c45c1e83-a512-4a1e-80e4-0c6a83b5c0dd", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.  ", "original_text": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c040a7fb9237184b29f14393f2caf34c7d8c8070304c73cb5ad9c1cb6330b8b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e37f5bcb-6a09-4617-b98d-65cd0a34500d", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n ", "original_text": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.  "}, "hash": "5d1509d9b89907446ae6ce2e14f16984fa26f8090bfc2e7768171742d3808f7a", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 50, "end_char_idx": 65, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e37f5bcb-6a09-4617-b98d-65cd0a34500d": {"__data__": {"id_": "e37f5bcb-6a09-4617-b98d-65cd0a34500d", "embedding": null, "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n ", "original_text": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4a9a024-2edc-43e3-adfb-c17ec81f7aa8", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  ", "original_text": "Good morning.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b06b25e1bae1202927dfce99666346045277a45ece97953b59e376994a26da2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a529249-22ad-472d-9bf6-61690d4d1cfb", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.  ", "original_text": "I guess I'm a little bit surprised.  "}, "hash": "147db25cb980bb293580fb5b76cd77454695dace80b539d9f91e5ae3f1150aab", "class_name": "RelatedNodeInfo"}}, "text": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.  ", "start_char_idx": 65, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a529249-22ad-472d-9bf6-61690d4d1cfb": {"__data__": {"id_": "7a529249-22ad-472d-9bf6-61690d4d1cfb", "embedding": null, "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.  ", "original_text": "I guess I'm a little bit surprised.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e37f5bcb-6a09-4617-b98d-65cd0a34500d", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n ", "original_text": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99b5d056b914d32090e89fc7be9ae7e1ec2b6751baaa79ab61baa0517bf8f87f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "234ef09b-dc09-44cc-857f-a5548b84cb6a", "node_type": "1", "metadata": {"window": "Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n", "original_text": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  "}, "hash": "1e976d1b10a327862def7b841fdcfe2384d6aa13cea8350091bca43bf7c83ffd", "class_name": "RelatedNodeInfo"}}, "text": "I guess I'm a little bit surprised.  ", "start_char_idx": 155, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "234ef09b-dc09-44cc-857f-a5548b84cb6a": {"__data__": {"id_": "234ef09b-dc09-44cc-857f-a5548b84cb6a", "embedding": null, "metadata": {"window": "Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n", "original_text": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a529249-22ad-472d-9bf6-61690d4d1cfb", "node_type": "1", "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.  ", "original_text": "I guess I'm a little bit surprised.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47ce3ea90814df573edce1fa3bcfb77f075fe329c8edf89e3059ca33cc130929", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "634dd078-1a65-4f36-9edb-93109204ca18", "node_type": "1", "metadata": {"window": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.  ", "original_text": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n "}, "hash": "196f974ceaf2d1fe6fa5519de6cf714f94da65f2811c188d578249db86f1c191", "class_name": "RelatedNodeInfo"}}, "text": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  ", "start_char_idx": 192, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "634dd078-1a65-4f36-9edb-93109204ca18": {"__data__": {"id_": "634dd078-1a65-4f36-9edb-93109204ca18", "embedding": null, "metadata": {"window": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.  ", "original_text": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "234ef09b-dc09-44cc-857f-a5548b84cb6a", "node_type": "1", "metadata": {"window": "Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n", "original_text": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "195a3d1f0c60cbf697bfc9a4dc91ed1fb90d2d50911432e1250c2ddee1a9fd70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5271c1b-fa02-4269-bc96-8d5c5b973015", "node_type": "1", "metadata": {"window": "I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.  ", "original_text": "We also had an early flu  season.  "}, "hash": "4d9e1fe245d2c3c38768e307364161043388e2d31b677b9c9986e30ac80f4baf", "class_name": "RelatedNodeInfo"}}, "text": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n ", "start_char_idx": 344, "end_char_idx": 475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5271c1b-fa02-4269-bc96-8d5c5b973015": {"__data__": {"id_": "f5271c1b-fa02-4269-bc96-8d5c5b973015", "embedding": null, "metadata": {"window": "I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.  ", "original_text": "We also had an early flu  season.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "634dd078-1a65-4f36-9edb-93109204ca18", "node_type": "1", "metadata": {"window": "So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.  ", "original_text": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28fca85316b72ec067cacf4662f6ad3b7ef72981900db89e6b3bbb45434b90c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "199d3766-59f9-4c68-aa2b-ea1686849b48", "node_type": "1", "metadata": {"window": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.  ", "original_text": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n"}, "hash": "819c23eaea72e75524126102600c4641728ef90d6469152023300a359bfadb7a", "class_name": "RelatedNodeInfo"}}, "text": "We also had an early flu  season.  ", "start_char_idx": 475, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "199d3766-59f9-4c68-aa2b-ea1686849b48": {"__data__": {"id_": "199d3766-59f9-4c68-aa2b-ea1686849b48", "embedding": null, "metadata": {"window": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.  ", "original_text": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5271c1b-fa02-4269-bc96-8d5c5b973015", "node_type": "1", "metadata": {"window": "I guess I'm a little bit surprised.   We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.  ", "original_text": "We also had an early flu  season.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d00366ace6863540a156c28f779f53174cee1353e3ea7aa223cf2538d0d0c308", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e809a6fc-ee38-4e50-9ae7-c77214106958", "node_type": "1", "metadata": {"window": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n ", "original_text": "Mike Kaufmann :  I think I'll start here.  "}, "hash": "3de7270aece7f47e90c19c2685d91f769dee9354f513a0d5c62b18a60cc6de00", "class_name": "RelatedNodeInfo"}}, "text": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n", "start_char_idx": 510, "end_char_idx": 635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e809a6fc-ee38-4e50-9ae7-c77214106958": {"__data__": {"id_": "e809a6fc-ee38-4e50-9ae7-c77214106958", "embedding": null, "metadata": {"window": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n ", "original_text": "Mike Kaufmann :  I think I'll start here.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "199d3766-59f9-4c68-aa2b-ea1686849b48", "node_type": "1", "metadata": {"window": "We've seen both inpatient and emergency depar tment volumes \nincreasing here for the last, call it, you know, give or take, two, three, four quarters.   And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.  ", "original_text": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c7e8e3f5d34c2e0d39811d93d53e6b965426e4680b204229b48e50ba449d51d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acddffde-9ab2-4203-a031-e0588f3c86a3", "node_type": "1", "metadata": {"window": "We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.  ", "original_text": "And then if there's anything to add, Dave can do that.  "}, "hash": "97b6532b74455ae86c86c982b95cacf6eddd1fb797b0f2c94091ec010f5f2d01", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  I think I'll start here.  ", "start_char_idx": 635, "end_char_idx": 678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acddffde-9ab2-4203-a031-e0588f3c86a3": {"__data__": {"id_": "acddffde-9ab2-4203-a031-e0588f3c86a3", "embedding": null, "metadata": {"window": "We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.  ", "original_text": "And then if there's anything to add, Dave can do that.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e809a6fc-ee38-4e50-9ae7-c77214106958", "node_type": "1", "metadata": {"window": "And it's not only increasing - \naccelerating the increase at least according to some internal data and external data we have.  \n \n  We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n ", "original_text": "Mike Kaufmann :  I think I'll start here.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "777b51df8637cfc647bfd150ffa01acce32176085011bcf71ddcf5deccfed8b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98e71484-32b6-43d5-9083-5f0aa4b741ff", "node_type": "1", "metadata": {"window": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.  ", "original_text": "I would say this.  "}, "hash": "b9282f9ee2d2dbdc4d7418a82bfbe1534f2ba449375f3dd2fa2e7cbdaa7e1d0d", "class_name": "RelatedNodeInfo"}}, "text": "And then if there's anything to add, Dave can do that.  ", "start_char_idx": 678, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98e71484-32b6-43d5-9083-5f0aa4b741ff": {"__data__": {"id_": "98e71484-32b6-43d5-9083-5f0aa4b741ff", "embedding": null, "metadata": {"window": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.  ", "original_text": "I would say this.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acddffde-9ab2-4203-a031-e0588f3c86a3", "node_type": "1", "metadata": {"window": "We also had an early flu  season.   So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.  ", "original_text": "And then if there's anything to add, Dave can do that.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92debb31ee27b30795cf1bd559b623f6fc0065704991ecde90e3fdbfac0d4f0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89a13819-8633-407a-b624-f41a529c203e", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n ", "original_text": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n "}, "hash": "d8cf525dd089afc256be05cdb896c5fcac73305dc1a6692b33ba9197314643ec", "class_name": "RelatedNodeInfo"}}, "text": "I would say this.  ", "start_char_idx": 734, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89a13819-8633-407a-b624-f41a529c203e": {"__data__": {"id_": "89a13819-8633-407a-b624-f41a529c203e", "embedding": null, "metadata": {"window": "Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n ", "original_text": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98e71484-32b6-43d5-9083-5f0aa4b741ff", "node_type": "1", "metadata": {"window": "So what's going on in med -surg, med -surg distribution in the U.S, and what are \nthe challenges that you're seeing now?  \n \n Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.  ", "original_text": "I would say this.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74b96142aa6edae5d81e551f9c0ba3c8241f87992e3580e40f7a5ad2c4906b3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a9fe426-5d1a-43d0-8777-14d56c5244eb", "node_type": "1", "metadata": {"window": "And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  ", "original_text": "So it's hard for me to comment on what you're seeing.  "}, "hash": "fecaf7fdf98283ef170495298814a2292fe52c2fffd9a9292ed97357b465ea9b", "class_name": "RelatedNodeInfo"}}, "text": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n ", "start_char_idx": 753, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a9fe426-5d1a-43d0-8777-14d56c5244eb": {"__data__": {"id_": "8a9fe426-5d1a-43d0-8777-14d56c5244eb", "embedding": null, "metadata": {"window": "And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  ", "original_text": "So it's hard for me to comment on what you're seeing.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89a13819-8633-407a-b624-f41a529c203e", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  I think I'll start here.   And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n ", "original_text": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "460d4ba037dbf0ea3db1dfcbff8b885f0c491815f296a04b44ea7dbab3d4e703", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f56e66cb-a7b4-4122-a478-2cbf7927b253", "node_type": "1", "metadata": {"window": "I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n ", "original_text": "But we haven't seen a nything, I would say, dramatic in that \nspot.  "}, "hash": "0716d8151844ba0eb4d08b1971dab72e002fd2effe0bb4e54f1657b8938d6cab", "class_name": "RelatedNodeInfo"}}, "text": "So it's hard for me to comment on what you're seeing.  ", "start_char_idx": 952, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f56e66cb-a7b4-4122-a478-2cbf7927b253": {"__data__": {"id_": "f56e66cb-a7b4-4122-a478-2cbf7927b253", "embedding": null, "metadata": {"window": "I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n ", "original_text": "But we haven't seen a nything, I would say, dramatic in that \nspot.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a9fe426-5d1a-43d0-8777-14d56c5244eb", "node_type": "1", "metadata": {"window": "And then if there's anything to add, Dave can do that.   I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  ", "original_text": "So it's hard for me to comment on what you're seeing.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0ec3fa2e07326ad380a39bd7a9be47719fdd8e3e77fa513d31aa32bd785d6b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aeca256-3399-4064-b6fb-07af85f9ce9b", "node_type": "1", "metadata": {"window": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.  ", "original_text": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n "}, "hash": "3379ab9ca3b518ae054c92c26c1c11bce1da303216948378921ece25eca711cb", "class_name": "RelatedNodeInfo"}}, "text": "But we haven't seen a nything, I would say, dramatic in that \nspot.  ", "start_char_idx": 1007, "end_char_idx": 1076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aeca256-3399-4064-b6fb-07af85f9ce9b": {"__data__": {"id_": "2aeca256-3399-4064-b6fb-07af85f9ce9b", "embedding": null, "metadata": {"window": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.  ", "original_text": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f56e66cb-a7b4-4122-a478-2cbf7927b253", "node_type": "1", "metadata": {"window": "I would say this.   First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n ", "original_text": "But we haven't seen a nything, I would say, dramatic in that \nspot.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "355edd5d957e9c0d451b5bda60f98db6bba00171fa6fa75e9fb51f93d01558cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e7293a0-5912-442b-b847-886f121c91fc", "node_type": "1", "metadata": {"window": "So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n ", "original_text": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  "}, "hash": "2cf4961b419143d151abfce82792badefb299b8c4644a00b36f306e908a9f9db", "class_name": "RelatedNodeInfo"}}, "text": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n ", "start_char_idx": 1076, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e7293a0-5912-442b-b847-886f121c91fc": {"__data__": {"id_": "5e7293a0-5912-442b-b847-886f121c91fc", "embedding": null, "metadata": {"window": "So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n ", "original_text": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aeca256-3399-4064-b6fb-07af85f9ce9b", "node_type": "1", "metadata": {"window": "First of a ll, \nwe're not seeing necessarily anything that would say that the actual med -surg historical volumes of very low -\nsingle -digit type of growth has changed significantly out there.  \n \n  So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.  ", "original_text": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "253b3a1908c68e1f1b8af22fc10412a826c7075cb6a7065b6517f169daee9a2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "642ee90e-3fff-47aa-afd0-85abb3f4d230", "node_type": "1", "metadata": {"window": "But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.  ", "original_text": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n "}, "hash": "5ff698e17bb6aa43b1f3c9f019e3c16166fd8fba792f62384b9d19ba7cfa3862", "class_name": "RelatedNodeInfo"}}, "text": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  ", "start_char_idx": 1181, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "642ee90e-3fff-47aa-afd0-85abb3f4d230": {"__data__": {"id_": "642ee90e-3fff-47aa-afd0-85abb3f4d230", "embedding": null, "metadata": {"window": "But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.  ", "original_text": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e7293a0-5912-442b-b847-886f121c91fc", "node_type": "1", "metadata": {"window": "So it's hard for me to comment on what you're seeing.   But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n ", "original_text": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cad21fffbff8e452f398614322e2187aa75a871745aa48b8bd3129315b3cf7dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e944017a-cabe-488c-9ab8-ba10e7e960c7", "node_type": "1", "metadata": {"window": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And so I think we really need to get another quarter or two behind us to understand overall.  "}, "hash": "244ffb3b39270fa310a4cef20388ba4dec2e1da8a51c0995bac05260dde5122d", "class_name": "RelatedNodeInfo"}}, "text": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n ", "start_char_idx": 1321, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e944017a-cabe-488c-9ab8-ba10e7e960c7": {"__data__": {"id_": "e944017a-cabe-488c-9ab8-ba10e7e960c7", "embedding": null, "metadata": {"window": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And so I think we really need to get another quarter or two behind us to understand overall.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "642ee90e-3fff-47aa-afd0-85abb3f4d230", "node_type": "1", "metadata": {"window": "But we haven't seen a nything, I would say, dramatic in that \nspot.   Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.  ", "original_text": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2be9556aae74eb9953d22bdd93e1bf6b648b83f9869bb26e926f4948ee953d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50d5bcc7-80c1-4b70-b4dd-83d1eb5b7b25", "node_type": "1", "metadata": {"window": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n "}, "hash": "7a8c7ab003346cbc636b4b8e7c98ff9f176e31eb15e7c5e5ce4458db1a1074db", "class_name": "RelatedNodeInfo"}}, "text": "And so I think we really need to get another quarter or two behind us to understand overall.  ", "start_char_idx": 1411, "end_char_idx": 1505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50d5bcc7-80c1-4b70-b4dd-83d1eb5b7b25": {"__data__": {"id_": "50d5bcc7-80c1-4b70-b4dd-83d1eb5b7b25", "embedding": null, "metadata": {"window": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e944017a-cabe-488c-9ab8-ba10e7e960c7", "node_type": "1", "metadata": {"window": "Remember last year, we have a lot of lumpiness in our first couple of quarters related to the TSAs.  \n \n  And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And so I think we really need to get another quarter or two behind us to understand overall.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98e5c1d9f720d9981b5cbcb03c61f3eaec316dbf1e2b5a79d4bb1d1983be7200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4af8c8f5-56e2-46ca-8a93-4821170e0f54", "node_type": "1", "metadata": {"window": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "But there is nothing, I would say, big going on.  "}, "hash": "5cafee208d62077a088179cfe7fbc23adf63e1043f624a27816c104c01e77804", "class_name": "RelatedNodeInfo"}}, "text": "And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n ", "start_char_idx": 1505, "end_char_idx": 1629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4af8c8f5-56e2-46ca-8a93-4821170e0f54": {"__data__": {"id_": "4af8c8f5-56e2-46ca-8a93-4821170e0f54", "embedding": null, "metadata": {"window": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "But there is nothing, I would say, big going on.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50d5bcc7-80c1-4b70-b4dd-83d1eb5b7b25", "node_type": "1", "metadata": {"window": "And so, some of our compare is, you know, we think caused by the fact that we're comparing to last year as w e \nwere going off those TSAs.   And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a55ac4711c1b11878892a0bc46ad70effb90f47433c4b72043223564f73e8f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e2ccd3c-568f-4770-833f-cfe463f6af0c", "node_type": "1", "metadata": {"window": "And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid "}, "hash": "3ef54c581acb235e786774c4e6780881e8a359aa12614f32be0174d1126e2205", "class_name": "RelatedNodeInfo"}}, "text": "But there is nothing, I would say, big going on.  ", "start_char_idx": 1629, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e2ccd3c-568f-4770-833f-cfe463f6af0c": {"__data__": {"id_": "9e2ccd3c-568f-4770-833f-cfe463f6af0c", "embedding": null, "metadata": {"window": "And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f05a6675-6af7-4244-8fee-d2c465008cd5", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97475cbe33a08b7e03ee6abd27d66292480e9ab768e68b6a40b82951d13036a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4af8c8f5-56e2-46ca-8a93-4821170e0f54", "node_type": "1", "metadata": {"window": "And so if you look at our first half, we're roughly up 2%, which seems more in line.  \n \n  And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "But there is nothing, I would say, big going on.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aedf36bf08ce33aefe35295390964995bcf3b6cf92a2c543b8963ff015c4d789", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e00d9c07-90ce-4c75-aa9a-0b9714a02370", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.  ", "original_text": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.  "}, "hash": "940e458652602a6b0173c25f8708f157ffdf92405e1ac57cfd62f52cbb13b7de", "class_name": "RelatedNodeInfo"}}, "text": "And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "start_char_idx": 1679, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e00d9c07-90ce-4c75-aa9a-0b9714a02370": {"__data__": {"id_": "e00d9c07-90ce-4c75-aa9a-0b9714a02370", "embedding": null, "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.  ", "original_text": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e2ccd3c-568f-4770-833f-cfe463f6af0c", "node_type": "1", "metadata": {"window": "And so I think we really need to get another quarter or two behind us to understand overall.   And again, with this \nkit recall and gown reca ll, there is a few challenges there we're still trying to work through.  \n \n  But there is nothing, I would say, big going on.   And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "original_text": "And from all the work we've done by talking to our customers and \nto our reps, we still feel really confident about what we're doing in our commercial restructuring that over the mid ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "861ed4a8104610c347b14da085caf083e3162bb765f2c6842a2532a2eb279d29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "638e812c-a2ef-41fb-b312-e9877970c476", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  ", "original_text": "But we've got to get through these challenges for that \nto happen.  \n \n"}, "hash": "42d4da6e69c3b181857f5de3ac377ba2ffa48b0af07a75d3557a3b52be6b4d6e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.  ", "start_char_idx": 0, "end_char_idx": 83, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "638e812c-a2ef-41fb-b312-e9877970c476": {"__data__": {"id_": "638e812c-a2ef-41fb-b312-e9877970c476", "embedding": null, "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  ", "original_text": "But we've got to get through these challenges for that \nto happen.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e00d9c07-90ce-4c75-aa9a-0b9714a02370", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.  ", "original_text": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d15ac24cefd48a3851d5c5bacd54a8fe26aa7cef4b393d04931ce9d003bfd616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6679cf8e-029f-46b5-ae12-a62bc22ed91e", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n", "original_text": "Kevin Caliendo :  Right.  "}, "hash": "6eb67219eff141bda8df6c1c8283a3db229b96841ed8458985ff9f2cb3b480ed", "class_name": "RelatedNodeInfo"}}, "text": "But we've got to get through these challenges for that \nto happen.  \n \n", "start_char_idx": 83, "end_char_idx": 154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6679cf8e-029f-46b5-ae12-a62bc22ed91e": {"__data__": {"id_": "6679cf8e-029f-46b5-ae12-a62bc22ed91e", "embedding": null, "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n", "original_text": "Kevin Caliendo :  Right.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "638e812c-a2ef-41fb-b312-e9877970c476", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  ", "original_text": "But we've got to get through these challenges for that \nto happen.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "068c2fb2f1d719e44a9c1d6e1897f5154075ffb20d1a81f76bcfa091be3835e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbdd331b-2e1e-4470-88e1-908b66a103a0", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n", "original_text": "And I just - I know the kit recall really didn't p op up until January.  "}, "hash": "4cbb74918d4335c659bc90e2355858ebc4839311acbb3bc98ffd454cb2ed5531", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :  Right.  ", "start_char_idx": 154, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbdd331b-2e1e-4470-88e1-908b66a103a0": {"__data__": {"id_": "fbdd331b-2e1e-4470-88e1-908b66a103a0", "embedding": null, "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n", "original_text": "And I just - I know the kit recall really didn't p op up until January.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6679cf8e-029f-46b5-ae12-a62bc22ed91e", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n", "original_text": "Kevin Caliendo :  Right.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f439732cac6920918cb3c181add3dd7e32bcda2734de8c70363ac5d4d3795d77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03511ca6-3486-48d6-b4b4-6e9819d12fb9", "node_type": "1", "metadata": {"window": "But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  ", "original_text": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  "}, "hash": "8fba57afae6ae7ab78fdfaee1c62c26d8649763bd6284e418d2829342867e2cc", "class_name": "RelatedNodeInfo"}}, "text": "And I just - I know the kit recall really didn't p op up until January.  ", "start_char_idx": 180, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03511ca6-3486-48d6-b4b4-6e9819d12fb9": {"__data__": {"id_": "03511ca6-3486-48d6-b4b4-6e9819d12fb9", "embedding": null, "metadata": {"window": "But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  ", "original_text": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbdd331b-2e1e-4470-88e1-908b66a103a0", "node_type": "1", "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n", "original_text": "And I just - I know the kit recall really didn't p op up until January.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e39d2cf12b483f2eb1d1c2c52ca2a3adf18c3fd64b02edf7adce1406b54faf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba7d8655-a2a6-42ee-a8e4-a073d80cb2ff", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  ", "original_text": "Absolutely.  \n \n"}, "hash": "9e19ef76d44c69e442e4c623310c85f39ba4dd4a9e73c37c90afa06955d263a1", "class_name": "RelatedNodeInfo"}}, "text": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  ", "start_char_idx": 253, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba7d8655-a2a6-42ee-a8e4-a073d80cb2ff": {"__data__": {"id_": "ba7d8655-a2a6-42ee-a8e4-a073d80cb2ff", "embedding": null, "metadata": {"window": "Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  ", "original_text": "Absolutely.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03511ca6-3486-48d6-b4b4-6e9819d12fb9", "node_type": "1", "metadata": {"window": "But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  ", "original_text": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b838d569a6081b7f667a4f1e68926f0298ff72641a14ceb16d7259dc2eb8224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03fa5830-ef8c-447b-91dc-3957943c9819", "node_type": "1", "metadata": {"window": "And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n", "original_text": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n"}, "hash": "c5fe4383de955c02cf03a8f36dd66bc5ec9083609fbd0d5c400a72c3d9d02bb5", "class_name": "RelatedNodeInfo"}}, "text": "Absolutely.  \n \n", "start_char_idx": 370, "end_char_idx": 386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03fa5830-ef8c-447b-91dc-3957943c9819": {"__data__": {"id_": "03fa5830-ef8c-447b-91dc-3957943c9819", "embedding": null, "metadata": {"window": "And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n", "original_text": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba7d8655-a2a6-42ee-a8e4-a073d80cb2ff", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  ", "original_text": "Absolutely.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6954889578720983dcb8c84cd3cd89b252827c82bfb20e8f83fa87570e76b701", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeb76cd6-c9d1-405e-a5f6-e0dd7bea07bc", "node_type": "1", "metadata": {"window": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.  ", "original_text": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  "}, "hash": "9c2810549232d2b243bdcc1a7be52644b464dc708df6110953f4ea0637e1168f", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n", "start_char_idx": 386, "end_char_idx": 512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeb76cd6-c9d1-405e-a5f6-e0dd7bea07bc": {"__data__": {"id_": "aeb76cd6-c9d1-405e-a5f6-e0dd7bea07bc", "embedding": null, "metadata": {"window": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.  ", "original_text": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03fa5830-ef8c-447b-91dc-3957943c9819", "node_type": "1", "metadata": {"window": "And I just - I know the kit recall really didn't p op up until January.   So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n", "original_text": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfb69ebd9b2b8cc5596a32e2e7c7330d8fb6092a5f1a4e675197a8785d89545b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e0dff2b-cad7-40eb-8cce-f5e51da28a00", "node_type": "1", "metadata": {"window": "Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.  ", "original_text": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  "}, "hash": "6018ae413beefe452102102c750cb2f0a9281aa370ca396d3f74db03f70a910d", "class_name": "RelatedNodeInfo"}}, "text": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  ", "start_char_idx": 512, "end_char_idx": 715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e0dff2b-cad7-40eb-8cce-f5e51da28a00": {"__data__": {"id_": "6e0dff2b-cad7-40eb-8cce-f5e51da28a00", "embedding": null, "metadata": {"window": "Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.  ", "original_text": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeb76cd6-c9d1-405e-a5f6-e0dd7bea07bc", "node_type": "1", "metadata": {"window": "So I was clearly talking more \nabout, you know, the last couple of quarters, it just...  \n \nMike Kaufmann :  Right.   Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.  ", "original_text": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8ae5604e0ba6a145764e5440d2c9ccfdf2b7df346f9ee2b57bc5a965277182", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ee21561-e6d5-4cdc-b882-18031522dcae", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.  ", "original_text": "And the first half is really - it's very much in line with \nour expectations.  \n \n"}, "hash": "0b866b7b4ff2c3ca29e82d99b0539bc88fd434ccda2ba34eb3b79d9bf4cfae04", "class_name": "RelatedNodeInfo"}}, "text": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  ", "start_char_idx": 715, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ee21561-e6d5-4cdc-b882-18031522dcae": {"__data__": {"id_": "3ee21561-e6d5-4cdc-b882-18031522dcae", "embedding": null, "metadata": {"window": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.  ", "original_text": "And the first half is really - it's very much in line with \nour expectations.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e0dff2b-cad7-40eb-8cce-f5e51da28a00", "node_type": "1", "metadata": {"window": "Absolutely.  \n \n Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.  ", "original_text": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc5fc9e1ab966daf024fcfd3da361fa1da3e91e53629a72bd3fec4df89242c06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40361b07-7e70-4684-97b4-721b4c90f23a", "node_type": "1", "metadata": {"window": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n ", "original_text": "Mike Kaufmann :  Thanks again for the question.  "}, "hash": "4139c152b62aed1eefb7f96acab792a377b293c3c6b4504bf54b45bf626de24e", "class_name": "RelatedNodeInfo"}}, "text": "And the first half is really - it's very much in line with \nour expectations.  \n \n", "start_char_idx": 818, "end_char_idx": 900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40361b07-7e70-4684-97b4-721b4c90f23a": {"__data__": {"id_": "40361b07-7e70-4684-97b4-721b4c90f23a", "embedding": null, "metadata": {"window": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n ", "original_text": "Mike Kaufmann :  Thanks again for the question.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ee21561-e6d5-4cdc-b882-18031522dcae", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  I guess maybe the TSA is an issue, we need to go back and revisit, but we can take this up o n offline.  \n \n David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.  ", "original_text": "And the first half is really - it's very much in line with \nour expectations.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75a53bc56ed25e6cdfa5527522325ae0522bc6c1e95c1b8b1f7cc6d304741b1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51617b4f-6e0b-470d-8bd0-6a6434dcd499", "node_type": "1", "metadata": {"window": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.  ", "original_text": "All right so let me close.  "}, "hash": "9a18560d48ed631770557adfc7fa5cbc912978f4e6e1c7297f330fe041511719", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Thanks again for the question.  ", "start_char_idx": 900, "end_char_idx": 949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51617b4f-6e0b-470d-8bd0-6a6434dcd499": {"__data__": {"id_": "51617b4f-6e0b-470d-8bd0-6a6434dcd499", "embedding": null, "metadata": {"window": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.  ", "original_text": "All right so let me close.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40361b07-7e70-4684-97b4-721b4c90f23a", "node_type": "1", "metadata": {"window": "David Evans :  Yes, Eric, I would just - I would reiterate a little bit what Mike said, which is I wouldn't read too much into \nsingle quarter of Q2 because of all the transition is going on last year.   I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n ", "original_text": "Mike Kaufmann :  Thanks again for the question.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "173488120a4ad58859ffc8ed3212ddae1c88b1524c73ac82f0d4d3c2802c769e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6023e385-471c-4f2b-bfb1-eaf2a7798c6f", "node_type": "1", "metadata": {"window": "And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.  ", "original_text": "I'd like to close by saying, we remain focu sed \non our customers and their patients.  "}, "hash": "c69267b511e2784e76bee3760948ce48f623d76579c75a95730c673cde27e315", "class_name": "RelatedNodeInfo"}}, "text": "All right so let me close.  ", "start_char_idx": 949, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6023e385-471c-4f2b-bfb1-eaf2a7798c6f": {"__data__": {"id_": "6023e385-471c-4f2b-bfb1-eaf2a7798c6f", "embedding": null, "metadata": {"window": "And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.  ", "original_text": "I'd like to close by saying, we remain focu sed \non our customers and their patients.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51617b4f-6e0b-470d-8bd0-6a6434dcd499", "node_type": "1", "metadata": {"window": "I'm really looking at our first half and \nsaying, how is the first half compared to our expectations?   And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.  ", "original_text": "All right so let me close.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a5d758ced622b18238134fc44a5d0f944ccb8d2878e73bc901c91215d1d4fdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f689272f-e38f-43ed-8350-81d5fe6ce0e0", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n", "original_text": "And we will continue to deliver on our strategic priorities.  \n \n "}, "hash": "06d07bdf38fe1b3214ae6fafb4e341f188b45c66ab34ebc0f637372fcf12b950", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to close by saying, we remain focu sed \non our customers and their patients.  ", "start_char_idx": 977, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f689272f-e38f-43ed-8350-81d5fe6ce0e0": {"__data__": {"id_": "f689272f-e38f-43ed-8350-81d5fe6ce0e0", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n", "original_text": "And we will continue to deliver on our strategic priorities.  \n \n ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6023e385-471c-4f2b-bfb1-eaf2a7798c6f", "node_type": "1", "metadata": {"window": "And the first half is really - it's very much in line with \nour expectations.  \n \n Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.  ", "original_text": "I'd like to close by saying, we remain focu sed \non our customers and their patients.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2d1372f76e78fe238f931457c3df5e389987109e894818c3c0fa8c49a4d1c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6edb8eb-ca22-4591-b113-03d988eb14c5", "node_type": "1", "metadata": {"window": "All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.   ", "original_text": "Thanks for your questions and your time today.  "}, "hash": "02e224ff9bb5202e6f4fca0272b586e7f89e0a35ab909fe7bbed54a75aaf6817", "class_name": "RelatedNodeInfo"}}, "text": "And we will continue to deliver on our strategic priorities.  \n \n ", "start_char_idx": 1064, "end_char_idx": 1130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6edb8eb-ca22-4591-b113-03d988eb14c5": {"__data__": {"id_": "a6edb8eb-ca22-4591-b113-03d988eb14c5", "embedding": null, "metadata": {"window": "All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.   ", "original_text": "Thanks for your questions and your time today.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f689272f-e38f-43ed-8350-81d5fe6ce0e0", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks again for the question.   All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n", "original_text": "And we will continue to deliver on our strategic priorities.  \n \n ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e57c9d09a1355f220ea3c0605b1b0dd3b25862658bddd1d141430c77818374e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16a4df6-6d35-4a11-8ee4-e18224d2d34f", "node_type": "1", "metadata": {"window": "I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.  ", "original_text": "And we look forward to speaking with each of you soon.  "}, "hash": "27920fa32c4a0126bbe0dada66134137103a1c19bf8a3d8562704583c6677e46", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for your questions and your time today.  ", "start_char_idx": 1130, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16a4df6-6d35-4a11-8ee4-e18224d2d34f": {"__data__": {"id_": "d16a4df6-6d35-4a11-8ee4-e18224d2d34f", "embedding": null, "metadata": {"window": "I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.  ", "original_text": "And we look forward to speaking with each of you soon.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6edb8eb-ca22-4591-b113-03d988eb14c5", "node_type": "1", "metadata": {"window": "All right so let me close.   I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.   ", "original_text": "Thanks for your questions and your time today.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b576f60d9ebb6780013157a119b6b837353d21385295cbcaa07bd3732fcc137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d691d71-c848-4fab-9fec-ebadbcbc69e8", "node_type": "1", "metadata": {"window": "And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Take \ncare.  \n \n"}, "hash": "64f089b0f7190b22a2f70aac06f02b04063ce0f1ea14808d41b97c2976599942", "class_name": "RelatedNodeInfo"}}, "text": "And we look forward to speaking with each of you soon.  ", "start_char_idx": 1178, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d691d71-c848-4fab-9fec-ebadbcbc69e8": {"__data__": {"id_": "9d691d71-c848-4fab-9fec-ebadbcbc69e8", "embedding": null, "metadata": {"window": "And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Take \ncare.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d16a4df6-6d35-4a11-8ee4-e18224d2d34f", "node_type": "1", "metadata": {"window": "I'd like to close by saying, we remain focu sed \non our customers and their patients.   And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.  ", "original_text": "And we look forward to speaking with each of you soon.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "525c1a1399cb89c5eb923a277783337ed0f0bb3ce713f3183f4f4f1ec73b7505", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a34865e-6af9-4c99-8081-95c3f8c9c8a3", "node_type": "1", "metadata": {"window": "Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Operator :  And this concludes today's call.   "}, "hash": "1229e3bb5436b0bdbc442a318656180f364a26781110e0541f79b169c58722b9", "class_name": "RelatedNodeInfo"}}, "text": "Take \ncare.  \n \n", "start_char_idx": 1234, "end_char_idx": 1250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a34865e-6af9-4c99-8081-95c3f8c9c8a3": {"__data__": {"id_": "3a34865e-6af9-4c99-8081-95c3f8c9c8a3", "embedding": null, "metadata": {"window": "Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Operator :  And this concludes today's call.   ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d691d71-c848-4fab-9fec-ebadbcbc69e8", "node_type": "1", "metadata": {"window": "And we will continue to deliver on our strategic priorities.  \n \n  Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Take \ncare.  \n \n", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d11ea9689794a62f1a97a52a142faaec4c75fc931ef5cbbf04d1690476620bea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb10da04-4215-4733-82b0-eab6686177cf", "node_type": "1", "metadata": {"window": "And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Thank you for your participation.  "}, "hash": "59b33a8d52cf557a398e5e5a375a080ff46fd4a2043bd02c950da794a64a59f7", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And this concludes today's call.   ", "start_char_idx": 1250, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb10da04-4215-4733-82b0-eab6686177cf": {"__data__": {"id_": "fb10da04-4215-4733-82b0-eab6686177cf", "embedding": null, "metadata": {"window": "And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Thank you for your participation.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a34865e-6af9-4c99-8081-95c3f8c9c8a3", "node_type": "1", "metadata": {"window": "Thanks for your questions and your time today.   And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Operator :  And this concludes today's call.   ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c61765ea3c09e2196f84de3df1be42699d0c03996fdebea0ecd13939dff0eb6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92991152-97cf-4935-8f77-59a7d90bb39d", "node_type": "1", "metadata": {"window": "Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "You may now disconnect.  \n "}, "hash": "f27b485e79c1ac57c1190b882e3d1915476a71e5a756c61deb24daca97b80ca5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your participation.  ", "start_char_idx": 1297, "end_char_idx": 1332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92991152-97cf-4935-8f77-59a7d90bb39d": {"__data__": {"id_": "92991152-97cf-4935-8f77-59a7d90bb39d", "embedding": null, "metadata": {"window": "Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "You may now disconnect.  \n ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762", "node_type": "4", "metadata": {"page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40a6ddbbd1d1771e1228e44aa42a9f5d479ad8c9ca8518dcefec978b7b04bf4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb10da04-4215-4733-82b0-eab6686177cf", "node_type": "1", "metadata": {"window": "And we look forward to speaking with each of you soon.   Take \ncare.  \n \n Operator :  And this concludes today's call.    Thank you for your participation.   You may now disconnect.  \n ", "original_text": "Thank you for your participation.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c65e0914abbdce178924150e2c106d5cb7b1c3a9eba0fccd700204990e211ff8", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect.  \n ", "start_char_idx": 1332, "end_char_idx": 1359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"c89b6943-ceba-41a7-bd7c-e961a261e049": {"doc_hash": "1211dca2b6440c2ebf20bd43661d0a60f5efa046b24bc2df621998c2890607a1", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "a0ada1e1-f202-4a39-9cd8-4d0f835fb0cc": {"doc_hash": "d3466f3bffe3e3b669b660fd6ae543e9d5aa1f7ace6425f0bc0dc1e7e20414b1", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "bdd6a008-1f96-4e64-bc2e-c23a86f28355": {"doc_hash": "9ea2fce5ac40cbe184cb391b78e202ffea9e0bb69eac398fe9cce87d455d8e60", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "3a34a219-7e3f-4499-8f0d-490b07bb4378": {"doc_hash": "240cbdf25be11f475ec840cc88a1bf66d01ecbc85067bbfcb3e73018403a0e47", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "0f7f91b7-68a8-421b-a2be-1d8f55c81392": {"doc_hash": "78d85c48eb740e83f1feac613345cfcd4a6845c787f08450ae01e74844715760", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "a60e38a5-62b3-44a4-978e-949494c6beca": {"doc_hash": "fdd55efe1280ed4dc13604a623d02b15ae925e4fe4ff30f2ce87fb52411ec54c", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "3ae358db-f428-43cc-b1cd-e0c3213c9183": {"doc_hash": "adc28832cfd7a36907081c982f1330b226e3cb9461665b890975baaa11c414f2", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "d76d0c58-49a5-4776-a2ea-71708dc2f0da": {"doc_hash": "1c8cfb6087b87824c9dc1a7425baa639b225197bcb9dd6441bf46be982a6dfb1", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "18399038-8cca-4dc1-ba4c-b7109c0bd8d8": {"doc_hash": "a49438ae9ee5ca562ff9142bb5fe35f4a9aaaae1e1e984af4f0896b74760576b", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "a761b164-f8b7-4389-ac10-d7f534de31fe": {"doc_hash": "ad98563470488c27d88b4e86fcc2607cd571a4266f62ab1df0264299afaec662", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "7dafcb8d-757f-440b-951f-5676dc82751a": {"doc_hash": "55f47e63b1b0c1d9b614e0d3cac6b9456948a92420893745bfe11c3b76287078", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "91ac359f-5026-4789-82b5-b1a408320fed": {"doc_hash": "19f83d6e66aae20365a2e7bfabf4746ff81701ae4145f4e53b24bc062aeb76ae", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "42c63a7d-5780-4dfe-8929-d8009ef1234c": {"doc_hash": "06b731579f5682031a00b27faabae420e4d30ce90af86b6a0b419efd5583b4e1", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "19262729-0c15-4bce-b65a-6d4cac96e8e2": {"doc_hash": "fced7f3bf60d52d7c136835d2e6fb0c9808da7503eaa660c50d0644900f5dd8f", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "902b1233-9101-45f4-8f78-4a78a0fdb558": {"doc_hash": "0d531c8a5ff004751fd20725829f2404402b0901dda84c96917dcf69aa5b34e0", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "74cc82c9-998c-464e-8b6b-287cf2b79b5c": {"doc_hash": "6409e87d93037e63d8d03ed44396113474077eed83a0cadb3583f817f00153f9", "ref_doc_id": "af269006-76bc-4068-96c6-227a07e11bb7"}, "d8fba7c2-c137-4daa-8fa3-dc320f9e5009": {"doc_hash": "1fcb2e74e3d356201c22deaa7b6c601c4da1e56580f0064320cc3d09da6f5dee", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "d37f99ee-f3e3-4385-a36e-b558c0128f4f": {"doc_hash": "68d908086fdfbff572598c54e132b8429d385d6b1e50c7d491b4f03d37e5101b", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "f3fea566-03c1-4c7f-8bb9-a8e1135f49fd": {"doc_hash": "e0c6e9392a18d083c7cc396cdcac996d947c183c4feb0844cc4467f22aeb638c", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "2e33f761-cf28-4a57-b335-75cbad2954e8": {"doc_hash": "f0be2e7b2b775a5554e5f1d29a526f018cf7f1c235e75754248468856b1da788", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "8eb55bc8-ed9d-40f9-8893-ace50c047c8b": {"doc_hash": "c25f18d4b1db498260ff6c4effb9b305dccd200043ff7155637084963932dbac", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "f4800b25-2eb2-4cda-9481-4e4c85d163ac": {"doc_hash": "c0fa7017faef332b3ebbfa9caec8f8de10d95205aa9b76e205c4cefd40562f92", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "c15c8f24-c1c7-41f1-9c79-8c1890cddf22": {"doc_hash": "eba5a735ee0a5045cbb28ac759d7ff35c68b238406150fcd419f7b0f64c36805", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "95dc3cd4-efa1-4551-bdcf-b929ccc6cf5b": {"doc_hash": "756fe796defeffc84ea1be80cd30fc38aa0a9b60c2a958377184351b286033c1", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "900d24f4-583f-45fe-a4a0-a773f4ba6b25": {"doc_hash": "705bd5b9fe11cb16d71241374d51e279f9b19287a565ebce26e9fed60c98c72b", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "d1f73120-8229-4a94-b3fe-7c161e2bfb79": {"doc_hash": "48700930ad3154a6c55069829e583a1acd333934adc5fc8a58a2e4c3f89c7d5d", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "abfc2837-c4da-4fe6-b677-ddefed700d69": {"doc_hash": "1fbb106ed2a1a135ded0c89bea82f077d98332390f3e89d442513720f649bdd8", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "9dd1f6a2-0620-476f-b960-fcbc3cbf9fc9": {"doc_hash": "71c31324e875a9b65ca93135fed369021a717d8fdf311506e20435fa1a1dc4a9", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "8e6fe5f8-6aca-4140-b280-601e330bc3d2": {"doc_hash": "b8b922d500bb66fb23c5a1abfdb39437145ea8009a6462fc760d00cc18b957f6", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "2bc1913d-dc30-40de-9adc-6df0a0fdd418": {"doc_hash": "aa9320251337d34ccb623ade0b98609c23508d6163d286c93670dcfb08ed1450", "ref_doc_id": "07348c34-4a6d-4c98-b8c0-5feeff99a3b5"}, "2efd8089-b1a5-42fd-9522-5e3bb253d199": {"doc_hash": "c3d89d0429043034a72f1f650d9ff341725959ae077444faeb887c920b97a215", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "17034fbe-c1c9-4666-84a7-0a67f7b75ae9": {"doc_hash": "00e208c48b9084074eeeea864ba402806d229a7c0cebb8a12b8eba5d554b0c5d", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "e8d46667-a64f-4b02-b362-dcea7e4ffa45": {"doc_hash": "677ae63e64ae1601ffe05e81e11623c801c69ccce2950f857a072758fb83ab11", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "85b50308-1d45-411b-875a-b57527220867": {"doc_hash": "813f54da8819d28f3280d8b5b04a9697831c7ab7d9a847d6268272ac89ccf856", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "5505e726-4674-4007-adbe-4b28af49a1c0": {"doc_hash": "46219f5459c53594dd2f7d48dfaa174478b8b2624817d22072776a86a9a2839e", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "06148208-620c-4638-8a66-736166bf947b": {"doc_hash": "2f24e0ff1982ea52d9cfc8a61ae6027ef98b75a382d502f017f3046dcc211eeb", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "9a7608f4-2a6f-4a17-b2be-635769ec8ae4": {"doc_hash": "884aedbb62c36e830dc633972dfcf7f2decbbf74213caf6b070060f7614fdfb7", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "ac88de4f-5d0e-4f7d-9b12-301c6a4f06d5": {"doc_hash": "9c40fb14a11806e2cccdd080f71acfa3f6a7130089e21470cfa585f6fadd5a62", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "dcd8d0e0-4462-462c-a080-1814eb4e847b": {"doc_hash": "170657f82f08701b1a86114c199f961f62c864cdcd53cb76b06093242e085a46", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "fadea879-ae05-44f9-a8b1-2816e96a9161": {"doc_hash": "d9e3007f585ccb63b532acee033ab4343d064e8ceffa73e25e5525429e6f4835", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "97539298-8ccb-40dc-8fd6-05e4800865ad": {"doc_hash": "7c5906314b9aa1d72fcd627d4d919b83774a48b58856a2feef68271d63e6b74e", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "93b7c70d-0f8b-47a2-be4b-001a5dbd197e": {"doc_hash": "c4799ac6693b20869ea8685fad948e68129b82a72f0a0d52c3dfa20dbac22cf2", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "c5591788-d47a-4280-9aa1-4f814fc40ccc": {"doc_hash": "60e57f00a3c9313cc1f9071ef3f0410adfaf49ce09fb8fc18a6fc5c54142e660", "ref_doc_id": "1eb1521d-1157-4a5c-be91-606a8dc80df8"}, "8a4d9317-a608-4c80-8602-ea2bbeb0eae6": {"doc_hash": "c9df6b245af84209509abc954cebf451109f6875f2412f419da1ca0b1b75cbe3", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "7665f24c-6ff2-4430-b2db-cb95aeaf3d4a": {"doc_hash": "b719b0cdd644b7bc6c70788ad750f40c584edf923cd05320d7c4293a78aabbd0", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "c018158f-5d0a-433b-8bed-9f39829de3b6": {"doc_hash": "37d79e22ec2e02eb917596d08f7c1bd368f34df97f214f7f37fc26e3e7ad9bb2", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "c7a2c38a-6e29-42bc-af46-01beb44b301e": {"doc_hash": "44e16a3dd8a65e99295be47801648b50d90cbbd74130df5c39cf955e7d9fd8ec", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "edbfe7a8-48e1-48a5-b28a-b719a912c9f3": {"doc_hash": "35d100ec5bea48d77a80f7b67078267eaf03bc98d90abd95edf728d2a02c72e4", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "fe59a99f-c01d-4299-93b0-d44b54b7e5a1": {"doc_hash": "5a19aa39d82363b94f9eed344e19bc1a2d3dfb906ca8f404fc5a5aa3539023a9", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "95c73c0e-c246-462a-88df-6c67f5ecf8d3": {"doc_hash": "9e3bb802c57a7ff169d12fa1b7b23c67d0f12fa63ea939b007e1df9dd740aeb0", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "91cee9b6-16ab-432f-8c2b-957463065708": {"doc_hash": "e921c8a03b89bb12bd4261d0030649bf16832e09b4dc4f6bb4f2674d7e14848e", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "e3676df2-f7fa-45ed-88c4-fdf3a619e3a0": {"doc_hash": "250a8c6b23e023332dffd87b8507345eb36ae850632744cc2ddec0eb4bd38b5a", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "3d482e3a-9ba6-4682-b227-0f7881ae843f": {"doc_hash": "5f6d522317d4b54eeabfa0775478013633d3aee83ff5ff2a14ca692b6a246005", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "915a6a4e-5397-44f6-9b7c-72159c25ca8e": {"doc_hash": "4f4fcb9d752a05cba883fed0a3f24ba6dc48d7d13b8f0a305d9cc14cd7dd6f6b", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "d641e702-896e-42c8-8e7f-1f4a0557ce53": {"doc_hash": "1b1bcc8a8885fb72c6f55466633066b41907ca837ca8ae00d8e451b45e84eb07", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "e9edf9ed-fee5-4d67-94ad-6dba19dbd68f": {"doc_hash": "1f6b567b02651c82dc3ea7dccb8877cf75be967c284483e340e6349083a42a5f", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "9b01bc1c-0503-471f-a048-01c5d584b86f": {"doc_hash": "3c22eac4b993b992c5f7d529edec25bff4fd45c4b9a3d87ca9d3a0634880fa42", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "ad9d15d2-065e-4b98-93f3-98d0ff335382": {"doc_hash": "dafbba24e9bf68f30fedd9d99cd3f21b299901c0a23a8363735c8c5021d5fe27", "ref_doc_id": "ebb19d3b-272a-419c-a9fc-709f0ca764ec"}, "9e70f41c-210b-4726-b677-330da84243ce": {"doc_hash": "87a7456941cc63d4b3143c87254ce955a5d0b6fd1d5422269b5eb916f512778a", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "654a15b8-1a06-4aae-b809-a82a4ef0c1ae": {"doc_hash": "212e75befb7687fc313f68d8ad72fa601854dbe228ea91a67ccf156f63125739", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "65541b51-b687-45a2-b299-037fea73e1d8": {"doc_hash": "4be71a29c244dee7a0b01753a018a63d5ce1c8ea6d6f7730721dc0a0e99d14b6", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "74606245-fac7-4c2a-b8cb-c5cecf747ab8": {"doc_hash": "fa5ed769e8b2dfa8827fd5c7b3beb47720ed5cabcee4e6bb73538b0d99000377", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "f4f48e45-b4af-465c-990d-cd25be88e443": {"doc_hash": "1e9a33892cdea08f803d5f9af4651888ff51a5fe8be24c97e70ff51a1cd7e8aa", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "a2241410-6956-47fb-827e-09435c5c62e9": {"doc_hash": "4a5fb2c3d4d0056ebb06e77020a0374c05c039d83866e7ec572e6ac9d6dc2c64", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "cfb532a1-6963-42d3-bf05-8b2895076cb7": {"doc_hash": "a371db99793413a7c544fcfff1df4923bddfa2ba80a375a22cd4a9e8b12cc68f", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "7abdc2fc-bcd1-4043-b0ca-1f9d712a5f07": {"doc_hash": "f9e21c4d32e90986cab04fd580665a15886af5111f4c554bb6e06dc093cdd912", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "7b6fb996-61f4-456a-9cb9-e2cfb7c1d86b": {"doc_hash": "235fde3837dc781b5a7a07a4f2e9b7d338a0e6cd8dfe1e99beb5872ce48c9c1f", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "34ee716d-d0f0-4f12-aef4-465847d41e11": {"doc_hash": "92ffefe5e0a73ebb38092033b11bca355aed2a7d0f6961de2dc5e03cf3100fa9", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "a2188222-1bb2-4c2e-a64a-e2a083e1b3b7": {"doc_hash": "35971899ab223a865e144aaad2bf1c726f865a785ee2faa978ffe03e6515c77e", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "ecacf74c-d7c8-4e04-b690-2573b50de193": {"doc_hash": "ec22dddd60a46eb41f30b9d65a9717c0aaad4fde5c16a1c628c5cec335cac57e", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "1a2284bc-11fa-409c-8765-f0703b8550a5": {"doc_hash": "7d3d91b2bf588e1fcb941cbf6f8837398b958145faff8e09677a43c97b09cf27", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "d5df2e9a-bfbd-4cf4-b442-e3a814f55868": {"doc_hash": "1d520b8952d5ba44c6b140f512f9c8f2fb10bef0e5322fd44d92348034d33339", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "9ba9e8fd-007a-46bd-bcd9-9aed5e72acd7": {"doc_hash": "7f4a61cbf3bb2b306500f25bcd04e71ef630897cd5518837ad0a1b339903aacb", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "4311298d-1d98-4aaa-82df-5a8c7db921ba": {"doc_hash": "38a92b14d8ed47f74fd3a2d7c6d3bf1d5a77dc8bba1613ba145d8658f77cdebf", "ref_doc_id": "17a501ea-b213-439f-9cb6-5c45fdc40fed"}, "d7d3e7ce-7503-4c02-99eb-fed61ca75d84": {"doc_hash": "9d8b2bd6757749c746a0e7c622c881b6eb15818f873316e776fde7a9c06076cb", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "b69f956e-1b37-498e-a626-8d46b318d6c8": {"doc_hash": "fb5a8eaf256af3724bd44317fbd05b894a555dbdd5349ab5df44326b6a6431e3", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "71216225-ff67-451c-a7fc-24a2d3dcec7a": {"doc_hash": "dcb9ea9213b708810f8de9a4ef393f83082190ed2f4cf034d5ee3e2dd11b322f", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "b1f3ef1d-49af-4630-b718-0f0721d9e423": {"doc_hash": "ca1fe8b1cb6a666c95915a364fcd214a1d3ea8bb2e8df600fb18f97a7d501bec", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "4f7b0905-a523-4a12-b460-9700dfcf196c": {"doc_hash": "1d3f212814d32d5e4ed259d788a4b61d8b1dc2db529a0791f4e2912f8da679bb", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "2ab418bb-93ee-4553-bf33-59e3d57b9751": {"doc_hash": "8ec3d61bf2b9e6fd980aee99710fe0e11079a12e0a4de36b585185be4ec0ee19", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "e72c1b71-6ee3-4522-884f-c2daace298a0": {"doc_hash": "f379e43cf2e267d6a0eee22d99ca4de872b5200227884a9853d64ae7a65fd63c", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "32608809-57d6-40f4-ba57-d68f4c508285": {"doc_hash": "102505448d9c4bb72fb3557559460a33200da4d23647fa6da201cf4653b0cd8b", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "f50dfd06-0867-4383-87d2-161e39bcfea0": {"doc_hash": "e61e89759389944a84c6f1f759a998c2adde48872c4d57212799f04f2b2070d5", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "a937a5e4-b0f4-4ccb-a8ff-35c104a0df40": {"doc_hash": "2add93dea82b575d73627c7b21209aa24a9c6fd987775781721dcf32194d683a", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "4254c6bc-0172-48c4-ac96-a3ba5c2aa51d": {"doc_hash": "ca480e35561f77a115d3e8d9d888abcb6ea0c8aa00ed0e21163d2b0d549978c4", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "89268ee2-1d52-4b33-9ca8-56e7ce1d6149": {"doc_hash": "7a1d9d657d36f3093eb1db6b56cf63ed230afaf239121e17495eb2d6cc208c46", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "8d700dec-30f9-4d56-ab7f-d7f27979d5ee": {"doc_hash": "5fa5ca5bf35ac050964311ebb12326e911caef30139ecfd5d5b4cb5add19b35a", "ref_doc_id": "75493068-a001-47b5-a8af-1f802ca5060e"}, "26bec142-c9e4-480d-9770-453a253474ef": {"doc_hash": "9b112bf45146000a80e396c1dd3de942a1622a82c35a2836807d546b144517f1", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "09d0c0be-5f1e-4107-91f0-7e2b610e95cc": {"doc_hash": "d8e06b7c31a21482550b1d7a9dee43c576508530f747f129acc3ec61a9740de9", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "0915d9ea-3a5e-4fbe-86be-4d965c3598c1": {"doc_hash": "a30c07d7114860330b63ec0e134e509291ed022ae633e5b77575862994d8e661", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "866a18dd-f803-4fb8-91ed-bfec821fd92c": {"doc_hash": "61b5f2bfd4bc0e818b3ba2b3948d57c7a1bed643b33bd7a7171326be001e03c0", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "aca32458-9f28-4913-bc89-e9d265351181": {"doc_hash": "e5185b6504190aaf9a8134f4fe32f77e056fd9c1dbd14e75cda5d11ef7ba3154", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "e06e0115-3042-4f67-bfd1-f0acdc5238cc": {"doc_hash": "12cd07e605c0b5f98ff85c9b599326f9c246e0c7c06207573f65343f29ec5a43", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "5867bf86-3498-4864-8c56-5ade1e5fd5d1": {"doc_hash": "af87b061e5458acb68c50576b755c475825aed8723600b4e894899891fbf409a", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "de822dce-b180-4539-92af-9e5fc7aa5141": {"doc_hash": "7469d65fb9054533d0387defc81dcb28ad6b08612fc7c2cc8e30ef6142b2dec9", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "e6b548c2-cc90-4331-907a-ec15ea9d0463": {"doc_hash": "c64a8899641e8fba9f27ac9414a41b33a6ab6a1dd16b35cef36f0943a374b970", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "48b6afbd-e585-4e26-a627-46b6d96265fc": {"doc_hash": "3731ef462eaf03a2cbf6e49f7c52907a7815d9a091396b7a35318c3408db085f", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "d2c9191a-f5b9-43af-96c6-f3e9a8e4ba44": {"doc_hash": "376ef5969b42f2de9d5e292415aaea9b7da3d05ac55d10be3832dadf6ee8be07", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "ee33cff2-ae3a-41d0-8195-f4f734d1f99c": {"doc_hash": "d79ea17dfe1fefb093d640d746a61023f67fe4a3295db2ad9e4f78d68b2dd2e1", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "c6c1552a-52bc-44d3-95ec-400f72ed01b7": {"doc_hash": "664331da8f47f726a44d5731cac2cbaf1471a8e9bcdad89ab5237f84bbfde957", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "288d0477-ad22-4479-826e-79ee5993fb43": {"doc_hash": "52cfd08fc519bb477a2419e541ccfb8b759058c4b8f6a8b9daf12feba008f28f", "ref_doc_id": "01248c14-ddd5-43e7-bddb-21d57408d50b"}, "58848c5e-ff41-41a1-81b7-3d666fcc4b14": {"doc_hash": "23ef61ee00a39543563096282aadf99031e3f28d3cf7e60a3ffff4f746f5f656", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "f859c378-15b9-4f46-8bae-753352f5fbda": {"doc_hash": "49484d299e3c030fb21ce6f4481c6c1a2ef69f4ba75d3a0ef1ecfe2a7dcb5986", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "bafd2de2-f0a0-40cc-b30b-91573bf79e13": {"doc_hash": "e279527ee76624d675a9854674af01fa196303a49e6ab4a1eebe7410e4ed37ae", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "06d1d948-fcf7-4e88-97e7-543f7538f965": {"doc_hash": "8322eefebbb92b064b74be86e4bf3047ea70685d8d1949276f3b809b99f64dc3", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "682098c2-a4ad-4a65-bc0f-938475347488": {"doc_hash": "784b45560c56710d9147f47633df96f40a5f87fab0735b3ea42cec4dc5f75ed3", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "c094aa57-8c88-4b93-8e8a-df040a9427b4": {"doc_hash": "b1024bea05a80a5db13c1a6d2dec54dbdad6df1451dd849b157d4bad238ca0a0", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "5925d02a-260a-4b45-b368-7a52d339738a": {"doc_hash": "185fbd9449b1ae580645fad7178f73acbdbdf8bac0e1f67b5d79d96322f47bff", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "362a794b-86c9-48e1-8b9e-d1ec39e30a7d": {"doc_hash": "4c6a53a5bba9662a01268a431373da982f40e452a8a0ab54ce59bd94fdb9c1eb", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "02755e37-62d8-45f4-b0a8-22aeb99553d6": {"doc_hash": "5680c7923f6f187d51db25757684fb3eaf55aa57c4b083f83a6f0f5057c690f0", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "33bedb07-8d84-4e0c-9446-bcb88bc61319": {"doc_hash": "c3851f93d7e01ae106f4b9bc80c3bfc9ebfb94842bc598897ea6aec01b5209f7", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "b60b2636-d650-4609-ac16-fa478c1ca248": {"doc_hash": "990edd1283d321eac4a1920ba06953a0fde9b05f50dbee359dca4ae386665df9", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "02ba5a61-8c36-4535-9282-0e8098082ba5": {"doc_hash": "ad634aecb60f66b3b19c859db7b6424b9db8ab75fb2d70d8a7d3374dea99cb6b", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "70829e39-bdb9-4b0b-ad3a-bb8586bf5acc": {"doc_hash": "3842c215098fb52143aa361650acdec6290cc068fbe52c453c66ca2e9c0e562e", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "3adb3f5e-cf99-460d-8fdc-fd6040bb932e": {"doc_hash": "2c12e1682fcba8fa3cee84e9520f4c9e5784aba3c891f4311dfec8da3bf272a1", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "45aa2d3e-bd00-483c-b7d2-6a9e3817eec8": {"doc_hash": "6bf621fa26050434a1390901fd9272248c2914fbd5756f98a6c0d80076e2f037", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "843a3f02-2f61-4aeb-aed5-4bd6459ce9fa": {"doc_hash": "1a80e28f8f541e5a342b1d487c3c1394d7174709c0394e39161b0e5a5654f92f", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "dd9f3734-761f-4f60-9c91-37ff7e03565c": {"doc_hash": "aefe1a135648822e2489c2266050b723df8721f583e20544dcef4612fe5c5731", "ref_doc_id": "135ec149-e16f-48bb-b74e-4297365a398d"}, "a9b41f07-973c-48a1-800f-1f077c359642": {"doc_hash": "9d3e52dd7827f53667c3383e800390049bf6915862e716332bd59edbb7f9d2cb", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "69135622-76bb-4c07-9d12-d23848aa0d94": {"doc_hash": "2755592db92c913897c8541774a2222e5b38ae259bdd939e129a22c75ba8517e", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "2a610a38-af97-4076-8a7e-56679d165e07": {"doc_hash": "4acb1462f5fff4bf1aaead938bc33c030b2ce62cccc463666917a298feac182e", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "fba44f03-928f-43c9-8d9e-3a8fab1fbfac": {"doc_hash": "a5f75259e3539ff08a3a0d3368df757138c37485ffa10d5e3f262a49780c58a9", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "feb3193d-6120-4bba-9c4a-26f2a4fb4172": {"doc_hash": "0833a12329aa889cb60df004e37d5f6984222058eb7f30d43b11fbac86e86f6a", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "0f2d95f2-fd1e-4a52-b007-c84c62916c2d": {"doc_hash": "d05238a3c20adddea26cb07bd8f1ff787aad70e39d7c1ec6dc945e4adf95eb21", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "5346f73c-acc5-4e54-ac5e-9eadb531be04": {"doc_hash": "8b23169e0c3e0dcb7b41a05392c814a01272dee490b9cf3e5b6288f613aad685", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "88f03664-ec82-40bb-a27e-c2d9b5114fec": {"doc_hash": "e1bb9f5a68309f6d6534b6e85ab85911e9e6fa87fe06d8ef873b98bd3b9e3646", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "a22be1f1-7f01-4a18-b490-a289e80819d6": {"doc_hash": "16f47e6d102ee56d265eca60bad23462a5fa0e96476a98db602dca0c56dd8ad9", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "3ef027db-09e0-48ed-8e67-3d7e679589cf": {"doc_hash": "007e950c42743e5601176529a1a139f5cb7c13f490db7eb2ff6615a793dba0e6", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "11457ac4-6034-4168-801b-209347fceab2": {"doc_hash": "118ae57a9884cfbfa14a777cb69d366d77815e337bff7629144ab3d6619f95b7", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "6e67cc47-5ba9-4bbe-b52f-05c33d906336": {"doc_hash": "666c9e10651769388e2a1aa926871a794ab04f23c92286e9d24d70c7655aaf32", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "d677d34d-baca-4f41-aedb-9fde87363ba3": {"doc_hash": "a47151d66eaf48bfe3f26a375bd47050a1f503a81c69200d50f366d4226ddb73", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "e3747ad1-d44d-4d65-b8ec-31a4aecb6a8b": {"doc_hash": "933527e574509ce22ed003b663cd6f534c3012dd1ec1d8d733f202a5284a07b2", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "1d7a1a56-99cb-49de-9b58-319f44af55cd": {"doc_hash": "bb1fd2114efa1f19f174739b8fe4842f351aad830e91d3b23dcb2b9690938e15", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "1b2b517b-3c45-49be-8866-6cf89ca68716": {"doc_hash": "95c81ac0375f9e7ea8d20df582cd98ff17a925655612c321a54b2663a43c601d", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "842f4863-2504-485e-a658-933101d2c985": {"doc_hash": "08fd11daf4ebb5fca7739e695c3654229a504bf23fdf3bd6c0417e4db0ded145", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "647ac908-8dd8-470d-84c7-614a787ff95c": {"doc_hash": "32c6858c88f7586d4f2f587d693e1c52cfa54b6437fd6d833ac8b3f4b4fc27d5", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "ab63efff-c51a-461b-900c-116a9b74579a": {"doc_hash": "db0c1097eb4c3156649b3da281427c9eb894e39c0948940758d8c904d47a9f42", "ref_doc_id": "0852aca3-2db5-4fae-b330-9bc9d288a552"}, "9139bcc9-cd17-467f-a667-b7a527ecdeb1": {"doc_hash": "36c60fa0f5d443db4a0871188c4b499707616e1bb7d1f36cae750247f258ba7c", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "3b7d2b29-0adc-4d6e-8638-79692caf018e": {"doc_hash": "28078085a3076cddee64aa6d04d19b66169a0b87a87f70906f376ba289e38266", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "e4241d25-04f6-4f69-8bef-667cca67aca8": {"doc_hash": "7dc8c6992d1ca80f7f73c50c7f7fd373d319c4319ee780a1067dd15df9ed0e0b", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "a5bbaf20-4680-4882-83b9-e52c8b12563d": {"doc_hash": "50bd7aac4fe965abb626233f382c50777be77bced7d3890c673f81b95d13bcdc", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "a56232b0-7818-43cd-8b97-c9eb9dc06478": {"doc_hash": "bd995664d25158de8df353b2871d2813a61bcb47e7f89d292420f854e96327ab", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "267d19bf-c90d-4fe2-aafa-a282fa485686": {"doc_hash": "bbfd5db04caf3bb94accf6c77c413f64b0b73c45ec3d471d143752e14e30f73d", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "0b9b3942-ebe6-4f9c-947b-fa2e87a35057": {"doc_hash": "7dc2124cf608f3b2f33616905df505a9f8546505118668893b5f0a0422a9c844", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "4930ff8f-271b-4d90-b403-5f7de0dd4365": {"doc_hash": "dd5a7e0c9b01f15ca0eccc7f76894c419efc4ce0b96ea2b8ac9e9ae9bde7ad7e", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "e03189d2-f6e9-468d-af1a-c242bf47a9dd": {"doc_hash": "881b4992a0dcdfce0785728c95b8a225b6ba01786a84afb6bfeffd0bd4ab4333", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "3fcaef7d-cda6-47c2-bc97-8cb051f896bb": {"doc_hash": "3398a480e64c2b3528fd56b56b82c44aec6365aba689c82318d16104d41a767e", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "76638140-c614-426c-bbcd-b4a9bf9904cd": {"doc_hash": "355d691ebfe2f6f4fc89baf703f78b7c79465804f335a5a8146b2b0cbd02ae0f", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "8642afcf-227b-4858-b727-698aa5362d98": {"doc_hash": "a1951372fb99b591f6178f72d3aab96b0d11a43cbee997fc351a6ed34a4cf13e", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "b6ef050c-0f9e-42c1-bfa0-f504400198f6": {"doc_hash": "e2d50671105319534a5b013c04561a01a6508776840caad905ee68a22efb92e6", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "7bb7ea52-0f1a-4e5d-8a5d-2d0a14cb8415": {"doc_hash": "718f11d1d299b4a066e60ac7d17e89a43569f6bb361fcccd057d9ddc686b5bdc", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "9c052b15-3d54-4d83-844a-7d5baf22c3bb": {"doc_hash": "e9b203f44ff849bcc52a73e37e4802762fbf3fba92b52627f9bb35a9134bb68c", "ref_doc_id": "1ca50656-4b33-4930-8de6-396f6665d59a"}, "757b4c50-3704-403e-b355-ba7dac18c0c6": {"doc_hash": "dfdece2486837b4c20827f324a2b6456dec68c7f1c82436ac67fb0c7f3626854", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "53f46995-dd55-4cbd-b8f5-7cc973cb1e6c": {"doc_hash": "5cf262cf96838850aba64b97f167a66e19f6f8b89c9e15e65a7d6bbf68423a0c", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "560b7236-5d77-4949-852c-f4c6633404b2": {"doc_hash": "0cdd9e725f9d52ec13df523847145b3176d1ec259bcc980e99222dbb24a0a3b0", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "a7785220-69e8-4375-b585-2a6ac7f3bdbe": {"doc_hash": "3f2cfe92dc755a908fa5348ce529e893a697ae4e46a1900354537c076804266c", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "4abbc5af-6ff5-4b4c-97e4-598709476001": {"doc_hash": "1f957832ed6091137cb6d9310ac8e0adf602c4d6cea8f21859db711fb4a06c59", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "8403a479-7333-4e0e-af5c-b3aa28850fe7": {"doc_hash": "6a92d929aaaf64bd28f371c83c254394e01f457e0aa3884bd90c5f07b71920a1", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "72052fd3-0d33-4663-bce9-9f0f79478738": {"doc_hash": "595e472d548b64354c9a46058414ec3b92f331e3df1136a6686967f19a3c6531", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "2c140c8f-14d3-4352-9225-3f7f4d53196f": {"doc_hash": "fcb203ee322d50cfd02643b6b414c93790e854309bdfe91e8306aad1e29d833e", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "f4866f63-1e66-438b-95e4-8f79aa63405b": {"doc_hash": "441791558dd34d6ef99ab04b199330f402a0b6da346a62db5135a778bc090b56", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "451a16de-a0de-4f31-bb4a-4af1094d1000": {"doc_hash": "9ffcbcf5e7cbafa4db4ed231b21ddf467d14325c89b793b81623bda7cef8838e", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "bf30973d-1d9c-4768-9c62-4ec9ce74d4f0": {"doc_hash": "adc003513a8ff322c1eb4cae3f04bd578d0b2dd58836a5f4beb9b2135a1c6240", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "bc07711a-ba64-41d4-a2de-6b8e39627208": {"doc_hash": "10f8c584e883c8767cac0fc7fffe77323014f92804b52737f85683c2bc073472", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "c9c55f4d-c08f-4dc4-9d5b-a736c6ae0925": {"doc_hash": "5ed1b1581f5406b8517b5d9da08de456bf8b3a9486c940b819d4a5b181b8eb8b", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "33a6224e-0095-4708-8602-aecc94271eb5": {"doc_hash": "f38173ee11abc7e91ba331bddf310436bfd6ecccf471c70f1c751fe1f425a3b1", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "53444d06-f00f-4e01-a226-1a1c4f56d1a1": {"doc_hash": "57f0800f9cadabdd34f6bb8f87251b46d9e8b574dc695ecc6ed90c4e2ce20ca2", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "26816b8e-429f-45c2-be8d-4cf2085c7b3e": {"doc_hash": "e2c9e4c8e40b80a579cbe56ed6c7a881c64b17038ada0c986c971dc537c4c85b", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "e40b9e18-03e5-4ac6-ac7b-478172d0f0ca": {"doc_hash": "854eed273e93b125286c72b5aa6776315e4ba17cf18e0e14c0ca4d8f34093d6c", "ref_doc_id": "d2387a0e-defa-4a4c-b426-09b5c56ea295"}, "7981e866-9b63-4902-bbe2-3301aefb25ae": {"doc_hash": "462d15696d4df4e277f40440ebbfa6ef21a0bc0b275c5b85b3b25ea2a65f34d8", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "a4dbab9d-2233-4e54-8f26-f57d53c874a9": {"doc_hash": "40253ab4b40eb3bf278712d851b8b9db2f0f4127f62dd7a26faa84ed32fe5b5e", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "61b64baf-7e35-4342-b773-882c372c1f61": {"doc_hash": "b93a1187bda003b56fb0c1b26e7bb85605403cb794cd391b3324c593f565c26b", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "1ebe255c-cb01-46ec-bfe3-08dd13de60fc": {"doc_hash": "ce1e47a12cc22da2e495aa8045eb640d12b91da7df62c2a89c8943126931c152", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "2df2aa94-1b10-427a-8f12-901b78206eaa": {"doc_hash": "88dd8ddac0361bf491cfc6b08f9fc313bcefb97fbf99dc92ed49192ec4c0c475", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "8933b933-08ca-4f35-bd86-eb7a9b0356de": {"doc_hash": "a2b76059b77949f13a657cf0e4c68769b6a6eaf1d72a7684857d018b052e6a83", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "8f2a0c80-1474-4372-8cfc-65097240cfd8": {"doc_hash": "39e9673698fc09d2c0e595d819b1c0e815cae35802ec1274e53386b641a367c4", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "c779f519-6d40-42ef-ba08-7ede125c22d7": {"doc_hash": "ced9e5c1140ae5a93a6e350ec8a003d57427e3aa6a859a2cfa28113b3a837949", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "ef8f4ec5-588f-43e2-b8c4-92f820d9b865": {"doc_hash": "70bb81d7925f12556ac2a4d58dcc316420159a2a285e0f8721a196dfb76d37b2", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "818d1d59-1697-4ef9-be27-fdcd7dcec32f": {"doc_hash": "5195df4a8e38c46fef8c6e7e251191b2647ea309e82dfb68f32392bc933b17f3", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "1f5fd2e8-e803-4aeb-970f-381af58a464b": {"doc_hash": "0cec259e6a8bdb0e471c302e0d81b2ac01cd8091dce7cfeed9ff2a1b275aa086", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "97e54a2a-72a8-4c19-9568-747ce271bc48": {"doc_hash": "05316ebcb9b727ec42642c1c3a93e5adf2039e38f996fe564741d2a6799e0021", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "227fb644-4d79-4521-aefe-d3ef6338b30b": {"doc_hash": "504d79541deb306bcd4fc9aabdde8b76a36441fafed1a9de8b8b4143d865d3ec", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "64217d82-5c7d-4879-bb97-8493b6452dd8": {"doc_hash": "402813d0d5fdd13c74ce8fee026f6bcbd1dbb81908c8984af174460593c86f6a", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "cc72b49d-2a08-418f-9114-3c384440f2dd": {"doc_hash": "d0c62bdf9ce22ed1a41e35fdc7ea5b440bdb05d453aebd9fc36fff6980bd44ae", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "75fa039d-b4f6-43bc-8f05-60bf6f1182c9": {"doc_hash": "d96e9101a92afffec079c0cd428d7975902e8fe8fb4c723255dc80f6c0a1af46", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "6f87dd4d-50ed-441d-9265-af165d926d31": {"doc_hash": "20920278fdbe8fec63ea8313f0b1222562f62688351cfaa5edf0bbca9ebbec94", "ref_doc_id": "96fe8a54-832b-4185-a72b-e8c072e46848"}, "d6ea48b1-5929-4d10-8fe9-dc7b26b483ae": {"doc_hash": "2e815027fd9c4feda6ac1b47b12075523442c465d62da4da6c9951f74fddccf0", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "88eb73c2-a272-49f9-8e65-821dec52e323": {"doc_hash": "e0fdb0f2d41d0f6bfcc0d62195fa1d4b75709047066cd0651d65180379877d19", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "e2b9a854-bb63-400b-8a7c-2e10c89737a4": {"doc_hash": "5537e524b6b53e8fa4c0fb3a3528661441afefc95c181982072219fbd0eaab20", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "e55b871e-bd86-483b-8b3b-b8e3b9f30747": {"doc_hash": "beb0281b83c85411bf77523307f8fb75ab7495d847474b25372dc8a4dbc69a84", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "254283ee-98f2-4535-bcbf-99cd87554ba1": {"doc_hash": "cadc4b7b25e3f5e0cd0611ac6b28758351b761e6cd6d34301e5d04ba6b3b9f7f", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "402d9b26-09c0-4343-9c14-9a103f1fa406": {"doc_hash": "c25a61114b7e67a200785bcafe46f1bd8cb8932e2ad4924b03311210d87a144f", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "96000cfe-76c1-466b-931f-7890651ab0a2": {"doc_hash": "b68ccb45a1162323f478ee6ccb75eaf070eb2e1fb641fafb5480bfd17a0eb0a3", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "81b801e7-8d1d-4c14-ac3b-51325e29083f": {"doc_hash": "2ae34d8115ef6a5556ee0b34007f9803b31eb8fd86d2ad60822c635097e59c83", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "307b87af-d5b8-46e0-af50-5688a48850b2": {"doc_hash": "2e1b088dbe21567b83d73e35311ae255e77839775fb3e401e920424b825ec53e", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "78021071-210c-4bed-bac8-f516ea87ef0d": {"doc_hash": "92782adb8685d8fce5f3cd3a2c8ce19211ee290ab28b83fdd5680d774fdbbeb7", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "24757615-fb62-40ba-ad27-432476c65eec": {"doc_hash": "fc21c6bdc734d05f4a25ffa904bc661564d2d6e8918e4b93fadfe9d71d0f94cb", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "f386b0ea-8f8e-41c4-8e93-733fa9a7d10b": {"doc_hash": "6e2ab5065aec599900448425262cf3d9d174eb90277692478963c6dfb228eb68", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "7dde51aa-0197-4175-9166-111348bbd62b": {"doc_hash": "25fbaaf21b9458d770845184b7090a4f46af3d07fceced14e0df4947c0eadc9c", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "d7739945-19f0-44b1-ac4a-bedb17d559d8": {"doc_hash": "7fa8d00702a06d62ff2572f96668a96b5b757def1cb4325a214f49d6cbc816ad", "ref_doc_id": "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421"}, "ae6dd3f7-d504-47c8-81bf-11aa10822b53": {"doc_hash": "c77e5eadc4f69687a442fc609177f60d0727ddde795e3b756c3561124adbd45a", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "255a3bcd-80db-4df9-908d-d023349da887": {"doc_hash": "4285d0155f035b3efb71aed6d72108031dd5d0ba0a6a992f145e0bfa3173a109", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "5a4e3f57-1d22-48b7-a85c-1d0a71f884d7": {"doc_hash": "0e18aeb5258854e7377c90d0b394feeeb20a24a844cb48c48922b3bfbc6daab0", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "15a718c4-1bc6-41eb-acb3-b01a6280e957": {"doc_hash": "c7f28ac7d319aa7304080ede758716707ef48536e629fd0b2c6f419c673de175", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "cce5d40c-404e-4ff7-8465-5697bf7bf6ce": {"doc_hash": "81e06fb4acd082e614576973bc2f25fce9c91461b9c9dcc531604a65a0a30d97", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "e38bab70-e75c-4ed7-a462-903b2311e90a": {"doc_hash": "fac7d2a7d182e23139f35f32175537f146e5944e30db42662c2795fcf6052fa5", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "c99a5412-9fb3-4fc5-9dee-5605c3b66d25": {"doc_hash": "66e85272ba238213bd74a55633ccd01c41bf55c5e1e3dd15de5d5547db2aa541", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "5d9b6061-5c28-4d2c-9bb3-c0a0b27e6924": {"doc_hash": "471c5fd833caa3bf04e671057d48198f8f7a6f9cfc2e425774a8dea1453a6744", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "f04ae789-293e-4c39-b281-512683403ccc": {"doc_hash": "fd5fcb6346d0b3f49992faef97140ecf5bc56a969635c8c8b274694c03a848a0", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "00996555-1e67-46f7-bea6-295ca42ce203": {"doc_hash": "893b0de1a93c9372186b5f7cbc114865abffea89d8f65c47c9d4fd3e5fad7bdd", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "65ee96bb-bc55-4e07-8b8b-10f6bbd23b49": {"doc_hash": "0e8af7508d6c23b9b2c5ed19de04d9b5f70fca29d73da2446bb4405c59f53221", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "a6fab380-2411-4dcf-8eed-d85b5afb3fa1": {"doc_hash": "22a4870857dbe61a2172a8336f10f9938672ae5f229b616bf4fc70657e1a15fe", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "47bfd398-9d27-4d2e-be59-5b1665212573": {"doc_hash": "cec3469c699231990ef8be097eea2d1455df4e1fb6d8db9686793259382218c7", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "fe3729d5-f085-4d53-962b-67247e9bc35b": {"doc_hash": "e3030897ea4f94e227a21a62ff517070150f738ddae215a25df2fdce64585eae", "ref_doc_id": "da1c31a4-dd5b-4b8b-9f3b-09672b531870"}, "b6d6d7c7-d442-41d2-8363-df549ed9ca92": {"doc_hash": "f487ae5e4da6af848d1c918015b7949c2e9398093b199af275f6f02bec97db43", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "20b90c31-5a02-4fdd-8f5b-aacf41f8fbef": {"doc_hash": "060bb920f5d0fb4bed843a8156126c84e6aaf0561b183c130893245dff2b8eea", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "35188314-ccbf-4a1a-a482-897cd167aafa": {"doc_hash": "e3ae8b39b2e3d573d759e69bd23cc0091afc6a54c1621d660c760f8ef3fc7e5e", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "f2d44571-d7f6-4613-86da-1e660b2187b5": {"doc_hash": "fc64e9e8a8768a8356da12705d0f2b95318d1305c29c42e66dc546dbcdfde3d7", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "6f4fb5b3-5bd3-425f-8916-23ce7c614e90": {"doc_hash": "ba49fb795d8058fb2a68036265f8772fda811bf3020d76224b1f1edbccaa5023", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "c97cc2ce-73e1-404c-b99a-33c6b228f246": {"doc_hash": "12897165c66c857df9c80405e5bf5551707e0ee4b4a18b030cf1f59f215dc08d", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "b6b76e01-b458-47e5-824f-cd85a12a8e97": {"doc_hash": "70b204cfc5b11870c9b14fbbea6409ff29372d85e01f2ca0cd070ca4fcce3f77", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "6c160d19-064a-4310-9907-3e0c34ec2919": {"doc_hash": "e2970154834fb5b1ddaf70327acabf60a7c91a60fae110c138653b7a2ea3b285", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "684b31a3-e88a-43e6-b479-78953ff2d83d": {"doc_hash": "df06c4fb3b5f0358e971e9cacd1feda59f32178bebfb5fcbfbb1cb19a54eb319", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "04ef5d15-0e03-43db-90ba-eb5e691a9810": {"doc_hash": "e064a957589efc8efecdbcb416ca029c5defaa18ff081340fe7bdd9163fe8e25", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "1e58e92c-ec9f-454e-ab88-fbd5831b43bb": {"doc_hash": "d0dd985d1742ee3948570012f9fa8b7e1ee97ee44beb2afa420b9e11a019665c", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "96ed7c18-d5e7-4b2b-84e7-21279ce811ff": {"doc_hash": "cd38d4ff4d6d3bf00440f68984b356faf70373cd6100241bf4b49b9e145a2d95", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "05cca7e8-1b47-4cfc-ba1e-0e9f249c7ed5": {"doc_hash": "b084258e44d2265cac721b606c9bbf02c828d5c165a78e5f0eede527b5b51336", "ref_doc_id": "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37"}, "94e30b10-cdc9-4788-9b5b-4fd99ea92f7f": {"doc_hash": "155237e22d803bdae6578e288104f3267e20847f5fe4a0b5a42a4059a63cb980", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "f6f792d9-f482-44fc-aceb-2d6926a9649f": {"doc_hash": "93ecf349c6aa0832d5643d05515007762e27ac716aa8e5536fb8a8f92162bb13", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "45f449eb-ec3d-4cf7-98fc-cea3a66899f9": {"doc_hash": "a8341d693741705d6f65450d3642552d33415057ba8fb45955802241895d9ae5", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "295a929e-56ae-43c7-8650-265c20d01e8b": {"doc_hash": "1d410011f47e2a42317dbaa3150694e0cd5a2a1ea0a6a0835da4b8aa9804a325", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "f8a1b89c-6431-4176-a4fc-62de7df92215": {"doc_hash": "3c061bd3f067e8f5a769b76bf6bf2bd114cf3df13b35835ed6ea0b8b06863cd5", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "c10ff758-2e20-4e71-a1cf-9b27675ad14a": {"doc_hash": "0e8143037e941ca4abf6e1faccda14d1597c3b3d0d71d79318e1cdc67fac7026", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "f1a61136-1608-436c-bbda-31f5a2b20004": {"doc_hash": "64ba18f8414da9cb1c9a0d35cd05ba328a98af97e2f586ba42aab43664266a04", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "299d962e-c365-4ea3-a702-2225f497f587": {"doc_hash": "bdec9d87bdf8349b8166666ece521fbc03ee66e0278679cd204955603108cdd3", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "74406c4b-bb67-4ba3-81a8-07f194f0e5c2": {"doc_hash": "0c77f656634d53d13b2255a6c9f2234cb7e5aad29e3434d63c1027000703023d", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "c0bdaa90-d446-4368-b307-b7bd5ab3c703": {"doc_hash": "681a8b13e1d29136f3b6205e11e8a4f3d2d76072a6b85b5c565f8a1bcbbb2049", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "a2d43ad5-30cf-41cf-ac65-3d354b709b2d": {"doc_hash": "b6aa4a26cdaddc90b5a5db7de547322e5bbee38ae14025b7150db3128db5a31c", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "d44b464b-2a4f-4fa9-bc0a-23ea87329b84": {"doc_hash": "3de68f23092c0b7833279c262dbe4b5f46e07d909453846c2cb9bf5b2c147fe9", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "56c74a56-6d44-4f0e-bde2-e9aa2df2ef14": {"doc_hash": "5dce496050de8e77b46df8769e317e46d18f1fc90f20a8356d86c6fb3d8d7235", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "599953d0-521e-4c46-b502-6597b7771269": {"doc_hash": "9574fdf6a8f479c88b5aa72f8bb9783ab1db05a959f17f4b934de6bedd01f5a7", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "4a178da4-a655-4036-b4fe-b64bbf19e36b": {"doc_hash": "0959c6e35747603218d64b5820eec8b0654701c7faedbc7eb255d5376e2abce9", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "ef383a25-32c8-490f-84ea-60d67a5b1d58": {"doc_hash": "051ee9e68c1af0b78808287d55a4260ad8ce45267b5a0eae8ad4088588d2b1f2", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "902d7723-1edf-4ac6-8449-6039fc18b448": {"doc_hash": "44dbdef46fb91c8e3ceeaaf53077099ed2c8d681dbd77f3892aad73409d0cfa1", "ref_doc_id": "76d6afd3-472e-4f14-bdec-478a7b3175a2"}, "ad08b168-8ee0-441f-85ad-1fbad50ffa08": {"doc_hash": "dd78e994c5920b97433e1714632d34d27f0fe40ba16dddc4110adf0ec7d3177a", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "e8b3b53d-3661-4942-b9d2-fa3ebbefb1c4": {"doc_hash": "b6fff9208f6f02bcd2338fde238dee3505062a5985477d47c2c7ed8f80f307a6", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "105ade8e-c668-4b07-a548-1b2ddbcba761": {"doc_hash": "850e2fbc9ece5c220f04f0de3886c0dfd71af9e7f54820be308e450ecae736c5", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "05094f87-96c5-42a9-86c7-3291ea7ca06a": {"doc_hash": "df863d32273eaa29a868c51a5a95d981fb0ae706407218af46f099fd423441f3", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "dfcb524b-f829-4720-ae6f-44f9d855feaa": {"doc_hash": "8629719620152ea9c12fcca54b3a7bf34b457b517dc8415ee600fc6093e12584", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "38c6c671-caeb-45b3-831d-06f72bee23b2": {"doc_hash": "5074b97598849072aa498a6479f351c0a74eb3b8f03dad245e36dbbc1da62ee3", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "fde3dc5e-2b3e-4dce-a845-a4af822168d7": {"doc_hash": "566289e5866282e0e724fec856bf6f3b6b25d88174f7c771d8a4f263720dd5ad", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "20853244-e1c4-40f3-bc7b-cdce8be1b513": {"doc_hash": "6fa1554a2c77a16105e45e5e177d3d806e1fab571cc4951d790b095931d55a89", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "bd8b48b6-ef9a-46b9-923f-f7e108fb1d08": {"doc_hash": "13c9bbd592b9dc693412a3d09fb9a5cb900b743597219c84d2aebccc898ac383", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "77e8de5d-c94e-4677-9876-976cdd1e7218": {"doc_hash": "6e617d2c6d0b9d362cf2fc85a3158cad30736af932f2aee84ff92fc4ef168222", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "843e9acf-63d7-4258-87fa-f636cfb57cf5": {"doc_hash": "e563ba85fd259311401cfb3ab6d0eac35dbc3f488d606e994da19f0db5ea5f20", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "bb1ee752-a26f-4830-9675-ba5b3dbfe7ce": {"doc_hash": "d883a41845744cd9b61cdcd1a6b313bac3f2581c91b9bd882bfae9e532b78eee", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "2625f123-df23-454a-a934-b90848cfaa9d": {"doc_hash": "f6755b5d41a15f1238e29b70de9ef22ea3f013b2ae9446cd3e3d63c524ae57fa", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "eb980769-7cf2-4148-9c40-a08475e340f3": {"doc_hash": "c137b3284353f01f22b0d5db08385e8420bfa8aec1cd4fb9b41314e009cf85c4", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "54bebece-4b12-43fe-9dee-ff56a4c35e34": {"doc_hash": "ae4bd9735f7c0bbf6a3d1d58200bb5bbd78ac303b2ad200e782b9c16c3622fd2", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "fc35fc73-2f9c-4bc0-b857-209bef4d1a32": {"doc_hash": "74a655273c6913cee84e0a8a40c633e747955d7e2bb3ade72af1153e01a1c960", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "08e53813-e661-4eb8-97e6-a59474d9f1e2": {"doc_hash": "2f0717e61d761a3c0f8dccfbd06dfa278b8ef4f12b38bf32334db8f0064a97c1", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "7cbdbf80-7488-45f6-8511-0eff77b022aa": {"doc_hash": "f3c7a7171ba64b2be58e9cf15a068e1772d30a48aeefb0f73d51cbdc0c7ad853", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "af2c138c-f7e4-4154-9ec1-a7ef3a99b3c9": {"doc_hash": "b88d21e402287769c3ba835dced280e03ffb44c2c7468e1d088c77e661edf99a", "ref_doc_id": "26d39df9-9910-4a9d-a829-04e3781d6c12"}, "2501271f-fdb2-456f-82c2-a2c34399c6e3": {"doc_hash": "25ef134aeb317f8f9205108106d1efda4b1844e363bf61f34fbba366ec69fd58", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "cc6fe74c-ea8a-4301-9fa0-a2db1e27b452": {"doc_hash": "d00a33537f22fca03dc091d078b64dfbc343467fb8847b4b5fcedeb992034471", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "339bac2f-7588-432a-964c-121398d2aec4": {"doc_hash": "ef73cb97fde1f0339fd08bca8cc1c0b7f3a7ec787a1a55e448cca991ef14720d", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "8bb266a0-8815-42af-9bd4-1a981f02fd38": {"doc_hash": "8cf98c51f1e32c6d5c513e46aefa5eca6e35a3fa3582892e2a7277514205f9e9", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "eb56aff1-5d62-40f8-b293-bda010f39b3a": {"doc_hash": "b0e260856b85b52ea50e49bfae58e8813ee9ee8d44a8bd49fe6c52b42f61f2b8", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "d53faa94-a61a-40a7-97b4-e986016501ca": {"doc_hash": "21095c720604e01f9a4fd33d468a6aa415561afd27674b5ceb9d0927e61f2d47", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "343a2eba-ffe5-423a-813d-02e908b8f148": {"doc_hash": "b28559d6d0a4dec70fee88aec7013bece7d91fca1d2c7c2ebef0b2571138a745", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "4e49ffea-c28d-4119-9fa8-0d2ec7202b8e": {"doc_hash": "6dbebec22a907e3c81d3030152c463a14bd162bbd7980993b06e800ef41e8006", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "73a5b421-43ff-47cc-bbb2-aa5fbbe317c4": {"doc_hash": "a7abe651951c0d456e3ba5848fda4786e5e54b6ad0dc82ee45e195e7034a1352", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "ebe8ed9c-e507-4c7a-8f9e-fe1ce5bb5fb6": {"doc_hash": "5808d0375988167a8e07167454d3aee40ceb294971567d777a17001036cbbbf7", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "fb01aa35-ed44-4ce6-8c62-954166bc3551": {"doc_hash": "c144eca4f52561ba23e30f46fe1f2ca6d8ce24095f2a1aaa0d4660914dea1550", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "3d3b419a-5e52-4db4-8f0e-4381c9cd5b16": {"doc_hash": "6a566ecd244f00197b114c2a100f9a02bc50ad9e9159d32033b062d8638448d0", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "54094481-35a7-4cac-99c8-eca9e755921a": {"doc_hash": "fd60b71118917088e56feb3d8937f8b94acb0e27784afa323448a5ddafa164eb", "ref_doc_id": "9942db7f-1c27-41eb-83a6-1b4802668146"}, "de02a0f4-3afd-40d5-a9f6-b279de812e21": {"doc_hash": "bd9a0662444680cfcc3da9277af67f9bbc97f1119badcf6e4fb5d294d09ca45e", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "a86bcf23-8c1a-4147-b6ed-a80cb69b6e03": {"doc_hash": "e9d301af71572d626a4eb781887dc6ae23aad0d34c51494d79029fcb80cb6ad8", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "27c0aecb-0711-45dc-9580-1a49b89432c0": {"doc_hash": "f8fdaae197e33bc96526932353429430e0f9d2e621b9ba0c5f9a683160ad51d3", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "dae5c380-4a08-4164-9877-b1d9f901c318": {"doc_hash": "7c1a63feecb41c9cb3db6275f87c929f512d8e2b5525ed0d479ecd7a17bac3a4", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "ded71b0a-019d-43c8-b2ff-258338975827": {"doc_hash": "1f6b5ed820384269c83f1c88320df0a1cd0edc546b4b0fd0e82f8a0919e5a0fb", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "7c56f52d-7ab2-463f-8215-189536592707": {"doc_hash": "843c16528a10876a2ed062919700fbec182d9262ba099e3087692247d253accd", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "31f6feab-2d45-41a2-8c44-f8aea272f6d6": {"doc_hash": "f9f1dc34303cb917bfe6be18271c9c87934b08a7a80cdbda003b603dfb4d52ba", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "d5d6a03a-b675-4227-8274-ab9d04554815": {"doc_hash": "67c80f1848e8cc8676db5bd7a0828afaf76ab65c9a171e223e0de14d0a2fbe11", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "3fd614ce-b15e-4ecf-aab2-36d0fb467ddd": {"doc_hash": "57be24201ab0e2ae59b14de828ea2d7f1c37a3ccc0bc856142db9bfe6f61a65d", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "d5ec56c5-63d5-42d0-bc68-7f54960eec53": {"doc_hash": "8dbad75c5d2b2713e9cbe024363c0e6ce8be8de09092e4a39637a5873e4c6693", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "a1c6bcc0-0888-49c1-bebf-9b9bab26acba": {"doc_hash": "3b68be30718f0f6aaf27d15a26d1e69c6a2492cf5adfdf823b950401cde6338f", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "51eb2f4a-71b9-4c8c-b88b-4a0a5a134309": {"doc_hash": "0001bcd0d2b511b5824a2d5898e3bf1094534cb73099f12d5839684ac4a0e883", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "d9760cdc-1a0c-4e2b-8abc-66ccc6e5624d": {"doc_hash": "d1b81d8d7fc7fe0956c2649368d86bd43a83c36cf535dbf9cb27cdc8d391a9f3", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "b591e5d1-2791-4876-ba14-74eba6bc9834": {"doc_hash": "d04e1c71a07d245081296d365c397751ff322e516318bc9c6918f80b8a797ed2", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "84a10928-c403-4ca6-9100-5ec10bbea583": {"doc_hash": "2bfe501c50a7ff621dfa3e07c3505a317f9d981ce21beaecbce36a35bc18f54e", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "ac0cde38-927e-42df-95bc-b4e90b7f293b": {"doc_hash": "e2de4029b5896f60a5aa61489cf5f698870622dc10a725e8ca4b905fee4daa93", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "5ec031a4-1601-4905-8aec-c53f59974b2d": {"doc_hash": "59f0e396c0c682df73fb525cf8edcb05185306008a26249b78c1c2e319471333", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "6851d501-2b04-42fd-94ca-a1ef9ae4dc1b": {"doc_hash": "96d32fee2263a0a3ee9ca70d881771858dfacbd023078f7e469da3dc9eea2e56", "ref_doc_id": "3f3770d7-d84b-4ea5-ab8a-e301b94a2999"}, "d9b0f526-f7d6-4d0a-b4c3-e38f893559b0": {"doc_hash": "3651bd24087831898935d7e3296201b62ff36b723df9f1505fe47e5593ec887c", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "ea511c25-49f8-4c50-bacf-ebc152380625": {"doc_hash": "37999181e6be777a683a8a0ba4dbea8ffec36fb21039146d3394f2a6100ca4a1", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "b05e4e85-7d80-49b0-a085-73db6b921014": {"doc_hash": "7d64ca8d38aaf0967c0c8a3706c9d732ac90e9c5a47dcb424e6601c1e877eed7", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "737e6a60-b3ae-4e46-ae74-6b6740831163": {"doc_hash": "acd0028dcfcb97654cbd6178413b430aac588ffd2f5e3f51d8e45d1dcfd1b6ec", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "d458441c-6d55-486f-a37b-2230925750ca": {"doc_hash": "e776e8fae8d83f3cdac714d136c7fd47cfda7f9f474efc51397b9e30fca5d224", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "d4814a69-4fdc-4c76-a913-d5295357e60a": {"doc_hash": "83538b877485d0312ba3301fd4140d524b9dbe4d7a232a7d398541f6070649c2", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "90ed62eb-03f2-4130-b00e-256b42825af4": {"doc_hash": "83e75819e32251c301a9128d4005dc26896d4cf129f626fd8fcd818ed8a9a771", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "284bde84-9f2f-4965-a766-a727a7f864f1": {"doc_hash": "a31a6ddc8d9f22b30fc7efcb62efaf30b2d3a746c27b1842d6fd06b37706fe41", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "686f4b8d-6bbb-4d62-b47f-764f849a4b32": {"doc_hash": "34573aba2300e0ee5001f28da1baec87d288886d4c18dce4d23093b97396ecab", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "6e4b760d-8e8a-4427-b3d7-3a0c01efca4a": {"doc_hash": "68fff916267cbdf7501c7b13c361aa0de0ec212870dd46aea49e54bc6234dce9", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "a46435d2-6fc6-4952-8062-af3523be6204": {"doc_hash": "05bb962e8cb8c8edd6e63426e50293f85d6d02bd7fdb30464c51b81b9cf52c88", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "22bc21fb-b6a9-457b-92da-a1e0def3f434": {"doc_hash": "c3fb0818ca23b96dbff9c718a5e34cca8fc6e6157035273896bbe9f022371d96", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "9d2cfcaf-cbd5-4b53-b525-ee556a5245c2": {"doc_hash": "97e95888e8aa4be09059efb56ce4a46194c57e86d8a461b7b02d22415d2fc36d", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "9c04234e-5c3b-4d00-bdf6-0468a29af4b1": {"doc_hash": "68f86adca9063dfbec3c81f7dadb0158bdfeb5ff7a09a6e71416d3fb1d8bfe51", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "36fdec5d-4d22-4d0b-825a-94e48a7bc21e": {"doc_hash": "fc8b55b1a867ef36ffb4a37c36f2559d0c105e6d53fae045672e4f06725360f8", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "61b8b572-a94a-4f85-a9f3-300a53cae88d": {"doc_hash": "469cf559c4c0f50d6b1735867a01290da386be52a0ecf9ef887d3c36e7aa897f", "ref_doc_id": "798df53f-049d-4a69-9e12-285cc64ea53d"}, "35613848-d4a5-4eb1-88ea-ecf60370383d": {"doc_hash": "51197bdd851975786d9651ad0426c5806669ced6c015aa460f9f58c64bb12e8b", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "7c311a21-4ba7-4191-b45b-aa9823541bb3": {"doc_hash": "1bcc9f161fbb9c1d3ec4833e3ce5292e1b80801cf9ce384431693fbf9883c19a", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "0d626230-71c2-45c1-9eb7-f8128b944094": {"doc_hash": "62bddda2f089ddd1c438acec14dfbd0ec26352790f48089a0040b729ea70096d", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "1ee2e620-c3b0-4697-b8cf-bb57f0f31cca": {"doc_hash": "6453bedafa00f522d23286a68999075e77c5c10165af3af36b9ab9283e494bd3", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "733f9f72-a98b-4d71-8f48-764c3dca75dd": {"doc_hash": "bcaac53d7e7daa2c5bd5696475449b423e6e4233ba6fcda0e3f3175d3c897163", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "f4baf248-b2cb-460d-9abf-51c3015fde55": {"doc_hash": "68ff97048eb9227c577e939c4e60cb70fe08f29c94f0d7528945e36989da5886", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "c5f64f4b-16ed-4e59-970e-9a1a1c1e25b9": {"doc_hash": "4143fc290b9c5f78648b57f7ea741fa14f3d9d4d9c8940d0b3c3268bf030c9d5", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "d3369c22-7b53-40f9-b291-c1e21938cee6": {"doc_hash": "00df753ef35b0765fbd98d4de99e7d1941da0ed7b26e5c2932924f60d256f085", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "27d7da06-3302-4d72-ae87-777fcd503494": {"doc_hash": "564555c4ddac5212843077b1b98e1ffa053eaed686f7baf584a465b91edbd88a", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "87fa3cf2-640a-4b47-8764-47065b9b2751": {"doc_hash": "fd2ba6d45682f42f0fe25549b587dff2396ae395997e8ddf2ccb39df5d3ec64a", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "e74c2955-cdfe-47bc-9fa4-74fa314ef399": {"doc_hash": "82e6e0b6d20946119fbd9c2a73a392793284139387ebd0c40fac922826cc22c8", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "0a17d907-f364-419e-9600-5ed2d824782c": {"doc_hash": "715cac1867385e50f343b9490d97517797cf728daf33b475ae76713b842f1b2a", "ref_doc_id": "ba6dbff2-3657-4bde-a7c9-b08f028272f8"}, "2d39feec-6c57-4be1-bafa-2295eee99be6": {"doc_hash": "5da7e30b39b62afdfd1081a6d4cd75db27bd36df902710efb43faef5ab71030f", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "dd3eb872-fdbc-4aca-9ddc-49d9cc4a215b": {"doc_hash": "5e486cbbf66a761702ab13bdd15926d4b1bcb477439a340d76e72a9aeb34a1ac", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "ae2b5eb0-14f0-4f79-90c3-95ce51f53514": {"doc_hash": "14f71c9e7e88478b511a4c81cb6480524db691c14e990ec15353b9a5423b25b0", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "562be8e2-101e-4b53-8847-1a2cb2e088a4": {"doc_hash": "e2eb3f73ff90bbdc645c459bf5ae660929f866a747993f4897f5f36be5070a1b", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "bba7ffe8-b580-4f16-8ce0-aec02583a1dd": {"doc_hash": "ecf270d2649f43126a873950f6cd0c7757411d38e4bcd53a057e4ba221c5fbcb", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "d5cdd403-3c64-48b5-bfa9-ee46c9b7392a": {"doc_hash": "3770bf1ab9938a9d0531706b2b7433168c8a1f16f2b2a2283f7f04101c24a432", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "850add53-64d7-4493-aaf7-03a746affb77": {"doc_hash": "3eb383524d2b813d642a86bb30e3bc89b2e0e9cc796d048d01e7c230c9ddf29f", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "1d21f253-56e5-4d04-864d-6426da5a1d3b": {"doc_hash": "1ca6d34079cc8a23e517693d20b4d36e4f20dec18a7ad000e90c3532eb711a20", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "a382d9d5-fd41-4b96-ac71-f6bc678e4636": {"doc_hash": "5845e07b948cc218fd42ffc912d4ee287b7869af9f6902b1af3bf200c1f2f8aa", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "46115c72-61a6-48b3-8b14-d939e5f4b04a": {"doc_hash": "18d1e77ad7d9e4b4406405ce8bbbe19ed23ee6fd490d8f6e53f16ff5bf7e5cd7", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "fbc19273-4191-4b38-8aff-6ce27d6a5a76": {"doc_hash": "8fb8957a47d969ae703527ff5f43799ddefe294cf8f8b91a7e0d5298cd11f54b", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "5ebfa653-b085-47b4-a396-ef7a986630d5": {"doc_hash": "51b045236eb66241c772fee469029fb5351908100d7dd8471a8ee4a64780b364", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "31258b32-0cef-4d97-81fa-852d7588ba29": {"doc_hash": "65204cfb87bff0117cc1cc5682d6a52c19bc59b9baa0ed4f91b83724fd1d9983", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "c4baab8e-5db7-4dcb-a597-a63be7ee2c26": {"doc_hash": "7fa13fd42b0750bb3ae7f170e5964290240c61d0cf61bb1ceaa2472727c94128", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "7c0d699c-3b98-4628-abac-21edf8d57314": {"doc_hash": "5fdb4699dc35c9d5927840d4173eb9fad57dbdecee4f4675590bc0412eadf96f", "ref_doc_id": "fc3b790b-6695-439b-97a4-376d5825da86"}, "1a65603c-d79e-43fc-9b09-09dee68feb3a": {"doc_hash": "0c2fea77969c138504ee50ad6539b7b7eef551a3ccd222fefcb279de36b211fd", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "03b46831-827b-4b04-a4b0-1ece90f1c094": {"doc_hash": "2e9f2651512c7c5a95c1cf92498a1faf9aab6299bdf84c92b063f9d8a55164b4", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "541a1f17-d5aa-4311-97f4-82609c4bc11a": {"doc_hash": "d9d159af01beed17a862b48954aff7bcf5fecbd7015a9951b2007901fee27ab1", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "9ea96f33-3e66-4c2b-8a02-6a7b23349c6b": {"doc_hash": "988092c2a7fe905e278aafba8955f6c24d2d79a9e8f6ef3625ba64ae803fbd9c", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "f054ad45-4e7d-4a17-91ac-6ddd1956d261": {"doc_hash": "7ef910da40b9614cb7a78f85184eb53fcd4a27d2cdd308940737bbf094a277f5", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "d7dd3d00-9209-4e8c-b2d8-703b1594b54c": {"doc_hash": "a85ce459cc4baaa45bdcbd5d17b05f482699bb05d0cca01eca2d6b142d915da2", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "a42a454a-ce65-4a57-9fb3-abaf0da27563": {"doc_hash": "1fe5d07702ca13b2f7672cb1d0d9100b1f50a1508b0644c5d10c44273ed97106", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "96dff063-4046-47b0-8b5f-0761f2157f41": {"doc_hash": "ed017067ad10eda3de83da7643f1bf2f905d12b441004b6803a8f8e0e29db2f0", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "495114a6-aebb-4b46-b0a3-ed14a6c22fa3": {"doc_hash": "adc63af0b3343dfb85498051a31d2a892927c9366e521cbad9532630d96fef9d", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "1a30562a-e7f6-4503-a136-959613fe0a8e": {"doc_hash": "21b138550f953b5cac369ef7b2b3cf26baaea1cfe2b6de26bea6def2c15596f8", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "538b2475-375f-44cf-9ee4-3b5fc962e2d0": {"doc_hash": "ec2cb50b992b1f82957cdb14f37d6f26d2350a7c583dc0cccdb8d29629ea929a", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "cc88419c-bf97-41b5-895b-e79dc6715f60": {"doc_hash": "29dfd6ddb1b6d595eab2987072e20601ec011971fecc84b2525f00739efdb20a", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "66f6fef0-8158-45b9-b778-8325cfb5c81b": {"doc_hash": "8e6a66f6c981e2cc32810dc2dd6353bcfbab44581a490603dfacbcfc6f1a7d79", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "0a717fb2-4592-4493-b87d-05e184527667": {"doc_hash": "d6f7eb53cf6da09c47a99dfecde7c34833dca0df6d54259026f7a28572535375", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "4e1fc756-6a11-4ffb-a71f-1c594ac1319d": {"doc_hash": "1b1565150f642ba6e364b8fa734f57c125da1d583bd4594b3ee7369fee434852", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "344d25a2-f424-45f0-83de-b435832563bb": {"doc_hash": "ff2b68b126a4d832795932e289b2959d357ace5b498883b6dc539b06956dde24", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "e4036d46-6ca1-4e8a-b143-2e6f36974be3": {"doc_hash": "b8dfa9b70dee87a0ca26721b18ed40f65af192d1cb851c16d799d57778e7d3a0", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "0945c749-88d6-4e0b-8492-222e996332ed": {"doc_hash": "e29c52a4101e72b569b7d4787f37be85be065d5f7ee433d54e160324715e8fd4", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "bbd65cd7-f116-47f2-8da6-ff66f0354e19": {"doc_hash": "9e5f70bc39e0470cb0c3d0cb3f6feef8d1084198126a8f9f9863d6dd24464864", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "e01d9b04-fd65-443e-a2da-074e63ac1c7d": {"doc_hash": "54dabc6bef8411d69cd6e8e5f72b9647c610039d4eec0a213d336e0191936851", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "9c3af8b7-b806-4b4e-bde6-e0133a196ff1": {"doc_hash": "a2f044163d9cdc9f97cc1353a4286e6333ce04216c4b07f62f894d53600d3098", "ref_doc_id": "396558cd-e0c3-42b3-9b42-0b28bc0c5151"}, "c7b5e996-8975-4f9f-8423-48d9d5241106": {"doc_hash": "347893306434a04a2774195bd5b0827801ee9914e5e8608f21d13fe860d343b4", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "2cb7682e-c286-4fcf-a59e-fc99cc63e538": {"doc_hash": "72c1fbe5050f3bbdec15796d627574956b64aec0c354730aec3f45121ef3c643", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "ddf2ef2c-5da9-484a-87f0-bd3148b8767a": {"doc_hash": "fe056fb9d98eff85c7f09291e259fb034e27738bbf9ae175cb05b7c03c8dae02", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "d98c31d8-9b7b-4b6b-b486-bf9b51ff71bd": {"doc_hash": "e15daa05dfc8c1b63ad08b17c33130419b68dbf217e237ab7068ee6fcc5e7205", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "0828968b-7ed0-4988-9503-1d2340e2fb6c": {"doc_hash": "d8750b831b22b11fa423904f244e34962b7785bf07f99cc2beb8719dd6cadaf6", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "3fb08a09-0650-49b7-8a7a-4714d6627ea5": {"doc_hash": "a3dc8b999a3e932237eefdce960bb78a0eaaba14e1e293bdc55e796656053395", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "199fa66e-de93-40de-805f-cb88e3504e30": {"doc_hash": "1f59f8a8749b2c26194385dc64f0e196de5f0edb126e43de4e10f0a67311e525", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "1a563560-abba-40dc-ba87-c85edda19865": {"doc_hash": "04ccdb484263654409355e2cbbc10968164d0d12474323700cc9179a9baae36f", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "3f4ad125-6e51-4490-92bc-43c73b77af26": {"doc_hash": "21c41cbeb9a26cfa1bc0357b8555afbb5d69c664fab26d2c2c15277be422c891", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "99cfcae4-8f95-4889-bd08-0c0bafc14765": {"doc_hash": "932b708f3356dda30cc84be4e457190757a4fca4be9e7fb8985022fb061b0a82", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "6677bd44-06c6-4044-bac3-e30e28d9a489": {"doc_hash": "2662ac49f763d6a1f8be17953c29a9657b560c5a60fb8f9b23cada8d3e70179e", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "0f13d60e-acb3-41ae-815e-c6a90f4e893b": {"doc_hash": "158066cc3bd30287c6ddd79d686e1d5078dde199fe7adc038fd7cd25a49a2e6c", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "41f45016-fbb7-47a7-98c2-c25f322124b5": {"doc_hash": "f53359d87cf9abc5445f6649b8af6363bd9bdfcaa2dbb468bdd61a4ce718bfac", "ref_doc_id": "e0e94eb7-948a-4cab-a0d9-55f11cec1a03"}, "56b83ecc-f865-48b3-9577-2532f4912d8b": {"doc_hash": "306d2c994d9057bc4150950b9d4134cc5199ddb8f3c4b7d7c0de3e460f596f3b", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "2a176b7f-94e8-4c65-accd-2f2ba884348d": {"doc_hash": "076aae1afe3c89533639c26c08db627bb57194c7f0fe7ae3b305521ad4046188", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "f1754cff-ee70-4483-bb55-b079bd2de45a": {"doc_hash": "6fde5e798797aaa68a5a5a9b1dd1abf3d56bc15fc180b0dd3d7a2fcd21b24e90", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "1439cb7c-9496-471d-a3ec-e147ffc9dd2f": {"doc_hash": "0ccb18dcc6218de4b677033efb14ec786e86c7d954310f54e5cedd4d307c3003", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "0022580f-2889-4860-b406-37f6c3882093": {"doc_hash": "03a17007618ca9a18d2c51d2ccea44f32dab16caa621db84d27a0b2aa6b1bc40", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "b33fb33c-06e1-4e14-bd21-ec1bd4436a94": {"doc_hash": "029f0f5cddb91c1631abd8bfed7d5ac7c86da8f17daaea282b1c0e3c885393a0", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "35dc6362-2284-43a2-9240-3d151158979f": {"doc_hash": "b338ceffb3cefd7ac16ce461a82fd1b05a012888711bc8e27bca1d43332b2921", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "25fc5cf5-26aa-41e9-876e-8f1d0f4e0283": {"doc_hash": "aab61f0946fe43783c84883c5c163d72ff370d2892e45275564ec99522d913c0", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "e1f844d6-99d3-4fbd-a4d0-fc49df12aa07": {"doc_hash": "dbc2e9c64be55b8a4ef9f0e1dbd85f5dc702f87cbe9f5d7edc633c11fa1528e9", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "562d4300-84de-4844-afb4-5f800588d763": {"doc_hash": "8c12c348b8a397093e8ac7c71a0b47202c00684c6dce4ea634d30398e255d826", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "4acb5999-5bce-4fda-92c4-5269b52da6b7": {"doc_hash": "e734dae3d07a805ed284e30605bc1381bf844f75051347fdabb55187a4ac7635", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "f911b390-8197-48b8-b0fb-5640620aa71e": {"doc_hash": "fcc02a6e2490ed82c3630999416d871e7d5f4cff530f73ce97ab4bb2827840ac", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "81c2e082-e3e6-4808-936b-1f3e5f723765": {"doc_hash": "f8f2fa65998e7beace1bcf52faa78265f60f9a506f1bb983de9278c0dcb8b267", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "d78ce1d1-e97e-49a7-8391-ece5dcc2a8ac": {"doc_hash": "a4880bb61d585e4fb68c85be388b686682330d3443dcf798a3eecbf469eb54ad", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "51cf7232-b00f-46f7-8144-58a5cd9794ab": {"doc_hash": "0f132d78f8c48da3ec7659164d524f52dc876723ae0263f81243eaa858a99776", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "01491980-f2e2-48ec-920f-e85b06711aac": {"doc_hash": "c88e312cc0c8122c4fc2dfa3c62b2cd58359f895f154f06ac495947d9f763c36", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "876acda1-c0e7-483a-b489-96d07cce638f": {"doc_hash": "d073e31f6290fd8cca7718083693ebe246aeb8bf4848a32fd6d3d98d70019359", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "1134666d-fd17-4c34-9fe3-c3a718b36304": {"doc_hash": "2225bfc647e83bf9f408afbff54558098c3144e0ae2546542af45b12602d0c51", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "d8b5f1e4-4803-4e07-9074-d62a12048737": {"doc_hash": "6b7859ed7991aff0c01aacc11bd1d86be1bffa44c5c86c8b13f8b4232845545e", "ref_doc_id": "b0658900-7bd2-49d4-96ed-ae6d007700e6"}, "03fd2ccb-8aff-4d0b-b474-8db3870282c7": {"doc_hash": "166704fae387a1a09d91e4ce8bbe56488eafb079826138bd7b41c960cf792b81", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "416ad303-a2a4-463f-8369-c8ded4317e1b": {"doc_hash": "f9364fe369dd9b9ea76d0aec0e68237dca0957d206b61cd782943454c4d58e49", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "1b5b7a1c-4f20-404d-af60-d5f2397d7bcb": {"doc_hash": "87f0575f1e47c9a37d931d301141ed7c612d4e8b672ef71b097d243c2f68a4b9", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "193912fc-f10d-4d71-b1eb-43985214e884": {"doc_hash": "2b8093fa4334cafb80ed135020a27dba940437c51891865f13ce2b0fffb8f514", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "eda82a6c-5b19-44c2-a117-70a20ea56873": {"doc_hash": "62965038fa8eff2d37869e4bb356635da58f97c80b01aa28537e85ecac0e3559", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "9b3eb4e4-0d14-41c8-aafc-8a86d0a50c44": {"doc_hash": "7cd48f2830270297b5fb3f09cd8624aa68ed4cc24a1c04f1687bf09318d4955a", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "4e69173e-fbfc-44c3-9f9d-6f8d22eb4991": {"doc_hash": "aec7e2ebb55175fd00a468e40bd7fad8f4020ab63a84cfa84b113b611df624c8", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "7766d183-a5b0-44d8-8a95-695dc7515602": {"doc_hash": "a0daf01eef800e32bb5f1b43b64293b068957294a27de93f6b4226542e93d7e8", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "6e314057-9a2b-45b2-8de4-c71cfb602aa8": {"doc_hash": "552736545743454fe84e862cb142918e54da3b0f94b07c22b9f3aea562faf101", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "a7b7f40e-6fe6-45a2-a27e-573096cb6bb5": {"doc_hash": "83331b43b047ca5d9f883af0125aa9df45e5cc1e89a6c3e5f127c143160f2777", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "a72d2e27-4adb-4ec0-a011-361111b74011": {"doc_hash": "1da21529c7bd00510a652a6ba4ff1677923eb3518c39f29e891b6c089d7bf8d9", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "82627fe5-a223-4037-a5ce-c70da964f9e3": {"doc_hash": "c4c022c4bc50bbacbc6e7bbc4636c9cec5a54dc738dc2c83ae916678889a0e49", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "201d8a04-fa5e-4f35-9a84-fb16a3ee9a62": {"doc_hash": "a34cdaebf4dfa8485db6a9e35ff0b04fded6c4626f8b8d8db2c1aa61de1b8e9e", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "34ff659a-52e4-40ea-bad8-bba3d71b700a": {"doc_hash": "019bc4b1beec7b9f9ceb8039589d9488146ccd542781f820f11668cb7592225d", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "7945270a-63ed-4494-9047-8de4e458da96": {"doc_hash": "5223bf136e1e78b1b5c75786babbe8df8e45a816659a5d93acf19e4ff73de72a", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "2bf2ccfa-3a73-4315-b14c-f4e884d8486b": {"doc_hash": "e99ba8334ca3ead70c7ff60c8a039ec7067df2c2e8c16186754f6e78cf3c345b", "ref_doc_id": "057abce5-d1f2-4f2f-b58a-f284551d1e29"}, "1f3f0622-2405-4149-b525-8d9dd1453c3b": {"doc_hash": "f18202aae336ca1b53b844e31c2de0353a4c2369efa898a7dd846a446d4fcf97", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "7b33a8a8-a392-452e-bb20-450051e0f9a2": {"doc_hash": "6bb7d59826d1ccb9350ad140c8f26d76489c8adfb95a95e0d3a9af089d2710e3", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "690517dc-ee93-41e4-b29f-6e2bb97e01a8": {"doc_hash": "e7b1852b63f70861e4cdea1d8c887c01e7fed0b40b2b7d89a67c2e475cb2f6ac", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "edf1cca1-fe7e-41f5-b8fb-d1b731047a6f": {"doc_hash": "ac38d932064abeacaee822d327e77cd5fb43119734f1bad8a652e11d6a26f295", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "59dc3930-7e19-4dbf-b934-70ab993d540a": {"doc_hash": "576a4333fe5bc95737752a8bd507740a212bf93e4140c7daf63eba74830c50a9", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "84be6d16-7f20-475b-9bad-726ff4da4bbd": {"doc_hash": "9206080f06c2cc3a28cddfbc0755f5c404f7d10fae0bebdd66e5bee663bc0243", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "548b6aed-0bd4-4775-91e9-e59823c248f8": {"doc_hash": "ed8f959f8769088052a4e4a95a1d17f66bbce566998ac3aac5a567aa66a05f3c", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "8c92dac4-e8be-4309-a8cd-57c22eb28df0": {"doc_hash": "2223a88818693c5219152521d4225ad98267b9e0c65fd1626f595fa8820a399b", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "e699b969-1269-465d-ab4c-69b7718dad7c": {"doc_hash": "add71aaad8cff5cb1cdb9c59bc1bcf5ca59fa053276236925b5dc712ea058a70", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "abf5f1b5-3358-4283-b96d-7a782e100c80": {"doc_hash": "35c7d6f72f16987258031de87d7268b889227918cb121cddbc5dd77dcb2c9fe8", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "b95c2b70-d216-4666-8699-32133fd76e0b": {"doc_hash": "0de5bcc48048f2b039a8fdad03d29778cf61cd5f2922949390b5df0c10c272b1", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "06edd1cd-601f-4916-beeb-3eebe084cf12": {"doc_hash": "cd0d82511b49ed13cd608eff90b560908913f1643c0b438222b84c7c02112db7", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "de0b621d-b918-4be0-b26c-ef03d753469d": {"doc_hash": "46c055924424f31e251539c2df3bf1450ce5a49bbcc5d1f080e572c30e5c77a3", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "42dc7c66-8399-438d-bcc0-c0f0e38c1152": {"doc_hash": "bb3a9e4f7a9dd908aa15edefd6a466e57475932846ad06d06126143db9772308", "ref_doc_id": "a5e85b94-6264-4b17-a195-3eb3f253987d"}, "93206f79-2940-432f-9f21-00a94801254e": {"doc_hash": "501707820ebbff1a77a3bff0ed2f5f07258f6d0a5fd0132efcd3973b7c112d8f", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "2b58757b-c0f0-461a-b85d-660f235cd215": {"doc_hash": "c93138df851f37eaa2843392f26e767e8e1c4ccc6361e0a0a0c9deb2d6359bf3", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "0f1af34f-c395-499b-810a-92bc6ed64735": {"doc_hash": "5c222efcef79e6f25feb64130acf31336480f1f272de3d7235c96fb2821fe432", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "96233ab0-4db1-44d1-96a7-678d7aecdbd1": {"doc_hash": "fa77c4ca14ceb1b55e654371b0122b3ee2fee981884de848092cb9e8a818f578", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "c7ed85ca-a46f-488e-994b-2b49bb7c7610": {"doc_hash": "a8562da3bf83864e274cb691464dc7e6b5a6f49677349154a958a7d87073f45f", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "873b4896-6f16-49a9-b586-007207ea64dd": {"doc_hash": "bafadfcf8aba9257edf2f2845b4d12f6cf7a1ad5926694ae1c3776ed92581fe5", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "145ed10a-2d6d-4dd5-b0a7-f05aa520a63b": {"doc_hash": "802a6275416ea976930ff0d433c7edddf30f14591782cac8e030c4b70bf8d962", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "20431225-30c0-4fcf-a822-67fe2c8b6975": {"doc_hash": "eafe5c9219f0f868fa63282db5cccae4d55e68a3cc9fc0a11740cc229b0621bd", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "e45aff6c-3461-4529-9adb-e7df4521577a": {"doc_hash": "49d365dd02cf277392cdceafe42fc81bed934becaa024e53bb807fd29d304411", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "c8cf7963-f85e-4dc1-a275-33c5a3ac90f7": {"doc_hash": "1afc1441617d706e6e939ae88708d04af410b36ce20f21f194e769b834711b09", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "d4d8e325-174f-4660-a3ce-ba45ac03dd3a": {"doc_hash": "efe5d4212312e60635c9fdd26eef82a1f7f2d6ae5ffd18066a84665cc807fe88", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "70471d16-2ae5-49c8-9c14-b03e7f8ca07a": {"doc_hash": "f848bea9ad32d4c8bede62eb79327780c58a15cdfac03e73eb59df8693498fad", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "ce307d13-8402-4436-a510-02ad7076eb90": {"doc_hash": "4e5ad186157028ae4e01bd10c0acdcca722a754068e4c04e7551907dbe1e12bc", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "463fabf5-2946-42c4-a574-1e1f99b5f1ca": {"doc_hash": "2df683a3ee4a1a6739a69d3e30269b9b1a5a5d54c95f66c4d78b976dda785c79", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "cbdac471-e097-45b2-bafb-de390dd4e04f": {"doc_hash": "233ad3d9670a33542052c88b21848f15faaab951a429498ae8dcb377e3feb141", "ref_doc_id": "e45cb5a3-a714-4ee6-8445-39a0f3327495"}, "51ccc4ba-02e9-40c4-a77a-b916486e3bf6": {"doc_hash": "c02abcc06122b0e786439f08c2612d500c0f30e86fdd0f6e4f384f8835c35164", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "53b9c76d-a53a-4393-8044-a4ebc3fefb15": {"doc_hash": "eb909a548ce25614196527ace9d6c587ffd66ae1ff9ad3ca393973eb1c2551ce", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "fb05c82f-3bdb-4f66-b5ce-32c8fe3ca049": {"doc_hash": "45c9036dfab53a8bc8f88e9fdfc23d8d470fb2d0d67832b7a37a5a148835c9a7", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "ed4236b6-a90a-434c-b595-b3ffaa28fb48": {"doc_hash": "1ae68acbb436ca4ef54b743d24cad5576b357341a20b77ac4bb2db81266d5a82", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "3e65fce5-1360-477d-8ba7-d2edb0c6f424": {"doc_hash": "6e58a11620755512eb447a287aeeee9590a437494e8bb4af3ece61233e6e6e54", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "4f0d8291-9867-4bfd-902a-8f38b4814874": {"doc_hash": "708d73e78f897e0d260569ce7eecb81bd81deea3c9015fa0249a392ed8e3cc67", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "1d4df627-14d3-4c90-8144-b63e0ec72b37": {"doc_hash": "f77928009ba7babcfbc40fb453bd5ed5a8b0206990e7f7fa922acc9cd2edf93d", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "1b925084-bd1c-4693-b67c-009f3c56569c": {"doc_hash": "87ae3bfbd17515c4e8be3c826fcb786ca9c29b6419ba395d4cb953d73c8fd8fa", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "81fbe40e-a6bf-48a2-98de-45f6192c766b": {"doc_hash": "26a530821a13b14d63301a0133590df3027b172c8adad30a1b4a1318b13559be", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "86521992-99e6-4ec1-b5c5-a44f57c1eeb7": {"doc_hash": "9f31e01d67f7195592ab610a0a76350a05be5df89cfc1686b861eade233a063c", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "141f9779-abad-483f-a8f4-1a01e986c669": {"doc_hash": "d77899cdec5db3a6efc0bbc6f1df686a8438d2fe0396b712976e1da79a1477ee", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "eab65f11-0e33-45b3-b247-8b1e0a631143": {"doc_hash": "6da86c17c37475484dbe7a83841505fe18ec63a62c209727e5319a8dde8d1da1", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "f22db9c5-ee23-4ca8-89c2-b331ae4c305a": {"doc_hash": "e005ccfdee16d2cd9483a12d95db35a5b7ce3cc3cb4410e0e379cbba174722dc", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "9a948380-558d-45dc-8f94-db31e54f6f8a": {"doc_hash": "0ca7ba751d9e3b7fbc50307af2c4968363573e13d2ae936fd9c95b7455dc1a3d", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "ececa927-4528-4579-902d-a2b435a90571": {"doc_hash": "c8a0454480afca197265e6180ebaad78462431bccbc7d55c1dfb0fbcb36e0a1f", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "dcd76bc8-c6b3-43dd-ba65-bf49cb61bfff": {"doc_hash": "6a5e9352c8e62b40d0d58457f245997633e9a9219709d9dc2d400727c23e352d", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "508f5b5e-f3c1-4886-9ca0-33e38c87c950": {"doc_hash": "2c059cca8f5a11c52e1266caf6c93961dbd28ab48b8944c467ab519e225bb0fd", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "56f09357-15e8-4b44-9ac3-8017c3618bd8": {"doc_hash": "b61a05b53798849206a96154ecd58938b3bccf844da727a529fbe03e7bc71ee1", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "d5509037-39f3-40bb-90e9-2e1ed4ec36a3": {"doc_hash": "67e02070f02252d6bb749973412f67995921a8e9bdae6656f892deff0f865d31", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "6dcb3f19-fd43-477d-8783-aa30ec0e1752": {"doc_hash": "cbc7df8aa8030f69ef28229e140f6d13a5a2347502d075acbcfe94d454b38ab4", "ref_doc_id": "d8ffa405-fbaf-4a88-b20d-c31b1d76c766"}, "bb37b972-4b77-486a-b0ee-378e2a9004f4": {"doc_hash": "a88ec84678be93e9676443fd311e566773e6c694a741b129cdda59907866bb8f", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "5330d980-0ee7-40a6-a07f-b3573d7ce12d": {"doc_hash": "c422c16a985c4e8bddde575d5a2d56ca19e23b5ef574fc3f28bbe7effa243678", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "128f275d-0abd-469f-ac6e-0440b8fae149": {"doc_hash": "e750c8f9ca52d78bb27f0c2c5003979a8cd409df98f5f9a0fcc339dd021e8d5e", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "244f0af6-2fba-4a0e-8c1d-6de94e36c45a": {"doc_hash": "e1527ddf67202005ab7cabab72f16ffb6b495f10b28b658cbd690947f39f8d0d", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "3d4fe2c9-b4ef-4719-ba3f-747a71e422f7": {"doc_hash": "7cfe56325d9b9cacfd90d5a584f937c32d776a5d1c0a00dc424fd85d32fa6854", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "19487790-9ef4-4231-ace6-428225e6c4b2": {"doc_hash": "fb17085d1b5d8a2773035dd8bc0ee5972ccdb66abf2bf62b7181d2f5e93a59c4", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "6b911d4c-30cd-40fb-95c1-1a1998a579e7": {"doc_hash": "724f9aac4d6e321ddbc1da2d71daa8f51e119bc6bd6750ca6713b9a645e47cbc", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "2e1ab682-3cc1-4017-ba33-685c092f5824": {"doc_hash": "9b114880d56d5afca724c615bd85982fdd0671532eb6acfb54bb4418945312d5", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "dd5a9f82-4afa-42c5-a19d-68bbccd24469": {"doc_hash": "95f5c0412d2acaeab1f253522a21e488577faff089a8b87ca0221438b9664665", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "a7e2da8e-6535-498b-94d0-9e52f524d091": {"doc_hash": "f392ff242d6561a7d12ec390ea5157cde6a168fa8ab3270587baebc45371b2b7", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "01339826-2bbe-474c-ae84-3902e5598353": {"doc_hash": "6233ef48d1efb91551d3d6e70a5b761febb83327f95d5bb80f7d58dc6fbb4335", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "1740f898-ca85-41cf-bcf7-e0a6c1549032": {"doc_hash": "90b4a943e06425b3ae0114823d672958da687c72b39a45c196eceb5370d0f20f", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "1b892a56-e671-42e0-a8fc-a52afdbcbd28": {"doc_hash": "34ba01f6c8dab6189b29f98173524396b64e30dfdb047945bcc3d55da7a8eb99", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "3abab5cb-4794-4f82-a1af-41020eadc6d7": {"doc_hash": "6144071f811f19bcdb8870ab1171cef6639975a5b689311a967e89b5312acdc5", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "313d8acf-67be-4f3c-8182-815235cc00b7": {"doc_hash": "483d3c188f58b93c48524085b5c49d7f1f326aad1f0b7fe80f099786cd6d9691", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "5eb1019f-28a5-4ccd-b544-95e744155529": {"doc_hash": "bf6dbf12970090cc810948b98505c99ab941c1b540fd4b57c32f3a2d8d079033", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "956e5429-69f4-48a6-b220-68c1fb1d87d3": {"doc_hash": "5f0e093e554bc0e91ab614823b29f4862766ab3b18a6237fefe020e203b620de", "ref_doc_id": "9915696b-dd41-40f0-ae0c-71bb342359de"}, "c45c1e83-a512-4a1e-80e4-0c6a83b5c0dd": {"doc_hash": "c040a7fb9237184b29f14393f2caf34c7d8c8070304c73cb5ad9c1cb6330b8b4", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "c4a9a024-2edc-43e3-adfb-c17ec81f7aa8": {"doc_hash": "5b06b25e1bae1202927dfce99666346045277a45ece97953b59e376994a26da2", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "e37f5bcb-6a09-4617-b98d-65cd0a34500d": {"doc_hash": "99b5d056b914d32090e89fc7be9ae7e1ec2b6751baaa79ab61baa0517bf8f87f", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "7a529249-22ad-472d-9bf6-61690d4d1cfb": {"doc_hash": "47ce3ea90814df573edce1fa3bcfb77f075fe329c8edf89e3059ca33cc130929", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "234ef09b-dc09-44cc-857f-a5548b84cb6a": {"doc_hash": "195a3d1f0c60cbf697bfc9a4dc91ed1fb90d2d50911432e1250c2ddee1a9fd70", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "634dd078-1a65-4f36-9edb-93109204ca18": {"doc_hash": "28fca85316b72ec067cacf4662f6ad3b7ef72981900db89e6b3bbb45434b90c1", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "f5271c1b-fa02-4269-bc96-8d5c5b973015": {"doc_hash": "d00366ace6863540a156c28f779f53174cee1353e3ea7aa223cf2538d0d0c308", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "199d3766-59f9-4c68-aa2b-ea1686849b48": {"doc_hash": "7c7e8e3f5d34c2e0d39811d93d53e6b965426e4680b204229b48e50ba449d51d", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "e809a6fc-ee38-4e50-9ae7-c77214106958": {"doc_hash": "777b51df8637cfc647bfd150ffa01acce32176085011bcf71ddcf5deccfed8b2", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "acddffde-9ab2-4203-a031-e0588f3c86a3": {"doc_hash": "92debb31ee27b30795cf1bd559b623f6fc0065704991ecde90e3fdbfac0d4f0a", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "98e71484-32b6-43d5-9083-5f0aa4b741ff": {"doc_hash": "74b96142aa6edae5d81e551f9c0ba3c8241f87992e3580e40f7a5ad2c4906b3a", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "89a13819-8633-407a-b624-f41a529c203e": {"doc_hash": "460d4ba037dbf0ea3db1dfcbff8b885f0c491815f296a04b44ea7dbab3d4e703", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "8a9fe426-5d1a-43d0-8777-14d56c5244eb": {"doc_hash": "a0ec3fa2e07326ad380a39bd7a9be47719fdd8e3e77fa513d31aa32bd785d6b8", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "f56e66cb-a7b4-4122-a478-2cbf7927b253": {"doc_hash": "355edd5d957e9c0d451b5bda60f98db6bba00171fa6fa75e9fb51f93d01558cd", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "2aeca256-3399-4064-b6fb-07af85f9ce9b": {"doc_hash": "253b3a1908c68e1f1b8af22fc10412a826c7075cb6a7065b6517f169daee9a2e", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "5e7293a0-5912-442b-b847-886f121c91fc": {"doc_hash": "cad21fffbff8e452f398614322e2187aa75a871745aa48b8bd3129315b3cf7dc", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "642ee90e-3fff-47aa-afd0-85abb3f4d230": {"doc_hash": "f2be9556aae74eb9953d22bdd93e1bf6b648b83f9869bb26e926f4948ee953d6", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "e944017a-cabe-488c-9ab8-ba10e7e960c7": {"doc_hash": "98e5c1d9f720d9981b5cbcb03c61f3eaec316dbf1e2b5a79d4bb1d1983be7200", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "50d5bcc7-80c1-4b70-b4dd-83d1eb5b7b25": {"doc_hash": "a55ac4711c1b11878892a0bc46ad70effb90f47433c4b72043223564f73e8f4c", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "4af8c8f5-56e2-46ca-8a93-4821170e0f54": {"doc_hash": "aedf36bf08ce33aefe35295390964995bcf3b6cf92a2c543b8963ff015c4d789", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "9e2ccd3c-568f-4770-833f-cfe463f6af0c": {"doc_hash": "861ed4a8104610c347b14da085caf083e3162bb765f2c6842a2532a2eb279d29", "ref_doc_id": "f05a6675-6af7-4244-8fee-d2c465008cd5"}, "e00d9c07-90ce-4c75-aa9a-0b9714a02370": {"doc_hash": "d15ac24cefd48a3851d5c5bacd54a8fe26aa7cef4b393d04931ce9d003bfd616", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "638e812c-a2ef-41fb-b312-e9877970c476": {"doc_hash": "068c2fb2f1d719e44a9c1d6e1897f5154075ffb20d1a81f76bcfa091be3835e2", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "6679cf8e-029f-46b5-ae12-a62bc22ed91e": {"doc_hash": "f439732cac6920918cb3c181add3dd7e32bcda2734de8c70363ac5d4d3795d77", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "fbdd331b-2e1e-4470-88e1-908b66a103a0": {"doc_hash": "63e39d2cf12b483f2eb1d1c2c52ca2a3adf18c3fd64b02edf7adce1406b54faf", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "03511ca6-3486-48d6-b4b4-6e9819d12fb9": {"doc_hash": "6b838d569a6081b7f667a4f1e68926f0298ff72641a14ceb16d7259dc2eb8224", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "ba7d8655-a2a6-42ee-a8e4-a073d80cb2ff": {"doc_hash": "6954889578720983dcb8c84cd3cd89b252827c82bfb20e8f83fa87570e76b701", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "03fa5830-ef8c-447b-91dc-3957943c9819": {"doc_hash": "cfb69ebd9b2b8cc5596a32e2e7c7330d8fb6092a5f1a4e675197a8785d89545b", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "aeb76cd6-c9d1-405e-a5f6-e0dd7bea07bc": {"doc_hash": "9a8ae5604e0ba6a145764e5440d2c9ccfdf2b7df346f9ee2b57bc5a965277182", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "6e0dff2b-cad7-40eb-8cce-f5e51da28a00": {"doc_hash": "bc5fc9e1ab966daf024fcfd3da361fa1da3e91e53629a72bd3fec4df89242c06", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "3ee21561-e6d5-4cdc-b882-18031522dcae": {"doc_hash": "75a53bc56ed25e6cdfa5527522325ae0522bc6c1e95c1b8b1f7cc6d304741b1d", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "40361b07-7e70-4684-97b4-721b4c90f23a": {"doc_hash": "173488120a4ad58859ffc8ed3212ddae1c88b1524c73ac82f0d4d3c2802c769e", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "51617b4f-6e0b-470d-8bd0-6a6434dcd499": {"doc_hash": "4a5d758ced622b18238134fc44a5d0f944ccb8d2878e73bc901c91215d1d4fdb", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "6023e385-471c-4f2b-bfb1-eaf2a7798c6f": {"doc_hash": "e2d1372f76e78fe238f931457c3df5e389987109e894818c3c0fa8c49a4d1c55", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "f689272f-e38f-43ed-8350-81d5fe6ce0e0": {"doc_hash": "7e57c9d09a1355f220ea3c0605b1b0dd3b25862658bddd1d141430c77818374e", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "a6edb8eb-ca22-4591-b113-03d988eb14c5": {"doc_hash": "2b576f60d9ebb6780013157a119b6b837353d21385295cbcaa07bd3732fcc137", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "d16a4df6-6d35-4a11-8ee4-e18224d2d34f": {"doc_hash": "525c1a1399cb89c5eb923a277783337ed0f0bb3ce713f3183f4f4f1ec73b7505", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "9d691d71-c848-4fab-9fec-ebadbcbc69e8": {"doc_hash": "d11ea9689794a62f1a97a52a142faaec4c75fc931ef5cbbf04d1690476620bea", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "3a34865e-6af9-4c99-8081-95c3f8c9c8a3": {"doc_hash": "c61765ea3c09e2196f84de3df1be42699d0c03996fdebea0ecd13939dff0eb6d", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "fb10da04-4215-4733-82b0-eab6686177cf": {"doc_hash": "c65e0914abbdce178924150e2c106d5cb7b1c3a9eba0fccd700204990e211ff8", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}, "92991152-97cf-4935-8f77-59a7d90bb39d": {"doc_hash": "8cf7e78a47b80ae71f99df034f7e3fa3d22c71100933e491441a42f2f7c7f39d", "ref_doc_id": "54aae0f9-2d2d-4b3f-85ed-7107806d0762"}}, "docstore/ref_doc_info": {"af269006-76bc-4068-96c6-227a07e11bb7": {"node_ids": ["c89b6943-ceba-41a7-bd7c-e961a261e049", "a0ada1e1-f202-4a39-9cd8-4d0f835fb0cc", "bdd6a008-1f96-4e64-bc2e-c23a86f28355", "3a34a219-7e3f-4499-8f0d-490b07bb4378", "0f7f91b7-68a8-421b-a2be-1d8f55c81392", "a60e38a5-62b3-44a4-978e-949494c6beca", "3ae358db-f428-43cc-b1cd-e0c3213c9183", "d76d0c58-49a5-4776-a2ea-71708dc2f0da", "18399038-8cca-4dc1-ba4c-b7109c0bd8d8", "a761b164-f8b7-4389-ac10-d7f534de31fe", "7dafcb8d-757f-440b-951f-5676dc82751a", "91ac359f-5026-4789-82b5-b1a408320fed", "42c63a7d-5780-4dfe-8929-d8009ef1234c", "19262729-0c15-4bce-b65a-6d4cac96e8e2", "902b1233-9101-45f4-8f78-4a78a0fdb558", "74cc82c9-998c-464e-8b6b-287cf2b79b5c"], "metadata": {"window": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  6th, 201 9 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Cardinal Health, Inc.  second quarter fiscal year 2020 earnings call.   Today's \nconference is being recorded.  ", "original_text": " \nPage 1 of 32 \n \nQ2 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "07348c34-4a6d-4c98-b8c0-5feeff99a3b5": {"node_ids": ["d8fba7c2-c137-4daa-8fa3-dc320f9e5009", "d37f99ee-f3e3-4385-a36e-b558c0128f4f", "f3fea566-03c1-4c7f-8bb9-a8e1135f49fd", "2e33f761-cf28-4a57-b335-75cbad2954e8", "8eb55bc8-ed9d-40f9-8893-ace50c047c8b", "f4800b25-2eb2-4cda-9481-4e4c85d163ac", "c15c8f24-c1c7-41f1-9c79-8c1890cddf22", "95dc3cd4-efa1-4551-bdcf-b929ccc6cf5b", "900d24f4-583f-45fe-a4a0-a773f4ba6b25", "d1f73120-8229-4a94-b3fe-7c161e2bfb79", "abfc2837-c4da-4fe6-b677-ddefed700d69", "9dd1f6a2-0620-476f-b960-fcbc3cbf9fc9", "8e6fe5f8-6aca-4140-b280-601e330bc3d2", "2bc1913d-dc30-40de-9adc-6df0a0fdd418"], "metadata": {"window": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n Mike Kaufmann :  Good morning, and thanks for joining us.   Before we discuss our Q2 performance and our outlook for the \nyear, I would like to reiterate a few things we shared last Thursday regarding voluntary recalls for any Level 3 \nsurgical gowns and certain Presource Packs containing those affected gowns.   The full press release and \nadditional information regarding this issue can be found on our Web site.  \n \n ", "original_text": " \nPage 2 of 32 \n \n With that I'll now turn the call over to Mike.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1eb1521d-1157-4a5c-be91-606a8dc80df8": {"node_ids": ["2efd8089-b1a5-42fd-9522-5e3bb253d199", "17034fbe-c1c9-4666-84a7-0a67f7b75ae9", "e8d46667-a64f-4b02-b362-dcea7e4ffa45", "85b50308-1d45-411b-875a-b57527220867", "5505e726-4674-4007-adbe-4b28af49a1c0", "06148208-620c-4638-8a66-736166bf947b", "9a7608f4-2a6f-4a17-b2be-635769ec8ae4", "ac88de4f-5d0e-4f7d-9b12-301c6a4f06d5", "dcd8d0e0-4462-462c-a080-1814eb4e847b", "fadea879-ae05-44f9-a8b1-2816e96a9161", "97539298-8ccb-40dc-8fd6-05e4800865ad", "93b7c70d-0f8b-47a2-be4b-001a5dbd197e", "c5591788-d47a-4280-9aa1-4f814fc40ccc"], "metadata": {"window": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n David Evans :  Thanks, Mike.   I'll start with an overv iew of our performance for the second fiscal quarter and then provide \nan update to our fiscal '20 guidance.   In Q2, we delivered earnings of $1.52 per share, an increase of 18% from \nthe prior year.  \n \n ", "original_text": " \nPage 3 of 32 \n \n \n I'll now turn the call over to Dave to walk through our Q2 results and updated fiscal '20 outlook and then I'll share \nsome thoughts on our path forward.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ebb19d3b-272a-419c-a9fc-709f0ca764ec": {"node_ids": ["8a4d9317-a608-4c80-8602-ea2bbeb0eae6", "7665f24c-6ff2-4430-b2db-cb95aeaf3d4a", "c018158f-5d0a-433b-8bed-9f39829de3b6", "c7a2c38a-6e29-42bc-af46-01beb44b301e", "edbfe7a8-48e1-48a5-b28a-b719a912c9f3", "fe59a99f-c01d-4299-93b0-d44b54b7e5a1", "95c73c0e-c246-462a-88df-6c67f5ecf8d3", "91cee9b6-16ab-432f-8c2b-957463065708", "e3676df2-f7fa-45ed-88c4-fdf3a619e3a0", "3d482e3a-9ba6-4682-b227-0f7881ae843f", "915a6a4e-5397-44f6-9b7c-72159c25ca8e", "d641e702-896e-42c8-8e7f-1f4a0557ce53", "e9edf9ed-fee5-4d67-94ad-6dba19dbd68f", "9b01bc1c-0503-471f-a048-01c5d584b86f", "ad9d15d2-065e-4b98-93f3-98d0ff335382"], "metadata": {"window": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.   Average diluted shares outstanding were 294 million, \nabout 6 million fewer than last year.  \n \n  During the quarter, we completed the $350 million accelerated share repurchase program initiated in Q1.   We \nrepurchased 7.3 million shares over the first two quarters at an average value of $48 per share.  ", "original_text": " \nPage 4 of 32 \n \n Our effective tax rate for the quarter was 25%, nearly 4 percentage points lower than the prior year, primarily due \nto the favorable impact of changes in the jurisdictional mix.  ", "page_label": "4", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "17a501ea-b213-439f-9cb6-5c45fdc40fed": {"node_ids": ["9e70f41c-210b-4726-b677-330da84243ce", "654a15b8-1a06-4aae-b809-a82a4ef0c1ae", "65541b51-b687-45a2-b299-037fea73e1d8", "74606245-fac7-4c2a-b8cb-c5cecf747ab8", "f4f48e45-b4af-465c-990d-cd25be88e443", "a2241410-6956-47fb-827e-09435c5c62e9", "cfb532a1-6963-42d3-bf05-8b2895076cb7", "7abdc2fc-bcd1-4043-b0ca-1f9d712a5f07", "7b6fb996-61f4-456a-9cb9-e2cfb7c1d86b", "34ee716d-d0f0-4f12-aef4-465847d41e11", "a2188222-1bb2-4c2e-a64a-e2a083e1b3b7", "ecacf74c-d7c8-4e04-b690-2573b50de193", "1a2284bc-11fa-409c-8765-f0703b8550a5", "d5df2e9a-bfbd-4cf4-b442-e3a814f55868", "9ba9e8fd-007a-46bd-bcd9-9aed5e72acd7", "4311298d-1d98-4aaa-82df-5a8c7db921ba"], "metadata": {"window": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.   These tailwinds were partially offset by pharma distribution customer contract \nrenewals.  \n \n  Transitioning to medical, revenue for the segment was flat to prior year at $4 billion.   Growth in Cardinal Health at \nHome was offset by a decline in products and distribution.  ", "original_text": " \nPage 5 of 32 \n \n Brand sales and mix also positively contribute as we manage changing dynamics to capture the value we create \nthrough our supply chain.  ", "page_label": "5", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "75493068-a001-47b5-a8af-1f802ca5060e": {"node_ids": ["d7d3e7ce-7503-4c02-99eb-fed61ca75d84", "b69f956e-1b37-498e-a626-8d46b318d6c8", "71216225-ff67-451c-a7fc-24a2d3dcec7a", "b1f3ef1d-49af-4630-b718-0f0721d9e423", "4f7b0905-a523-4a12-b460-9700dfcf196c", "2ab418bb-93ee-4553-bf33-59e3d57b9751", "e72c1b71-6ee3-4522-884f-c2daace298a0", "32608809-57d6-40f4-ba57-d68f4c508285", "f50dfd06-0867-4383-87d2-161e39bcfea0", "a937a5e4-b0f4-4ccb-a8ff-35c104a0df40", "4254c6bc-0172-48c4-ac96-a3ba5c2aa51d", "89268ee2-1d52-4b33-9ca8-56e7ce1d6149", "8d700dec-30f9-4d56-ab7f-d7f27979d5ee"], "metadata": {"window": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.   First from a year -\nover-year comparison perspective, recall that it was in Q4 of last year when we started to see an improvement in \nthe generic market's  dynamics.   That means we'll be comping more challenging performance in Q4 of this year.  \n \n  Second, we now expect opioid -related legal costs to be in the range of $100 million to $125 million for the year, \nwith the majority of the year -over-year increase oc curring in the back half of the year.  ", "original_text": " \nPage 6 of 32 \n \n \n A few additional items to note in the pharma segment as we look to the second half of the year.  ", "page_label": "6", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "01248c14-ddd5-43e7-bddb-21d57408d50b": {"node_ids": ["26bec142-c9e4-480d-9770-453a253474ef", "09d0c0be-5f1e-4107-91f0-7e2b610e95cc", "0915d9ea-3a5e-4fbe-86be-4d965c3598c1", "866a18dd-f803-4fb8-91ed-bfec821fd92c", "aca32458-9f28-4913-bc89-e9d265351181", "e06e0115-3042-4f67-bfd1-f0acdc5238cc", "5867bf86-3498-4864-8c56-5ade1e5fd5d1", "de822dce-b180-4539-92af-9e5fc7aa5141", "e6b548c2-cc90-4331-907a-ec15ea9d0463", "48b6afbd-e585-4e26-a627-46b6d96265fc", "d2c9191a-f5b9-43af-96c6-f3e9a8e4ba44", "ee33cff2-ae3a-41d0-8195-f4f734d1f99c", "c6c1552a-52bc-44d3-95ec-400f72ed01b7", "288d0477-ad22-4479-826e-79ee5993fb43"], "metadata": {"window": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.   With the favorability I discussed, we now \nexpect pharmaceu tical segment profit to decline low single digits.   This is a significant improvement from our \noriginal expectation of a low double digit decline.  \n \n  With that, let me turn it back over to Mike.  \n \n", "original_text": " \nPage 7 of 32 \n \n Regarding our segment assumptions, we are making one update.  ", "page_label": "7", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "135ec149-e16f-48bb-b74e-4297365a398d": {"node_ids": ["58848c5e-ff41-41a1-81b7-3d666fcc4b14", "f859c378-15b9-4f46-8bae-753352f5fbda", "bafd2de2-f0a0-40cc-b30b-91573bf79e13", "06d1d948-fcf7-4e88-97e7-543f7538f965", "682098c2-a4ad-4a65-bc0f-938475347488", "c094aa57-8c88-4b93-8e8a-df040a9427b4", "5925d02a-260a-4b45-b368-7a52d339738a", "362a794b-86c9-48e1-8b9e-d1ec39e30a7d", "02755e37-62d8-45f4-b0a8-22aeb99553d6", "33bedb07-8d84-4e0c-9446-bcb88bc61319", "b60b2636-d650-4609-ac16-fa478c1ca248", "02ba5a61-8c36-4535-9282-0e8098082ba5", "70829e39-bdb9-4b0b-ad3a-bb8586bf5acc", "3adb3f5e-cf99-460d-8fdc-fd6040bb932e", "45aa2d3e-bd00-483c-b7d2-6a9e3817eec8", "843a3f02-2f61-4aeb-aed5-4bd6459ce9fa", "dd9f3734-761f-4f60-9c91-37ff7e03565c"], "metadata": {"window": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.   We will provide an update on our next call.  \n \n  At the enterprise level, we remai n committed to a disciplined capital allocation approach that prioritizes reinvesting \nin the business, maintaining a strong balance sheet and modestly growing our dividend.   Opportunistically, we will \ncontinue to explore share repurchases and M&A.  \n \n ", "original_text": " \nPage 8 of 32 \n \ncommercial and supply chain initiatives, we remain confident in the underlying strategies of these work streams \nand we are dedicated to their success.  ", "page_label": "8", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0852aca3-2db5-4fae-b330-9bc9d288a552": {"node_ids": ["a9b41f07-973c-48a1-800f-1f077c359642", "69135622-76bb-4c07-9d12-d23848aa0d94", "2a610a38-af97-4076-8a7e-56679d165e07", "fba44f03-928f-43c9-8d9e-3a8fab1fbfac", "feb3193d-6120-4bba-9c4a-26f2a4fb4172", "0f2d95f2-fd1e-4a52-b007-c84c62916c2d", "5346f73c-acc5-4e54-ac5e-9eadb531be04", "88f03664-ec82-40bb-a27e-c2d9b5114fec", "a22be1f1-7f01-4a18-b490-a289e80819d6", "3ef027db-09e0-48ed-8e67-3d7e679589cf", "11457ac4-6034-4168-801b-209347fceab2", "6e67cc47-5ba9-4bbe-b52f-05c33d906336", "d677d34d-baca-4f41-aedb-9fde87363ba3", "e3747ad1-d44d-4d65-b8ec-31a4aecb6a8b", "1d7a1a56-99cb-49de-9b58-319f44af55cd", "1b2b517b-3c45-49be-8866-6cf89ca68716", "842f4863-2504-485e-a658-933101d2c985", "647ac908-8dd8-470d-84c7-614a787ff95c", "ab63efff-c51a-461b-900c-116a9b74579a"], "metadata": {"window": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n David Evans :  Yes, Glen, this is Dave.   Good question.   So as you can see, we collected the direct costs and included \nthose in our charge of $96 million.   ", "original_text": " \nPage 9 of 32 \n \n So by maintaining the guidance there, it kind of implies that, you know, the operating performance would be pretty \nweak in the second hal f.  And I'm just kind of curious if I'm looking at that correctly or if there is anything else \nthere.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1ca50656-4b33-4930-8de6-396f6665d59a": {"node_ids": ["9139bcc9-cd17-467f-a667-b7a527ecdeb1", "3b7d2b29-0adc-4d6e-8638-79692caf018e", "e4241d25-04f6-4f69-8bef-667cca67aca8", "a5bbaf20-4680-4882-83b9-e52c8b12563d", "a56232b0-7818-43cd-8b97-c9eb9dc06478", "267d19bf-c90d-4fe2-aafa-a282fa485686", "0b9b3942-ebe6-4f9c-947b-fa2e87a35057", "4930ff8f-271b-4d90-b403-5f7de0dd4365", "e03189d2-f6e9-468d-af1a-c242bf47a9dd", "3fcaef7d-cda6-47c2-bc97-8cb051f896bb", "76638140-c614-426c-bbcd-b4a9bf9904cd", "8642afcf-227b-4858-b727-698aa5362d98", "b6ef050c-0f9e-42c1-bfa0-f504400198f6", "7bb7ea52-0f1a-4e5d-8a5d-2d0a14cb8415", "9c052b15-3d54-4d83-844a-7d5baf22c3bb"], "metadata": {"window": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.   And even when it's agreed to, it's got to get papered and then we've got to \nwork through implementation of the various components of it.  \n \n  And so when you begin to look at all of those costs and the way that spen d we believe will ramp up, we believe \nthat you're right.   The costs are going to go from 85, which was our original, to 100 to 125 with a significant portion \nramping up in Q3 and even probably a little more in Q4.  ", "original_text": " \nPage 10 of 32 \n \n And so to get this over the goal line, there's a lot of work that's going to be done, you know, over the next several \nweeks and months to get that done.  ", "page_label": "10", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d2387a0e-defa-4a4c-b426-09b5c56ea295": {"node_ids": ["757b4c50-3704-403e-b355-ba7dac18c0c6", "53f46995-dd55-4cbd-b8f5-7cc973cb1e6c", "560b7236-5d77-4949-852c-f4c6633404b2", "a7785220-69e8-4375-b585-2a6ac7f3bdbe", "4abbc5af-6ff5-4b4c-97e4-598709476001", "8403a479-7333-4e0e-af5c-b3aa28850fe7", "72052fd3-0d33-4663-bce9-9f0f79478738", "2c140c8f-14d3-4352-9225-3f7f4d53196f", "f4866f63-1e66-438b-95e4-8f79aa63405b", "451a16de-a0de-4f31-bb4a-4af1094d1000", "bf30973d-1d9c-4768-9c62-4ec9ce74d4f0", "bc07711a-ba64-41d4-a2de-6b8e39627208", "c9c55f4d-c08f-4dc4-9d5b-a736c6ae0925", "33a6224e-0095-4708-8602-aecc94271eb5", "53444d06-f00f-4e01-a226-1a1c4f56d1a1", "26816b8e-429f-45c2-be8d-4cf2085c7b3e", "e40b9e18-03e5-4ac6-ac7b-478172d0f0ca"], "metadata": {"window": " \nPage 11 of 32 \n \n They have been working with all 50 states.   We continue to get the feedback from those states and look to the \nvarious components of the details of the agreement.   But it wouldn't be appropriate for me right now to try to tell \nyou or handicap how many states are in or out.  \n \n  But I will tell you that the four AGs that we talked to continue to make progress.  ", "original_text": " \nPage 11 of 32 \n \n They have been working with all 50 states.  ", "page_label": "11", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "96fe8a54-832b-4185-a72b-e8c072e46848": {"node_ids": ["7981e866-9b63-4902-bbe2-3301aefb25ae", "a4dbab9d-2233-4e54-8f26-f57d53c874a9", "61b64baf-7e35-4342-b773-882c372c1f61", "1ebe255c-cb01-46ec-bfe3-08dd13de60fc", "2df2aa94-1b10-427a-8f12-901b78206eaa", "8933b933-08ca-4f35-bd86-eb7a9b0356de", "8f2a0c80-1474-4372-8cfc-65097240cfd8", "c779f519-6d40-42ef-ba08-7ede125c22d7", "ef8f4ec5-588f-43e2-b8c4-92f820d9b865", "818d1d59-1697-4ef9-be27-fdcd7dcec32f", "1f5fd2e8-e803-4aeb-970f-381af58a464b", "97e54a2a-72a8-4c19-9568-747ce271bc48", "227fb644-4d79-4521-aefe-d3ef6338b30b", "64217d82-5c7d-4879-bb97-8493b6452dd8", "cc72b49d-2a08-418f-9114-3c384440f2dd", "75fa039d-b4f6-43bc-8f05-60bf6f1182c9", "6f87dd4d-50ed-441d-9265-af165d926d31"], "metadata": {"window": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.   So while volumes were a little lighter than we had expected \noriginally this year, due to the situation as we mentioned with Fred's that went bank rupt and some other \ncustomers that are winding down a few stores, we are still seeing volume growth.  \n \n  And then the other big factor is going to be just market dynamics.   We've seen significant improvement in the \noverall market dynamics on the pricing side .  ", "original_text": " \nPage 12 of 32 \n \n We really believe we have industry -leading servic e levels and that really helps lead to maintaining and growing \nour volumes, which is an important part of it.  ", "page_label": "12", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "13db3eeb-d2fb-49b3-bbfe-dd55e1f4d421": {"node_ids": ["d6ea48b1-5929-4d10-8fe9-dc7b26b483ae", "88eb73c2-a272-49f9-8e65-821dec52e323", "e2b9a854-bb63-400b-8a7c-2e10c89737a4", "e55b871e-bd86-483b-8b3b-b8e3b9f30747", "254283ee-98f2-4535-bcbf-99cd87554ba1", "402d9b26-09c0-4343-9c14-9a103f1fa406", "96000cfe-76c1-466b-931f-7890651ab0a2", "81b801e7-8d1d-4c14-ac3b-51325e29083f", "307b87af-d5b8-46e0-af50-5688a48850b2", "78021071-210c-4bed-bac8-f516ea87ef0d", "24757615-fb62-40ba-ad27-432476c65eec", "f386b0ea-8f8e-41c4-8e93-733fa9a7d10b", "7dde51aa-0197-4175-9166-111348bbd62b", "d7739945-19f0-44b1-ac4a-bedb17d559d8"], "metadata": {"window": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?   And is any of that in your second \nhalf outlook?  \n \n Mike Kaufmann :  Yes, I'll start with as far as the second half outlook goes, we basically are just taking the trends that \nwe've seen for the first half of the year around generics.   The overall programs in kind of forecasting those out for \nthe rest of the year, we're not projecting necessarily a ny improvements or inflation or anything like that.  \n \n ", "original_text": " \nPage 13 of 32 \n \nwhat could be the potential implications on potential return to generic inflation?  ", "page_label": "13", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "da1c31a4-dd5b-4b8b-9f3b-09672b531870": {"node_ids": ["ae6dd3f7-d504-47c8-81bf-11aa10822b53", "255a3bcd-80db-4df9-908d-d023349da887", "5a4e3f57-1d22-48b7-a85c-1d0a71f884d7", "15a718c4-1bc6-41eb-acb3-b01a6280e957", "cce5d40c-404e-4ff7-8465-5697bf7bf6ce", "e38bab70-e75c-4ed7-a462-903b2311e90a", "c99a5412-9fb3-4fc5-9dee-5605c3b66d25", "5d9b6061-5c28-4d2c-9bb3-c0a0b27e6924", "f04ae789-293e-4c39-b281-512683403ccc", "00996555-1e67-46f7-bea6-295ca42ce203", "65ee96bb-bc55-4e07-8b8b-10f6bbd23b49", "a6fab380-2411-4dcf-8eed-d85b5afb3fa1", "47bfd398-9d27-4d2e-be59-5b1665212573", "fe3729d5-f085-4d53-962b-67247e9bc35b"], "metadata": {"window": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.   I do think it's \nsomething that based on  the amount of supply in the supply chain is something the industry should be able to \nwork through.   But it's hard to say how long this will last and it's something that we're going to have to keep an \neye on and we will.  \n \n Kevin Moran :  Next question, pleas e. \n \nOperator :  We'll go to our next question from Lisa Gill with JPMorgan.  \n \n", "original_text": " \nPage 14 of 32 \n \n \n Where we have, we've worked with manufacturers to try to increase supplies ahead of this.  ", "page_label": "14", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7d5e882c-1d1f-4bfc-89a3-1d5ac4f19a37": {"node_ids": ["b6d6d7c7-d442-41d2-8363-df549ed9ca92", "20b90c31-5a02-4fdd-8f5b-aacf41f8fbef", "35188314-ccbf-4a1a-a482-897cd167aafa", "f2d44571-d7f6-4613-86da-1e660b2187b5", "6f4fb5b3-5bd3-425f-8916-23ce7c614e90", "c97cc2ce-73e1-404c-b99a-33c6b228f246", "b6b76e01-b458-47e5-824f-cd85a12a8e97", "6c160d19-064a-4310-9907-3e0c34ec2919", "684b31a3-e88a-43e6-b479-78953ff2d83d", "04ef5d15-0e03-43db-90ba-eb5e691a9810", "1e58e92c-ec9f-454e-ab88-fbd5831b43bb", "96ed7c18-d5e7-4b2b-84e7-21279ce811ff", "05cca7e8-1b47-4cfc-ba1e-0e9f249c7ed5"], "metadata": {"window": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.   So we continue to be excited \nabout the specialty area.  \n \n  As far as it relates to IPI, I would say this.   First of all we're in favor of anything that can help reduce the  cost of \nhealthcare to the US healthcare system.  ", "original_text": " \nPage 15 of 32 \n \n So we are seeing good momentum across all three areas in that business and continue to feel good about not \nonly their quality of service to the customers with some of the investments we're making in the businesses that \nwe'll be able to talk about more here in the future, including a recent investment we've made in Vineti that was  \nannounced that we believe will also be an area of helping in the cell and gene area.  ", "page_label": "15", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "76d6afd3-472e-4f14-bdec-478a7b3175a2": {"node_ids": ["94e30b10-cdc9-4788-9b5b-4fd99ea92f7f", "f6f792d9-f482-44fc-aceb-2d6926a9649f", "45f449eb-ec3d-4cf7-98fc-cea3a66899f9", "295a929e-56ae-43c7-8650-265c20d01e8b", "f8a1b89c-6431-4176-a4fc-62de7df92215", "c10ff758-2e20-4e71-a1cf-9b27675ad14a", "f1a61136-1608-436c-bbda-31f5a2b20004", "299d962e-c365-4ea3-a702-2225f497f587", "74406c4b-bb67-4ba3-81a8-07f194f0e5c2", "c0bdaa90-d446-4368-b307-b7bd5ab3c703", "a2d43ad5-30cf-41cf-ac65-3d354b709b2d", "d44b464b-2a4f-4fa9-bc0a-23ea87329b84", "56c74a56-6d44-4f0e-bde2-e9aa2df2ef14", "599953d0-521e-4c46-b502-6597b7771269", "4a178da4-a655-4036-b4fe-b64bbf19e36b", "ef383a25-32c8-490f-84ea-60d67a5b1d58", "902d7723-1edf-4ac6-8449-6039fc18b448"], "metadata": {"window": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.   We really look at any of this \nlegislation with a true lens to our customers and the impact on them.   And we want to make sure, and have \ncommented on past legislation that's been out there, that we have to be really careful that type of legislation \ndoesn't reduce access or reduce the ability of our customers and themselves to be able to work with the actual \npatients to provide the type of care that we know that they deserve.  \n \n Lisa Gill :  Thank you.  \n \n", "original_text": " \nPage 16 of 32 \n \n The pi ece that's really important to us though is the impact to our customers.  ", "page_label": "16", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "26d39df9-9910-4a9d-a829-04e3781d6c12": {"node_ids": ["ad08b168-8ee0-441f-85ad-1fbad50ffa08", "e8b3b53d-3661-4942-b9d2-fa3ebbefb1c4", "105ade8e-c668-4b07-a548-1b2ddbcba761", "05094f87-96c5-42a9-86c7-3291ea7ca06a", "dfcb524b-f829-4720-ae6f-44f9d855feaa", "38c6c671-caeb-45b3-831d-06f72bee23b2", "fde3dc5e-2b3e-4dce-a845-a4af822168d7", "20853244-e1c4-40f3-bc7b-cdce8be1b513", "bd8b48b6-ef9a-46b9-923f-f7e108fb1d08", "77e8de5d-c94e-4677-9876-976cdd1e7218", "843e9acf-63d7-4258-87fa-f636cfb57cf5", "bb1ee752-a26f-4830-9675-ba5b3dbfe7ce", "2625f123-df23-454a-a934-b90848cfaa9d", "eb980769-7cf2-4148-9c40-a08475e340f3", "54bebece-4b12-43fe-9dee-ff56a4c35e34", "fc35fc73-2f9c-4bc0-b857-209bef4d1a32", "08e53813-e661-4eb8-97e6-a59474d9f1e2", "7cbdbf80-7488-45f6-8511-0eff77b022aa", "af2c138c-f7e4-4154-9ec1-a7ef3a99b3c9"], "metadata": {"window": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.   Q4, we don't expect to see the same year -over-\nyear improvement  because Q4 of last year, if you go back and look at that, was a quarter - it was the first quarter \nwhere we began to see the inflection in this deflationary trend.   And so we have a much more challenging comp in \nQ4. \n \n  With respect to the accelerated launc h of new items, that's not necessarily a one timer.  ", "original_text": " \nPage 17 of 32 \n \nexpect to see year -over-year some healthy improvement in Q3.  ", "page_label": "17", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9942db7f-1c27-41eb-83a6-1b4802668146": {"node_ids": ["2501271f-fdb2-456f-82c2-a2c34399c6e3", "cc6fe74c-ea8a-4301-9fa0-a2db1e27b452", "339bac2f-7588-432a-964c-121398d2aec4", "8bb266a0-8815-42af-9bd4-1a981f02fd38", "eb56aff1-5d62-40f8-b293-bda010f39b3a", "d53faa94-a61a-40a7-97b4-e986016501ca", "343a2eba-ffe5-423a-813d-02e908b8f148", "4e49ffea-c28d-4119-9fa8-0d2ec7202b8e", "73a5b421-43ff-47cc-bbb2-aa5fbbe317c4", "ebe8ed9c-e507-4c7a-8f9e-fe1ce5bb5fb6", "fb01aa35-ed44-4ce6-8c62-954166bc3551", "3d3b419a-5e52-4db4-8f0e-4381c9cd5b16", "54094481-35a7-4cac-99c8-eca9e755921a"], "metadata": {"window": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.   While they \ndon't provide a lot more value than normal branded items and they generally act like that, there are some smaller \nopportunities on the earnings side to earn slightly better there .   That's been a piece of it.  \n \n  We've seen really nice growth in our services business upstream with wins in our 3PL business in our hub and \nsome of our other businesses have continued to grow.  ", "original_text": " \nPage 18 of 32 \n \n Part of it is some of the uptake of  some of the biosimilars, you know, here and there, some of that.  ", "page_label": "18", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3f3770d7-d84b-4ea5-ab8a-e301b94a2999": {"node_ids": ["de02a0f4-3afd-40d5-a9f6-b279de812e21", "a86bcf23-8c1a-4147-b6ed-a80cb69b6e03", "27c0aecb-0711-45dc-9580-1a49b89432c0", "dae5c380-4a08-4164-9877-b1d9f901c318", "ded71b0a-019d-43c8-b2ff-258338975827", "7c56f52d-7ab2-463f-8215-189536592707", "31f6feab-2d45-41a2-8c44-f8aea272f6d6", "d5d6a03a-b675-4227-8274-ab9d04554815", "3fd614ce-b15e-4ecf-aab2-36d0fb467ddd", "d5ec56c5-63d5-42d0-bc68-7f54960eec53", "a1c6bcc0-0888-49c1-bebf-9b9bab26acba", "51eb2f4a-71b9-4c8c-b88b-4a0a5a134309", "d9760cdc-1a0c-4e2b-8abc-66ccc6e5624d", "b591e5d1-2791-4876-ba14-74eba6bc9834", "84a10928-c403-4ca6-9100-5ec10bbea583", "ac0cde38-927e-42df-95bc-b4e90b7f293b", "5ec031a4-1601-4905-8aec-c53f59974b2d", "6851d501-2b04-42fd-94ca-a1ef9ae4dc1b"], "metadata": {"window": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.   Thanks.  \n \n David Evans :  Well, Stephen, this Dave.   So I'd say your assumptions are all pretty spot on.  ", "original_text": " \nPage 19 of 32 \n \n So I was wanted to check and see whether, you know, you agree with that logic or anything has changed about \nthe sizing of the renewals throughout the year and therefore whether we should be expecting, you know, segment \nprofit to return to growth on a rep orted basis as we move into next year.  ", "page_label": "19", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "798df53f-049d-4a69-9e12-285cc64ea53d": {"node_ids": ["d9b0f526-f7d6-4d0a-b4c3-e38f893559b0", "ea511c25-49f8-4c50-bacf-ebc152380625", "b05e4e85-7d80-49b0-a085-73db6b921014", "737e6a60-b3ae-4e46-ae74-6b6740831163", "d458441c-6d55-486f-a37b-2230925750ca", "d4814a69-4fdc-4c76-a913-d5295357e60a", "90ed62eb-03f2-4130-b00e-256b42825af4", "284bde84-9f2f-4965-a766-a727a7f864f1", "686f4b8d-6bbb-4d62-b47f-764f849a4b32", "6e4b760d-8e8a-4427-b3d7-3a0c01efca4a", "a46435d2-6fc6-4952-8062-af3523be6204", "22bc21fb-b6a9-457b-92da-a1e0def3f434", "9d2cfcaf-cbd5-4b53-b525-ee556a5245c2", "9c04234e-5c3b-4d00-bdf6-0468a29af4b1", "36fdec5d-4d22-4d0b-825a-94e48a7bc21e", "61b8b572-a94a-4f85-a9f3-300a53cae88d"], "metadata": {"window": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.   It is something to be more of a mid -term or longer -term driver, particularly if they become \ninterchangeable.   And then I think, for sure, in my opinion would change o n their ability to be a much bigger driver \nfor us.  \n \n Erin Wright :  Okay, great.  ", "original_text": " \nPage 20 of 32 \n \n But I would not call them a large driver  of anything over this year or over the short term, but something we'll keep \nour eye on.  ", "page_label": "20", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ba6dbff2-3657-4bde-a7c9-b08f028272f8": {"node_ids": ["35613848-d4a5-4eb1-88ea-ecf60370383d", "7c311a21-4ba7-4191-b45b-aa9823541bb3", "0d626230-71c2-45c1-9eb7-f8128b944094", "1ee2e620-c3b0-4697-b8cf-bb57f0f31cca", "733f9f72-a98b-4d71-8f48-764c3dca75dd", "f4baf248-b2cb-460d-9abf-51c3015fde55", "c5f64f4b-16ed-4e59-970e-9a1a1c1e25b9", "d3369c22-7b53-40f9-b291-c1e21938cee6", "27d7da06-3302-4d72-ae87-777fcd503494", "87fa3cf2-640a-4b47-8764-47065b9b2751", "e74c2955-cdfe-47bc-9fa4-74fa314ef399", "0a17d907-f364-419e-9600-5ed2d824782c"], "metadata": {"window": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.   We have deployed some of our sales reps as well as other people into the \nfield to be actually located at the hospi tal locations helping them manage through this challenge that is out there.  \n \n  And it's really important to us that we take care of our customers and our patients.   So because of that, it would \nslow down where we expect to be.  \n \n ", "original_text": " \nPage 21 of 32 \n \n But as I no ted, particularly well - both of them, but probably a little bit even more in the commercial side, it has \nbeen slowed with the gowns recall.  ", "page_label": "21", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fc3b790b-6695-439b-97a4-376d5825da86": {"node_ids": ["2d39feec-6c57-4be1-bafa-2295eee99be6", "dd3eb872-fdbc-4aca-9ddc-49d9cc4a215b", "ae2b5eb0-14f0-4f79-90c3-95ce51f53514", "562be8e2-101e-4b53-8847-1a2cb2e088a4", "bba7ffe8-b580-4f16-8ce0-aec02583a1dd", "d5cdd403-3c64-48b5-bfa9-ee46c9b7392a", "850add53-64d7-4493-aaf7-03a746affb77", "1d21f253-56e5-4d04-864d-6426da5a1d3b", "a382d9d5-fd41-4b96-ac71-f6bc678e4636", "46115c72-61a6-48b3-8b14-d939e5f4b04a", "fbc19273-4191-4b38-8aff-6ce27d6a5a76", "5ebfa653-b085-47b4-a396-ef7a986630d5", "31258b32-0cef-4d97-81fa-852d7588ba29", "c4baab8e-5db7-4dcb-a597-a63be7ee2c26", "7c0d699c-3b98-4628-abac-21edf8d57314"], "metadata": {"window": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?   How do you think about areas where \nyou think your customers are asking f or you to do more?   And versus previous capital deployment and M&A \nopportunities, are there any other components or pieces of the business that you think makes sense to beef up \nright now?  \n \n Mike Kaufmann :  Yes, as I mentioned, we still feel really good abou t having several areas that we would consider \nstrategic growth areas.  ", "original_text": " \nPage 22 of 32 \n \n How do you think about that against the backdrop of capital deployment?  ", "page_label": "22", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "396558cd-e0c3-42b3-9b42-0b28bc0c5151": {"node_ids": ["1a65603c-d79e-43fc-9b09-09dee68feb3a", "03b46831-827b-4b04-a4b0-1ece90f1c094", "541a1f17-d5aa-4311-97f4-82609c4bc11a", "9ea96f33-3e66-4c2b-8a02-6a7b23349c6b", "f054ad45-4e7d-4a17-91ac-6ddd1956d261", "d7dd3d00-9209-4e8c-b2d8-703b1594b54c", "a42a454a-ce65-4a57-9fb3-abaf0da27563", "96dff063-4046-47b0-8b5f-0761f2157f41", "495114a6-aebb-4b46-b0a3-ed14a6c22fa3", "1a30562a-e7f6-4503-a136-959613fe0a8e", "538b2475-375f-44cf-9ee4-3b5fc962e2d0", "cc88419c-bf97-41b5-895b-e79dc6715f60", "66f6fef0-8158-45b9-b778-8325cfb5c81b", "0a717fb2-4592-4493-b87d-05e184527667", "4e1fc756-6a11-4ffb-a71f-1c594ac1319d", "344d25a2-f424-45f0-83de-b435832563bb", "e4036d46-6ca1-4e8a-b143-2e6f36974be3", "0945c749-88d6-4e0b-8492-222e996332ed", "bbd65cd7-f116-47f2-8da6-ff66f0354e19", "e01d9b04-fd65-443e-a2da-074e63ac1c7d", "9c3af8b7-b806-4b4e-bde6-e0133a196ff1"], "metadata": {"window": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.   We are focusing \non deploying capital to cost out projects.   We're providing cap ital in areas where we need capacity for growth.   But \nthen we are also deploying some capital to explore new growth areas.  \n \n ", "original_text": " \nPage 23 of 32 \n \n We've got our maintenance capital, where clearly you've heard initiatives like our supply chain.  ", "page_label": "23", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e0e94eb7-948a-4cab-a0d9-55f11cec1a03": {"node_ids": ["c7b5e996-8975-4f9f-8423-48d9d5241106", "2cb7682e-c286-4fcf-a59e-fc99cc63e538", "ddf2ef2c-5da9-484a-87f0-bd3148b8767a", "d98c31d8-9b7b-4b6b-b486-bf9b51ff71bd", "0828968b-7ed0-4988-9503-1d2340e2fb6c", "3fb08a09-0650-49b7-8a7a-4714d6627ea5", "199fa66e-de93-40de-805f-cb88e3504e30", "1a563560-abba-40dc-ba87-c85edda19865", "3f4ad125-6e51-4490-92bc-43c73b77af26", "99cfcae4-8f95-4889-bd08-0c0bafc14765", "6677bd44-06c6-4044-bac3-e30e28d9a489", "0f13d60e-acb3-41ae-815e-c6a90f4e893b", "41f45016-fbb7-47a7-98c2-c25f322124b5"], "metadata": {"window": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.   You know, we've been very disciplined over several years in our \npharma distribution business to make sure that we're splitting out our pricing on our specialty so that it is priced \ndifferently than normal brand so that we don't - so we can make a fair return on the specialty drugs.  \n \n  And we continue that discipline with  any new business or renewals with either, as I've said before, specific pricing \nin that area to maintain appropriate profitability or some types of mix type of penalties in agreements to make sure \nthat if their mix goes the wrong way that the overall cost  of goods adjust.  \n \n  So we continue to be very focused on that in the PD area.  ", "original_text": " \nPage 24 of 32 \n \n From a change in price standpoint, I'll look at it.  ", "page_label": "24", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b0658900-7bd2-49d4-96ed-ae6d007700e6": {"node_ids": ["56b83ecc-f865-48b3-9577-2532f4912d8b", "2a176b7f-94e8-4c65-accd-2f2ba884348d", "f1754cff-ee70-4483-bb55-b079bd2de45a", "1439cb7c-9496-471d-a3ec-e147ffc9dd2f", "0022580f-2889-4860-b406-37f6c3882093", "b33fb33c-06e1-4e14-bd21-ec1bd4436a94", "35dc6362-2284-43a2-9240-3d151158979f", "25fc5cf5-26aa-41e9-876e-8f1d0f4e0283", "e1f844d6-99d3-4fbd-a4d0-fc49df12aa07", "562d4300-84de-4844-afb4-5f800588d763", "4acb5999-5bce-4fda-92c4-5269b52da6b7", "f911b390-8197-48b8-b0fb-5640620aa71e", "81c2e082-e3e6-4808-936b-1f3e5f723765", "d78ce1d1-e97e-49a7-8391-ece5dcc2a8ac", "51cf7232-b00f-46f7-8144-58a5cd9794ab", "01491980-f2e2-48ec-920f-e85b06711aac", "876acda1-c0e7-483a-b489-96d07cce638f", "1134666d-fd17-4c34-9fe3-c3a718b36304", "d8b5f1e4-4803-4e07-9074-d62a12048737"], "metadata": {"window": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.   But fr om an overall perspective of drivers, at this point in time I would not \nsay that is a significant driver.   But I think over time, it will get to be a more and more potential driver for specialty.  \n Next question please.  \n \n", "original_text": " \nPage 25 of 32 \n \n \n And those are where we can make a little bit of extra dollars when we work with our downstream customers to \nprefer either the brand or the biosimilar.  ", "page_label": "25", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "057abce5-d1f2-4f2f-b58a-f284551d1e29": {"node_ids": ["03fd2ccb-8aff-4d0b-b474-8db3870282c7", "416ad303-a2a4-463f-8369-c8ded4317e1b", "1b5b7a1c-4f20-404d-af60-d5f2397d7bcb", "193912fc-f10d-4d71-b1eb-43985214e884", "eda82a6c-5b19-44c2-a117-70a20ea56873", "9b3eb4e4-0d14-41c8-aafc-8a86d0a50c44", "4e69173e-fbfc-44c3-9f9d-6f8d22eb4991", "7766d183-a5b0-44d8-8a95-695dc7515602", "6e314057-9a2b-45b2-8de4-c71cfb602aa8", "a7b7f40e-6fe6-45a2-a27e-573096cb6bb5", "a72d2e27-4adb-4ec0-a011-361111b74011", "82627fe5-a223-4037-a5ce-c70da964f9e3", "201d8a04-fa5e-4f35-9a84-fb16a3ee9a62", "34ff659a-52e4-40ea-bad8-bba3d71b700a", "7945270a-63ed-4494-9047-8de4e458da96", "2bf2ccfa-3a73-4315-b14c-f4e884d8486b"], "metadata": {"window": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n  I can't quantify for you th e exact amount of that, but we're encouraged that we are seeing more and more \nopportunities as we build this culture within the organization of encouraging people to seek out new opportunities \nfor ongoing cost improvements, growth drivers, et cetera, et ce tera.   So I think the program is one that we should \ndeem as a real success.  \n \n James Auh :  Okay.  ", "original_text": " \nPage 26 of 32 \n \n \n With respect to the level of reinvestment, we are continually encouraging our organization to press Mike and I with \nlots of difficult choices and challenges to reinvest this with high -returning projects.  \n \n ", "page_label": "26", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a5e85b94-6264-4b17-a195-3eb3f253987d": {"node_ids": ["1f3f0622-2405-4149-b525-8d9dd1453c3b", "7b33a8a8-a392-452e-bb20-450051e0f9a2", "690517dc-ee93-41e4-b29f-6e2bb97e01a8", "edf1cca1-fe7e-41f5-b8fb-d1b731047a6f", "59dc3930-7e19-4dbf-b934-70ab993d540a", "84be6d16-7f20-475b-9bad-726ff4da4bbd", "548b6aed-0bd4-4775-91e9-e59823c248f8", "8c92dac4-e8be-4309-a8cd-57c22eb28df0", "e699b969-1269-465d-ab4c-69b7718dad7c", "abf5f1b5-3358-4283-b96d-7a782e100c80", "b95c2b70-d216-4666-8699-32133fd76e0b", "06edd1cd-601f-4916-beeb-3eebe084cf12", "de0b621d-b918-4be0-b26c-ef03d753469d", "42dc7c66-8399-438d-bcc0-c0f0e38c1152"], "metadata": {"window": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n Mike Kaufmann :  Yes, we won't, obviously, be able to give a lot of de tail on market share.   But I can give you a little color \nis that there - the reason why this is such a - has a large impact is that a lot of surgeries in the U.S.  use kits.  \n \n ", "original_text": " \nPage 27 of 32 \n \nbroadly, maybe starting with market share where your customers are turning and impact on other elements of the \nbusiness?  \n \n", "page_label": "27", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e45cb5a3-a714-4ee6-8445-39a0f3327495": {"node_ids": ["93206f79-2940-432f-9f21-00a94801254e", "2b58757b-c0f0-461a-b85d-660f235cd215", "0f1af34f-c395-499b-810a-92bc6ed64735", "96233ab0-4db1-44d1-96a7-678d7aecdbd1", "c7ed85ca-a46f-488e-994b-2b49bb7c7610", "873b4896-6f16-49a9-b586-007207ea64dd", "145ed10a-2d6d-4dd5-b0a7-f05aa520a63b", "20431225-30c0-4fcf-a822-67fe2c8b6975", "e45aff6c-3461-4529-9adb-e7df4521577a", "c8cf7963-f85e-4dc1-a275-33c5a3ac90f7", "d4d8e325-174f-4660-a3ce-ba45ac03dd3a", "70471d16-2ae5-49c8-9c14-b03e7f8ca07a", "ce307d13-8402-4436-a510-02ad7076eb90", "463fabf5-2946-42c4-a574-1e1f99b5f1ca", "cbdac471-e097-45b2-bafb-de390dd4e04f"], "metadata": {"window": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n  So we have deployed hundreds of people.   We've taken out not only our medical segment, but the pharma team \nand corporate functions hav e also volunteered and sent people even to the Vice President level out to the field to \npack kits, pull things together for customers at their locations to do the best we can.   And so  I believe that the way \nwe're responding to this is really, really import ant. \n \n ", "original_text": " \nPage 28 of 32 \n \nownership for thi s and said we're going to do everything we can to make the customer's life as good as we can \nknowing the circumstances.  \n \n ", "page_label": "28", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d8ffa405-fbaf-4a88-b20d-c31b1d76c766": {"node_ids": ["51ccc4ba-02e9-40c4-a77a-b916486e3bf6", "53b9c76d-a53a-4393-8044-a4ebc3fefb15", "fb05c82f-3bdb-4f66-b5ce-32c8fe3ca049", "ed4236b6-a90a-434c-b595-b3ffaa28fb48", "3e65fce5-1360-477d-8ba7-d2edb0c6f424", "4f0d8291-9867-4bfd-902a-8f38b4814874", "1d4df627-14d3-4c90-8144-b63e0ec72b37", "1b925084-bd1c-4693-b67c-009f3c56569c", "81fbe40e-a6bf-48a2-98de-45f6192c766b", "86521992-99e6-4ec1-b5c5-a44f57c1eeb7", "141f9779-abad-483f-a8f4-1a01e986c669", "eab65f11-0e33-45b3-b247-8b1e0a631143", "f22db9c5-ee23-4ca8-89c2-b331ae4c305a", "9a948380-558d-45dc-8f94-db31e54f6f8a", "ececa927-4528-4579-902d-a2b435a90571", "dcd76bc8-c6b3-43dd-ba65-bf49cb61bfff", "508f5b5e-f3c1-4886-9ca0-33e38c87c950", "56f09357-15e8-4b44-9ac3-8017c3618bd8", "d5509037-39f3-40bb-90e9-2e1ed4ec36a3", "6dcb3f19-fd43-477d-8783-aa30ec0e1752"], "metadata": {"window": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n Kevin Caliendo :  Hi, thanks for taking my question.   I just want to go back to the opioid comment.   I think you called out \nthat it could take weeks or months to get this done, and that would run into two pretty high -profile state trials that \nare scheduled.  \n \n ", "original_text": " \nPage 29 of 32 \n \nOperator :  We'll take our next question from Kevin Caliendo with UBS.  \n \n", "page_label": "29", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9915696b-dd41-40f0-ae0c-71bb342359de": {"node_ids": ["bb37b972-4b77-486a-b0ee-378e2a9004f4", "5330d980-0ee7-40a6-a07f-b3573d7ce12d", "128f275d-0abd-469f-ac6e-0440b8fae149", "244f0af6-2fba-4a0e-8c1d-6de94e36c45a", "3d4fe2c9-b4ef-4719-ba3f-747a71e422f7", "19487790-9ef4-4231-ace6-428225e6c4b2", "6b911d4c-30cd-40fb-95c1-1a1998a579e7", "2e1ab682-3cc1-4017-ba33-685c092f5824", "dd5a9f82-4afa-42c5-a19d-68bbccd24469", "a7e2da8e-6535-498b-94d0-9e52f524d091", "01339826-2bbe-474c-ae84-3902e5598353", "1740f898-ca85-41cf-bcf7-e0a6c1549032", "1b892a56-e671-42e0-a8fc-a52afdbcbd28", "3abab5cb-4794-4f82-a1af-41020eadc6d7", "313d8acf-67be-4f3c-8182-815235cc00b7", "5eb1019f-28a5-4ccd-b544-95e744155529", "956e5429-69f4-48a6-b220-68c1fb1d87d3"], "metadata": {"window": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.   And so we continue to be focused on - and that's why \nwe put that range out.  \n \n Kevin Caliendo :  If I can ask one really quick follow -up on the API issu e, I think Ricky brought it up earlier.   You said that \nyou thought there was enough supply in the chain to manage it.  ", "original_text": " \nPage 30 of 32 \n \n \n There's a lot of work to be done that will take legal costs.  ", "page_label": "30", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f05a6675-6af7-4244-8fee-d2c465008cd5": {"node_ids": ["c45c1e83-a512-4a1e-80e4-0c6a83b5c0dd", "c4a9a024-2edc-43e3-adfb-c17ec81f7aa8", "e37f5bcb-6a09-4617-b98d-65cd0a34500d", "7a529249-22ad-472d-9bf6-61690d4d1cfb", "234ef09b-dc09-44cc-857f-a5548b84cb6a", "634dd078-1a65-4f36-9edb-93109204ca18", "f5271c1b-fa02-4269-bc96-8d5c5b973015", "199d3766-59f9-4c68-aa2b-ea1686849b48", "e809a6fc-ee38-4e50-9ae7-c77214106958", "acddffde-9ab2-4203-a031-e0588f3c86a3", "98e71484-32b6-43d5-9083-5f0aa4b741ff", "89a13819-8633-407a-b624-f41a529c203e", "8a9fe426-5d1a-43d0-8777-14d56c5244eb", "f56e66cb-a7b4-4122-a478-2cbf7927b253", "2aeca256-3399-4064-b6fb-07af85f9ce9b", "5e7293a0-5912-442b-b847-886f121c91fc", "642ee90e-3fff-47aa-afd0-85abb3f4d230", "e944017a-cabe-488c-9ab8-ba10e7e960c7", "50d5bcc7-80c1-4b70-b4dd-83d1eb5b7b25", "4af8c8f5-56e2-46ca-8a93-4821170e0f54", "9e2ccd3c-568f-4770-833f-cfe463f6af0c"], "metadata": {"window": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.   Good morning.   So in med -surg distribution, you cited that as both a headwind for revenue \nand profit.   I guess I'm a little bit surprised.  ", "original_text": " \nPage 31 of 32 \n \nEric Coldwell :  Hey, thanks.  ", "page_label": "31", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "54aae0f9-2d2d-4b3f-85ed-7107806d0762": {"node_ids": ["e00d9c07-90ce-4c75-aa9a-0b9714a02370", "638e812c-a2ef-41fb-b312-e9877970c476", "6679cf8e-029f-46b5-ae12-a62bc22ed91e", "fbdd331b-2e1e-4470-88e1-908b66a103a0", "03511ca6-3486-48d6-b4b4-6e9819d12fb9", "ba7d8655-a2a6-42ee-a8e4-a073d80cb2ff", "03fa5830-ef8c-447b-91dc-3957943c9819", "aeb76cd6-c9d1-405e-a5f6-e0dd7bea07bc", "6e0dff2b-cad7-40eb-8cce-f5e51da28a00", "3ee21561-e6d5-4cdc-b882-18031522dcae", "40361b07-7e70-4684-97b4-721b4c90f23a", "51617b4f-6e0b-470d-8bd0-6a6434dcd499", "6023e385-471c-4f2b-bfb1-eaf2a7798c6f", "f689272f-e38f-43ed-8350-81d5fe6ce0e0", "a6edb8eb-ca22-4591-b113-03d988eb14c5", "d16a4df6-6d35-4a11-8ee4-e18224d2d34f", "9d691d71-c848-4fab-9fec-ebadbcbc69e8", "3a34865e-6af9-4c99-8081-95c3f8c9c8a3", "fb10da04-4215-4733-82b0-eab6686177cf", "92991152-97cf-4935-8f77-59a7d90bb39d"], "metadata": {"window": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.   But we've got to get through these challenges for that \nto happen.  \n \n Kevin Caliendo :  Right.   And I just - I know the kit recall really didn't p op up until January.  ", "original_text": " \nPage 32 of 32 \n \nto long term, that's going to be a large value creator for us.  ", "page_label": "32", "file_name": "CAH-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 164825, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}